answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
sequence
text
stringlengths
5
72.4k
tokens
sequence
types
sequence
Bcl10 is a Protein, IkappaBbeta is a Protein, Bcl10 is a Protein, CARMA1 is a Protein, MALT1 is a Protein, Bcl10 is a Protein, Bcl10 is a Protein, Bcl10 is a Protein, Bcl10 is a Protein
110_task1
Sentence: NF-kappaB inhibition due to PKC-dependent Bcl10 degradation Western blot analysis revealed an up-regulation of phosphorylated-PKC after 24 h treatment of Jurkat T-cells with PMA or HK E. coli (figure 7a), while IkappaBbeta levels remained unaffected (figure 7b). Bcl10 is a signalling protein that acts upstream of NF-kappaB in concert with CARMA1 and MALT1 and has been suggested to directly regulate NF-kappaB activity in T-cells [27]. Therefore, Bcl10 activation was evaluated in both control and PMA stimulated cells after 10 min, 1 h, 6 h, and 24 h using western blot analysis. The Bcl10 levels decreased following treatment with PMA, while in control cells, Bcl10 returned to higher levels by 24 h (figure 7c). This suggests that Bcl10 is involved in the PMA dependent inhibition of NF-kappaB activation. Instructions: please typing these entity words according to sentence: Bcl10, IkappaBbeta, Bcl10, CARMA1, MALT1, Bcl10, Bcl10, Bcl10, Bcl10 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
NF-kappaB inhibition due to PKC-dependent Bcl10 degradation Western blot analysis revealed an up-regulation of phosphorylated-PKC after 24 h treatment of Jurkat T-cells with PMA or HK E. coli (figure 7a), while IkappaBbeta levels remained unaffected (figure 7b). Bcl10 is a signalling protein that acts upstream of NF-kappaB in concert with CARMA1 and MALT1 and has been suggested to directly regulate NF-kappaB activity in T-cells [27]. Therefore, Bcl10 activation was evaluated in both control and PMA stimulated cells after 10 min, 1 h, 6 h, and 24 h using western blot analysis. The Bcl10 levels decreased following treatment with PMA, while in control cells, Bcl10 returned to higher levels by 24 h (figure 7c). This suggests that Bcl10 is involved in the PMA dependent inhibition of NF-kappaB activation.
[ "NF", "-", "kappaB", "inhibition", "due", "to", "PKC", "-", "dependent", "Bcl10", "degradation", "\n", "Western", "blot", "analysis", "revealed", "an", "up", "-", "regulation", "of", "phosphorylated", "-", "PKC", "after", "24", "h", "treatment", "of", "Jurkat", "T", "-", "cells", "with", "PMA", "or", "HK", "E.", "coli", "(", "figure", "7a", ")", ",", "while", "IkappaBbeta", "levels", "remained", "unaffected", "(", "figure", "7b", ")", ".", "Bcl10", "is", "a", "signalling", "protein", "that", "acts", "upstream", "of", "NF", "-", "kappaB", "in", "concert", "with", "CARMA1", "and", "MALT1", "and", "has", "been", "suggested", "to", "directly", "regulate", "NF", "-", "kappaB", "activity", "in", "T", "-", "cells", "[", "27", "]", ".", "Therefore", ",", "Bcl10", "activation", "was", "evaluated", "in", "both", "control", "and", "PMA", "stimulated", "cells", "after", "10", "min", ",", "1", "h", ",", "6", "h", ",", "and", "24", "h", "using", "western", "blot", "analysis", ".", "The", "Bcl10", "levels", "decreased", "following", "treatment", "with", "PMA", ",", "while", "in", "control", "cells", ",", "Bcl10", "returned", "to", "higher", "levels", "by", "24", "h", "(", "figure", "7c", ")", ".", "This", "suggests", "that", "Bcl10", "is", "involved", "in", "the", "PMA", "dependent", "inhibition", "of", "NF", "-", "kappaB", "activation", "." ]
[ "Protein" ]
Bcl10, IkappaBbeta, Bcl10, CARMA1, MALT1, Bcl10, Bcl10, Bcl10, Bcl10
110_task2
Sentence: NF-kappaB inhibition due to PKC-dependent Bcl10 degradation Western blot analysis revealed an up-regulation of phosphorylated-PKC after 24 h treatment of Jurkat T-cells with PMA or HK E. coli (figure 7a), while IkappaBbeta levels remained unaffected (figure 7b). Bcl10 is a signalling protein that acts upstream of NF-kappaB in concert with CARMA1 and MALT1 and has been suggested to directly regulate NF-kappaB activity in T-cells [27]. Therefore, Bcl10 activation was evaluated in both control and PMA stimulated cells after 10 min, 1 h, 6 h, and 24 h using western blot analysis. The Bcl10 levels decreased following treatment with PMA, while in control cells, Bcl10 returned to higher levels by 24 h (figure 7c). This suggests that Bcl10 is involved in the PMA dependent inhibition of NF-kappaB activation. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
NF-kappaB inhibition due to PKC-dependent Bcl10 degradation Western blot analysis revealed an up-regulation of phosphorylated-PKC after 24 h treatment of Jurkat T-cells with PMA or HK E. coli (figure 7a), while IkappaBbeta levels remained unaffected (figure 7b). Bcl10 is a signalling protein that acts upstream of NF-kappaB in concert with CARMA1 and MALT1 and has been suggested to directly regulate NF-kappaB activity in T-cells [27]. Therefore, Bcl10 activation was evaluated in both control and PMA stimulated cells after 10 min, 1 h, 6 h, and 24 h using western blot analysis. The Bcl10 levels decreased following treatment with PMA, while in control cells, Bcl10 returned to higher levels by 24 h (figure 7c). This suggests that Bcl10 is involved in the PMA dependent inhibition of NF-kappaB activation.
[ "NF", "-", "kappaB", "inhibition", "due", "to", "PKC", "-", "dependent", "Bcl10", "degradation", "\n", "Western", "blot", "analysis", "revealed", "an", "up", "-", "regulation", "of", "phosphorylated", "-", "PKC", "after", "24", "h", "treatment", "of", "Jurkat", "T", "-", "cells", "with", "PMA", "or", "HK", "E.", "coli", "(", "figure", "7a", ")", ",", "while", "IkappaBbeta", "levels", "remained", "unaffected", "(", "figure", "7b", ")", ".", "Bcl10", "is", "a", "signalling", "protein", "that", "acts", "upstream", "of", "NF", "-", "kappaB", "in", "concert", "with", "CARMA1", "and", "MALT1", "and", "has", "been", "suggested", "to", "directly", "regulate", "NF", "-", "kappaB", "activity", "in", "T", "-", "cells", "[", "27", "]", ".", "Therefore", ",", "Bcl10", "activation", "was", "evaluated", "in", "both", "control", "and", "PMA", "stimulated", "cells", "after", "10", "min", ",", "1", "h", ",", "6", "h", ",", "and", "24", "h", "using", "western", "blot", "analysis", ".", "The", "Bcl10", "levels", "decreased", "following", "treatment", "with", "PMA", ",", "while", "in", "control", "cells", ",", "Bcl10", "returned", "to", "higher", "levels", "by", "24", "h", "(", "figure", "7c", ")", ".", "This", "suggests", "that", "Bcl10", "is", "involved", "in", "the", "PMA", "dependent", "inhibition", "of", "NF", "-", "kappaB", "activation", "." ]
[ "Protein" ]
cladribine is a compound, fludarabine is a compound, cyclophosphamide is a compound, Bcl-2 is a protein, Mcl is a protein
DS.d683_task0
Sentence: We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O" ]
We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1.
[ "We", "have", "also", "observed", "that", "the", "reduction", "of", "transition", "at", "95+/-3", "degrees", "C", "in", "thermal", "scans", "of", "nuclear", "preparations", "isolated", "from", "blood", "of", "B", "-", "CLL", "randomized", "patients", "who", "showed", "response", "to", "cladribine", "or", "fludarabine", "combined", "with", "cyclophosphamide", ",", "i.e", ".", ",", "CC", "and", "FC", ",", "respectively", ",", "corresponded", "with", "the", "decrease", "or", "disappearance", "of", "anti", "-", "apoptotic", "proteins", "Bcl-2", "and", "/", "or", "Mcl", "1", "." ]
[ "compound", "protein" ]
cladribine is a compound, fludarabine is a compound, cyclophosphamide is a compound, Bcl-2 is a protein, Mcl is a protein
DS.d683_task1
Sentence: We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1. Instructions: please typing these entity words according to sentence: cladribine, fludarabine, cyclophosphamide, Bcl-2, Mcl Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O" ]
We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1.
[ "We", "have", "also", "observed", "that", "the", "reduction", "of", "transition", "at", "95+/-3", "degrees", "C", "in", "thermal", "scans", "of", "nuclear", "preparations", "isolated", "from", "blood", "of", "B", "-", "CLL", "randomized", "patients", "who", "showed", "response", "to", "cladribine", "or", "fludarabine", "combined", "with", "cyclophosphamide", ",", "i.e", ".", ",", "CC", "and", "FC", ",", "respectively", ",", "corresponded", "with", "the", "decrease", "or", "disappearance", "of", "anti", "-", "apoptotic", "proteins", "Bcl-2", "and", "/", "or", "Mcl", "1", "." ]
[ "compound", "protein" ]
cladribine, fludarabine, cyclophosphamide, Bcl-2, Mcl
DS.d683_task2
Sentence: We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O" ]
We have also observed that the reduction of transition at 95+/-3 degrees C in thermal scans of nuclear preparations isolated from blood of B-CLL randomized patients who showed response to cladribine or fludarabine combined with cyclophosphamide, i.e., CC and FC, respectively, corresponded with the decrease or disappearance of anti-apoptotic proteins Bcl-2 and/or Mcl 1.
[ "We", "have", "also", "observed", "that", "the", "reduction", "of", "transition", "at", "95+/-3", "degrees", "C", "in", "thermal", "scans", "of", "nuclear", "preparations", "isolated", "from", "blood", "of", "B", "-", "CLL", "randomized", "patients", "who", "showed", "response", "to", "cladribine", "or", "fludarabine", "combined", "with", "cyclophosphamide", ",", "i.e", ".", ",", "CC", "and", "FC", ",", "respectively", ",", "corresponded", "with", "the", "decrease", "or", "disappearance", "of", "anti", "-", "apoptotic", "proteins", "Bcl-2", "and", "/", "or", "Mcl", "1", "." ]
[ "compound", "protein" ]
Malignant schwannomas is an umlsterm, nerve sheath tumors is an umlsterm, peripheral nerve is an umlsterm, lower extremities is an umlsterm, hips is an umlsterm, buttocks is an umlsterm, upper extremities is an umlsterm, knowledge is an umlsterm, malignant schwannoma is an umlsterm, rectum is an umlsterm, disease is an umlsterm, literature is an umlsterm
DerRadiologe.60360663.eng.abstr_task0
Sentence: Malignant schwannomas are rare . These malignomas are primary nerve sheath tumors that usually arise from a peripheral nerve . They appear most frequently in the lower extremities , including the hips and buttocks ( 34.8 % ) , the upper extremities ( 23.4 % ) , and in the trunk ( 17 % ) . To the best of our knowledge , this is the first reported case of a malignant schwannoma of the rectum . We describe the rare disease with reference to the literature . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]
Malignant schwannomas are rare . These malignomas are primary nerve sheath tumors that usually arise from a peripheral nerve . They appear most frequently in the lower extremities , including the hips and buttocks ( 34.8 % ) , the upper extremities ( 23.4 % ) , and in the trunk ( 17 % ) . To the best of our knowledge , this is the first reported case of a malignant schwannoma of the rectum . We describe the rare disease with reference to the literature .
[ "Malignant", "schwannomas", "are", "rare", ".", "These", "malignomas", "are", "primary", "nerve", "sheath", "tumors", "that", "usually", "arise", "from", "a", "peripheral", "nerve", ".", "They", "appear", "most", "frequently", "in", "the", "lower", "extremities", ",", "including", "the", "hips", "and", "buttocks", "(", "34.8", "%", ")", ",", "the", "upper", "extremities", "(", "23.4", "%", ")", ",", "and", "in", "the", "trunk", "(", "17", "%", ")", ".", "To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "a", "malignant", "schwannoma", "of", "the", "rectum", ".", "We", "describe", "the", "rare", "disease", "with", "reference", "to", "the", "literature", "." ]
[ "umlsterm" ]
Malignant schwannomas is an umlsterm, nerve sheath tumors is an umlsterm, peripheral nerve is an umlsterm, lower extremities is an umlsterm, hips is an umlsterm, buttocks is an umlsterm, upper extremities is an umlsterm, knowledge is an umlsterm, malignant schwannoma is an umlsterm, rectum is an umlsterm, disease is an umlsterm, literature is an umlsterm
DerRadiologe.60360663.eng.abstr_task1
Sentence: Malignant schwannomas are rare . These malignomas are primary nerve sheath tumors that usually arise from a peripheral nerve . They appear most frequently in the lower extremities , including the hips and buttocks ( 34.8 % ) , the upper extremities ( 23.4 % ) , and in the trunk ( 17 % ) . To the best of our knowledge , this is the first reported case of a malignant schwannoma of the rectum . We describe the rare disease with reference to the literature . Instructions: please typing these entity words according to sentence: Malignant schwannomas, nerve sheath tumors, peripheral nerve, lower extremities, hips, buttocks, upper extremities, knowledge, malignant schwannoma, rectum, disease, literature Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]
Malignant schwannomas are rare . These malignomas are primary nerve sheath tumors that usually arise from a peripheral nerve . They appear most frequently in the lower extremities , including the hips and buttocks ( 34.8 % ) , the upper extremities ( 23.4 % ) , and in the trunk ( 17 % ) . To the best of our knowledge , this is the first reported case of a malignant schwannoma of the rectum . We describe the rare disease with reference to the literature .
[ "Malignant", "schwannomas", "are", "rare", ".", "These", "malignomas", "are", "primary", "nerve", "sheath", "tumors", "that", "usually", "arise", "from", "a", "peripheral", "nerve", ".", "They", "appear", "most", "frequently", "in", "the", "lower", "extremities", ",", "including", "the", "hips", "and", "buttocks", "(", "34.8", "%", ")", ",", "the", "upper", "extremities", "(", "23.4", "%", ")", ",", "and", "in", "the", "trunk", "(", "17", "%", ")", ".", "To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "a", "malignant", "schwannoma", "of", "the", "rectum", ".", "We", "describe", "the", "rare", "disease", "with", "reference", "to", "the", "literature", "." ]
[ "umlsterm" ]
Malignant schwannomas, nerve sheath tumors, peripheral nerve, lower extremities, hips, buttocks, upper extremities, knowledge, malignant schwannoma, rectum, disease, literature
DerRadiologe.60360663.eng.abstr_task2
Sentence: Malignant schwannomas are rare . These malignomas are primary nerve sheath tumors that usually arise from a peripheral nerve . They appear most frequently in the lower extremities , including the hips and buttocks ( 34.8 % ) , the upper extremities ( 23.4 % ) , and in the trunk ( 17 % ) . To the best of our knowledge , this is the first reported case of a malignant schwannoma of the rectum . We describe the rare disease with reference to the literature . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]
Malignant schwannomas are rare . These malignomas are primary nerve sheath tumors that usually arise from a peripheral nerve . They appear most frequently in the lower extremities , including the hips and buttocks ( 34.8 % ) , the upper extremities ( 23.4 % ) , and in the trunk ( 17 % ) . To the best of our knowledge , this is the first reported case of a malignant schwannoma of the rectum . We describe the rare disease with reference to the literature .
[ "Malignant", "schwannomas", "are", "rare", ".", "These", "malignomas", "are", "primary", "nerve", "sheath", "tumors", "that", "usually", "arise", "from", "a", "peripheral", "nerve", ".", "They", "appear", "most", "frequently", "in", "the", "lower", "extremities", ",", "including", "the", "hips", "and", "buttocks", "(", "34.8", "%", ")", ",", "the", "upper", "extremities", "(", "23.4", "%", ")", ",", "and", "in", "the", "trunk", "(", "17", "%", ")", ".", "To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "a", "malignant", "schwannoma", "of", "the", "rectum", ".", "We", "describe", "the", "rare", "disease", "with", "reference", "to", "the", "literature", "." ]
[ "umlsterm" ]
delusion is an umlsterm, cognition is an umlsterm, nature is an umlsterm, delusion is an umlsterm, cognition is an umlsterm, development is an umlsterm, subliminal perception is an umlsterm, feeling is an umlsterm, feeling is an umlsterm, knowledge is an umlsterm, direct is an umlsterm, self - reference is an umlsterm, feeling is an umlsterm, power is an umlsterm, delusion is an umlsterm, information processing is an umlsterm, feeling is an umlsterm, delusion is an umlsterm, delusional idea is an umlsterm, feeling is an umlsterm, delusion is an umlsterm, analysis is an umlsterm, delusion is an umlsterm, understanding is an umlsterm, delusion is an umlsterm, diagnosis is an umlsterm, mood is an umlsterm, perception is an umlsterm
DerNervenarzt.80690390.eng.abstr_task0
Sentence: Taking into account the different concepts of delusion and analysing rational and intuitive cognition , the present phenomenological-conceptual study aims at defining the essential nature of delusion . Intuitive cognition as a result of holistic processing is founded in the development of polysensoric-kinaesthetic basic pictures ( eidetic matrices ) , which are recognized preverbally and prereflexively by subliminal perception of corresponding eidetic structures . A positive match between a matrix and a given phenomenon produces an eidetic feeling . This eidetic feeling encompasses three aspects . The first is a preverbal knowledge of something as something definite . As a direct self-reference , the second is the feeling of an object-inherent significance of the given phenomenon for the subject itself . Thirdly , a power vector is perceived to derive from the object . The application of this concept allows us to consider delusion as a disturbance in the system of holistic information processing . This disturbance is characterized by a disinhibition and actualization of eidetic matrices in different ways . The resulting eidetic feeling we call delusion ; its expression in thoughts and words we call a delusional idea . All features of an eidetic feeling can be demonstrated in delusion . Owing to their special intensity and suspended reason , they mostly appear to be unique . The analysis of the eidetic structures of delusion allows a deeper understanding of delusion and facilitates both its diagnosis and its differentiation . Heterogeneous terms , such as delusional mood , idea of meaning , idea of reference , delusional notion and delusional perception emerge in an understandable context . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Taking into account the different concepts of delusion and analysing rational and intuitive cognition , the present phenomenological-conceptual study aims at defining the essential nature of delusion . Intuitive cognition as a result of holistic processing is founded in the development of polysensoric-kinaesthetic basic pictures ( eidetic matrices ) , which are recognized preverbally and prereflexively by subliminal perception of corresponding eidetic structures . A positive match between a matrix and a given phenomenon produces an eidetic feeling . This eidetic feeling encompasses three aspects . The first is a preverbal knowledge of something as something definite . As a direct self-reference , the second is the feeling of an object-inherent significance of the given phenomenon for the subject itself . Thirdly , a power vector is perceived to derive from the object . The application of this concept allows us to consider delusion as a disturbance in the system of holistic information processing . This disturbance is characterized by a disinhibition and actualization of eidetic matrices in different ways . The resulting eidetic feeling we call delusion ; its expression in thoughts and words we call a delusional idea . All features of an eidetic feeling can be demonstrated in delusion . Owing to their special intensity and suspended reason , they mostly appear to be unique . The analysis of the eidetic structures of delusion allows a deeper understanding of delusion and facilitates both its diagnosis and its differentiation . Heterogeneous terms , such as delusional mood , idea of meaning , idea of reference , delusional notion and delusional perception emerge in an understandable context .
[ "Taking", "into", "account", "the", "different", "concepts", "of", "delusion", "and", "analysing", "rational", "and", "intuitive", "cognition", ",", "the", "present", "phenomenological", "-", "conceptual", "study", "aims", "at", "defining", "the", "essential", "nature", "of", "delusion", ".", "Intuitive", "cognition", "as", "a", "result", "of", "holistic", "processing", "is", "founded", "in", "the", "development", "of", "polysensoric", "-", "kinaesthetic", "basic", "pictures", "(", "eidetic", "matrices", ")", ",", "which", "are", "recognized", "preverbally", "and", "prereflexively", "by", "subliminal", "perception", "of", "corresponding", "eidetic", "structures", ".", "A", "positive", "match", "between", "a", "matrix", "and", "a", "given", "phenomenon", "produces", "an", "eidetic", "feeling", ".", "This", "eidetic", "feeling", "encompasses", "three", "aspects", ".", "The", "first", "is", "a", "preverbal", "knowledge", "of", "something", "as", "something", "definite", ".", "As", "a", "direct", "self", "-", "reference", ",", "the", "second", "is", "the", "feeling", "of", "an", "object", "-", "inherent", "significance", "of", "the", "given", "phenomenon", "for", "the", "subject", "itself", ".", "Thirdly", ",", "a", "power", "vector", "is", "perceived", "to", "derive", "from", "the", "object", ".", "The", "application", "of", "this", "concept", "allows", "us", "to", "consider", "delusion", "as", "a", "disturbance", "in", "the", "system", "of", "holistic", "information", "processing", ".", "This", "disturbance", "is", "characterized", "by", "a", "disinhibition", "and", "actualization", "of", "eidetic", "matrices", "in", "different", "ways", ".", "The", "resulting", "eidetic", "feeling", "we", "call", "delusion", ";", "its", "expression", "in", "thoughts", "and", "words", "we", "call", "a", "delusional", "idea", ".", "All", "features", "of", "an", "eidetic", "feeling", "can", "be", "demonstrated", "in", "delusion", ".", "Owing", "to", "their", "special", "intensity", "and", "suspended", "reason", ",", "they", "mostly", "appear", "to", "be", "unique", ".", "The", "analysis", "of", "the", "eidetic", "structures", "of", "delusion", "allows", "a", "deeper", "understanding", "of", "delusion", "and", "facilitates", "both", "its", "diagnosis", "and", "its", "differentiation", ".", "Heterogeneous", "terms", ",", "such", "as", "delusional", "mood", ",", "idea", "of", "meaning", ",", "idea", "of", "reference", ",", "delusional", "notion", "and", "delusional", "perception", "emerge", "in", "an", "understandable", "context", "." ]
[ "umlsterm" ]
delusion is an umlsterm, cognition is an umlsterm, nature is an umlsterm, delusion is an umlsterm, cognition is an umlsterm, development is an umlsterm, subliminal perception is an umlsterm, feeling is an umlsterm, feeling is an umlsterm, knowledge is an umlsterm, direct is an umlsterm, self - reference is an umlsterm, feeling is an umlsterm, power is an umlsterm, delusion is an umlsterm, information processing is an umlsterm, feeling is an umlsterm, delusion is an umlsterm, delusional idea is an umlsterm, feeling is an umlsterm, delusion is an umlsterm, analysis is an umlsterm, delusion is an umlsterm, understanding is an umlsterm, delusion is an umlsterm, diagnosis is an umlsterm, mood is an umlsterm, perception is an umlsterm
DerNervenarzt.80690390.eng.abstr_task1
Sentence: Taking into account the different concepts of delusion and analysing rational and intuitive cognition , the present phenomenological-conceptual study aims at defining the essential nature of delusion . Intuitive cognition as a result of holistic processing is founded in the development of polysensoric-kinaesthetic basic pictures ( eidetic matrices ) , which are recognized preverbally and prereflexively by subliminal perception of corresponding eidetic structures . A positive match between a matrix and a given phenomenon produces an eidetic feeling . This eidetic feeling encompasses three aspects . The first is a preverbal knowledge of something as something definite . As a direct self-reference , the second is the feeling of an object-inherent significance of the given phenomenon for the subject itself . Thirdly , a power vector is perceived to derive from the object . The application of this concept allows us to consider delusion as a disturbance in the system of holistic information processing . This disturbance is characterized by a disinhibition and actualization of eidetic matrices in different ways . The resulting eidetic feeling we call delusion ; its expression in thoughts and words we call a delusional idea . All features of an eidetic feeling can be demonstrated in delusion . Owing to their special intensity and suspended reason , they mostly appear to be unique . The analysis of the eidetic structures of delusion allows a deeper understanding of delusion and facilitates both its diagnosis and its differentiation . Heterogeneous terms , such as delusional mood , idea of meaning , idea of reference , delusional notion and delusional perception emerge in an understandable context . Instructions: please typing these entity words according to sentence: delusion, cognition, nature, delusion, cognition, development, subliminal perception, feeling, feeling, knowledge, direct, self - reference, feeling, power, delusion, information processing, feeling, delusion, delusional idea, feeling, delusion, analysis, delusion, understanding, delusion, diagnosis, mood, perception Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Taking into account the different concepts of delusion and analysing rational and intuitive cognition , the present phenomenological-conceptual study aims at defining the essential nature of delusion . Intuitive cognition as a result of holistic processing is founded in the development of polysensoric-kinaesthetic basic pictures ( eidetic matrices ) , which are recognized preverbally and prereflexively by subliminal perception of corresponding eidetic structures . A positive match between a matrix and a given phenomenon produces an eidetic feeling . This eidetic feeling encompasses three aspects . The first is a preverbal knowledge of something as something definite . As a direct self-reference , the second is the feeling of an object-inherent significance of the given phenomenon for the subject itself . Thirdly , a power vector is perceived to derive from the object . The application of this concept allows us to consider delusion as a disturbance in the system of holistic information processing . This disturbance is characterized by a disinhibition and actualization of eidetic matrices in different ways . The resulting eidetic feeling we call delusion ; its expression in thoughts and words we call a delusional idea . All features of an eidetic feeling can be demonstrated in delusion . Owing to their special intensity and suspended reason , they mostly appear to be unique . The analysis of the eidetic structures of delusion allows a deeper understanding of delusion and facilitates both its diagnosis and its differentiation . Heterogeneous terms , such as delusional mood , idea of meaning , idea of reference , delusional notion and delusional perception emerge in an understandable context .
[ "Taking", "into", "account", "the", "different", "concepts", "of", "delusion", "and", "analysing", "rational", "and", "intuitive", "cognition", ",", "the", "present", "phenomenological", "-", "conceptual", "study", "aims", "at", "defining", "the", "essential", "nature", "of", "delusion", ".", "Intuitive", "cognition", "as", "a", "result", "of", "holistic", "processing", "is", "founded", "in", "the", "development", "of", "polysensoric", "-", "kinaesthetic", "basic", "pictures", "(", "eidetic", "matrices", ")", ",", "which", "are", "recognized", "preverbally", "and", "prereflexively", "by", "subliminal", "perception", "of", "corresponding", "eidetic", "structures", ".", "A", "positive", "match", "between", "a", "matrix", "and", "a", "given", "phenomenon", "produces", "an", "eidetic", "feeling", ".", "This", "eidetic", "feeling", "encompasses", "three", "aspects", ".", "The", "first", "is", "a", "preverbal", "knowledge", "of", "something", "as", "something", "definite", ".", "As", "a", "direct", "self", "-", "reference", ",", "the", "second", "is", "the", "feeling", "of", "an", "object", "-", "inherent", "significance", "of", "the", "given", "phenomenon", "for", "the", "subject", "itself", ".", "Thirdly", ",", "a", "power", "vector", "is", "perceived", "to", "derive", "from", "the", "object", ".", "The", "application", "of", "this", "concept", "allows", "us", "to", "consider", "delusion", "as", "a", "disturbance", "in", "the", "system", "of", "holistic", "information", "processing", ".", "This", "disturbance", "is", "characterized", "by", "a", "disinhibition", "and", "actualization", "of", "eidetic", "matrices", "in", "different", "ways", ".", "The", "resulting", "eidetic", "feeling", "we", "call", "delusion", ";", "its", "expression", "in", "thoughts", "and", "words", "we", "call", "a", "delusional", "idea", ".", "All", "features", "of", "an", "eidetic", "feeling", "can", "be", "demonstrated", "in", "delusion", ".", "Owing", "to", "their", "special", "intensity", "and", "suspended", "reason", ",", "they", "mostly", "appear", "to", "be", "unique", ".", "The", "analysis", "of", "the", "eidetic", "structures", "of", "delusion", "allows", "a", "deeper", "understanding", "of", "delusion", "and", "facilitates", "both", "its", "diagnosis", "and", "its", "differentiation", ".", "Heterogeneous", "terms", ",", "such", "as", "delusional", "mood", ",", "idea", "of", "meaning", ",", "idea", "of", "reference", ",", "delusional", "notion", "and", "delusional", "perception", "emerge", "in", "an", "understandable", "context", "." ]
[ "umlsterm" ]
delusion, cognition, nature, delusion, cognition, development, subliminal perception, feeling, feeling, knowledge, direct, self - reference, feeling, power, delusion, information processing, feeling, delusion, delusional idea, feeling, delusion, analysis, delusion, understanding, delusion, diagnosis, mood, perception
DerNervenarzt.80690390.eng.abstr_task2
Sentence: Taking into account the different concepts of delusion and analysing rational and intuitive cognition , the present phenomenological-conceptual study aims at defining the essential nature of delusion . Intuitive cognition as a result of holistic processing is founded in the development of polysensoric-kinaesthetic basic pictures ( eidetic matrices ) , which are recognized preverbally and prereflexively by subliminal perception of corresponding eidetic structures . A positive match between a matrix and a given phenomenon produces an eidetic feeling . This eidetic feeling encompasses three aspects . The first is a preverbal knowledge of something as something definite . As a direct self-reference , the second is the feeling of an object-inherent significance of the given phenomenon for the subject itself . Thirdly , a power vector is perceived to derive from the object . The application of this concept allows us to consider delusion as a disturbance in the system of holistic information processing . This disturbance is characterized by a disinhibition and actualization of eidetic matrices in different ways . The resulting eidetic feeling we call delusion ; its expression in thoughts and words we call a delusional idea . All features of an eidetic feeling can be demonstrated in delusion . Owing to their special intensity and suspended reason , they mostly appear to be unique . The analysis of the eidetic structures of delusion allows a deeper understanding of delusion and facilitates both its diagnosis and its differentiation . Heterogeneous terms , such as delusional mood , idea of meaning , idea of reference , delusional notion and delusional perception emerge in an understandable context . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Taking into account the different concepts of delusion and analysing rational and intuitive cognition , the present phenomenological-conceptual study aims at defining the essential nature of delusion . Intuitive cognition as a result of holistic processing is founded in the development of polysensoric-kinaesthetic basic pictures ( eidetic matrices ) , which are recognized preverbally and prereflexively by subliminal perception of corresponding eidetic structures . A positive match between a matrix and a given phenomenon produces an eidetic feeling . This eidetic feeling encompasses three aspects . The first is a preverbal knowledge of something as something definite . As a direct self-reference , the second is the feeling of an object-inherent significance of the given phenomenon for the subject itself . Thirdly , a power vector is perceived to derive from the object . The application of this concept allows us to consider delusion as a disturbance in the system of holistic information processing . This disturbance is characterized by a disinhibition and actualization of eidetic matrices in different ways . The resulting eidetic feeling we call delusion ; its expression in thoughts and words we call a delusional idea . All features of an eidetic feeling can be demonstrated in delusion . Owing to their special intensity and suspended reason , they mostly appear to be unique . The analysis of the eidetic structures of delusion allows a deeper understanding of delusion and facilitates both its diagnosis and its differentiation . Heterogeneous terms , such as delusional mood , idea of meaning , idea of reference , delusional notion and delusional perception emerge in an understandable context .
[ "Taking", "into", "account", "the", "different", "concepts", "of", "delusion", "and", "analysing", "rational", "and", "intuitive", "cognition", ",", "the", "present", "phenomenological", "-", "conceptual", "study", "aims", "at", "defining", "the", "essential", "nature", "of", "delusion", ".", "Intuitive", "cognition", "as", "a", "result", "of", "holistic", "processing", "is", "founded", "in", "the", "development", "of", "polysensoric", "-", "kinaesthetic", "basic", "pictures", "(", "eidetic", "matrices", ")", ",", "which", "are", "recognized", "preverbally", "and", "prereflexively", "by", "subliminal", "perception", "of", "corresponding", "eidetic", "structures", ".", "A", "positive", "match", "between", "a", "matrix", "and", "a", "given", "phenomenon", "produces", "an", "eidetic", "feeling", ".", "This", "eidetic", "feeling", "encompasses", "three", "aspects", ".", "The", "first", "is", "a", "preverbal", "knowledge", "of", "something", "as", "something", "definite", ".", "As", "a", "direct", "self", "-", "reference", ",", "the", "second", "is", "the", "feeling", "of", "an", "object", "-", "inherent", "significance", "of", "the", "given", "phenomenon", "for", "the", "subject", "itself", ".", "Thirdly", ",", "a", "power", "vector", "is", "perceived", "to", "derive", "from", "the", "object", ".", "The", "application", "of", "this", "concept", "allows", "us", "to", "consider", "delusion", "as", "a", "disturbance", "in", "the", "system", "of", "holistic", "information", "processing", ".", "This", "disturbance", "is", "characterized", "by", "a", "disinhibition", "and", "actualization", "of", "eidetic", "matrices", "in", "different", "ways", ".", "The", "resulting", "eidetic", "feeling", "we", "call", "delusion", ";", "its", "expression", "in", "thoughts", "and", "words", "we", "call", "a", "delusional", "idea", ".", "All", "features", "of", "an", "eidetic", "feeling", "can", "be", "demonstrated", "in", "delusion", ".", "Owing", "to", "their", "special", "intensity", "and", "suspended", "reason", ",", "they", "mostly", "appear", "to", "be", "unique", ".", "The", "analysis", "of", "the", "eidetic", "structures", "of", "delusion", "allows", "a", "deeper", "understanding", "of", "delusion", "and", "facilitates", "both", "its", "diagnosis", "and", "its", "differentiation", ".", "Heterogeneous", "terms", ",", "such", "as", "delusional", "mood", ",", "idea", "of", "meaning", ",", "idea", "of", "reference", ",", "delusional", "notion", "and", "delusional", "perception", "emerge", "in", "an", "understandable", "context", "." ]
[ "umlsterm" ]
tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoraciones is a MORFOLOGIA_NEOPLASIA, coriocarcinoma is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA, lesión hepática is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA
819_task0
Sentence: Anamnesis El caso comienza al ingresar en agosto de 2015, en el Servicio de Ginecología, una paciente de 22 años, recién llegada de Argelia. La paciente explica una clínica de dolor en fosa iliaca derecha y dispareunia de varios meses de evolución, así como tos hemoptoica. Refiere al ingreso que está de vacaciones. No obstante, finalmente confiesa que ya conocía parcialmente el diagnóstico y, sabiendo que el tratamiento le sería prácticamente imposible realizarlo en su país de origen, viaja a España para tratamiento. Se trata de una paciente sin alergias ni hábitos tóxicos. Como antecedentes, explica haber sufrido un embarazo molar en 2013 con legrado y seguimiento mediante B-HCG hasta normalización de niveles. Además, explica también que sufrió un aborto espontáneo con legrado en marzo de 2015, con metrorragias posteriores hasta julio sin estudios diagnósticos posteriores. Exploración física La paciente presenta un ECOG de 1 y constantes normales salvo una taquicardia en torno a 140 lpm persistente. La auscultación pulmonar y cardiaca no muestra alteraciones. No presenta focalidad neurológica alguna. Durante la exploración abdominal, refiere dolor a la presión en fosa iliaca derecha, aunque el abdomen es blando y depresible. No se aprecia sangrado vaginal, observando además un cérvix dentro de la normalidad. En cuanto al tacto vaginal, se palpa tumoración dolorosa al tacto en área izquierda del útero y en Douglas. Pruebas complementarias » Ecografía transvaginal: donde se aprecia un ovario izquierdo que ocupa área izquierda uterina y Douglas de 12 cm con múltiples formaciones quísticas en su interior. Se intenta tomar una biopsia de endometrio por aspiración que resulta fallida por estenosis cervical. » Estudio analítico de sangre donde destaca un dímero D de 1.200 ng/ml, una TSH < 0,01 uUI/ml y un FT4 de 3,2 ng/dl (lo que indica un hipertiroidismo marcado). Se incluye una bHCG que da un resultado de más de 225.000 mUI/ml. » Radiografía de tórax que muestra un infiltrado bilateral con una imagen nodular en pulmón derecho y un electrocardiograma que muestra taquicardia sinusal a 136 lpm. » Se realiza un cambio de adscripción a Oncología y se solicita body TC que informa de metástasis de enfermedad trofoblástica gestacional pulmonares bilaterales, hepáticas y renales, así como tumoraciones pélvicas quísticas septadas de probable origen anexial. Diagnóstico Se trata de una enfermedad trofoblástica gestacional de tipo coriocarcinoma avanzada de alto riesgo por el estadio IV al diagnóstico (enfermedad metastásica extrapulmonar), que predice resistencia a monoterapia, requiriendo la quimioterapia en combinación. Tratamiento El 31/08/2015 inicia tratamiento quimioterápico de "enfriamiento" mediante esquema con cisplatino-etopósido pues se ha visto que previo a EMA-CO mejora la supervivencia. El 01/09/2015 ingresa en la UCI por shock hipovolémico secundario a hemotórax en relación a sangrado de las metástasis pulmonares. Una vez estable, se decide continuar con el tratamiento quimioterápico el 01/09/2015 iniciando el C1 de esquema EMA-CO. La paciente presenta una evolución correcta y se mantiene estable, por lo que se traslada de nuevo a planta de hospitalización pese a precisar soporte transfusional. Aquí conviene hacer un inciso y explicar en qué consiste el esquema EMA-CO. Se trata de un esquema alternante en el que cada semana se alternan EMA y CO. EMA contiene etopósido 100 mg/m2 en infusión iv de 30 minutos D1 y D2 del ciclo, actinomicina D a dosis de 0,5 mg en bolo iv D1 y D2, y metotrexato a dosis de 300 mg/m2 en infusión iv durante 12 h D1 con rescate de ácido folínico 24 h tras comenzar la perfusión de metotrexato. La segunda parte del esquema o CO consiste en administrar D8 de cada ciclo vincristina a dosis de 1 mg/m2 iv en bolo (dosis máxima de 2 mg) y ciclofosfamida a dosis de 600 mg/m2 iv en infusión de 30 minutos. Lo recomendado es administrar ciclos hasta normalización de bHCG y, a partir de ese momento, administrar 3C más para consolidar. Una vez en planta de hospitalización, inicia una neutropenia febril con foco en el catéter central que obliga a retrasar el tratamiento. Además, se inicia pauta de factores estimulantes de colonias. El 21/09/2015 continúa con el tratamiento quimioterápico, pero el 23/09/2015 inicia cuadro de dolor agudo abdominal, visualizándose en TC urgente sangrado activo a nivel hepático que se puede embolizar sin incidencias pudiendo ser dada de alta transcurridos unos días. Tras todo lo ocurrido, se decide continuar el tratamiento programando ingresos para cada ciclo. Se administran en total 6C de EMA-CO recibiendo el último el 15/12/2015 presentando buena tolerancia en los ciclos sucesivos. Evolución La TC de valoración de respuesta posquimioterapia del 13/01/2016 muestra marcada disminución del tamaño de las metástasis, en relación a respuesta parcial (RP), sin signos de sangrado activo ni lesiones ocupantes de espacio de nueva aparición. Ante la respuesta por TC, se solicita PET-TC que informa de leve realce en la metástasis pulmonar de mayor tamaño, siendo el resto de lesiones pulmonares, la única hepática visualizada y la lesión renal no metabólicas. Con dichos resultados se presenta el caso en comité multidisciplinar para valorar un rescate quirúrgico de la lesión hepática y, en función de los resultados, de las metástasis pulmonares. El 13/04/2016 se realiza hepatectomía derecha (previa embolización). La anatomía patológica informa de la presencia de necrosis tumoral con ausencia de tumor viable. En las TC de seguimiento, se informa de disminución progresiva de las lesiones pulmonares, manteniéndose la respuesta parcial. En este momento, ante los resultados de anatomía patológica y los estudios de imagen, se considera a la paciente no candidata a cirugía de las lesiones pulmonares y se continúa el seguimiento con bHCG y pruebas de imagen. En cuanto a la dinámica de bHCG, al diagnóstico en agosto de 2015 presentaba unos niveles de 225.000 mUI/ml, que tras hemotórax se eleva hasta 817.000 mUI/ml, pero tras inicio de EMA-CO se produce un patrón de descenso rápido y sostenido en ciclos sucesivos, alcanzándose tras 3C de tratamiento niveles. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis El caso comienza al ingresar en agosto de 2015, en el Servicio de Ginecología, una paciente de 22 años, recién llegada de Argelia. La paciente explica una clínica de dolor en fosa iliaca derecha y dispareunia de varios meses de evolución, así como tos hemoptoica. Refiere al ingreso que está de vacaciones. No obstante, finalmente confiesa que ya conocía parcialmente el diagnóstico y, sabiendo que el tratamiento le sería prácticamente imposible realizarlo en su país de origen, viaja a España para tratamiento. Se trata de una paciente sin alergias ni hábitos tóxicos. Como antecedentes, explica haber sufrido un embarazo molar en 2013 con legrado y seguimiento mediante B-HCG hasta normalización de niveles. Además, explica también que sufrió un aborto espontáneo con legrado en marzo de 2015, con metrorragias posteriores hasta julio sin estudios diagnósticos posteriores. Exploración física La paciente presenta un ECOG de 1 y constantes normales salvo una taquicardia en torno a 140 lpm persistente. La auscultación pulmonar y cardiaca no muestra alteraciones. No presenta focalidad neurológica alguna. Durante la exploración abdominal, refiere dolor a la presión en fosa iliaca derecha, aunque el abdomen es blando y depresible. No se aprecia sangrado vaginal, observando además un cérvix dentro de la normalidad. En cuanto al tacto vaginal, se palpa tumoración dolorosa al tacto en área izquierda del útero y en Douglas. Pruebas complementarias » Ecografía transvaginal: donde se aprecia un ovario izquierdo que ocupa área izquierda uterina y Douglas de 12 cm con múltiples formaciones quísticas en su interior. Se intenta tomar una biopsia de endometrio por aspiración que resulta fallida por estenosis cervical. » Estudio analítico de sangre donde destaca un dímero D de 1.200 ng/ml, una TSH < 0,01 uUI/ml y un FT4 de 3,2 ng/dl (lo que indica un hipertiroidismo marcado). Se incluye una bHCG que da un resultado de más de 225.000 mUI/ml. » Radiografía de tórax que muestra un infiltrado bilateral con una imagen nodular en pulmón derecho y un electrocardiograma que muestra taquicardia sinusal a 136 lpm. » Se realiza un cambio de adscripción a Oncología y se solicita body TC que informa de metástasis de enfermedad trofoblástica gestacional pulmonares bilaterales, hepáticas y renales, así como tumoraciones pélvicas quísticas septadas de probable origen anexial. Diagnóstico Se trata de una enfermedad trofoblástica gestacional de tipo coriocarcinoma avanzada de alto riesgo por el estadio IV al diagnóstico (enfermedad metastásica extrapulmonar), que predice resistencia a monoterapia, requiriendo la quimioterapia en combinación. Tratamiento El 31/08/2015 inicia tratamiento quimioterápico de "enfriamiento" mediante esquema con cisplatino-etopósido pues se ha visto que previo a EMA-CO mejora la supervivencia. El 01/09/2015 ingresa en la UCI por shock hipovolémico secundario a hemotórax en relación a sangrado de las metástasis pulmonares. Una vez estable, se decide continuar con el tratamiento quimioterápico el 01/09/2015 iniciando el C1 de esquema EMA-CO. La paciente presenta una evolución correcta y se mantiene estable, por lo que se traslada de nuevo a planta de hospitalización pese a precisar soporte transfusional. Aquí conviene hacer un inciso y explicar en qué consiste el esquema EMA-CO. Se trata de un esquema alternante en el que cada semana se alternan EMA y CO. EMA contiene etopósido 100 mg/m2 en infusión iv de 30 minutos D1 y D2 del ciclo, actinomicina D a dosis de 0,5 mg en bolo iv D1 y D2, y metotrexato a dosis de 300 mg/m2 en infusión iv durante 12 h D1 con rescate de ácido folínico 24 h tras comenzar la perfusión de metotrexato. La segunda parte del esquema o CO consiste en administrar D8 de cada ciclo vincristina a dosis de 1 mg/m2 iv en bolo (dosis máxima de 2 mg) y ciclofosfamida a dosis de 600 mg/m2 iv en infusión de 30 minutos. Lo recomendado es administrar ciclos hasta normalización de bHCG y, a partir de ese momento, administrar 3C más para consolidar. Una vez en planta de hospitalización, inicia una neutropenia febril con foco en el catéter central que obliga a retrasar el tratamiento. Además, se inicia pauta de factores estimulantes de colonias. El 21/09/2015 continúa con el tratamiento quimioterápico, pero el 23/09/2015 inicia cuadro de dolor agudo abdominal, visualizándose en TC urgente sangrado activo a nivel hepático que se puede embolizar sin incidencias pudiendo ser dada de alta transcurridos unos días. Tras todo lo ocurrido, se decide continuar el tratamiento programando ingresos para cada ciclo. Se administran en total 6C de EMA-CO recibiendo el último el 15/12/2015 presentando buena tolerancia en los ciclos sucesivos. Evolución La TC de valoración de respuesta posquimioterapia del 13/01/2016 muestra marcada disminución del tamaño de las metástasis, en relación a respuesta parcial (RP), sin signos de sangrado activo ni lesiones ocupantes de espacio de nueva aparición. Ante la respuesta por TC, se solicita PET-TC que informa de leve realce en la metástasis pulmonar de mayor tamaño, siendo el resto de lesiones pulmonares, la única hepática visualizada y la lesión renal no metabólicas. Con dichos resultados se presenta el caso en comité multidisciplinar para valorar un rescate quirúrgico de la lesión hepática y, en función de los resultados, de las metástasis pulmonares. El 13/04/2016 se realiza hepatectomía derecha (previa embolización). La anatomía patológica informa de la presencia de necrosis tumoral con ausencia de tumor viable. En las TC de seguimiento, se informa de disminución progresiva de las lesiones pulmonares, manteniéndose la respuesta parcial. En este momento, ante los resultados de anatomía patológica y los estudios de imagen, se considera a la paciente no candidata a cirugía de las lesiones pulmonares y se continúa el seguimiento con bHCG y pruebas de imagen. En cuanto a la dinámica de bHCG, al diagnóstico en agosto de 2015 presentaba unos niveles de 225.000 mUI/ml, que tras hemotórax se eleva hasta 817.000 mUI/ml, pero tras inicio de EMA-CO se produce un patrón de descenso rápido y sostenido en ciclos sucesivos, alcanzándose tras 3C de tratamiento niveles.
[ "Anamnesis", "\n", "El", "caso", "comienza", "al", "ingresar", "en", "agosto", "de", "2015", ",", "en", "el", "Servicio", "de", "Ginecología", ",", "una", "paciente", "de", "22", "años", ",", "recién", "llegada", "de", "Argelia", ".", "La", "paciente", "explica", "una", "clínica", "de", "dolor", "en", "fosa", "iliaca", "derecha", "y", "dispareunia", "de", "varios", "meses", "de", "evolución", ",", "así", "como", "tos", "hemoptoica", ".", "Refiere", "al", "ingreso", "que", "está", "de", "vacaciones", ".", "No", "obstante", ",", "finalmente", "confiesa", "que", "ya", "conocía", "parcialmente", "el", "diagnóstico", "y", ",", "sabiendo", "que", "el", "tratamiento", "le", "sería", "prácticamente", "imposible", "realizarlo", "en", "su", "país", "de", "origen", ",", "viaja", "a", "España", "para", "tratamiento", ".", "\n", "Se", "trata", "de", "una", "paciente", "sin", "alergias", "ni", "hábitos", "tóxicos", ".", "Como", "antecedentes", ",", "explica", "haber", "sufrido", "un", "embarazo", "molar", "en", "2013", "con", "legrado", "y", "seguimiento", "mediante", "B", "-", "HCG", "hasta", "normalización", "de", "niveles", ".", "Además", ",", "explica", "también", "que", "sufrió", "un", "aborto", "espontáneo", "con", "legrado", "en", "marzo", "de", "2015", ",", "con", "metrorragias", "posteriores", "hasta", "julio", "sin", "estudios", "diagnósticos", "posteriores", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "presenta", "un", "ECOG", "de", "1", "y", "constantes", "normales", "salvo", "una", "taquicardia", "en", "torno", "a", "140", "lpm", "persistente", ".", "La", "auscultación", "pulmonar", "y", "cardiaca", "no", "muestra", "alteraciones", ".", "No", "presenta", "focalidad", "neurológica", "alguna", ".", "Durante", "la", "exploración", "abdominal", ",", "refiere", "dolor", "a", "la", "presión", "en", "fosa", "iliaca", "derecha", ",", "aunque", "el", "abdomen", "es", "blando", "y", "depresible", ".", "No", "se", "aprecia", "sangrado", "vaginal", ",", "observando", "además", "un", "cérvix", "dentro", "de", "la", "normalidad", ".", "En", "cuanto", "al", "tacto", "vaginal", ",", "se", "palpa", "tumoración", "dolorosa", "al", "tacto", "en", "área", "izquierda", "del", "útero", "y", "en", "Douglas", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Ecografía", "transvaginal", ":", "donde", "se", "aprecia", "un", "ovario", "izquierdo", "que", "ocupa", "área", "izquierda", "uterina", "y", "Douglas", "de", "12", "cm", "con", "múltiples", "formaciones", "quísticas", "en", "su", "interior", ".", "Se", "intenta", "tomar", "una", "biopsia", "de", "endometrio", "por", "aspiración", "que", "resulta", "fallida", "por", "estenosis", "cervical", ".", "\n", "»", "Estudio", "analítico", "de", "sangre", "donde", "destaca", "un", "dímero", "D", "de", "1.200", "ng", "/", "ml", ",", "una", "TSH", "<", "0,01", "uUI", "/", "ml", "y", "un", "FT4", "de", "3,2", "ng", "/", "dl", "(", "lo", "que", "indica", "un", "hipertiroidismo", "marcado", ")", ".", "Se", "incluye", "una", "bHCG", "que", "da", "un", "resultado", "de", "más", "de", "225.000", "mUI", "/", "ml", ".", "\n", "»", "Radiografía", "de", "tórax", "que", "muestra", "un", "infiltrado", "bilateral", "con", "una", "imagen", "nodular", "en", "pulmón", "derecho", "y", "un", "electrocardiograma", "que", "muestra", "taquicardia", "sinusal", "a", "136", "lpm", ".", "\n", "»", "Se", "realiza", "un", "cambio", "de", "adscripción", "a", "Oncología", "y", "se", "solicita", "body", "TC", "que", "informa", "de", "metástasis", "de", "enfermedad", "trofoblástica", "gestacional", "pulmonares", "bilaterales", ",", "hepáticas", "y", "renales", ",", "así", "como", "tumoraciones", "pélvicas", "quísticas", "septadas", "de", "probable", "origen", "anexial", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "una", "enfermedad", "trofoblástica", "gestacional", "de", "tipo", "coriocarcinoma", "avanzada", "de", "alto", "riesgo", "por", "el", "estadio", "IV", "al", "diagnóstico", "(", "enfermedad", "metastásica", "extrapulmonar", ")", ",", "que", "predice", "resistencia", "a", "monoterapia", ",", "requiriendo", "la", "quimioterapia", "en", "combinación", ".", "\n\n", "Tratamiento", "\n", "El", "31/08/2015", "inicia", "tratamiento", "quimioterápico", "de", "\"", "enfriamiento", "\"", "mediante", "esquema", "con", "cisplatino", "-", "etopósido", "pues", "se", "ha", "visto", "que", "previo", "a", "EMA", "-", "CO", "mejora", "la", "supervivencia", ".", "El", "01/09/2015", "ingresa", "en", "la", "UCI", "por", "shock", "hipovolémico", "secundario", "a", "hemotórax", "en", "relación", "a", "sangrado", "de", "las", "metástasis", "pulmonares", ".", "Una", "vez", "estable", ",", "se", "decide", "continuar", "con", "el", "tratamiento", "quimioterápico", "el", "01/09/2015", "iniciando", "el", "C1", "de", "esquema", "EMA", "-", "CO", ".", "La", "paciente", "presenta", "una", "evolución", "correcta", "y", "se", "mantiene", "estable", ",", "por", "lo", "que", "se", "traslada", "de", "nuevo", "a", "planta", "de", "hospitalización", "pese", "a", "precisar", "soporte", "transfusional", ".", "\n", "Aquí", "conviene", "hacer", "un", "inciso", "y", "explicar", "en", "qué", "consiste", "el", "esquema", "EMA", "-", "CO", ".", "Se", "trata", "de", "un", "esquema", "alternante", "en", "el", "que", "cada", "semana", "se", "alternan", "EMA", "y", "CO", ".", "EMA", "contiene", "etopósido", "100", "mg", "/", "m2", "en", "infusión", "iv", "de", "30", "minutos", "D1", "y", "D2", "del", "ciclo", ",", "actinomicina", "D", "a", "dosis", "de", "0,5", "mg", "en", "bolo", "iv", "D1", "y", "D2", ",", "y", "metotrexato", "a", "dosis", "de", "300", "mg", "/", "m2", "en", "infusión", "iv", "durante", "12", "h", "D1", "con", "rescate", "de", "ácido", "folínico", "24", "h", "tras", "comenzar", "la", "perfusión", "de", "metotrexato", ".", "La", "segunda", "parte", "del", "esquema", "o", "CO", "consiste", "en", "administrar", "D8", "de", "cada", "ciclo", "vincristina", "a", "dosis", "de", "1", "mg", "/", "m2", "iv", "en", "bolo", "(", "dosis", "máxima", "de", "2", "mg", ")", "y", "ciclofosfamida", "a", "dosis", "de", "600", "mg", "/", "m2", "iv", "en", "infusión", "de", "30", "minutos", ".", "Lo", "recomendado", "es", "administrar", "ciclos", "hasta", "normalización", "de", "bHCG", "y", ",", "a", "partir", "de", "ese", "momento", ",", "administrar", "3C", "más", "para", "consolidar", ".", "\n", "Una", "vez", "en", "planta", "de", "hospitalización", ",", "inicia", "una", "neutropenia", "febril", "con", "foco", "en", "el", "catéter", "central", "que", "obliga", "a", "retrasar", "el", "tratamiento", ".", "Además", ",", "se", "inicia", "pauta", "de", "factores", "estimulantes", "de", "colonias", ".", "\n", "El", "21/09/2015", "continúa", "con", "el", "tratamiento", "quimioterápico", ",", "pero", "el", "23/09/2015", "inicia", "cuadro", "de", "dolor", "agudo", "abdominal", ",", "visualizándose", "en", "TC", "urgente", "sangrado", "activo", "a", "nivel", "hepático", "que", "se", "puede", "embolizar", "sin", "incidencias", "pudiendo", "ser", "dada", "de", "alta", "transcurridos", "unos", "días", ".", "\n", "Tras", "todo", "lo", "ocurrido", ",", "se", "decide", "continuar", "el", "tratamiento", "programando", "ingresos", "para", "cada", "ciclo", ".", "Se", "administran", "en", "total", "6C", "de", "EMA", "-", "CO", "recibiendo", "el", "último", "el", "15/12/2015", "presentando", "buena", "tolerancia", "en", "los", "ciclos", "sucesivos", ".", "\n\n", "Evolución", "\n", "La", "TC", "de", "valoración", "de", "respuesta", "posquimioterapia", "del", "13/01/2016", "muestra", "marcada", "disminución", "del", "tamaño", "de", "las", "metástasis", ",", "en", "relación", "a", "respuesta", "parcial", "(", "RP", ")", ",", "sin", "signos", "de", "sangrado", "activo", "ni", "lesiones", "ocupantes", "de", "espacio", "de", "nueva", "aparición", ".", "Ante", "la", "respuesta", "por", "TC", ",", "se", "solicita", "PET", "-", "TC", "que", "informa", "de", "leve", "realce", "en", "la", "metástasis", "pulmonar", "de", "mayor", "tamaño", ",", "siendo", "el", "resto", "de", "lesiones", "pulmonares", ",", "la", "única", "hepática", "visualizada", "y", "la", "lesión", "renal", "no", "metabólicas", ".", "\n", "Con", "dichos", "resultados", "se", "presenta", "el", "caso", "en", "comité", "multidisciplinar", "para", "valorar", "un", "rescate", "quirúrgico", "de", "la", "lesión", "hepática", "y", ",", "en", "función", "de", "los", "resultados", ",", "de", "las", "metástasis", "pulmonares", ".", "El", "13/04/2016", "se", "realiza", "hepatectomía", "derecha", "(", "previa", "embolización", ")", ".", "La", "anatomía", "patológica", "informa", "de", "la", "presencia", "de", "necrosis", "tumoral", "con", "ausencia", "de", "tumor", "viable", ".", "\n", "En", "las", "TC", "de", "seguimiento", ",", "se", "informa", "de", "disminución", "progresiva", "de", "las", "lesiones", "pulmonares", ",", "manteniéndose", "la", "respuesta", "parcial", ".", "\n", "En", "este", "momento", ",", "ante", "los", "resultados", "de", "anatomía", "patológica", "y", "los", "estudios", "de", "imagen", ",", "se", "considera", "a", "la", "paciente", "no", "candidata", "a", "cirugía", "de", "las", "lesiones", "pulmonares", "y", "se", "continúa", "el", "seguimiento", "con", "bHCG", "y", "pruebas", "de", "imagen", ".", "\n", "En", "cuanto", "a", "la", "dinámica", "de", "bHCG", ",", "al", "diagnóstico", "en", "agosto", "de", "2015", "presentaba", "unos", "niveles", "de", "\n", "225.000", "mUI", "/", "ml", ",", "que", "tras", "hemotórax", "se", "eleva", "hasta", "817.000", "mUI", "/", "ml", ",", "pero", "tras", "inicio", "de", "EMA", "-", "CO", "se", "produce", "un", "patrón", "de", "descenso", "rápido", "y", "sostenido", "en", "ciclos", "sucesivos", ",", "alcanzándose", "tras", "3C", "de", "tratamiento", "niveles", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
tumoración is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoraciones is a MORFOLOGIA_NEOPLASIA, coriocarcinoma is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA, lesión hepática is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA
819_task1
Sentence: Anamnesis El caso comienza al ingresar en agosto de 2015, en el Servicio de Ginecología, una paciente de 22 años, recién llegada de Argelia. La paciente explica una clínica de dolor en fosa iliaca derecha y dispareunia de varios meses de evolución, así como tos hemoptoica. Refiere al ingreso que está de vacaciones. No obstante, finalmente confiesa que ya conocía parcialmente el diagnóstico y, sabiendo que el tratamiento le sería prácticamente imposible realizarlo en su país de origen, viaja a España para tratamiento. Se trata de una paciente sin alergias ni hábitos tóxicos. Como antecedentes, explica haber sufrido un embarazo molar en 2013 con legrado y seguimiento mediante B-HCG hasta normalización de niveles. Además, explica también que sufrió un aborto espontáneo con legrado en marzo de 2015, con metrorragias posteriores hasta julio sin estudios diagnósticos posteriores. Exploración física La paciente presenta un ECOG de 1 y constantes normales salvo una taquicardia en torno a 140 lpm persistente. La auscultación pulmonar y cardiaca no muestra alteraciones. No presenta focalidad neurológica alguna. Durante la exploración abdominal, refiere dolor a la presión en fosa iliaca derecha, aunque el abdomen es blando y depresible. No se aprecia sangrado vaginal, observando además un cérvix dentro de la normalidad. En cuanto al tacto vaginal, se palpa tumoración dolorosa al tacto en área izquierda del útero y en Douglas. Pruebas complementarias » Ecografía transvaginal: donde se aprecia un ovario izquierdo que ocupa área izquierda uterina y Douglas de 12 cm con múltiples formaciones quísticas en su interior. Se intenta tomar una biopsia de endometrio por aspiración que resulta fallida por estenosis cervical. » Estudio analítico de sangre donde destaca un dímero D de 1.200 ng/ml, una TSH < 0,01 uUI/ml y un FT4 de 3,2 ng/dl (lo que indica un hipertiroidismo marcado). Se incluye una bHCG que da un resultado de más de 225.000 mUI/ml. » Radiografía de tórax que muestra un infiltrado bilateral con una imagen nodular en pulmón derecho y un electrocardiograma que muestra taquicardia sinusal a 136 lpm. » Se realiza un cambio de adscripción a Oncología y se solicita body TC que informa de metástasis de enfermedad trofoblástica gestacional pulmonares bilaterales, hepáticas y renales, así como tumoraciones pélvicas quísticas septadas de probable origen anexial. Diagnóstico Se trata de una enfermedad trofoblástica gestacional de tipo coriocarcinoma avanzada de alto riesgo por el estadio IV al diagnóstico (enfermedad metastásica extrapulmonar), que predice resistencia a monoterapia, requiriendo la quimioterapia en combinación. Tratamiento El 31/08/2015 inicia tratamiento quimioterápico de "enfriamiento" mediante esquema con cisplatino-etopósido pues se ha visto que previo a EMA-CO mejora la supervivencia. El 01/09/2015 ingresa en la UCI por shock hipovolémico secundario a hemotórax en relación a sangrado de las metástasis pulmonares. Una vez estable, se decide continuar con el tratamiento quimioterápico el 01/09/2015 iniciando el C1 de esquema EMA-CO. La paciente presenta una evolución correcta y se mantiene estable, por lo que se traslada de nuevo a planta de hospitalización pese a precisar soporte transfusional. Aquí conviene hacer un inciso y explicar en qué consiste el esquema EMA-CO. Se trata de un esquema alternante en el que cada semana se alternan EMA y CO. EMA contiene etopósido 100 mg/m2 en infusión iv de 30 minutos D1 y D2 del ciclo, actinomicina D a dosis de 0,5 mg en bolo iv D1 y D2, y metotrexato a dosis de 300 mg/m2 en infusión iv durante 12 h D1 con rescate de ácido folínico 24 h tras comenzar la perfusión de metotrexato. La segunda parte del esquema o CO consiste en administrar D8 de cada ciclo vincristina a dosis de 1 mg/m2 iv en bolo (dosis máxima de 2 mg) y ciclofosfamida a dosis de 600 mg/m2 iv en infusión de 30 minutos. Lo recomendado es administrar ciclos hasta normalización de bHCG y, a partir de ese momento, administrar 3C más para consolidar. Una vez en planta de hospitalización, inicia una neutropenia febril con foco en el catéter central que obliga a retrasar el tratamiento. Además, se inicia pauta de factores estimulantes de colonias. El 21/09/2015 continúa con el tratamiento quimioterápico, pero el 23/09/2015 inicia cuadro de dolor agudo abdominal, visualizándose en TC urgente sangrado activo a nivel hepático que se puede embolizar sin incidencias pudiendo ser dada de alta transcurridos unos días. Tras todo lo ocurrido, se decide continuar el tratamiento programando ingresos para cada ciclo. Se administran en total 6C de EMA-CO recibiendo el último el 15/12/2015 presentando buena tolerancia en los ciclos sucesivos. Evolución La TC de valoración de respuesta posquimioterapia del 13/01/2016 muestra marcada disminución del tamaño de las metástasis, en relación a respuesta parcial (RP), sin signos de sangrado activo ni lesiones ocupantes de espacio de nueva aparición. Ante la respuesta por TC, se solicita PET-TC que informa de leve realce en la metástasis pulmonar de mayor tamaño, siendo el resto de lesiones pulmonares, la única hepática visualizada y la lesión renal no metabólicas. Con dichos resultados se presenta el caso en comité multidisciplinar para valorar un rescate quirúrgico de la lesión hepática y, en función de los resultados, de las metástasis pulmonares. El 13/04/2016 se realiza hepatectomía derecha (previa embolización). La anatomía patológica informa de la presencia de necrosis tumoral con ausencia de tumor viable. En las TC de seguimiento, se informa de disminución progresiva de las lesiones pulmonares, manteniéndose la respuesta parcial. En este momento, ante los resultados de anatomía patológica y los estudios de imagen, se considera a la paciente no candidata a cirugía de las lesiones pulmonares y se continúa el seguimiento con bHCG y pruebas de imagen. En cuanto a la dinámica de bHCG, al diagnóstico en agosto de 2015 presentaba unos niveles de 225.000 mUI/ml, que tras hemotórax se eleva hasta 817.000 mUI/ml, pero tras inicio de EMA-CO se produce un patrón de descenso rápido y sostenido en ciclos sucesivos, alcanzándose tras 3C de tratamiento niveles. Instructions: please typing these entity words according to sentence: tumoración, metástasis, tumoraciones, coriocarcinoma, metastásica, metástasis, metástasis, metástasis, lesiones pulmonares, lesión hepática, metástasis, tumoral, tumor, lesiones pulmonares, lesiones pulmonares Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis El caso comienza al ingresar en agosto de 2015, en el Servicio de Ginecología, una paciente de 22 años, recién llegada de Argelia. La paciente explica una clínica de dolor en fosa iliaca derecha y dispareunia de varios meses de evolución, así como tos hemoptoica. Refiere al ingreso que está de vacaciones. No obstante, finalmente confiesa que ya conocía parcialmente el diagnóstico y, sabiendo que el tratamiento le sería prácticamente imposible realizarlo en su país de origen, viaja a España para tratamiento. Se trata de una paciente sin alergias ni hábitos tóxicos. Como antecedentes, explica haber sufrido un embarazo molar en 2013 con legrado y seguimiento mediante B-HCG hasta normalización de niveles. Además, explica también que sufrió un aborto espontáneo con legrado en marzo de 2015, con metrorragias posteriores hasta julio sin estudios diagnósticos posteriores. Exploración física La paciente presenta un ECOG de 1 y constantes normales salvo una taquicardia en torno a 140 lpm persistente. La auscultación pulmonar y cardiaca no muestra alteraciones. No presenta focalidad neurológica alguna. Durante la exploración abdominal, refiere dolor a la presión en fosa iliaca derecha, aunque el abdomen es blando y depresible. No se aprecia sangrado vaginal, observando además un cérvix dentro de la normalidad. En cuanto al tacto vaginal, se palpa tumoración dolorosa al tacto en área izquierda del útero y en Douglas. Pruebas complementarias » Ecografía transvaginal: donde se aprecia un ovario izquierdo que ocupa área izquierda uterina y Douglas de 12 cm con múltiples formaciones quísticas en su interior. Se intenta tomar una biopsia de endometrio por aspiración que resulta fallida por estenosis cervical. » Estudio analítico de sangre donde destaca un dímero D de 1.200 ng/ml, una TSH < 0,01 uUI/ml y un FT4 de 3,2 ng/dl (lo que indica un hipertiroidismo marcado). Se incluye una bHCG que da un resultado de más de 225.000 mUI/ml. » Radiografía de tórax que muestra un infiltrado bilateral con una imagen nodular en pulmón derecho y un electrocardiograma que muestra taquicardia sinusal a 136 lpm. » Se realiza un cambio de adscripción a Oncología y se solicita body TC que informa de metástasis de enfermedad trofoblástica gestacional pulmonares bilaterales, hepáticas y renales, así como tumoraciones pélvicas quísticas septadas de probable origen anexial. Diagnóstico Se trata de una enfermedad trofoblástica gestacional de tipo coriocarcinoma avanzada de alto riesgo por el estadio IV al diagnóstico (enfermedad metastásica extrapulmonar), que predice resistencia a monoterapia, requiriendo la quimioterapia en combinación. Tratamiento El 31/08/2015 inicia tratamiento quimioterápico de "enfriamiento" mediante esquema con cisplatino-etopósido pues se ha visto que previo a EMA-CO mejora la supervivencia. El 01/09/2015 ingresa en la UCI por shock hipovolémico secundario a hemotórax en relación a sangrado de las metástasis pulmonares. Una vez estable, se decide continuar con el tratamiento quimioterápico el 01/09/2015 iniciando el C1 de esquema EMA-CO. La paciente presenta una evolución correcta y se mantiene estable, por lo que se traslada de nuevo a planta de hospitalización pese a precisar soporte transfusional. Aquí conviene hacer un inciso y explicar en qué consiste el esquema EMA-CO. Se trata de un esquema alternante en el que cada semana se alternan EMA y CO. EMA contiene etopósido 100 mg/m2 en infusión iv de 30 minutos D1 y D2 del ciclo, actinomicina D a dosis de 0,5 mg en bolo iv D1 y D2, y metotrexato a dosis de 300 mg/m2 en infusión iv durante 12 h D1 con rescate de ácido folínico 24 h tras comenzar la perfusión de metotrexato. La segunda parte del esquema o CO consiste en administrar D8 de cada ciclo vincristina a dosis de 1 mg/m2 iv en bolo (dosis máxima de 2 mg) y ciclofosfamida a dosis de 600 mg/m2 iv en infusión de 30 minutos. Lo recomendado es administrar ciclos hasta normalización de bHCG y, a partir de ese momento, administrar 3C más para consolidar. Una vez en planta de hospitalización, inicia una neutropenia febril con foco en el catéter central que obliga a retrasar el tratamiento. Además, se inicia pauta de factores estimulantes de colonias. El 21/09/2015 continúa con el tratamiento quimioterápico, pero el 23/09/2015 inicia cuadro de dolor agudo abdominal, visualizándose en TC urgente sangrado activo a nivel hepático que se puede embolizar sin incidencias pudiendo ser dada de alta transcurridos unos días. Tras todo lo ocurrido, se decide continuar el tratamiento programando ingresos para cada ciclo. Se administran en total 6C de EMA-CO recibiendo el último el 15/12/2015 presentando buena tolerancia en los ciclos sucesivos. Evolución La TC de valoración de respuesta posquimioterapia del 13/01/2016 muestra marcada disminución del tamaño de las metástasis, en relación a respuesta parcial (RP), sin signos de sangrado activo ni lesiones ocupantes de espacio de nueva aparición. Ante la respuesta por TC, se solicita PET-TC que informa de leve realce en la metástasis pulmonar de mayor tamaño, siendo el resto de lesiones pulmonares, la única hepática visualizada y la lesión renal no metabólicas. Con dichos resultados se presenta el caso en comité multidisciplinar para valorar un rescate quirúrgico de la lesión hepática y, en función de los resultados, de las metástasis pulmonares. El 13/04/2016 se realiza hepatectomía derecha (previa embolización). La anatomía patológica informa de la presencia de necrosis tumoral con ausencia de tumor viable. En las TC de seguimiento, se informa de disminución progresiva de las lesiones pulmonares, manteniéndose la respuesta parcial. En este momento, ante los resultados de anatomía patológica y los estudios de imagen, se considera a la paciente no candidata a cirugía de las lesiones pulmonares y se continúa el seguimiento con bHCG y pruebas de imagen. En cuanto a la dinámica de bHCG, al diagnóstico en agosto de 2015 presentaba unos niveles de 225.000 mUI/ml, que tras hemotórax se eleva hasta 817.000 mUI/ml, pero tras inicio de EMA-CO se produce un patrón de descenso rápido y sostenido en ciclos sucesivos, alcanzándose tras 3C de tratamiento niveles.
[ "Anamnesis", "\n", "El", "caso", "comienza", "al", "ingresar", "en", "agosto", "de", "2015", ",", "en", "el", "Servicio", "de", "Ginecología", ",", "una", "paciente", "de", "22", "años", ",", "recién", "llegada", "de", "Argelia", ".", "La", "paciente", "explica", "una", "clínica", "de", "dolor", "en", "fosa", "iliaca", "derecha", "y", "dispareunia", "de", "varios", "meses", "de", "evolución", ",", "así", "como", "tos", "hemoptoica", ".", "Refiere", "al", "ingreso", "que", "está", "de", "vacaciones", ".", "No", "obstante", ",", "finalmente", "confiesa", "que", "ya", "conocía", "parcialmente", "el", "diagnóstico", "y", ",", "sabiendo", "que", "el", "tratamiento", "le", "sería", "prácticamente", "imposible", "realizarlo", "en", "su", "país", "de", "origen", ",", "viaja", "a", "España", "para", "tratamiento", ".", "\n", "Se", "trata", "de", "una", "paciente", "sin", "alergias", "ni", "hábitos", "tóxicos", ".", "Como", "antecedentes", ",", "explica", "haber", "sufrido", "un", "embarazo", "molar", "en", "2013", "con", "legrado", "y", "seguimiento", "mediante", "B", "-", "HCG", "hasta", "normalización", "de", "niveles", ".", "Además", ",", "explica", "también", "que", "sufrió", "un", "aborto", "espontáneo", "con", "legrado", "en", "marzo", "de", "2015", ",", "con", "metrorragias", "posteriores", "hasta", "julio", "sin", "estudios", "diagnósticos", "posteriores", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "presenta", "un", "ECOG", "de", "1", "y", "constantes", "normales", "salvo", "una", "taquicardia", "en", "torno", "a", "140", "lpm", "persistente", ".", "La", "auscultación", "pulmonar", "y", "cardiaca", "no", "muestra", "alteraciones", ".", "No", "presenta", "focalidad", "neurológica", "alguna", ".", "Durante", "la", "exploración", "abdominal", ",", "refiere", "dolor", "a", "la", "presión", "en", "fosa", "iliaca", "derecha", ",", "aunque", "el", "abdomen", "es", "blando", "y", "depresible", ".", "No", "se", "aprecia", "sangrado", "vaginal", ",", "observando", "además", "un", "cérvix", "dentro", "de", "la", "normalidad", ".", "En", "cuanto", "al", "tacto", "vaginal", ",", "se", "palpa", "tumoración", "dolorosa", "al", "tacto", "en", "área", "izquierda", "del", "útero", "y", "en", "Douglas", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Ecografía", "transvaginal", ":", "donde", "se", "aprecia", "un", "ovario", "izquierdo", "que", "ocupa", "área", "izquierda", "uterina", "y", "Douglas", "de", "12", "cm", "con", "múltiples", "formaciones", "quísticas", "en", "su", "interior", ".", "Se", "intenta", "tomar", "una", "biopsia", "de", "endometrio", "por", "aspiración", "que", "resulta", "fallida", "por", "estenosis", "cervical", ".", "\n", "»", "Estudio", "analítico", "de", "sangre", "donde", "destaca", "un", "dímero", "D", "de", "1.200", "ng", "/", "ml", ",", "una", "TSH", "<", "0,01", "uUI", "/", "ml", "y", "un", "FT4", "de", "3,2", "ng", "/", "dl", "(", "lo", "que", "indica", "un", "hipertiroidismo", "marcado", ")", ".", "Se", "incluye", "una", "bHCG", "que", "da", "un", "resultado", "de", "más", "de", "225.000", "mUI", "/", "ml", ".", "\n", "»", "Radiografía", "de", "tórax", "que", "muestra", "un", "infiltrado", "bilateral", "con", "una", "imagen", "nodular", "en", "pulmón", "derecho", "y", "un", "electrocardiograma", "que", "muestra", "taquicardia", "sinusal", "a", "136", "lpm", ".", "\n", "»", "Se", "realiza", "un", "cambio", "de", "adscripción", "a", "Oncología", "y", "se", "solicita", "body", "TC", "que", "informa", "de", "metástasis", "de", "enfermedad", "trofoblástica", "gestacional", "pulmonares", "bilaterales", ",", "hepáticas", "y", "renales", ",", "así", "como", "tumoraciones", "pélvicas", "quísticas", "septadas", "de", "probable", "origen", "anexial", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "una", "enfermedad", "trofoblástica", "gestacional", "de", "tipo", "coriocarcinoma", "avanzada", "de", "alto", "riesgo", "por", "el", "estadio", "IV", "al", "diagnóstico", "(", "enfermedad", "metastásica", "extrapulmonar", ")", ",", "que", "predice", "resistencia", "a", "monoterapia", ",", "requiriendo", "la", "quimioterapia", "en", "combinación", ".", "\n\n", "Tratamiento", "\n", "El", "31/08/2015", "inicia", "tratamiento", "quimioterápico", "de", "\"", "enfriamiento", "\"", "mediante", "esquema", "con", "cisplatino", "-", "etopósido", "pues", "se", "ha", "visto", "que", "previo", "a", "EMA", "-", "CO", "mejora", "la", "supervivencia", ".", "El", "01/09/2015", "ingresa", "en", "la", "UCI", "por", "shock", "hipovolémico", "secundario", "a", "hemotórax", "en", "relación", "a", "sangrado", "de", "las", "metástasis", "pulmonares", ".", "Una", "vez", "estable", ",", "se", "decide", "continuar", "con", "el", "tratamiento", "quimioterápico", "el", "01/09/2015", "iniciando", "el", "C1", "de", "esquema", "EMA", "-", "CO", ".", "La", "paciente", "presenta", "una", "evolución", "correcta", "y", "se", "mantiene", "estable", ",", "por", "lo", "que", "se", "traslada", "de", "nuevo", "a", "planta", "de", "hospitalización", "pese", "a", "precisar", "soporte", "transfusional", ".", "\n", "Aquí", "conviene", "hacer", "un", "inciso", "y", "explicar", "en", "qué", "consiste", "el", "esquema", "EMA", "-", "CO", ".", "Se", "trata", "de", "un", "esquema", "alternante", "en", "el", "que", "cada", "semana", "se", "alternan", "EMA", "y", "CO", ".", "EMA", "contiene", "etopósido", "100", "mg", "/", "m2", "en", "infusión", "iv", "de", "30", "minutos", "D1", "y", "D2", "del", "ciclo", ",", "actinomicina", "D", "a", "dosis", "de", "0,5", "mg", "en", "bolo", "iv", "D1", "y", "D2", ",", "y", "metotrexato", "a", "dosis", "de", "300", "mg", "/", "m2", "en", "infusión", "iv", "durante", "12", "h", "D1", "con", "rescate", "de", "ácido", "folínico", "24", "h", "tras", "comenzar", "la", "perfusión", "de", "metotrexato", ".", "La", "segunda", "parte", "del", "esquema", "o", "CO", "consiste", "en", "administrar", "D8", "de", "cada", "ciclo", "vincristina", "a", "dosis", "de", "1", "mg", "/", "m2", "iv", "en", "bolo", "(", "dosis", "máxima", "de", "2", "mg", ")", "y", "ciclofosfamida", "a", "dosis", "de", "600", "mg", "/", "m2", "iv", "en", "infusión", "de", "30", "minutos", ".", "Lo", "recomendado", "es", "administrar", "ciclos", "hasta", "normalización", "de", "bHCG", "y", ",", "a", "partir", "de", "ese", "momento", ",", "administrar", "3C", "más", "para", "consolidar", ".", "\n", "Una", "vez", "en", "planta", "de", "hospitalización", ",", "inicia", "una", "neutropenia", "febril", "con", "foco", "en", "el", "catéter", "central", "que", "obliga", "a", "retrasar", "el", "tratamiento", ".", "Además", ",", "se", "inicia", "pauta", "de", "factores", "estimulantes", "de", "colonias", ".", "\n", "El", "21/09/2015", "continúa", "con", "el", "tratamiento", "quimioterápico", ",", "pero", "el", "23/09/2015", "inicia", "cuadro", "de", "dolor", "agudo", "abdominal", ",", "visualizándose", "en", "TC", "urgente", "sangrado", "activo", "a", "nivel", "hepático", "que", "se", "puede", "embolizar", "sin", "incidencias", "pudiendo", "ser", "dada", "de", "alta", "transcurridos", "unos", "días", ".", "\n", "Tras", "todo", "lo", "ocurrido", ",", "se", "decide", "continuar", "el", "tratamiento", "programando", "ingresos", "para", "cada", "ciclo", ".", "Se", "administran", "en", "total", "6C", "de", "EMA", "-", "CO", "recibiendo", "el", "último", "el", "15/12/2015", "presentando", "buena", "tolerancia", "en", "los", "ciclos", "sucesivos", ".", "\n\n", "Evolución", "\n", "La", "TC", "de", "valoración", "de", "respuesta", "posquimioterapia", "del", "13/01/2016", "muestra", "marcada", "disminución", "del", "tamaño", "de", "las", "metástasis", ",", "en", "relación", "a", "respuesta", "parcial", "(", "RP", ")", ",", "sin", "signos", "de", "sangrado", "activo", "ni", "lesiones", "ocupantes", "de", "espacio", "de", "nueva", "aparición", ".", "Ante", "la", "respuesta", "por", "TC", ",", "se", "solicita", "PET", "-", "TC", "que", "informa", "de", "leve", "realce", "en", "la", "metástasis", "pulmonar", "de", "mayor", "tamaño", ",", "siendo", "el", "resto", "de", "lesiones", "pulmonares", ",", "la", "única", "hepática", "visualizada", "y", "la", "lesión", "renal", "no", "metabólicas", ".", "\n", "Con", "dichos", "resultados", "se", "presenta", "el", "caso", "en", "comité", "multidisciplinar", "para", "valorar", "un", "rescate", "quirúrgico", "de", "la", "lesión", "hepática", "y", ",", "en", "función", "de", "los", "resultados", ",", "de", "las", "metástasis", "pulmonares", ".", "El", "13/04/2016", "se", "realiza", "hepatectomía", "derecha", "(", "previa", "embolización", ")", ".", "La", "anatomía", "patológica", "informa", "de", "la", "presencia", "de", "necrosis", "tumoral", "con", "ausencia", "de", "tumor", "viable", ".", "\n", "En", "las", "TC", "de", "seguimiento", ",", "se", "informa", "de", "disminución", "progresiva", "de", "las", "lesiones", "pulmonares", ",", "manteniéndose", "la", "respuesta", "parcial", ".", "\n", "En", "este", "momento", ",", "ante", "los", "resultados", "de", "anatomía", "patológica", "y", "los", "estudios", "de", "imagen", ",", "se", "considera", "a", "la", "paciente", "no", "candidata", "a", "cirugía", "de", "las", "lesiones", "pulmonares", "y", "se", "continúa", "el", "seguimiento", "con", "bHCG", "y", "pruebas", "de", "imagen", ".", "\n", "En", "cuanto", "a", "la", "dinámica", "de", "bHCG", ",", "al", "diagnóstico", "en", "agosto", "de", "2015", "presentaba", "unos", "niveles", "de", "\n", "225.000", "mUI", "/", "ml", ",", "que", "tras", "hemotórax", "se", "eleva", "hasta", "817.000", "mUI", "/", "ml", ",", "pero", "tras", "inicio", "de", "EMA", "-", "CO", "se", "produce", "un", "patrón", "de", "descenso", "rápido", "y", "sostenido", "en", "ciclos", "sucesivos", ",", "alcanzándose", "tras", "3C", "de", "tratamiento", "niveles", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
tumoración, metástasis, tumoraciones, coriocarcinoma, metastásica, metástasis, metástasis, metástasis, lesiones pulmonares, lesión hepática, metástasis, tumoral, tumor, lesiones pulmonares, lesiones pulmonares
819_task2
Sentence: Anamnesis El caso comienza al ingresar en agosto de 2015, en el Servicio de Ginecología, una paciente de 22 años, recién llegada de Argelia. La paciente explica una clínica de dolor en fosa iliaca derecha y dispareunia de varios meses de evolución, así como tos hemoptoica. Refiere al ingreso que está de vacaciones. No obstante, finalmente confiesa que ya conocía parcialmente el diagnóstico y, sabiendo que el tratamiento le sería prácticamente imposible realizarlo en su país de origen, viaja a España para tratamiento. Se trata de una paciente sin alergias ni hábitos tóxicos. Como antecedentes, explica haber sufrido un embarazo molar en 2013 con legrado y seguimiento mediante B-HCG hasta normalización de niveles. Además, explica también que sufrió un aborto espontáneo con legrado en marzo de 2015, con metrorragias posteriores hasta julio sin estudios diagnósticos posteriores. Exploración física La paciente presenta un ECOG de 1 y constantes normales salvo una taquicardia en torno a 140 lpm persistente. La auscultación pulmonar y cardiaca no muestra alteraciones. No presenta focalidad neurológica alguna. Durante la exploración abdominal, refiere dolor a la presión en fosa iliaca derecha, aunque el abdomen es blando y depresible. No se aprecia sangrado vaginal, observando además un cérvix dentro de la normalidad. En cuanto al tacto vaginal, se palpa tumoración dolorosa al tacto en área izquierda del útero y en Douglas. Pruebas complementarias » Ecografía transvaginal: donde se aprecia un ovario izquierdo que ocupa área izquierda uterina y Douglas de 12 cm con múltiples formaciones quísticas en su interior. Se intenta tomar una biopsia de endometrio por aspiración que resulta fallida por estenosis cervical. » Estudio analítico de sangre donde destaca un dímero D de 1.200 ng/ml, una TSH < 0,01 uUI/ml y un FT4 de 3,2 ng/dl (lo que indica un hipertiroidismo marcado). Se incluye una bHCG que da un resultado de más de 225.000 mUI/ml. » Radiografía de tórax que muestra un infiltrado bilateral con una imagen nodular en pulmón derecho y un electrocardiograma que muestra taquicardia sinusal a 136 lpm. » Se realiza un cambio de adscripción a Oncología y se solicita body TC que informa de metástasis de enfermedad trofoblástica gestacional pulmonares bilaterales, hepáticas y renales, así como tumoraciones pélvicas quísticas septadas de probable origen anexial. Diagnóstico Se trata de una enfermedad trofoblástica gestacional de tipo coriocarcinoma avanzada de alto riesgo por el estadio IV al diagnóstico (enfermedad metastásica extrapulmonar), que predice resistencia a monoterapia, requiriendo la quimioterapia en combinación. Tratamiento El 31/08/2015 inicia tratamiento quimioterápico de "enfriamiento" mediante esquema con cisplatino-etopósido pues se ha visto que previo a EMA-CO mejora la supervivencia. El 01/09/2015 ingresa en la UCI por shock hipovolémico secundario a hemotórax en relación a sangrado de las metástasis pulmonares. Una vez estable, se decide continuar con el tratamiento quimioterápico el 01/09/2015 iniciando el C1 de esquema EMA-CO. La paciente presenta una evolución correcta y se mantiene estable, por lo que se traslada de nuevo a planta de hospitalización pese a precisar soporte transfusional. Aquí conviene hacer un inciso y explicar en qué consiste el esquema EMA-CO. Se trata de un esquema alternante en el que cada semana se alternan EMA y CO. EMA contiene etopósido 100 mg/m2 en infusión iv de 30 minutos D1 y D2 del ciclo, actinomicina D a dosis de 0,5 mg en bolo iv D1 y D2, y metotrexato a dosis de 300 mg/m2 en infusión iv durante 12 h D1 con rescate de ácido folínico 24 h tras comenzar la perfusión de metotrexato. La segunda parte del esquema o CO consiste en administrar D8 de cada ciclo vincristina a dosis de 1 mg/m2 iv en bolo (dosis máxima de 2 mg) y ciclofosfamida a dosis de 600 mg/m2 iv en infusión de 30 minutos. Lo recomendado es administrar ciclos hasta normalización de bHCG y, a partir de ese momento, administrar 3C más para consolidar. Una vez en planta de hospitalización, inicia una neutropenia febril con foco en el catéter central que obliga a retrasar el tratamiento. Además, se inicia pauta de factores estimulantes de colonias. El 21/09/2015 continúa con el tratamiento quimioterápico, pero el 23/09/2015 inicia cuadro de dolor agudo abdominal, visualizándose en TC urgente sangrado activo a nivel hepático que se puede embolizar sin incidencias pudiendo ser dada de alta transcurridos unos días. Tras todo lo ocurrido, se decide continuar el tratamiento programando ingresos para cada ciclo. Se administran en total 6C de EMA-CO recibiendo el último el 15/12/2015 presentando buena tolerancia en los ciclos sucesivos. Evolución La TC de valoración de respuesta posquimioterapia del 13/01/2016 muestra marcada disminución del tamaño de las metástasis, en relación a respuesta parcial (RP), sin signos de sangrado activo ni lesiones ocupantes de espacio de nueva aparición. Ante la respuesta por TC, se solicita PET-TC que informa de leve realce en la metástasis pulmonar de mayor tamaño, siendo el resto de lesiones pulmonares, la única hepática visualizada y la lesión renal no metabólicas. Con dichos resultados se presenta el caso en comité multidisciplinar para valorar un rescate quirúrgico de la lesión hepática y, en función de los resultados, de las metástasis pulmonares. El 13/04/2016 se realiza hepatectomía derecha (previa embolización). La anatomía patológica informa de la presencia de necrosis tumoral con ausencia de tumor viable. En las TC de seguimiento, se informa de disminución progresiva de las lesiones pulmonares, manteniéndose la respuesta parcial. En este momento, ante los resultados de anatomía patológica y los estudios de imagen, se considera a la paciente no candidata a cirugía de las lesiones pulmonares y se continúa el seguimiento con bHCG y pruebas de imagen. En cuanto a la dinámica de bHCG, al diagnóstico en agosto de 2015 presentaba unos niveles de 225.000 mUI/ml, que tras hemotórax se eleva hasta 817.000 mUI/ml, pero tras inicio de EMA-CO se produce un patrón de descenso rápido y sostenido en ciclos sucesivos, alcanzándose tras 3C de tratamiento niveles. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis El caso comienza al ingresar en agosto de 2015, en el Servicio de Ginecología, una paciente de 22 años, recién llegada de Argelia. La paciente explica una clínica de dolor en fosa iliaca derecha y dispareunia de varios meses de evolución, así como tos hemoptoica. Refiere al ingreso que está de vacaciones. No obstante, finalmente confiesa que ya conocía parcialmente el diagnóstico y, sabiendo que el tratamiento le sería prácticamente imposible realizarlo en su país de origen, viaja a España para tratamiento. Se trata de una paciente sin alergias ni hábitos tóxicos. Como antecedentes, explica haber sufrido un embarazo molar en 2013 con legrado y seguimiento mediante B-HCG hasta normalización de niveles. Además, explica también que sufrió un aborto espontáneo con legrado en marzo de 2015, con metrorragias posteriores hasta julio sin estudios diagnósticos posteriores. Exploración física La paciente presenta un ECOG de 1 y constantes normales salvo una taquicardia en torno a 140 lpm persistente. La auscultación pulmonar y cardiaca no muestra alteraciones. No presenta focalidad neurológica alguna. Durante la exploración abdominal, refiere dolor a la presión en fosa iliaca derecha, aunque el abdomen es blando y depresible. No se aprecia sangrado vaginal, observando además un cérvix dentro de la normalidad. En cuanto al tacto vaginal, se palpa tumoración dolorosa al tacto en área izquierda del útero y en Douglas. Pruebas complementarias » Ecografía transvaginal: donde se aprecia un ovario izquierdo que ocupa área izquierda uterina y Douglas de 12 cm con múltiples formaciones quísticas en su interior. Se intenta tomar una biopsia de endometrio por aspiración que resulta fallida por estenosis cervical. » Estudio analítico de sangre donde destaca un dímero D de 1.200 ng/ml, una TSH < 0,01 uUI/ml y un FT4 de 3,2 ng/dl (lo que indica un hipertiroidismo marcado). Se incluye una bHCG que da un resultado de más de 225.000 mUI/ml. » Radiografía de tórax que muestra un infiltrado bilateral con una imagen nodular en pulmón derecho y un electrocardiograma que muestra taquicardia sinusal a 136 lpm. » Se realiza un cambio de adscripción a Oncología y se solicita body TC que informa de metástasis de enfermedad trofoblástica gestacional pulmonares bilaterales, hepáticas y renales, así como tumoraciones pélvicas quísticas septadas de probable origen anexial. Diagnóstico Se trata de una enfermedad trofoblástica gestacional de tipo coriocarcinoma avanzada de alto riesgo por el estadio IV al diagnóstico (enfermedad metastásica extrapulmonar), que predice resistencia a monoterapia, requiriendo la quimioterapia en combinación. Tratamiento El 31/08/2015 inicia tratamiento quimioterápico de "enfriamiento" mediante esquema con cisplatino-etopósido pues se ha visto que previo a EMA-CO mejora la supervivencia. El 01/09/2015 ingresa en la UCI por shock hipovolémico secundario a hemotórax en relación a sangrado de las metástasis pulmonares. Una vez estable, se decide continuar con el tratamiento quimioterápico el 01/09/2015 iniciando el C1 de esquema EMA-CO. La paciente presenta una evolución correcta y se mantiene estable, por lo que se traslada de nuevo a planta de hospitalización pese a precisar soporte transfusional. Aquí conviene hacer un inciso y explicar en qué consiste el esquema EMA-CO. Se trata de un esquema alternante en el que cada semana se alternan EMA y CO. EMA contiene etopósido 100 mg/m2 en infusión iv de 30 minutos D1 y D2 del ciclo, actinomicina D a dosis de 0,5 mg en bolo iv D1 y D2, y metotrexato a dosis de 300 mg/m2 en infusión iv durante 12 h D1 con rescate de ácido folínico 24 h tras comenzar la perfusión de metotrexato. La segunda parte del esquema o CO consiste en administrar D8 de cada ciclo vincristina a dosis de 1 mg/m2 iv en bolo (dosis máxima de 2 mg) y ciclofosfamida a dosis de 600 mg/m2 iv en infusión de 30 minutos. Lo recomendado es administrar ciclos hasta normalización de bHCG y, a partir de ese momento, administrar 3C más para consolidar. Una vez en planta de hospitalización, inicia una neutropenia febril con foco en el catéter central que obliga a retrasar el tratamiento. Además, se inicia pauta de factores estimulantes de colonias. El 21/09/2015 continúa con el tratamiento quimioterápico, pero el 23/09/2015 inicia cuadro de dolor agudo abdominal, visualizándose en TC urgente sangrado activo a nivel hepático que se puede embolizar sin incidencias pudiendo ser dada de alta transcurridos unos días. Tras todo lo ocurrido, se decide continuar el tratamiento programando ingresos para cada ciclo. Se administran en total 6C de EMA-CO recibiendo el último el 15/12/2015 presentando buena tolerancia en los ciclos sucesivos. Evolución La TC de valoración de respuesta posquimioterapia del 13/01/2016 muestra marcada disminución del tamaño de las metástasis, en relación a respuesta parcial (RP), sin signos de sangrado activo ni lesiones ocupantes de espacio de nueva aparición. Ante la respuesta por TC, se solicita PET-TC que informa de leve realce en la metástasis pulmonar de mayor tamaño, siendo el resto de lesiones pulmonares, la única hepática visualizada y la lesión renal no metabólicas. Con dichos resultados se presenta el caso en comité multidisciplinar para valorar un rescate quirúrgico de la lesión hepática y, en función de los resultados, de las metástasis pulmonares. El 13/04/2016 se realiza hepatectomía derecha (previa embolización). La anatomía patológica informa de la presencia de necrosis tumoral con ausencia de tumor viable. En las TC de seguimiento, se informa de disminución progresiva de las lesiones pulmonares, manteniéndose la respuesta parcial. En este momento, ante los resultados de anatomía patológica y los estudios de imagen, se considera a la paciente no candidata a cirugía de las lesiones pulmonares y se continúa el seguimiento con bHCG y pruebas de imagen. En cuanto a la dinámica de bHCG, al diagnóstico en agosto de 2015 presentaba unos niveles de 225.000 mUI/ml, que tras hemotórax se eleva hasta 817.000 mUI/ml, pero tras inicio de EMA-CO se produce un patrón de descenso rápido y sostenido en ciclos sucesivos, alcanzándose tras 3C de tratamiento niveles.
[ "Anamnesis", "\n", "El", "caso", "comienza", "al", "ingresar", "en", "agosto", "de", "2015", ",", "en", "el", "Servicio", "de", "Ginecología", ",", "una", "paciente", "de", "22", "años", ",", "recién", "llegada", "de", "Argelia", ".", "La", "paciente", "explica", "una", "clínica", "de", "dolor", "en", "fosa", "iliaca", "derecha", "y", "dispareunia", "de", "varios", "meses", "de", "evolución", ",", "así", "como", "tos", "hemoptoica", ".", "Refiere", "al", "ingreso", "que", "está", "de", "vacaciones", ".", "No", "obstante", ",", "finalmente", "confiesa", "que", "ya", "conocía", "parcialmente", "el", "diagnóstico", "y", ",", "sabiendo", "que", "el", "tratamiento", "le", "sería", "prácticamente", "imposible", "realizarlo", "en", "su", "país", "de", "origen", ",", "viaja", "a", "España", "para", "tratamiento", ".", "\n", "Se", "trata", "de", "una", "paciente", "sin", "alergias", "ni", "hábitos", "tóxicos", ".", "Como", "antecedentes", ",", "explica", "haber", "sufrido", "un", "embarazo", "molar", "en", "2013", "con", "legrado", "y", "seguimiento", "mediante", "B", "-", "HCG", "hasta", "normalización", "de", "niveles", ".", "Además", ",", "explica", "también", "que", "sufrió", "un", "aborto", "espontáneo", "con", "legrado", "en", "marzo", "de", "2015", ",", "con", "metrorragias", "posteriores", "hasta", "julio", "sin", "estudios", "diagnósticos", "posteriores", ".", "\n\n", "Exploración", "física", "\n", "La", "paciente", "presenta", "un", "ECOG", "de", "1", "y", "constantes", "normales", "salvo", "una", "taquicardia", "en", "torno", "a", "140", "lpm", "persistente", ".", "La", "auscultación", "pulmonar", "y", "cardiaca", "no", "muestra", "alteraciones", ".", "No", "presenta", "focalidad", "neurológica", "alguna", ".", "Durante", "la", "exploración", "abdominal", ",", "refiere", "dolor", "a", "la", "presión", "en", "fosa", "iliaca", "derecha", ",", "aunque", "el", "abdomen", "es", "blando", "y", "depresible", ".", "No", "se", "aprecia", "sangrado", "vaginal", ",", "observando", "además", "un", "cérvix", "dentro", "de", "la", "normalidad", ".", "En", "cuanto", "al", "tacto", "vaginal", ",", "se", "palpa", "tumoración", "dolorosa", "al", "tacto", "en", "área", "izquierda", "del", "útero", "y", "en", "Douglas", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Ecografía", "transvaginal", ":", "donde", "se", "aprecia", "un", "ovario", "izquierdo", "que", "ocupa", "área", "izquierda", "uterina", "y", "Douglas", "de", "12", "cm", "con", "múltiples", "formaciones", "quísticas", "en", "su", "interior", ".", "Se", "intenta", "tomar", "una", "biopsia", "de", "endometrio", "por", "aspiración", "que", "resulta", "fallida", "por", "estenosis", "cervical", ".", "\n", "»", "Estudio", "analítico", "de", "sangre", "donde", "destaca", "un", "dímero", "D", "de", "1.200", "ng", "/", "ml", ",", "una", "TSH", "<", "0,01", "uUI", "/", "ml", "y", "un", "FT4", "de", "3,2", "ng", "/", "dl", "(", "lo", "que", "indica", "un", "hipertiroidismo", "marcado", ")", ".", "Se", "incluye", "una", "bHCG", "que", "da", "un", "resultado", "de", "más", "de", "225.000", "mUI", "/", "ml", ".", "\n", "»", "Radiografía", "de", "tórax", "que", "muestra", "un", "infiltrado", "bilateral", "con", "una", "imagen", "nodular", "en", "pulmón", "derecho", "y", "un", "electrocardiograma", "que", "muestra", "taquicardia", "sinusal", "a", "136", "lpm", ".", "\n", "»", "Se", "realiza", "un", "cambio", "de", "adscripción", "a", "Oncología", "y", "se", "solicita", "body", "TC", "que", "informa", "de", "metástasis", "de", "enfermedad", "trofoblástica", "gestacional", "pulmonares", "bilaterales", ",", "hepáticas", "y", "renales", ",", "así", "como", "tumoraciones", "pélvicas", "quísticas", "septadas", "de", "probable", "origen", "anexial", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "una", "enfermedad", "trofoblástica", "gestacional", "de", "tipo", "coriocarcinoma", "avanzada", "de", "alto", "riesgo", "por", "el", "estadio", "IV", "al", "diagnóstico", "(", "enfermedad", "metastásica", "extrapulmonar", ")", ",", "que", "predice", "resistencia", "a", "monoterapia", ",", "requiriendo", "la", "quimioterapia", "en", "combinación", ".", "\n\n", "Tratamiento", "\n", "El", "31/08/2015", "inicia", "tratamiento", "quimioterápico", "de", "\"", "enfriamiento", "\"", "mediante", "esquema", "con", "cisplatino", "-", "etopósido", "pues", "se", "ha", "visto", "que", "previo", "a", "EMA", "-", "CO", "mejora", "la", "supervivencia", ".", "El", "01/09/2015", "ingresa", "en", "la", "UCI", "por", "shock", "hipovolémico", "secundario", "a", "hemotórax", "en", "relación", "a", "sangrado", "de", "las", "metástasis", "pulmonares", ".", "Una", "vez", "estable", ",", "se", "decide", "continuar", "con", "el", "tratamiento", "quimioterápico", "el", "01/09/2015", "iniciando", "el", "C1", "de", "esquema", "EMA", "-", "CO", ".", "La", "paciente", "presenta", "una", "evolución", "correcta", "y", "se", "mantiene", "estable", ",", "por", "lo", "que", "se", "traslada", "de", "nuevo", "a", "planta", "de", "hospitalización", "pese", "a", "precisar", "soporte", "transfusional", ".", "\n", "Aquí", "conviene", "hacer", "un", "inciso", "y", "explicar", "en", "qué", "consiste", "el", "esquema", "EMA", "-", "CO", ".", "Se", "trata", "de", "un", "esquema", "alternante", "en", "el", "que", "cada", "semana", "se", "alternan", "EMA", "y", "CO", ".", "EMA", "contiene", "etopósido", "100", "mg", "/", "m2", "en", "infusión", "iv", "de", "30", "minutos", "D1", "y", "D2", "del", "ciclo", ",", "actinomicina", "D", "a", "dosis", "de", "0,5", "mg", "en", "bolo", "iv", "D1", "y", "D2", ",", "y", "metotrexato", "a", "dosis", "de", "300", "mg", "/", "m2", "en", "infusión", "iv", "durante", "12", "h", "D1", "con", "rescate", "de", "ácido", "folínico", "24", "h", "tras", "comenzar", "la", "perfusión", "de", "metotrexato", ".", "La", "segunda", "parte", "del", "esquema", "o", "CO", "consiste", "en", "administrar", "D8", "de", "cada", "ciclo", "vincristina", "a", "dosis", "de", "1", "mg", "/", "m2", "iv", "en", "bolo", "(", "dosis", "máxima", "de", "2", "mg", ")", "y", "ciclofosfamida", "a", "dosis", "de", "600", "mg", "/", "m2", "iv", "en", "infusión", "de", "30", "minutos", ".", "Lo", "recomendado", "es", "administrar", "ciclos", "hasta", "normalización", "de", "bHCG", "y", ",", "a", "partir", "de", "ese", "momento", ",", "administrar", "3C", "más", "para", "consolidar", ".", "\n", "Una", "vez", "en", "planta", "de", "hospitalización", ",", "inicia", "una", "neutropenia", "febril", "con", "foco", "en", "el", "catéter", "central", "que", "obliga", "a", "retrasar", "el", "tratamiento", ".", "Además", ",", "se", "inicia", "pauta", "de", "factores", "estimulantes", "de", "colonias", ".", "\n", "El", "21/09/2015", "continúa", "con", "el", "tratamiento", "quimioterápico", ",", "pero", "el", "23/09/2015", "inicia", "cuadro", "de", "dolor", "agudo", "abdominal", ",", "visualizándose", "en", "TC", "urgente", "sangrado", "activo", "a", "nivel", "hepático", "que", "se", "puede", "embolizar", "sin", "incidencias", "pudiendo", "ser", "dada", "de", "alta", "transcurridos", "unos", "días", ".", "\n", "Tras", "todo", "lo", "ocurrido", ",", "se", "decide", "continuar", "el", "tratamiento", "programando", "ingresos", "para", "cada", "ciclo", ".", "Se", "administran", "en", "total", "6C", "de", "EMA", "-", "CO", "recibiendo", "el", "último", "el", "15/12/2015", "presentando", "buena", "tolerancia", "en", "los", "ciclos", "sucesivos", ".", "\n\n", "Evolución", "\n", "La", "TC", "de", "valoración", "de", "respuesta", "posquimioterapia", "del", "13/01/2016", "muestra", "marcada", "disminución", "del", "tamaño", "de", "las", "metástasis", ",", "en", "relación", "a", "respuesta", "parcial", "(", "RP", ")", ",", "sin", "signos", "de", "sangrado", "activo", "ni", "lesiones", "ocupantes", "de", "espacio", "de", "nueva", "aparición", ".", "Ante", "la", "respuesta", "por", "TC", ",", "se", "solicita", "PET", "-", "TC", "que", "informa", "de", "leve", "realce", "en", "la", "metástasis", "pulmonar", "de", "mayor", "tamaño", ",", "siendo", "el", "resto", "de", "lesiones", "pulmonares", ",", "la", "única", "hepática", "visualizada", "y", "la", "lesión", "renal", "no", "metabólicas", ".", "\n", "Con", "dichos", "resultados", "se", "presenta", "el", "caso", "en", "comité", "multidisciplinar", "para", "valorar", "un", "rescate", "quirúrgico", "de", "la", "lesión", "hepática", "y", ",", "en", "función", "de", "los", "resultados", ",", "de", "las", "metástasis", "pulmonares", ".", "El", "13/04/2016", "se", "realiza", "hepatectomía", "derecha", "(", "previa", "embolización", ")", ".", "La", "anatomía", "patológica", "informa", "de", "la", "presencia", "de", "necrosis", "tumoral", "con", "ausencia", "de", "tumor", "viable", ".", "\n", "En", "las", "TC", "de", "seguimiento", ",", "se", "informa", "de", "disminución", "progresiva", "de", "las", "lesiones", "pulmonares", ",", "manteniéndose", "la", "respuesta", "parcial", ".", "\n", "En", "este", "momento", ",", "ante", "los", "resultados", "de", "anatomía", "patológica", "y", "los", "estudios", "de", "imagen", ",", "se", "considera", "a", "la", "paciente", "no", "candidata", "a", "cirugía", "de", "las", "lesiones", "pulmonares", "y", "se", "continúa", "el", "seguimiento", "con", "bHCG", "y", "pruebas", "de", "imagen", ".", "\n", "En", "cuanto", "a", "la", "dinámica", "de", "bHCG", ",", "al", "diagnóstico", "en", "agosto", "de", "2015", "presentaba", "unos", "niveles", "de", "\n", "225.000", "mUI", "/", "ml", ",", "que", "tras", "hemotórax", "se", "eleva", "hasta", "817.000", "mUI", "/", "ml", ",", "pero", "tras", "inicio", "de", "EMA", "-", "CO", "se", "produce", "un", "patrón", "de", "descenso", "rápido", "y", "sostenido", "en", "ciclos", "sucesivos", ",", "alcanzándose", "tras", "3C", "de", "tratamiento", "niveles", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
tissue factor gene is a Entity, c - Rel is a Protein, p65 is a Protein, heterodimers is a Entity, kappa B - like site is a Entity, NF - kappa B is a Entity, tissue factor is a Protein, TF is a Protein, TF is a Protein, nuclear complex is a Entity, kappa B - like site is a Entity, 5'-CGGAGTTTCC-3 ' is a Entity, 5'-flanking region is a Entity, TF is a Protein, nuclear complex is a Entity, TF is a Protein, TF is a Protein, site is a Entity, c - Rel is a Protein, p65 is a Protein, homodimers is a Entity, p50 is a Protein, p65 is a Protein, heterodimers is a Entity, p50 is a Protein, homodimers is a Entity, TF is a Protein, site is a Entity, cytosine at position 1 is a Entity, TF is a Protein, complex is a Entity, p50 is a Protein, p65 is a Protein, dimers is a Entity, c - Rel is a Protein, p65 is a Protein, dimers is a Entity, c - Rel is a Protein, p65 is a Protein, p50 is a Protein, TF is a Protein, complex is a Entity, c - Rel is a Protein, p65 is a Protein, heterodimers is a Entity, TF is a Protein, kappa B - like site is a Entity, TF is a Protein, site is a Entity, heterologous promoter is a Entity, c - Rel is a Protein, p65 is a Protein, c - Rel is a Protein, p65 is a Protein, heterodimers is a Entity, kappa B - like site is a Entity, TF is a Protein
741_task0
Sentence: Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Exposure of monocytic cells to bacterial lipopolysaccharide (LPS) activates the NF-kappa B/Rel family of proteins and leads to the rapid induction of inflammatory gene products, including tissue factor (TF). TF is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human monocytic cells that bound to a kappa B-like site, 5'-CGGAGTTTCC-3', in the 5'-flanking region of the human TF gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the TF gene. In vitro binding studies demonstrated that the TF site bound translated c-Rel and p65 homodimers but not p50/p65 heterodimers or p50 homodimers. Base-pair substitutions in the TF site indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the TF complex did not migrate with translated p50/p65 dimers but instead comigrated with c-Rel/p65 dimers. Antibodies against the NF-kappa B and Rel proteins and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the TF complex and further showed that c-Rel/p65 heterodimers selectively bound to the TF kappa B-like site. Functional studies indicated that the TF site conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel/p65 heterodimers to a novel kappa B-like site mediated LPS induction of TF gene expression in monocytic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]
Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Exposure of monocytic cells to bacterial lipopolysaccharide (LPS) activates the NF-kappa B/Rel family of proteins and leads to the rapid induction of inflammatory gene products, including tissue factor (TF). TF is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human monocytic cells that bound to a kappa B-like site, 5'-CGGAGTTTCC-3', in the 5'-flanking region of the human TF gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the TF gene. In vitro binding studies demonstrated that the TF site bound translated c-Rel and p65 homodimers but not p50/p65 heterodimers or p50 homodimers. Base-pair substitutions in the TF site indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the TF complex did not migrate with translated p50/p65 dimers but instead comigrated with c-Rel/p65 dimers. Antibodies against the NF-kappa B and Rel proteins and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the TF complex and further showed that c-Rel/p65 heterodimers selectively bound to the TF kappa B-like site. Functional studies indicated that the TF site conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel/p65 heterodimers to a novel kappa B-like site mediated LPS induction of TF gene expression in monocytic cells.
[ "Lipopolysaccharide", "induction", "of", "tissue", "factor", "gene", "expression", "in", "monocytic", "cells", "is", "mediated", "by", "binding", "of", "c", "-", "Rel", "/", "p65", "heterodimers", "to", "a", "kappa", "B", "-", "like", "site", ".", "\n", "Exposure", "of", "monocytic", "cells", "to", "bacterial", "lipopolysaccharide", "(", "LPS", ")", "activates", "the", "NF", "-", "kappa", "B", "/", "Rel", "family", "of", "proteins", "and", "leads", "to", "the", "rapid", "induction", "of", "inflammatory", "gene", "products", ",", "including", "tissue", "factor", "(", "TF", ")", ".", "TF", "is", "the", "primary", "cellular", "initiator", "of", "the", "coagulation", "protease", "cascades", ".", "Here", "we", "report", "the", "characterization", "of", "a", "nuclear", "complex", "from", "human", "monocytic", "cells", "that", "bound", "to", "a", "kappa", "B", "-", "like", "site", ",", "5'-CGGAGTTTCC-3", "'", ",", "in", "the", "5'-flanking", "region", "of", "the", "human", "TF", "gene", ".", "This", "nuclear", "complex", "was", "activated", "by", "LPS", "with", "kinetics", "that", "preceded", "induction", "of", "the", "TF", "gene", ".", "In", "vitro", "binding", "studies", "demonstrated", "that", "the", "TF", "site", "bound", "translated", "c", "-", "Rel", "and", "p65", "homodimers", "but", "not", "p50", "/", "p65", "heterodimers", "or", "p50", "homodimers", ".", "Base", "-", "pair", "substitutions", "in", "the", "TF", "site", "indicated", "that", "the", "presence", "of", "a", "cytosine", "at", "position", "1", "precluded", "binding", "of", "NF", "-", "kappa", "B.", "In", "fact", ",", "under", "low", "-", "ionic", "-", "strength", "conditions", ",", "the", "TF", "complex", "did", "not", "migrate", "with", "translated", "p50", "/", "p65", "dimers", "but", "instead", "comigrated", "with", "c", "-", "Rel", "/", "p65", "dimers", ".", "Antibodies", "against", "the", "NF", "-", "kappa", "B", "and", "Rel", "proteins", "and", "UV", "cross", "-", "linking", "studies", "revealed", "the", "presence", "of", "c", "-", "Rel", "and", "p65", "and", "the", "absence", "of", "p50", "in", "the", "TF", "complex", "and", "further", "showed", "that", "c", "-", "Rel", "/", "p65", "heterodimers", "selectively", "bound", "to", "the", "TF", "kappa", "B", "-", "like", "site", ".", "Functional", "studies", "indicated", "that", "the", "TF", "site", "conferred", "LPS", "inducibility", "on", "a", "heterologous", "promoter", "and", "was", "transactivated", "by", "c", "-", "Rel", "or", "p65", ".", "Taken", "together", ",", "our", "results", "demonstrated", "that", "binding", "of", "c", "-", "Rel", "/", "p65", "heterodimers", "to", "a", "novel", "kappa", "B", "-", "like", "site", "mediated", "LPS", "induction", "of", "TF", "gene", "expression", "in", "monocytic", "cells", ".", "\n" ]
[ "Entity", "Protein" ]
tissue factor gene is a Entity, c - Rel is a Protein, p65 is a Protein, heterodimers is a Entity, kappa B - like site is a Entity, NF - kappa B is a Entity, tissue factor is a Protein, TF is a Protein, TF is a Protein, nuclear complex is a Entity, kappa B - like site is a Entity, 5'-CGGAGTTTCC-3 ' is a Entity, 5'-flanking region is a Entity, TF is a Protein, nuclear complex is a Entity, TF is a Protein, TF is a Protein, site is a Entity, c - Rel is a Protein, p65 is a Protein, homodimers is a Entity, p50 is a Protein, p65 is a Protein, heterodimers is a Entity, p50 is a Protein, homodimers is a Entity, TF is a Protein, site is a Entity, cytosine at position 1 is a Entity, TF is a Protein, complex is a Entity, p50 is a Protein, p65 is a Protein, dimers is a Entity, c - Rel is a Protein, p65 is a Protein, dimers is a Entity, c - Rel is a Protein, p65 is a Protein, p50 is a Protein, TF is a Protein, complex is a Entity, c - Rel is a Protein, p65 is a Protein, heterodimers is a Entity, TF is a Protein, kappa B - like site is a Entity, TF is a Protein, site is a Entity, heterologous promoter is a Entity, c - Rel is a Protein, p65 is a Protein, c - Rel is a Protein, p65 is a Protein, heterodimers is a Entity, kappa B - like site is a Entity, TF is a Protein
741_task1
Sentence: Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Exposure of monocytic cells to bacterial lipopolysaccharide (LPS) activates the NF-kappa B/Rel family of proteins and leads to the rapid induction of inflammatory gene products, including tissue factor (TF). TF is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human monocytic cells that bound to a kappa B-like site, 5'-CGGAGTTTCC-3', in the 5'-flanking region of the human TF gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the TF gene. In vitro binding studies demonstrated that the TF site bound translated c-Rel and p65 homodimers but not p50/p65 heterodimers or p50 homodimers. Base-pair substitutions in the TF site indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the TF complex did not migrate with translated p50/p65 dimers but instead comigrated with c-Rel/p65 dimers. Antibodies against the NF-kappa B and Rel proteins and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the TF complex and further showed that c-Rel/p65 heterodimers selectively bound to the TF kappa B-like site. Functional studies indicated that the TF site conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel/p65 heterodimers to a novel kappa B-like site mediated LPS induction of TF gene expression in monocytic cells. Instructions: please typing these entity words according to sentence: tissue factor gene, c - Rel, p65, heterodimers, kappa B - like site, NF - kappa B, tissue factor, TF, TF, nuclear complex, kappa B - like site, 5'-CGGAGTTTCC-3 ', 5'-flanking region, TF, nuclear complex, TF, TF, site, c - Rel, p65, homodimers, p50, p65, heterodimers, p50, homodimers, TF, site, cytosine at position 1, TF, complex, p50, p65, dimers, c - Rel, p65, dimers, c - Rel, p65, p50, TF, complex, c - Rel, p65, heterodimers, TF, kappa B - like site, TF, site, heterologous promoter, c - Rel, p65, c - Rel, p65, heterodimers, kappa B - like site, TF Options: Entity, Protein
[ "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]
Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Exposure of monocytic cells to bacterial lipopolysaccharide (LPS) activates the NF-kappa B/Rel family of proteins and leads to the rapid induction of inflammatory gene products, including tissue factor (TF). TF is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human monocytic cells that bound to a kappa B-like site, 5'-CGGAGTTTCC-3', in the 5'-flanking region of the human TF gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the TF gene. In vitro binding studies demonstrated that the TF site bound translated c-Rel and p65 homodimers but not p50/p65 heterodimers or p50 homodimers. Base-pair substitutions in the TF site indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the TF complex did not migrate with translated p50/p65 dimers but instead comigrated with c-Rel/p65 dimers. Antibodies against the NF-kappa B and Rel proteins and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the TF complex and further showed that c-Rel/p65 heterodimers selectively bound to the TF kappa B-like site. Functional studies indicated that the TF site conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel/p65 heterodimers to a novel kappa B-like site mediated LPS induction of TF gene expression in monocytic cells.
[ "Lipopolysaccharide", "induction", "of", "tissue", "factor", "gene", "expression", "in", "monocytic", "cells", "is", "mediated", "by", "binding", "of", "c", "-", "Rel", "/", "p65", "heterodimers", "to", "a", "kappa", "B", "-", "like", "site", ".", "\n", "Exposure", "of", "monocytic", "cells", "to", "bacterial", "lipopolysaccharide", "(", "LPS", ")", "activates", "the", "NF", "-", "kappa", "B", "/", "Rel", "family", "of", "proteins", "and", "leads", "to", "the", "rapid", "induction", "of", "inflammatory", "gene", "products", ",", "including", "tissue", "factor", "(", "TF", ")", ".", "TF", "is", "the", "primary", "cellular", "initiator", "of", "the", "coagulation", "protease", "cascades", ".", "Here", "we", "report", "the", "characterization", "of", "a", "nuclear", "complex", "from", "human", "monocytic", "cells", "that", "bound", "to", "a", "kappa", "B", "-", "like", "site", ",", "5'-CGGAGTTTCC-3", "'", ",", "in", "the", "5'-flanking", "region", "of", "the", "human", "TF", "gene", ".", "This", "nuclear", "complex", "was", "activated", "by", "LPS", "with", "kinetics", "that", "preceded", "induction", "of", "the", "TF", "gene", ".", "In", "vitro", "binding", "studies", "demonstrated", "that", "the", "TF", "site", "bound", "translated", "c", "-", "Rel", "and", "p65", "homodimers", "but", "not", "p50", "/", "p65", "heterodimers", "or", "p50", "homodimers", ".", "Base", "-", "pair", "substitutions", "in", "the", "TF", "site", "indicated", "that", "the", "presence", "of", "a", "cytosine", "at", "position", "1", "precluded", "binding", "of", "NF", "-", "kappa", "B.", "In", "fact", ",", "under", "low", "-", "ionic", "-", "strength", "conditions", ",", "the", "TF", "complex", "did", "not", "migrate", "with", "translated", "p50", "/", "p65", "dimers", "but", "instead", "comigrated", "with", "c", "-", "Rel", "/", "p65", "dimers", ".", "Antibodies", "against", "the", "NF", "-", "kappa", "B", "and", "Rel", "proteins", "and", "UV", "cross", "-", "linking", "studies", "revealed", "the", "presence", "of", "c", "-", "Rel", "and", "p65", "and", "the", "absence", "of", "p50", "in", "the", "TF", "complex", "and", "further", "showed", "that", "c", "-", "Rel", "/", "p65", "heterodimers", "selectively", "bound", "to", "the", "TF", "kappa", "B", "-", "like", "site", ".", "Functional", "studies", "indicated", "that", "the", "TF", "site", "conferred", "LPS", "inducibility", "on", "a", "heterologous", "promoter", "and", "was", "transactivated", "by", "c", "-", "Rel", "or", "p65", ".", "Taken", "together", ",", "our", "results", "demonstrated", "that", "binding", "of", "c", "-", "Rel", "/", "p65", "heterodimers", "to", "a", "novel", "kappa", "B", "-", "like", "site", "mediated", "LPS", "induction", "of", "TF", "gene", "expression", "in", "monocytic", "cells", ".", "\n" ]
[ "Entity", "Protein" ]
tissue factor gene, c - Rel, p65, heterodimers, kappa B - like site, NF - kappa B, tissue factor, TF, TF, nuclear complex, kappa B - like site, 5'-CGGAGTTTCC-3 ', 5'-flanking region, TF, nuclear complex, TF, TF, site, c - Rel, p65, homodimers, p50, p65, heterodimers, p50, homodimers, TF, site, cytosine at position 1, TF, complex, p50, p65, dimers, c - Rel, p65, dimers, c - Rel, p65, p50, TF, complex, c - Rel, p65, heterodimers, TF, kappa B - like site, TF, site, heterologous promoter, c - Rel, p65, c - Rel, p65, heterodimers, kappa B - like site, TF
741_task2
Sentence: Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Exposure of monocytic cells to bacterial lipopolysaccharide (LPS) activates the NF-kappa B/Rel family of proteins and leads to the rapid induction of inflammatory gene products, including tissue factor (TF). TF is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human monocytic cells that bound to a kappa B-like site, 5'-CGGAGTTTCC-3', in the 5'-flanking region of the human TF gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the TF gene. In vitro binding studies demonstrated that the TF site bound translated c-Rel and p65 homodimers but not p50/p65 heterodimers or p50 homodimers. Base-pair substitutions in the TF site indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the TF complex did not migrate with translated p50/p65 dimers but instead comigrated with c-Rel/p65 dimers. Antibodies against the NF-kappa B and Rel proteins and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the TF complex and further showed that c-Rel/p65 heterodimers selectively bound to the TF kappa B-like site. Functional studies indicated that the TF site conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel/p65 heterodimers to a novel kappa B-like site mediated LPS induction of TF gene expression in monocytic cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]
Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Exposure of monocytic cells to bacterial lipopolysaccharide (LPS) activates the NF-kappa B/Rel family of proteins and leads to the rapid induction of inflammatory gene products, including tissue factor (TF). TF is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human monocytic cells that bound to a kappa B-like site, 5'-CGGAGTTTCC-3', in the 5'-flanking region of the human TF gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the TF gene. In vitro binding studies demonstrated that the TF site bound translated c-Rel and p65 homodimers but not p50/p65 heterodimers or p50 homodimers. Base-pair substitutions in the TF site indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the TF complex did not migrate with translated p50/p65 dimers but instead comigrated with c-Rel/p65 dimers. Antibodies against the NF-kappa B and Rel proteins and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the TF complex and further showed that c-Rel/p65 heterodimers selectively bound to the TF kappa B-like site. Functional studies indicated that the TF site conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel/p65 heterodimers to a novel kappa B-like site mediated LPS induction of TF gene expression in monocytic cells.
[ "Lipopolysaccharide", "induction", "of", "tissue", "factor", "gene", "expression", "in", "monocytic", "cells", "is", "mediated", "by", "binding", "of", "c", "-", "Rel", "/", "p65", "heterodimers", "to", "a", "kappa", "B", "-", "like", "site", ".", "\n", "Exposure", "of", "monocytic", "cells", "to", "bacterial", "lipopolysaccharide", "(", "LPS", ")", "activates", "the", "NF", "-", "kappa", "B", "/", "Rel", "family", "of", "proteins", "and", "leads", "to", "the", "rapid", "induction", "of", "inflammatory", "gene", "products", ",", "including", "tissue", "factor", "(", "TF", ")", ".", "TF", "is", "the", "primary", "cellular", "initiator", "of", "the", "coagulation", "protease", "cascades", ".", "Here", "we", "report", "the", "characterization", "of", "a", "nuclear", "complex", "from", "human", "monocytic", "cells", "that", "bound", "to", "a", "kappa", "B", "-", "like", "site", ",", "5'-CGGAGTTTCC-3", "'", ",", "in", "the", "5'-flanking", "region", "of", "the", "human", "TF", "gene", ".", "This", "nuclear", "complex", "was", "activated", "by", "LPS", "with", "kinetics", "that", "preceded", "induction", "of", "the", "TF", "gene", ".", "In", "vitro", "binding", "studies", "demonstrated", "that", "the", "TF", "site", "bound", "translated", "c", "-", "Rel", "and", "p65", "homodimers", "but", "not", "p50", "/", "p65", "heterodimers", "or", "p50", "homodimers", ".", "Base", "-", "pair", "substitutions", "in", "the", "TF", "site", "indicated", "that", "the", "presence", "of", "a", "cytosine", "at", "position", "1", "precluded", "binding", "of", "NF", "-", "kappa", "B.", "In", "fact", ",", "under", "low", "-", "ionic", "-", "strength", "conditions", ",", "the", "TF", "complex", "did", "not", "migrate", "with", "translated", "p50", "/", "p65", "dimers", "but", "instead", "comigrated", "with", "c", "-", "Rel", "/", "p65", "dimers", ".", "Antibodies", "against", "the", "NF", "-", "kappa", "B", "and", "Rel", "proteins", "and", "UV", "cross", "-", "linking", "studies", "revealed", "the", "presence", "of", "c", "-", "Rel", "and", "p65", "and", "the", "absence", "of", "p50", "in", "the", "TF", "complex", "and", "further", "showed", "that", "c", "-", "Rel", "/", "p65", "heterodimers", "selectively", "bound", "to", "the", "TF", "kappa", "B", "-", "like", "site", ".", "Functional", "studies", "indicated", "that", "the", "TF", "site", "conferred", "LPS", "inducibility", "on", "a", "heterologous", "promoter", "and", "was", "transactivated", "by", "c", "-", "Rel", "or", "p65", ".", "Taken", "together", ",", "our", "results", "demonstrated", "that", "binding", "of", "c", "-", "Rel", "/", "p65", "heterodimers", "to", "a", "novel", "kappa", "B", "-", "like", "site", "mediated", "LPS", "induction", "of", "TF", "gene", "expression", "in", "monocytic", "cells", ".", "\n" ]
[ "Entity", "Protein" ]
THUNDERBEAT is a Intervention_Surgical, standard electrosurgery is a Intervention_Surgical, gynecologic cancer is a Participant_Condition, operative time is a Outcome_Other, gynecologic tumors . is a Participant_Condition, Fifty is a Participant_Sample-size, cervical cancer is a Participant_Condition, neoadjuvant treatment ( is a Intervention_Physical, chemotherapy is a Intervention_Pharmacological, or radiochemotherapy ) is a Intervention_Physical, Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy is a Intervention_Surgical, 25 is a Participant_Sample-size, women is a Participant_Sex, median operative time is a Outcome_Other, shorter operating time . is a Outcome_Other, perioperative outcomes and postoperative complications is a Outcome_Adverse-effects, postoperative pain is a Outcome_Pain, uterine cancer is a Participant_Condition
62919_task0
Sentence: Randomized study comparing use of THUNDERBEAT technology vs standard electrosurgery during laparoscopic radical hysterectomy and pelvic lymphadenectomy for gynecologic cancer . STUDY OBJECTIVE To compare operative time with use of THUNDERBEAT ( TB ) vs standard electrosurgery ( SES ) during laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat gynecologic tumors . DESIGN Evidence obtained from a properly designed , randomized , controlled trial ( Canadian Task Force classification I ) . SETTING Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome , Italy . PATIENTS Fifty patients with early cervical cancer ( FIGO stages IA2 , IB1 , IIA < 2 cm ) or locally advanced cervical cancer ( FIGO stages IB2 , IIA > 2cm , IIB ) who received neoadjuvant treatment ( chemotherapy or radiochemotherapy ) and demonstrated a complete or partial clinical response and early stage endometrioid endometrial cancer ( FIGO stages IB , II ) were randomly assigned to undergo TB ( arm A ) or SES ( arm B ) . INTERVENTION Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy , using an easily reproducible technique was performed . MEASUREMENTS AND MAIN RESULTS Fifty patients were available for analysis , with 25 women randomly assigned to TB ( arm A ) and 25 to SES ( arm B ) . The median operative time was 85 minutes for TB vs 115 minutes for SES ( p = .001 ) . At multivariate analysis , endometrial cancer ( p = .001 ) and TB ( p = .001 ) were independently associated with shorter operating time . No differences in perioperative outcomes and postoperative complications were observed between the 2 arms . Patients who underwent TB reported less postoperative pain , both at rest ( p = .005 ) and after the Valsalva maneuver ( p = .008 ) , with less additional analgesic therapy other than standard therapy required in patients who underwent SES ( p = .02 ) . CONCLUSION TB is associated with shorter operative time and less postoperative pain than is the standard technique ( SES ) in patients with uterine cancer . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Participant_Sex, Outcome_Pain, Participant_Sample-size, Outcome_Other, Intervention_Surgical
[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Pharmacological", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
Randomized study comparing use of THUNDERBEAT technology vs standard electrosurgery during laparoscopic radical hysterectomy and pelvic lymphadenectomy for gynecologic cancer . STUDY OBJECTIVE To compare operative time with use of THUNDERBEAT ( TB ) vs standard electrosurgery ( SES ) during laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat gynecologic tumors . DESIGN Evidence obtained from a properly designed , randomized , controlled trial ( Canadian Task Force classification I ) . SETTING Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome , Italy . PATIENTS Fifty patients with early cervical cancer ( FIGO stages IA2 , IB1 , IIA < 2 cm ) or locally advanced cervical cancer ( FIGO stages IB2 , IIA > 2cm , IIB ) who received neoadjuvant treatment ( chemotherapy or radiochemotherapy ) and demonstrated a complete or partial clinical response and early stage endometrioid endometrial cancer ( FIGO stages IB , II ) were randomly assigned to undergo TB ( arm A ) or SES ( arm B ) . INTERVENTION Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy , using an easily reproducible technique was performed . MEASUREMENTS AND MAIN RESULTS Fifty patients were available for analysis , with 25 women randomly assigned to TB ( arm A ) and 25 to SES ( arm B ) . The median operative time was 85 minutes for TB vs 115 minutes for SES ( p = .001 ) . At multivariate analysis , endometrial cancer ( p = .001 ) and TB ( p = .001 ) were independently associated with shorter operating time . No differences in perioperative outcomes and postoperative complications were observed between the 2 arms . Patients who underwent TB reported less postoperative pain , both at rest ( p = .005 ) and after the Valsalva maneuver ( p = .008 ) , with less additional analgesic therapy other than standard therapy required in patients who underwent SES ( p = .02 ) . CONCLUSION TB is associated with shorter operative time and less postoperative pain than is the standard technique ( SES ) in patients with uterine cancer .
[ "Randomized", "study", "comparing", "use", "of", "THUNDERBEAT", "technology", "vs", "standard", "electrosurgery", "during", "laparoscopic", "radical", "hysterectomy", "and", "pelvic", "lymphadenectomy", "for", "gynecologic", "cancer", ".", "STUDY", "OBJECTIVE", "To", "compare", "operative", "time", "with", "use", "of", "THUNDERBEAT", "(", "TB", ")", "vs", "standard", "electrosurgery", "(", "SES", ")", "during", "laparoscopic", "radical", "hysterectomy", "and", "pelvic", "lymphadenectomy", "to", "treat", "gynecologic", "tumors", ".", "DESIGN", "Evidence", "obtained", "from", "a", "properly", "designed", ",", "randomized", ",", "controlled", "trial", "(", "Canadian", "Task", "Force", "classification", "I", ")", ".", "SETTING", "Gynecologic", "Oncology", "Unit", "of", "the", "Catholic", "University", "of", "the", "Sacred", "Heart", "in", "Rome", ",", "Italy", ".", "PATIENTS", "Fifty", "patients", "with", "early", "cervical", "cancer", "(", "FIGO", "stages", "IA2", ",", "IB1", ",", "IIA", "<", "2", "cm", ")", "or", "locally", "advanced", "cervical", "cancer", "(", "FIGO", "stages", "IB2", ",", "IIA", ">", "2", "cm", ",", "IIB", ")", "who", "received", "neoadjuvant", "treatment", "(", "chemotherapy", "or", "radiochemotherapy", ")", "and", "demonstrated", "a", "complete", "or", "partial", "clinical", "response", "and", "early", "stage", "endometrioid", "endometrial", "cancer", "(", "FIGO", "stages", "IB", ",", "II", ")", "were", "randomly", "assigned", "to", "undergo", "TB", "(", "arm", "A", ")", "or", "SES", "(", "arm", "B", ")", ".", "INTERVENTION", "Laparoscopic", "radical", "hysterectomy", "with", "bilateral", "pelvic", "lymphadenectomy", ",", "using", "an", "easily", "reproducible", "technique", "was", "performed", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", "Fifty", "patients", "were", "available", "for", "analysis", ",", "with", "25", "women", "randomly", "assigned", "to", "TB", "(", "arm", "A", ")", "and", "25", "to", "SES", "(", "arm", "B", ")", ".", "The", "median", "operative", "time", "was", "85", "minutes", "for", "TB", "vs", "115", "minutes", "for", "SES", "(", "p", "=", ".001", ")", ".", "At", "multivariate", "analysis", ",", "endometrial", "cancer", "(", "p", "=", ".001", ")", "and", "TB", "(", "p", "=", ".001", ")", "were", "independently", "associated", "with", "shorter", "operating", "time", ".", "No", "differences", "in", "perioperative", "outcomes", "and", "postoperative", "complications", "were", "observed", "between", "the", "2", "arms", ".", "Patients", "who", "underwent", "TB", "reported", "less", "postoperative", "pain", ",", "both", "at", "rest", "(", "p", "=", ".005", ")", "and", "after", "the", "Valsalva", "maneuver", "(", "p", "=", ".008", ")", ",", "with", "less", "additional", "analgesic", "therapy", "other", "than", "standard", "therapy", "required", "in", "patients", "who", "underwent", "SES", "(", "p", "=", ".02", ")", ".", "CONCLUSION", "TB", "is", "associated", "with", "shorter", "operative", "time", "and", "less", "postoperative", "pain", "than", "is", "the", "standard", "technique", "(", "SES", ")", "in", "patients", "with", "uterine", "cancer", "." ]
[ "Intervention_Surgical", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Physical", "Participant_Condition", "Outcome_Pain", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Sex" ]
THUNDERBEAT is a Intervention_Surgical, standard electrosurgery is a Intervention_Surgical, gynecologic cancer is a Participant_Condition, operative time is a Outcome_Other, gynecologic tumors . is a Participant_Condition, Fifty is a Participant_Sample-size, cervical cancer is a Participant_Condition, neoadjuvant treatment ( is a Intervention_Physical, chemotherapy is a Intervention_Pharmacological, or radiochemotherapy ) is a Intervention_Physical, Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy is a Intervention_Surgical, 25 is a Participant_Sample-size, women is a Participant_Sex, median operative time is a Outcome_Other, shorter operating time . is a Outcome_Other, perioperative outcomes and postoperative complications is a Outcome_Adverse-effects, postoperative pain is a Outcome_Pain, uterine cancer is a Participant_Condition
62919_task1
Sentence: Randomized study comparing use of THUNDERBEAT technology vs standard electrosurgery during laparoscopic radical hysterectomy and pelvic lymphadenectomy for gynecologic cancer . STUDY OBJECTIVE To compare operative time with use of THUNDERBEAT ( TB ) vs standard electrosurgery ( SES ) during laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat gynecologic tumors . DESIGN Evidence obtained from a properly designed , randomized , controlled trial ( Canadian Task Force classification I ) . SETTING Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome , Italy . PATIENTS Fifty patients with early cervical cancer ( FIGO stages IA2 , IB1 , IIA < 2 cm ) or locally advanced cervical cancer ( FIGO stages IB2 , IIA > 2cm , IIB ) who received neoadjuvant treatment ( chemotherapy or radiochemotherapy ) and demonstrated a complete or partial clinical response and early stage endometrioid endometrial cancer ( FIGO stages IB , II ) were randomly assigned to undergo TB ( arm A ) or SES ( arm B ) . INTERVENTION Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy , using an easily reproducible technique was performed . MEASUREMENTS AND MAIN RESULTS Fifty patients were available for analysis , with 25 women randomly assigned to TB ( arm A ) and 25 to SES ( arm B ) . The median operative time was 85 minutes for TB vs 115 minutes for SES ( p = .001 ) . At multivariate analysis , endometrial cancer ( p = .001 ) and TB ( p = .001 ) were independently associated with shorter operating time . No differences in perioperative outcomes and postoperative complications were observed between the 2 arms . Patients who underwent TB reported less postoperative pain , both at rest ( p = .005 ) and after the Valsalva maneuver ( p = .008 ) , with less additional analgesic therapy other than standard therapy required in patients who underwent SES ( p = .02 ) . CONCLUSION TB is associated with shorter operative time and less postoperative pain than is the standard technique ( SES ) in patients with uterine cancer . Instructions: please typing these entity words according to sentence: THUNDERBEAT, standard electrosurgery, gynecologic cancer, operative time, gynecologic tumors ., Fifty, cervical cancer, neoadjuvant treatment (, chemotherapy, or radiochemotherapy ), Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy, 25, women, median operative time, shorter operating time ., perioperative outcomes and postoperative complications, postoperative pain, uterine cancer Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Participant_Sex, Outcome_Pain, Participant_Sample-size, Outcome_Other, Intervention_Surgical
[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Pharmacological", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
Randomized study comparing use of THUNDERBEAT technology vs standard electrosurgery during laparoscopic radical hysterectomy and pelvic lymphadenectomy for gynecologic cancer . STUDY OBJECTIVE To compare operative time with use of THUNDERBEAT ( TB ) vs standard electrosurgery ( SES ) during laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat gynecologic tumors . DESIGN Evidence obtained from a properly designed , randomized , controlled trial ( Canadian Task Force classification I ) . SETTING Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome , Italy . PATIENTS Fifty patients with early cervical cancer ( FIGO stages IA2 , IB1 , IIA < 2 cm ) or locally advanced cervical cancer ( FIGO stages IB2 , IIA > 2cm , IIB ) who received neoadjuvant treatment ( chemotherapy or radiochemotherapy ) and demonstrated a complete or partial clinical response and early stage endometrioid endometrial cancer ( FIGO stages IB , II ) were randomly assigned to undergo TB ( arm A ) or SES ( arm B ) . INTERVENTION Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy , using an easily reproducible technique was performed . MEASUREMENTS AND MAIN RESULTS Fifty patients were available for analysis , with 25 women randomly assigned to TB ( arm A ) and 25 to SES ( arm B ) . The median operative time was 85 minutes for TB vs 115 minutes for SES ( p = .001 ) . At multivariate analysis , endometrial cancer ( p = .001 ) and TB ( p = .001 ) were independently associated with shorter operating time . No differences in perioperative outcomes and postoperative complications were observed between the 2 arms . Patients who underwent TB reported less postoperative pain , both at rest ( p = .005 ) and after the Valsalva maneuver ( p = .008 ) , with less additional analgesic therapy other than standard therapy required in patients who underwent SES ( p = .02 ) . CONCLUSION TB is associated with shorter operative time and less postoperative pain than is the standard technique ( SES ) in patients with uterine cancer .
[ "Randomized", "study", "comparing", "use", "of", "THUNDERBEAT", "technology", "vs", "standard", "electrosurgery", "during", "laparoscopic", "radical", "hysterectomy", "and", "pelvic", "lymphadenectomy", "for", "gynecologic", "cancer", ".", "STUDY", "OBJECTIVE", "To", "compare", "operative", "time", "with", "use", "of", "THUNDERBEAT", "(", "TB", ")", "vs", "standard", "electrosurgery", "(", "SES", ")", "during", "laparoscopic", "radical", "hysterectomy", "and", "pelvic", "lymphadenectomy", "to", "treat", "gynecologic", "tumors", ".", "DESIGN", "Evidence", "obtained", "from", "a", "properly", "designed", ",", "randomized", ",", "controlled", "trial", "(", "Canadian", "Task", "Force", "classification", "I", ")", ".", "SETTING", "Gynecologic", "Oncology", "Unit", "of", "the", "Catholic", "University", "of", "the", "Sacred", "Heart", "in", "Rome", ",", "Italy", ".", "PATIENTS", "Fifty", "patients", "with", "early", "cervical", "cancer", "(", "FIGO", "stages", "IA2", ",", "IB1", ",", "IIA", "<", "2", "cm", ")", "or", "locally", "advanced", "cervical", "cancer", "(", "FIGO", "stages", "IB2", ",", "IIA", ">", "2", "cm", ",", "IIB", ")", "who", "received", "neoadjuvant", "treatment", "(", "chemotherapy", "or", "radiochemotherapy", ")", "and", "demonstrated", "a", "complete", "or", "partial", "clinical", "response", "and", "early", "stage", "endometrioid", "endometrial", "cancer", "(", "FIGO", "stages", "IB", ",", "II", ")", "were", "randomly", "assigned", "to", "undergo", "TB", "(", "arm", "A", ")", "or", "SES", "(", "arm", "B", ")", ".", "INTERVENTION", "Laparoscopic", "radical", "hysterectomy", "with", "bilateral", "pelvic", "lymphadenectomy", ",", "using", "an", "easily", "reproducible", "technique", "was", "performed", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", "Fifty", "patients", "were", "available", "for", "analysis", ",", "with", "25", "women", "randomly", "assigned", "to", "TB", "(", "arm", "A", ")", "and", "25", "to", "SES", "(", "arm", "B", ")", ".", "The", "median", "operative", "time", "was", "85", "minutes", "for", "TB", "vs", "115", "minutes", "for", "SES", "(", "p", "=", ".001", ")", ".", "At", "multivariate", "analysis", ",", "endometrial", "cancer", "(", "p", "=", ".001", ")", "and", "TB", "(", "p", "=", ".001", ")", "were", "independently", "associated", "with", "shorter", "operating", "time", ".", "No", "differences", "in", "perioperative", "outcomes", "and", "postoperative", "complications", "were", "observed", "between", "the", "2", "arms", ".", "Patients", "who", "underwent", "TB", "reported", "less", "postoperative", "pain", ",", "both", "at", "rest", "(", "p", "=", ".005", ")", "and", "after", "the", "Valsalva", "maneuver", "(", "p", "=", ".008", ")", ",", "with", "less", "additional", "analgesic", "therapy", "other", "than", "standard", "therapy", "required", "in", "patients", "who", "underwent", "SES", "(", "p", "=", ".02", ")", ".", "CONCLUSION", "TB", "is", "associated", "with", "shorter", "operative", "time", "and", "less", "postoperative", "pain", "than", "is", "the", "standard", "technique", "(", "SES", ")", "in", "patients", "with", "uterine", "cancer", "." ]
[ "Intervention_Surgical", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Physical", "Participant_Condition", "Outcome_Pain", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Sex" ]
THUNDERBEAT, standard electrosurgery, gynecologic cancer, operative time, gynecologic tumors ., Fifty, cervical cancer, neoadjuvant treatment (, chemotherapy, or radiochemotherapy ), Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy, 25, women, median operative time, shorter operating time ., perioperative outcomes and postoperative complications, postoperative pain, uterine cancer
62919_task2
Sentence: Randomized study comparing use of THUNDERBEAT technology vs standard electrosurgery during laparoscopic radical hysterectomy and pelvic lymphadenectomy for gynecologic cancer . STUDY OBJECTIVE To compare operative time with use of THUNDERBEAT ( TB ) vs standard electrosurgery ( SES ) during laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat gynecologic tumors . DESIGN Evidence obtained from a properly designed , randomized , controlled trial ( Canadian Task Force classification I ) . SETTING Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome , Italy . PATIENTS Fifty patients with early cervical cancer ( FIGO stages IA2 , IB1 , IIA < 2 cm ) or locally advanced cervical cancer ( FIGO stages IB2 , IIA > 2cm , IIB ) who received neoadjuvant treatment ( chemotherapy or radiochemotherapy ) and demonstrated a complete or partial clinical response and early stage endometrioid endometrial cancer ( FIGO stages IB , II ) were randomly assigned to undergo TB ( arm A ) or SES ( arm B ) . INTERVENTION Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy , using an easily reproducible technique was performed . MEASUREMENTS AND MAIN RESULTS Fifty patients were available for analysis , with 25 women randomly assigned to TB ( arm A ) and 25 to SES ( arm B ) . The median operative time was 85 minutes for TB vs 115 minutes for SES ( p = .001 ) . At multivariate analysis , endometrial cancer ( p = .001 ) and TB ( p = .001 ) were independently associated with shorter operating time . No differences in perioperative outcomes and postoperative complications were observed between the 2 arms . Patients who underwent TB reported less postoperative pain , both at rest ( p = .005 ) and after the Valsalva maneuver ( p = .008 ) , with less additional analgesic therapy other than standard therapy required in patients who underwent SES ( p = .02 ) . CONCLUSION TB is associated with shorter operative time and less postoperative pain than is the standard technique ( SES ) in patients with uterine cancer . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Pharmacological", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O" ]
Randomized study comparing use of THUNDERBEAT technology vs standard electrosurgery during laparoscopic radical hysterectomy and pelvic lymphadenectomy for gynecologic cancer . STUDY OBJECTIVE To compare operative time with use of THUNDERBEAT ( TB ) vs standard electrosurgery ( SES ) during laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat gynecologic tumors . DESIGN Evidence obtained from a properly designed , randomized , controlled trial ( Canadian Task Force classification I ) . SETTING Gynecologic Oncology Unit of the Catholic University of the Sacred Heart in Rome , Italy . PATIENTS Fifty patients with early cervical cancer ( FIGO stages IA2 , IB1 , IIA < 2 cm ) or locally advanced cervical cancer ( FIGO stages IB2 , IIA > 2cm , IIB ) who received neoadjuvant treatment ( chemotherapy or radiochemotherapy ) and demonstrated a complete or partial clinical response and early stage endometrioid endometrial cancer ( FIGO stages IB , II ) were randomly assigned to undergo TB ( arm A ) or SES ( arm B ) . INTERVENTION Laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy , using an easily reproducible technique was performed . MEASUREMENTS AND MAIN RESULTS Fifty patients were available for analysis , with 25 women randomly assigned to TB ( arm A ) and 25 to SES ( arm B ) . The median operative time was 85 minutes for TB vs 115 minutes for SES ( p = .001 ) . At multivariate analysis , endometrial cancer ( p = .001 ) and TB ( p = .001 ) were independently associated with shorter operating time . No differences in perioperative outcomes and postoperative complications were observed between the 2 arms . Patients who underwent TB reported less postoperative pain , both at rest ( p = .005 ) and after the Valsalva maneuver ( p = .008 ) , with less additional analgesic therapy other than standard therapy required in patients who underwent SES ( p = .02 ) . CONCLUSION TB is associated with shorter operative time and less postoperative pain than is the standard technique ( SES ) in patients with uterine cancer .
[ "Randomized", "study", "comparing", "use", "of", "THUNDERBEAT", "technology", "vs", "standard", "electrosurgery", "during", "laparoscopic", "radical", "hysterectomy", "and", "pelvic", "lymphadenectomy", "for", "gynecologic", "cancer", ".", "STUDY", "OBJECTIVE", "To", "compare", "operative", "time", "with", "use", "of", "THUNDERBEAT", "(", "TB", ")", "vs", "standard", "electrosurgery", "(", "SES", ")", "during", "laparoscopic", "radical", "hysterectomy", "and", "pelvic", "lymphadenectomy", "to", "treat", "gynecologic", "tumors", ".", "DESIGN", "Evidence", "obtained", "from", "a", "properly", "designed", ",", "randomized", ",", "controlled", "trial", "(", "Canadian", "Task", "Force", "classification", "I", ")", ".", "SETTING", "Gynecologic", "Oncology", "Unit", "of", "the", "Catholic", "University", "of", "the", "Sacred", "Heart", "in", "Rome", ",", "Italy", ".", "PATIENTS", "Fifty", "patients", "with", "early", "cervical", "cancer", "(", "FIGO", "stages", "IA2", ",", "IB1", ",", "IIA", "<", "2", "cm", ")", "or", "locally", "advanced", "cervical", "cancer", "(", "FIGO", "stages", "IB2", ",", "IIA", ">", "2", "cm", ",", "IIB", ")", "who", "received", "neoadjuvant", "treatment", "(", "chemotherapy", "or", "radiochemotherapy", ")", "and", "demonstrated", "a", "complete", "or", "partial", "clinical", "response", "and", "early", "stage", "endometrioid", "endometrial", "cancer", "(", "FIGO", "stages", "IB", ",", "II", ")", "were", "randomly", "assigned", "to", "undergo", "TB", "(", "arm", "A", ")", "or", "SES", "(", "arm", "B", ")", ".", "INTERVENTION", "Laparoscopic", "radical", "hysterectomy", "with", "bilateral", "pelvic", "lymphadenectomy", ",", "using", "an", "easily", "reproducible", "technique", "was", "performed", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", "Fifty", "patients", "were", "available", "for", "analysis", ",", "with", "25", "women", "randomly", "assigned", "to", "TB", "(", "arm", "A", ")", "and", "25", "to", "SES", "(", "arm", "B", ")", ".", "The", "median", "operative", "time", "was", "85", "minutes", "for", "TB", "vs", "115", "minutes", "for", "SES", "(", "p", "=", ".001", ")", ".", "At", "multivariate", "analysis", ",", "endometrial", "cancer", "(", "p", "=", ".001", ")", "and", "TB", "(", "p", "=", ".001", ")", "were", "independently", "associated", "with", "shorter", "operating", "time", ".", "No", "differences", "in", "perioperative", "outcomes", "and", "postoperative", "complications", "were", "observed", "between", "the", "2", "arms", ".", "Patients", "who", "underwent", "TB", "reported", "less", "postoperative", "pain", ",", "both", "at", "rest", "(", "p", "=", ".005", ")", "and", "after", "the", "Valsalva", "maneuver", "(", "p", "=", ".008", ")", ",", "with", "less", "additional", "analgesic", "therapy", "other", "than", "standard", "therapy", "required", "in", "patients", "who", "underwent", "SES", "(", "p", "=", ".02", ")", ".", "CONCLUSION", "TB", "is", "associated", "with", "shorter", "operative", "time", "and", "less", "postoperative", "pain", "than", "is", "the", "standard", "technique", "(", "SES", ")", "in", "patients", "with", "uterine", "cancer", "." ]
[ "Intervention_Surgical", "Outcome_Adverse-effects", "Outcome_Other", "Intervention_Physical", "Participant_Condition", "Outcome_Pain", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Sex" ]
iliac artery is an umlsterm, total hip replacement is an umlsterm, vessels is an umlsterm, vessel is an umlsterm, patient is an umlsterm, operation is an umlsterm, ischemic is an umlsterm, syndromes is an umlsterm, lower limbs is an umlsterm, total hip replacement is an umlsterm, angiography is an umlsterm, cause is an umlsterm, thrombosis is an umlsterm, therapy is an umlsterm, thrombectomies is an umlsterm
DerUnfallchirurg.71000531.eng.abstr_task0
Sentence: We report on three arterial thromboses of the external iliac artery following total hip replacement . As a result of implanted cement/spongiosa or protrusion of the acetabular component , the iliac vessels were compressed . Furthermore , we report about one intraoperative arterial vessel lesion in a 65-year-old patient during a revision operation . We recommend that in case of acute ischemic syndromes of lower limbs following total hip replacement , an angiography should be performed in order to exclude an extravascular cause of thrombosis . For therapy in those cases extra-anatomic bypasses should be preferred to thrombectomies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
We report on three arterial thromboses of the external iliac artery following total hip replacement . As a result of implanted cement/spongiosa or protrusion of the acetabular component , the iliac vessels were compressed . Furthermore , we report about one intraoperative arterial vessel lesion in a 65-year-old patient during a revision operation . We recommend that in case of acute ischemic syndromes of lower limbs following total hip replacement , an angiography should be performed in order to exclude an extravascular cause of thrombosis . For therapy in those cases extra-anatomic bypasses should be preferred to thrombectomies .
[ "We", "report", "on", "three", "arterial", "thromboses", "of", "the", "external", "iliac", "artery", "following", "total", "hip", "replacement", ".", "As", "a", "result", "of", "implanted", "cement", "/", "spongiosa", "or", "protrusion", "of", "the", "acetabular", "component", ",", "the", "iliac", "vessels", "were", "compressed", ".", "Furthermore", ",", "we", "report", "about", "one", "intraoperative", "arterial", "vessel", "lesion", "in", "a", "65-year", "-", "old", "patient", "during", "a", "revision", "operation", ".", "We", "recommend", "that", "in", "case", "of", "acute", "ischemic", "syndromes", "of", "lower", "limbs", "following", "total", "hip", "replacement", ",", "an", "angiography", "should", "be", "performed", "in", "order", "to", "exclude", "an", "extravascular", "cause", "of", "thrombosis", ".", "For", "therapy", "in", "those", "cases", "extra", "-", "anatomic", "bypasses", "should", "be", "preferred", "to", "thrombectomies", "." ]
[ "umlsterm" ]
iliac artery is an umlsterm, total hip replacement is an umlsterm, vessels is an umlsterm, vessel is an umlsterm, patient is an umlsterm, operation is an umlsterm, ischemic is an umlsterm, syndromes is an umlsterm, lower limbs is an umlsterm, total hip replacement is an umlsterm, angiography is an umlsterm, cause is an umlsterm, thrombosis is an umlsterm, therapy is an umlsterm, thrombectomies is an umlsterm
DerUnfallchirurg.71000531.eng.abstr_task1
Sentence: We report on three arterial thromboses of the external iliac artery following total hip replacement . As a result of implanted cement/spongiosa or protrusion of the acetabular component , the iliac vessels were compressed . Furthermore , we report about one intraoperative arterial vessel lesion in a 65-year-old patient during a revision operation . We recommend that in case of acute ischemic syndromes of lower limbs following total hip replacement , an angiography should be performed in order to exclude an extravascular cause of thrombosis . For therapy in those cases extra-anatomic bypasses should be preferred to thrombectomies . Instructions: please typing these entity words according to sentence: iliac artery, total hip replacement, vessels, vessel, patient, operation, ischemic, syndromes, lower limbs, total hip replacement, angiography, cause, thrombosis, therapy, thrombectomies Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
We report on three arterial thromboses of the external iliac artery following total hip replacement . As a result of implanted cement/spongiosa or protrusion of the acetabular component , the iliac vessels were compressed . Furthermore , we report about one intraoperative arterial vessel lesion in a 65-year-old patient during a revision operation . We recommend that in case of acute ischemic syndromes of lower limbs following total hip replacement , an angiography should be performed in order to exclude an extravascular cause of thrombosis . For therapy in those cases extra-anatomic bypasses should be preferred to thrombectomies .
[ "We", "report", "on", "three", "arterial", "thromboses", "of", "the", "external", "iliac", "artery", "following", "total", "hip", "replacement", ".", "As", "a", "result", "of", "implanted", "cement", "/", "spongiosa", "or", "protrusion", "of", "the", "acetabular", "component", ",", "the", "iliac", "vessels", "were", "compressed", ".", "Furthermore", ",", "we", "report", "about", "one", "intraoperative", "arterial", "vessel", "lesion", "in", "a", "65-year", "-", "old", "patient", "during", "a", "revision", "operation", ".", "We", "recommend", "that", "in", "case", "of", "acute", "ischemic", "syndromes", "of", "lower", "limbs", "following", "total", "hip", "replacement", ",", "an", "angiography", "should", "be", "performed", "in", "order", "to", "exclude", "an", "extravascular", "cause", "of", "thrombosis", ".", "For", "therapy", "in", "those", "cases", "extra", "-", "anatomic", "bypasses", "should", "be", "preferred", "to", "thrombectomies", "." ]
[ "umlsterm" ]
iliac artery, total hip replacement, vessels, vessel, patient, operation, ischemic, syndromes, lower limbs, total hip replacement, angiography, cause, thrombosis, therapy, thrombectomies
DerUnfallchirurg.71000531.eng.abstr_task2
Sentence: We report on three arterial thromboses of the external iliac artery following total hip replacement . As a result of implanted cement/spongiosa or protrusion of the acetabular component , the iliac vessels were compressed . Furthermore , we report about one intraoperative arterial vessel lesion in a 65-year-old patient during a revision operation . We recommend that in case of acute ischemic syndromes of lower limbs following total hip replacement , an angiography should be performed in order to exclude an extravascular cause of thrombosis . For therapy in those cases extra-anatomic bypasses should be preferred to thrombectomies . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
We report on three arterial thromboses of the external iliac artery following total hip replacement . As a result of implanted cement/spongiosa or protrusion of the acetabular component , the iliac vessels were compressed . Furthermore , we report about one intraoperative arterial vessel lesion in a 65-year-old patient during a revision operation . We recommend that in case of acute ischemic syndromes of lower limbs following total hip replacement , an angiography should be performed in order to exclude an extravascular cause of thrombosis . For therapy in those cases extra-anatomic bypasses should be preferred to thrombectomies .
[ "We", "report", "on", "three", "arterial", "thromboses", "of", "the", "external", "iliac", "artery", "following", "total", "hip", "replacement", ".", "As", "a", "result", "of", "implanted", "cement", "/", "spongiosa", "or", "protrusion", "of", "the", "acetabular", "component", ",", "the", "iliac", "vessels", "were", "compressed", ".", "Furthermore", ",", "we", "report", "about", "one", "intraoperative", "arterial", "vessel", "lesion", "in", "a", "65-year", "-", "old", "patient", "during", "a", "revision", "operation", ".", "We", "recommend", "that", "in", "case", "of", "acute", "ischemic", "syndromes", "of", "lower", "limbs", "following", "total", "hip", "replacement", ",", "an", "angiography", "should", "be", "performed", "in", "order", "to", "exclude", "an", "extravascular", "cause", "of", "thrombosis", ".", "For", "therapy", "in", "those", "cases", "extra", "-", "anatomic", "bypasses", "should", "be", "preferred", "to", "thrombectomies", "." ]
[ "umlsterm" ]
solución antiséptica is a NORMALIZABLES, vacuna antitetánica is a UNCLEAR, gammaglobulina is a PROTEINAS, amoxilina - clavulánico is a NORMALIZABLES, metronidazol is a NORMALIZABLES, solución antiséptica is a NORMALIZABLES
329_task0
Sentence: Presentamos un caso de un varón de 18 años remitido al Hospital 12 de Octubre por el SAMUR, tras sufrir una herida por asta de toro en la región cérvicofacial izquierda durante los encierros de San Sebastián de Los Reyes en Agosto de 2005. Se realiza traslado inminente a quirófano, donde se evidencia la correcta intubación orotraqueal que había sido realizada in situ por el personal sanitario de la plaza de toros. Se comprueba la ausencia de alteraciones respiratorias y cardiovasculares, así como una situación hemodinámica estable. A continuación, bajo anestesia general, se procede a la realización de traqueotomía reglada y canalización de vía central y periféricas correspondientes. Posteriormente, se procede a una exploración inicial y diagnóstica, donde se evidencia una herida incisocontusa y anfractuosa desde la región supraclavicular izquierda alta hasta la comisura labial ipsilateral. Se objetiva la existencia de una fractura de cuerpo mandibular derecho, fractura conminuta de ángulo mandibular izquierdo, avulsión dental del sector incisal del maxilar superior, así como laceración severa de la musculatura lingual y suelo de boca. Asimismo, se observa una exposición del paquete yugulo-carotídeo izquierdo comprobándose la integridad total del mismo. Se realiza sutura interdental a nivel de los focos de fractura y de las partes blandas adyacentes, con objeto de restaurar provisionalmente la anatomía, y se traslada al paciente al Servicio de Radiología para la realización de TC craneofacial diagnóstico y con el objetivo de descartar la existencia de lesiones del sistema nervioso central y cervicales asociadas. Posteriormente y una vez en quirófano, se realiza laringoscopia directa que excluye la presencia de lesiones laringoesofágicas. Se realiza lavado meticuloso con cepillo quirúrgico y solución antiséptica de toda la cavidad oral y tejidos afectos. Se administra vacuna antitetánica y gammaglobulina, y se inicia el tratamiento sistémico intravenoso con amoxilina-clavulánico y metronidazol. Tras una correcta exposición de los focos de fractura a nivel del cuerpo mandibular derecho y ángulo mandibular izquierdo, favorecido por las características de la propia herida, se realiza reducción y osteosíntesis empleando para ello placas de reconstrucción mandibular 2.4 Synthes®, dada la presencia de conminución en una de ellas y el alto potencial de infección del lecho quirúrgico. Se procede a la exodoncia de los restos radiculares remanentes en el sector incisal superior y regularización ósea correspondiente. Se realiza sutura y restauración anatómica de la musculatura cervical, suelo de boca y lengua. Se realiza anastomosis microquirúrgica del nervio mentoniano derecho y lingual izquierdo. Se realiza sutura de piel y mucosa oral. Posteriormente el paciente es traladado al Servicio de UVI-Politrauma donde permanece 36 horas no presentando en este tiempo complicaciones neurológicas ni sistémicas. Tras la derivación a planta, se prosigue con el tratamiento antibiótico durante 10 días, realizándose curas diarias con solución antiséptica de la herida, tanto intraoral como cutánea. No se evidenció patología infecciosa en dicho territorio, presentando una evolución posterior favorable, siendo dado de alta al undécimo día. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS, UNCLEAR
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "I-UNCLEAR", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Presentamos un caso de un varón de 18 años remitido al Hospital 12 de Octubre por el SAMUR, tras sufrir una herida por asta de toro en la región cérvicofacial izquierda durante los encierros de San Sebastián de Los Reyes en Agosto de 2005. Se realiza traslado inminente a quirófano, donde se evidencia la correcta intubación orotraqueal que había sido realizada in situ por el personal sanitario de la plaza de toros. Se comprueba la ausencia de alteraciones respiratorias y cardiovasculares, así como una situación hemodinámica estable. A continuación, bajo anestesia general, se procede a la realización de traqueotomía reglada y canalización de vía central y periféricas correspondientes. Posteriormente, se procede a una exploración inicial y diagnóstica, donde se evidencia una herida incisocontusa y anfractuosa desde la región supraclavicular izquierda alta hasta la comisura labial ipsilateral. Se objetiva la existencia de una fractura de cuerpo mandibular derecho, fractura conminuta de ángulo mandibular izquierdo, avulsión dental del sector incisal del maxilar superior, así como laceración severa de la musculatura lingual y suelo de boca. Asimismo, se observa una exposición del paquete yugulo-carotídeo izquierdo comprobándose la integridad total del mismo. Se realiza sutura interdental a nivel de los focos de fractura y de las partes blandas adyacentes, con objeto de restaurar provisionalmente la anatomía, y se traslada al paciente al Servicio de Radiología para la realización de TC craneofacial diagnóstico y con el objetivo de descartar la existencia de lesiones del sistema nervioso central y cervicales asociadas. Posteriormente y una vez en quirófano, se realiza laringoscopia directa que excluye la presencia de lesiones laringoesofágicas. Se realiza lavado meticuloso con cepillo quirúrgico y solución antiséptica de toda la cavidad oral y tejidos afectos. Se administra vacuna antitetánica y gammaglobulina, y se inicia el tratamiento sistémico intravenoso con amoxilina-clavulánico y metronidazol. Tras una correcta exposición de los focos de fractura a nivel del cuerpo mandibular derecho y ángulo mandibular izquierdo, favorecido por las características de la propia herida, se realiza reducción y osteosíntesis empleando para ello placas de reconstrucción mandibular 2.4 Synthes®, dada la presencia de conminución en una de ellas y el alto potencial de infección del lecho quirúrgico. Se procede a la exodoncia de los restos radiculares remanentes en el sector incisal superior y regularización ósea correspondiente. Se realiza sutura y restauración anatómica de la musculatura cervical, suelo de boca y lengua. Se realiza anastomosis microquirúrgica del nervio mentoniano derecho y lingual izquierdo. Se realiza sutura de piel y mucosa oral. Posteriormente el paciente es traladado al Servicio de UVI-Politrauma donde permanece 36 horas no presentando en este tiempo complicaciones neurológicas ni sistémicas. Tras la derivación a planta, se prosigue con el tratamiento antibiótico durante 10 días, realizándose curas diarias con solución antiséptica de la herida, tanto intraoral como cutánea. No se evidenció patología infecciosa en dicho territorio, presentando una evolución posterior favorable, siendo dado de alta al undécimo día.
[ "Presentamos", "un", "caso", "de", "un", "varón", "de", "18", "años", "remitido", "al", "Hospital", "12", "de", "Octubre", "por", "el", "SAMUR", ",", "tras", "sufrir", "una", "herida", "por", "asta", "de", "toro", "en", "la", "región", "cérvicofacial", "izquierda", "durante", "los", "encierros", "de", "San", "Sebastián", "de", "Los", "Reyes", "en", "Agosto", "de", "2005", ".", "Se", "realiza", "traslado", "inminente", "a", "quirófano", ",", "donde", "se", "evidencia", "la", "correcta", "intubación", "orotraqueal", "que", "había", "sido", "realizada", "in", "situ", "por", "el", "personal", "sanitario", "de", "la", "plaza", "de", "toros", ".", "Se", "comprueba", "la", "ausencia", "de", "alteraciones", "respiratorias", "y", "cardiovasculares", ",", "así", "como", "una", "situación", "hemodinámica", "estable", ".", "\n", "A", "continuación", ",", "bajo", "anestesia", "general", ",", "se", "procede", "a", "la", "realización", "de", "traqueotomía", "reglada", "y", "canalización", "de", "vía", "central", "y", "periféricas", "correspondientes", ".", "Posteriormente", ",", "se", "procede", "a", "una", "exploración", "inicial", "y", "diagnóstica", ",", "donde", "se", "evidencia", "una", "herida", "incisocontusa", "y", "anfractuosa", "desde", "la", "región", "supraclavicular", "izquierda", "alta", "hasta", "la", "comisura", "labial", "ipsilateral", ".", "Se", "objetiva", "la", "existencia", "de", "una", "fractura", "de", "cuerpo", "mandibular", "derecho", ",", "fractura", "conminuta", "de", "ángulo", "mandibular", "izquierdo", ",", "avulsión", "dental", "del", "sector", "incisal", "del", "maxilar", "superior", ",", "así", "como", "laceración", "severa", "de", "la", "musculatura", "lingual", "y", "suelo", "de", "boca", ".", "Asimismo", ",", "se", "observa", "una", "exposición", "del", "paquete", "yugulo", "-", "carotídeo", "izquierdo", "comprobándose", "la", "integridad", "total", "del", "mismo", ".", "Se", "realiza", "sutura", "interdental", "a", "nivel", "de", "los", "focos", "de", "fractura", "y", "de", "las", "partes", "blandas", "adyacentes", ",", "con", "objeto", "de", "restaurar", "provisionalmente", "la", "anatomía", ",", "y", "se", "traslada", "al", "paciente", "al", "Servicio", "de", "Radiología", "para", "la", "realización", "de", "TC", "craneofacial", "diagnóstico", "y", "con", "el", "objetivo", "de", "descartar", "la", "existencia", "de", "lesiones", "del", "sistema", "nervioso", "central", "y", "cervicales", "asociadas", ".", "Posteriormente", "y", "una", "vez", "en", "quirófano", ",", "se", "realiza", "laringoscopia", "directa", "que", "excluye", "la", "presencia", "de", "lesiones", "laringoesofágicas", ".", "Se", "realiza", "lavado", "meticuloso", "con", "cepillo", "quirúrgico", "y", "solución", "antiséptica", "de", "toda", "la", "cavidad", "oral", "y", "tejidos", "afectos", ".", "Se", "administra", "vacuna", "antitetánica", "y", "gammaglobulina", ",", "y", "se", "inicia", "el", "tratamiento", "sistémico", "intravenoso", "con", "amoxilina", "-", "clavulánico", "y", "metronidazol", ".", "\n\n", "Tras", "una", "correcta", "exposición", "de", "los", "focos", "de", "fractura", "a", "nivel", "del", "cuerpo", "mandibular", "derecho", "y", "ángulo", "mandibular", "izquierdo", ",", "favorecido", "por", "las", "características", "de", "la", "propia", "herida", ",", "se", "realiza", "reducción", "y", "osteosíntesis", "empleando", "para", "ello", "placas", "de", "reconstrucción", "mandibular", "2.4", "Synthes", "®", ",", "dada", "la", "presencia", "de", "conminución", "en", "una", "de", "ellas", "y", "el", "alto", "potencial", "de", "infección", "del", "lecho", "quirúrgico", ".", "Se", "procede", "a", "la", "exodoncia", "de", "los", "restos", "radiculares", "remanentes", "en", "el", "sector", "incisal", "superior", "y", "regularización", "ósea", "correspondiente", ".", "Se", "realiza", "sutura", "y", "restauración", "anatómica", "de", "la", "musculatura", "cervical", ",", "suelo", "de", "boca", "y", "lengua", ".", "Se", "realiza", "anastomosis", "microquirúrgica", "del", "nervio", "mentoniano", "derecho", "y", "lingual", "izquierdo", ".", "Se", "realiza", "sutura", "de", "piel", "y", "mucosa", "oral", ".", "Posteriormente", "el", "paciente", "es", "traladado", "al", "Servicio", "de", "UVI", "-", "Politrauma", "donde", "permanece", "36", "horas", "no", "presentando", "en", "este", "tiempo", "complicaciones", "neurológicas", "ni", "sistémicas", ".", "Tras", "la", "derivación", "a", "planta", ",", "se", "prosigue", "con", "el", "tratamiento", "antibiótico", "durante", "10", "días", ",", "realizándose", "curas", "diarias", "con", "solución", "antiséptica", "de", "la", "herida", ",", "tanto", "intraoral", "como", "cutánea", ".", "No", "se", "evidenció", "patología", "infecciosa", "en", "dicho", "territorio", ",", "presentando", "una", "evolución", "posterior", "favorable", ",", "siendo", "dado", "de", "alta", "al", "undécimo", "día", ".", "\n\n" ]
[ "NORMALIZABLES", "UNCLEAR", "PROTEINAS" ]
solución antiséptica is a NORMALIZABLES, vacuna antitetánica is a UNCLEAR, gammaglobulina is a PROTEINAS, amoxilina - clavulánico is a NORMALIZABLES, metronidazol is a NORMALIZABLES, solución antiséptica is a NORMALIZABLES
329_task1
Sentence: Presentamos un caso de un varón de 18 años remitido al Hospital 12 de Octubre por el SAMUR, tras sufrir una herida por asta de toro en la región cérvicofacial izquierda durante los encierros de San Sebastián de Los Reyes en Agosto de 2005. Se realiza traslado inminente a quirófano, donde se evidencia la correcta intubación orotraqueal que había sido realizada in situ por el personal sanitario de la plaza de toros. Se comprueba la ausencia de alteraciones respiratorias y cardiovasculares, así como una situación hemodinámica estable. A continuación, bajo anestesia general, se procede a la realización de traqueotomía reglada y canalización de vía central y periféricas correspondientes. Posteriormente, se procede a una exploración inicial y diagnóstica, donde se evidencia una herida incisocontusa y anfractuosa desde la región supraclavicular izquierda alta hasta la comisura labial ipsilateral. Se objetiva la existencia de una fractura de cuerpo mandibular derecho, fractura conminuta de ángulo mandibular izquierdo, avulsión dental del sector incisal del maxilar superior, así como laceración severa de la musculatura lingual y suelo de boca. Asimismo, se observa una exposición del paquete yugulo-carotídeo izquierdo comprobándose la integridad total del mismo. Se realiza sutura interdental a nivel de los focos de fractura y de las partes blandas adyacentes, con objeto de restaurar provisionalmente la anatomía, y se traslada al paciente al Servicio de Radiología para la realización de TC craneofacial diagnóstico y con el objetivo de descartar la existencia de lesiones del sistema nervioso central y cervicales asociadas. Posteriormente y una vez en quirófano, se realiza laringoscopia directa que excluye la presencia de lesiones laringoesofágicas. Se realiza lavado meticuloso con cepillo quirúrgico y solución antiséptica de toda la cavidad oral y tejidos afectos. Se administra vacuna antitetánica y gammaglobulina, y se inicia el tratamiento sistémico intravenoso con amoxilina-clavulánico y metronidazol. Tras una correcta exposición de los focos de fractura a nivel del cuerpo mandibular derecho y ángulo mandibular izquierdo, favorecido por las características de la propia herida, se realiza reducción y osteosíntesis empleando para ello placas de reconstrucción mandibular 2.4 Synthes®, dada la presencia de conminución en una de ellas y el alto potencial de infección del lecho quirúrgico. Se procede a la exodoncia de los restos radiculares remanentes en el sector incisal superior y regularización ósea correspondiente. Se realiza sutura y restauración anatómica de la musculatura cervical, suelo de boca y lengua. Se realiza anastomosis microquirúrgica del nervio mentoniano derecho y lingual izquierdo. Se realiza sutura de piel y mucosa oral. Posteriormente el paciente es traladado al Servicio de UVI-Politrauma donde permanece 36 horas no presentando en este tiempo complicaciones neurológicas ni sistémicas. Tras la derivación a planta, se prosigue con el tratamiento antibiótico durante 10 días, realizándose curas diarias con solución antiséptica de la herida, tanto intraoral como cutánea. No se evidenció patología infecciosa en dicho territorio, presentando una evolución posterior favorable, siendo dado de alta al undécimo día. Instructions: please typing these entity words according to sentence: solución antiséptica, vacuna antitetánica, gammaglobulina, amoxilina - clavulánico, metronidazol, solución antiséptica Options: NORMALIZABLES, PROTEINAS, UNCLEAR
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "I-UNCLEAR", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Presentamos un caso de un varón de 18 años remitido al Hospital 12 de Octubre por el SAMUR, tras sufrir una herida por asta de toro en la región cérvicofacial izquierda durante los encierros de San Sebastián de Los Reyes en Agosto de 2005. Se realiza traslado inminente a quirófano, donde se evidencia la correcta intubación orotraqueal que había sido realizada in situ por el personal sanitario de la plaza de toros. Se comprueba la ausencia de alteraciones respiratorias y cardiovasculares, así como una situación hemodinámica estable. A continuación, bajo anestesia general, se procede a la realización de traqueotomía reglada y canalización de vía central y periféricas correspondientes. Posteriormente, se procede a una exploración inicial y diagnóstica, donde se evidencia una herida incisocontusa y anfractuosa desde la región supraclavicular izquierda alta hasta la comisura labial ipsilateral. Se objetiva la existencia de una fractura de cuerpo mandibular derecho, fractura conminuta de ángulo mandibular izquierdo, avulsión dental del sector incisal del maxilar superior, así como laceración severa de la musculatura lingual y suelo de boca. Asimismo, se observa una exposición del paquete yugulo-carotídeo izquierdo comprobándose la integridad total del mismo. Se realiza sutura interdental a nivel de los focos de fractura y de las partes blandas adyacentes, con objeto de restaurar provisionalmente la anatomía, y se traslada al paciente al Servicio de Radiología para la realización de TC craneofacial diagnóstico y con el objetivo de descartar la existencia de lesiones del sistema nervioso central y cervicales asociadas. Posteriormente y una vez en quirófano, se realiza laringoscopia directa que excluye la presencia de lesiones laringoesofágicas. Se realiza lavado meticuloso con cepillo quirúrgico y solución antiséptica de toda la cavidad oral y tejidos afectos. Se administra vacuna antitetánica y gammaglobulina, y se inicia el tratamiento sistémico intravenoso con amoxilina-clavulánico y metronidazol. Tras una correcta exposición de los focos de fractura a nivel del cuerpo mandibular derecho y ángulo mandibular izquierdo, favorecido por las características de la propia herida, se realiza reducción y osteosíntesis empleando para ello placas de reconstrucción mandibular 2.4 Synthes®, dada la presencia de conminución en una de ellas y el alto potencial de infección del lecho quirúrgico. Se procede a la exodoncia de los restos radiculares remanentes en el sector incisal superior y regularización ósea correspondiente. Se realiza sutura y restauración anatómica de la musculatura cervical, suelo de boca y lengua. Se realiza anastomosis microquirúrgica del nervio mentoniano derecho y lingual izquierdo. Se realiza sutura de piel y mucosa oral. Posteriormente el paciente es traladado al Servicio de UVI-Politrauma donde permanece 36 horas no presentando en este tiempo complicaciones neurológicas ni sistémicas. Tras la derivación a planta, se prosigue con el tratamiento antibiótico durante 10 días, realizándose curas diarias con solución antiséptica de la herida, tanto intraoral como cutánea. No se evidenció patología infecciosa en dicho territorio, presentando una evolución posterior favorable, siendo dado de alta al undécimo día.
[ "Presentamos", "un", "caso", "de", "un", "varón", "de", "18", "años", "remitido", "al", "Hospital", "12", "de", "Octubre", "por", "el", "SAMUR", ",", "tras", "sufrir", "una", "herida", "por", "asta", "de", "toro", "en", "la", "región", "cérvicofacial", "izquierda", "durante", "los", "encierros", "de", "San", "Sebastián", "de", "Los", "Reyes", "en", "Agosto", "de", "2005", ".", "Se", "realiza", "traslado", "inminente", "a", "quirófano", ",", "donde", "se", "evidencia", "la", "correcta", "intubación", "orotraqueal", "que", "había", "sido", "realizada", "in", "situ", "por", "el", "personal", "sanitario", "de", "la", "plaza", "de", "toros", ".", "Se", "comprueba", "la", "ausencia", "de", "alteraciones", "respiratorias", "y", "cardiovasculares", ",", "así", "como", "una", "situación", "hemodinámica", "estable", ".", "\n", "A", "continuación", ",", "bajo", "anestesia", "general", ",", "se", "procede", "a", "la", "realización", "de", "traqueotomía", "reglada", "y", "canalización", "de", "vía", "central", "y", "periféricas", "correspondientes", ".", "Posteriormente", ",", "se", "procede", "a", "una", "exploración", "inicial", "y", "diagnóstica", ",", "donde", "se", "evidencia", "una", "herida", "incisocontusa", "y", "anfractuosa", "desde", "la", "región", "supraclavicular", "izquierda", "alta", "hasta", "la", "comisura", "labial", "ipsilateral", ".", "Se", "objetiva", "la", "existencia", "de", "una", "fractura", "de", "cuerpo", "mandibular", "derecho", ",", "fractura", "conminuta", "de", "ángulo", "mandibular", "izquierdo", ",", "avulsión", "dental", "del", "sector", "incisal", "del", "maxilar", "superior", ",", "así", "como", "laceración", "severa", "de", "la", "musculatura", "lingual", "y", "suelo", "de", "boca", ".", "Asimismo", ",", "se", "observa", "una", "exposición", "del", "paquete", "yugulo", "-", "carotídeo", "izquierdo", "comprobándose", "la", "integridad", "total", "del", "mismo", ".", "Se", "realiza", "sutura", "interdental", "a", "nivel", "de", "los", "focos", "de", "fractura", "y", "de", "las", "partes", "blandas", "adyacentes", ",", "con", "objeto", "de", "restaurar", "provisionalmente", "la", "anatomía", ",", "y", "se", "traslada", "al", "paciente", "al", "Servicio", "de", "Radiología", "para", "la", "realización", "de", "TC", "craneofacial", "diagnóstico", "y", "con", "el", "objetivo", "de", "descartar", "la", "existencia", "de", "lesiones", "del", "sistema", "nervioso", "central", "y", "cervicales", "asociadas", ".", "Posteriormente", "y", "una", "vez", "en", "quirófano", ",", "se", "realiza", "laringoscopia", "directa", "que", "excluye", "la", "presencia", "de", "lesiones", "laringoesofágicas", ".", "Se", "realiza", "lavado", "meticuloso", "con", "cepillo", "quirúrgico", "y", "solución", "antiséptica", "de", "toda", "la", "cavidad", "oral", "y", "tejidos", "afectos", ".", "Se", "administra", "vacuna", "antitetánica", "y", "gammaglobulina", ",", "y", "se", "inicia", "el", "tratamiento", "sistémico", "intravenoso", "con", "amoxilina", "-", "clavulánico", "y", "metronidazol", ".", "\n\n", "Tras", "una", "correcta", "exposición", "de", "los", "focos", "de", "fractura", "a", "nivel", "del", "cuerpo", "mandibular", "derecho", "y", "ángulo", "mandibular", "izquierdo", ",", "favorecido", "por", "las", "características", "de", "la", "propia", "herida", ",", "se", "realiza", "reducción", "y", "osteosíntesis", "empleando", "para", "ello", "placas", "de", "reconstrucción", "mandibular", "2.4", "Synthes", "®", ",", "dada", "la", "presencia", "de", "conminución", "en", "una", "de", "ellas", "y", "el", "alto", "potencial", "de", "infección", "del", "lecho", "quirúrgico", ".", "Se", "procede", "a", "la", "exodoncia", "de", "los", "restos", "radiculares", "remanentes", "en", "el", "sector", "incisal", "superior", "y", "regularización", "ósea", "correspondiente", ".", "Se", "realiza", "sutura", "y", "restauración", "anatómica", "de", "la", "musculatura", "cervical", ",", "suelo", "de", "boca", "y", "lengua", ".", "Se", "realiza", "anastomosis", "microquirúrgica", "del", "nervio", "mentoniano", "derecho", "y", "lingual", "izquierdo", ".", "Se", "realiza", "sutura", "de", "piel", "y", "mucosa", "oral", ".", "Posteriormente", "el", "paciente", "es", "traladado", "al", "Servicio", "de", "UVI", "-", "Politrauma", "donde", "permanece", "36", "horas", "no", "presentando", "en", "este", "tiempo", "complicaciones", "neurológicas", "ni", "sistémicas", ".", "Tras", "la", "derivación", "a", "planta", ",", "se", "prosigue", "con", "el", "tratamiento", "antibiótico", "durante", "10", "días", ",", "realizándose", "curas", "diarias", "con", "solución", "antiséptica", "de", "la", "herida", ",", "tanto", "intraoral", "como", "cutánea", ".", "No", "se", "evidenció", "patología", "infecciosa", "en", "dicho", "territorio", ",", "presentando", "una", "evolución", "posterior", "favorable", ",", "siendo", "dado", "de", "alta", "al", "undécimo", "día", ".", "\n\n" ]
[ "NORMALIZABLES", "UNCLEAR", "PROTEINAS" ]
solución antiséptica, vacuna antitetánica, gammaglobulina, amoxilina - clavulánico, metronidazol, solución antiséptica
329_task2
Sentence: Presentamos un caso de un varón de 18 años remitido al Hospital 12 de Octubre por el SAMUR, tras sufrir una herida por asta de toro en la región cérvicofacial izquierda durante los encierros de San Sebastián de Los Reyes en Agosto de 2005. Se realiza traslado inminente a quirófano, donde se evidencia la correcta intubación orotraqueal que había sido realizada in situ por el personal sanitario de la plaza de toros. Se comprueba la ausencia de alteraciones respiratorias y cardiovasculares, así como una situación hemodinámica estable. A continuación, bajo anestesia general, se procede a la realización de traqueotomía reglada y canalización de vía central y periféricas correspondientes. Posteriormente, se procede a una exploración inicial y diagnóstica, donde se evidencia una herida incisocontusa y anfractuosa desde la región supraclavicular izquierda alta hasta la comisura labial ipsilateral. Se objetiva la existencia de una fractura de cuerpo mandibular derecho, fractura conminuta de ángulo mandibular izquierdo, avulsión dental del sector incisal del maxilar superior, así como laceración severa de la musculatura lingual y suelo de boca. Asimismo, se observa una exposición del paquete yugulo-carotídeo izquierdo comprobándose la integridad total del mismo. Se realiza sutura interdental a nivel de los focos de fractura y de las partes blandas adyacentes, con objeto de restaurar provisionalmente la anatomía, y se traslada al paciente al Servicio de Radiología para la realización de TC craneofacial diagnóstico y con el objetivo de descartar la existencia de lesiones del sistema nervioso central y cervicales asociadas. Posteriormente y una vez en quirófano, se realiza laringoscopia directa que excluye la presencia de lesiones laringoesofágicas. Se realiza lavado meticuloso con cepillo quirúrgico y solución antiséptica de toda la cavidad oral y tejidos afectos. Se administra vacuna antitetánica y gammaglobulina, y se inicia el tratamiento sistémico intravenoso con amoxilina-clavulánico y metronidazol. Tras una correcta exposición de los focos de fractura a nivel del cuerpo mandibular derecho y ángulo mandibular izquierdo, favorecido por las características de la propia herida, se realiza reducción y osteosíntesis empleando para ello placas de reconstrucción mandibular 2.4 Synthes®, dada la presencia de conminución en una de ellas y el alto potencial de infección del lecho quirúrgico. Se procede a la exodoncia de los restos radiculares remanentes en el sector incisal superior y regularización ósea correspondiente. Se realiza sutura y restauración anatómica de la musculatura cervical, suelo de boca y lengua. Se realiza anastomosis microquirúrgica del nervio mentoniano derecho y lingual izquierdo. Se realiza sutura de piel y mucosa oral. Posteriormente el paciente es traladado al Servicio de UVI-Politrauma donde permanece 36 horas no presentando en este tiempo complicaciones neurológicas ni sistémicas. Tras la derivación a planta, se prosigue con el tratamiento antibiótico durante 10 días, realizándose curas diarias con solución antiséptica de la herida, tanto intraoral como cutánea. No se evidenció patología infecciosa en dicho territorio, presentando una evolución posterior favorable, siendo dado de alta al undécimo día. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "I-UNCLEAR", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Presentamos un caso de un varón de 18 años remitido al Hospital 12 de Octubre por el SAMUR, tras sufrir una herida por asta de toro en la región cérvicofacial izquierda durante los encierros de San Sebastián de Los Reyes en Agosto de 2005. Se realiza traslado inminente a quirófano, donde se evidencia la correcta intubación orotraqueal que había sido realizada in situ por el personal sanitario de la plaza de toros. Se comprueba la ausencia de alteraciones respiratorias y cardiovasculares, así como una situación hemodinámica estable. A continuación, bajo anestesia general, se procede a la realización de traqueotomía reglada y canalización de vía central y periféricas correspondientes. Posteriormente, se procede a una exploración inicial y diagnóstica, donde se evidencia una herida incisocontusa y anfractuosa desde la región supraclavicular izquierda alta hasta la comisura labial ipsilateral. Se objetiva la existencia de una fractura de cuerpo mandibular derecho, fractura conminuta de ángulo mandibular izquierdo, avulsión dental del sector incisal del maxilar superior, así como laceración severa de la musculatura lingual y suelo de boca. Asimismo, se observa una exposición del paquete yugulo-carotídeo izquierdo comprobándose la integridad total del mismo. Se realiza sutura interdental a nivel de los focos de fractura y de las partes blandas adyacentes, con objeto de restaurar provisionalmente la anatomía, y se traslada al paciente al Servicio de Radiología para la realización de TC craneofacial diagnóstico y con el objetivo de descartar la existencia de lesiones del sistema nervioso central y cervicales asociadas. Posteriormente y una vez en quirófano, se realiza laringoscopia directa que excluye la presencia de lesiones laringoesofágicas. Se realiza lavado meticuloso con cepillo quirúrgico y solución antiséptica de toda la cavidad oral y tejidos afectos. Se administra vacuna antitetánica y gammaglobulina, y se inicia el tratamiento sistémico intravenoso con amoxilina-clavulánico y metronidazol. Tras una correcta exposición de los focos de fractura a nivel del cuerpo mandibular derecho y ángulo mandibular izquierdo, favorecido por las características de la propia herida, se realiza reducción y osteosíntesis empleando para ello placas de reconstrucción mandibular 2.4 Synthes®, dada la presencia de conminución en una de ellas y el alto potencial de infección del lecho quirúrgico. Se procede a la exodoncia de los restos radiculares remanentes en el sector incisal superior y regularización ósea correspondiente. Se realiza sutura y restauración anatómica de la musculatura cervical, suelo de boca y lengua. Se realiza anastomosis microquirúrgica del nervio mentoniano derecho y lingual izquierdo. Se realiza sutura de piel y mucosa oral. Posteriormente el paciente es traladado al Servicio de UVI-Politrauma donde permanece 36 horas no presentando en este tiempo complicaciones neurológicas ni sistémicas. Tras la derivación a planta, se prosigue con el tratamiento antibiótico durante 10 días, realizándose curas diarias con solución antiséptica de la herida, tanto intraoral como cutánea. No se evidenció patología infecciosa en dicho territorio, presentando una evolución posterior favorable, siendo dado de alta al undécimo día.
[ "Presentamos", "un", "caso", "de", "un", "varón", "de", "18", "años", "remitido", "al", "Hospital", "12", "de", "Octubre", "por", "el", "SAMUR", ",", "tras", "sufrir", "una", "herida", "por", "asta", "de", "toro", "en", "la", "región", "cérvicofacial", "izquierda", "durante", "los", "encierros", "de", "San", "Sebastián", "de", "Los", "Reyes", "en", "Agosto", "de", "2005", ".", "Se", "realiza", "traslado", "inminente", "a", "quirófano", ",", "donde", "se", "evidencia", "la", "correcta", "intubación", "orotraqueal", "que", "había", "sido", "realizada", "in", "situ", "por", "el", "personal", "sanitario", "de", "la", "plaza", "de", "toros", ".", "Se", "comprueba", "la", "ausencia", "de", "alteraciones", "respiratorias", "y", "cardiovasculares", ",", "así", "como", "una", "situación", "hemodinámica", "estable", ".", "\n", "A", "continuación", ",", "bajo", "anestesia", "general", ",", "se", "procede", "a", "la", "realización", "de", "traqueotomía", "reglada", "y", "canalización", "de", "vía", "central", "y", "periféricas", "correspondientes", ".", "Posteriormente", ",", "se", "procede", "a", "una", "exploración", "inicial", "y", "diagnóstica", ",", "donde", "se", "evidencia", "una", "herida", "incisocontusa", "y", "anfractuosa", "desde", "la", "región", "supraclavicular", "izquierda", "alta", "hasta", "la", "comisura", "labial", "ipsilateral", ".", "Se", "objetiva", "la", "existencia", "de", "una", "fractura", "de", "cuerpo", "mandibular", "derecho", ",", "fractura", "conminuta", "de", "ángulo", "mandibular", "izquierdo", ",", "avulsión", "dental", "del", "sector", "incisal", "del", "maxilar", "superior", ",", "así", "como", "laceración", "severa", "de", "la", "musculatura", "lingual", "y", "suelo", "de", "boca", ".", "Asimismo", ",", "se", "observa", "una", "exposición", "del", "paquete", "yugulo", "-", "carotídeo", "izquierdo", "comprobándose", "la", "integridad", "total", "del", "mismo", ".", "Se", "realiza", "sutura", "interdental", "a", "nivel", "de", "los", "focos", "de", "fractura", "y", "de", "las", "partes", "blandas", "adyacentes", ",", "con", "objeto", "de", "restaurar", "provisionalmente", "la", "anatomía", ",", "y", "se", "traslada", "al", "paciente", "al", "Servicio", "de", "Radiología", "para", "la", "realización", "de", "TC", "craneofacial", "diagnóstico", "y", "con", "el", "objetivo", "de", "descartar", "la", "existencia", "de", "lesiones", "del", "sistema", "nervioso", "central", "y", "cervicales", "asociadas", ".", "Posteriormente", "y", "una", "vez", "en", "quirófano", ",", "se", "realiza", "laringoscopia", "directa", "que", "excluye", "la", "presencia", "de", "lesiones", "laringoesofágicas", ".", "Se", "realiza", "lavado", "meticuloso", "con", "cepillo", "quirúrgico", "y", "solución", "antiséptica", "de", "toda", "la", "cavidad", "oral", "y", "tejidos", "afectos", ".", "Se", "administra", "vacuna", "antitetánica", "y", "gammaglobulina", ",", "y", "se", "inicia", "el", "tratamiento", "sistémico", "intravenoso", "con", "amoxilina", "-", "clavulánico", "y", "metronidazol", ".", "\n\n", "Tras", "una", "correcta", "exposición", "de", "los", "focos", "de", "fractura", "a", "nivel", "del", "cuerpo", "mandibular", "derecho", "y", "ángulo", "mandibular", "izquierdo", ",", "favorecido", "por", "las", "características", "de", "la", "propia", "herida", ",", "se", "realiza", "reducción", "y", "osteosíntesis", "empleando", "para", "ello", "placas", "de", "reconstrucción", "mandibular", "2.4", "Synthes", "®", ",", "dada", "la", "presencia", "de", "conminución", "en", "una", "de", "ellas", "y", "el", "alto", "potencial", "de", "infección", "del", "lecho", "quirúrgico", ".", "Se", "procede", "a", "la", "exodoncia", "de", "los", "restos", "radiculares", "remanentes", "en", "el", "sector", "incisal", "superior", "y", "regularización", "ósea", "correspondiente", ".", "Se", "realiza", "sutura", "y", "restauración", "anatómica", "de", "la", "musculatura", "cervical", ",", "suelo", "de", "boca", "y", "lengua", ".", "Se", "realiza", "anastomosis", "microquirúrgica", "del", "nervio", "mentoniano", "derecho", "y", "lingual", "izquierdo", ".", "Se", "realiza", "sutura", "de", "piel", "y", "mucosa", "oral", ".", "Posteriormente", "el", "paciente", "es", "traladado", "al", "Servicio", "de", "UVI", "-", "Politrauma", "donde", "permanece", "36", "horas", "no", "presentando", "en", "este", "tiempo", "complicaciones", "neurológicas", "ni", "sistémicas", ".", "Tras", "la", "derivación", "a", "planta", ",", "se", "prosigue", "con", "el", "tratamiento", "antibiótico", "durante", "10", "días", ",", "realizándose", "curas", "diarias", "con", "solución", "antiséptica", "de", "la", "herida", ",", "tanto", "intraoral", "como", "cutánea", ".", "No", "se", "evidenció", "patología", "infecciosa", "en", "dicho", "territorio", ",", "presentando", "una", "evolución", "posterior", "favorable", ",", "siendo", "dado", "de", "alta", "al", "undécimo", "día", ".", "\n\n" ]
[ "NORMALIZABLES", "UNCLEAR", "PROTEINAS" ]
LDL receptor is a Protein
650_task0
Sentence: Lymphocytes from CML patients lack a 47 kDa factor having affinity for a genomic sterol regulatory sequence. Deranged cellular cholesterol homeostasis has been widely recognized in the initiation as well as progression of various types of cancers including chronic myeloid leukaemia (CML). Since the human genomic sterol regulatory element (SRE) has been shown to regulate various key genes involved in this phenomenon, the present study revealed the existence of a unique 47 kDa protein factor having affinity for this SRE sequence in lymphocytes from normal subjects, as well as its absence in lymphocytes from untreated CML patients. However, this factor appeared when these CML patients achieved complete haematological remission (CHR) through alpha-interferon therapy. Furthermore, an inverse relationship was also observed between the LDL receptor gene expression at the transcriptional level and the binding affinity of this 47 kDa protein factor to the SRE sequence. Based upon these results we propose that this factor may have a role in pathophysiology of chronic myeloid leukaemia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Lymphocytes from CML patients lack a 47 kDa factor having affinity for a genomic sterol regulatory sequence. Deranged cellular cholesterol homeostasis has been widely recognized in the initiation as well as progression of various types of cancers including chronic myeloid leukaemia (CML). Since the human genomic sterol regulatory element (SRE) has been shown to regulate various key genes involved in this phenomenon, the present study revealed the existence of a unique 47 kDa protein factor having affinity for this SRE sequence in lymphocytes from normal subjects, as well as its absence in lymphocytes from untreated CML patients. However, this factor appeared when these CML patients achieved complete haematological remission (CHR) through alpha-interferon therapy. Furthermore, an inverse relationship was also observed between the LDL receptor gene expression at the transcriptional level and the binding affinity of this 47 kDa protein factor to the SRE sequence. Based upon these results we propose that this factor may have a role in pathophysiology of chronic myeloid leukaemia.
[ "Lymphocytes", "from", "CML", "patients", "lack", "a", "47", "kDa", "factor", "having", "affinity", "for", "a", "genomic", "sterol", "regulatory", "sequence", ".", "\n", "Deranged", "cellular", "cholesterol", "homeostasis", "has", "been", "widely", "recognized", "in", "the", "initiation", "as", "well", "as", "progression", "of", "various", "types", "of", "cancers", "including", "chronic", "myeloid", "leukaemia", "(", "CML", ")", ".", "Since", "the", "human", "genomic", "sterol", "regulatory", "element", "(", "SRE", ")", "has", "been", "shown", "to", "regulate", "various", "key", "genes", "involved", "in", "this", "phenomenon", ",", "the", "present", "study", "revealed", "the", "existence", "of", "a", "unique", "47", "kDa", "protein", "factor", "having", "affinity", "for", "this", "SRE", "sequence", "in", "lymphocytes", "from", "normal", "subjects", ",", "as", "well", "as", "its", "absence", "in", "lymphocytes", "from", "untreated", "CML", "patients", ".", "However", ",", "this", "factor", "appeared", "when", "these", "CML", "patients", "achieved", "complete", "haematological", "remission", "(", "CHR", ")", "through", "alpha", "-", "interferon", "therapy", ".", "Furthermore", ",", "an", "inverse", "relationship", "was", "also", "observed", "between", "the", "LDL", "receptor", "gene", "expression", "at", "the", "transcriptional", "level", "and", "the", "binding", "affinity", "of", "this", "47", "kDa", "protein", "factor", "to", "the", "SRE", "sequence", ".", "Based", "upon", "these", "results", "we", "propose", "that", "this", "factor", "may", "have", "a", "role", "in", "pathophysiology", "of", "chronic", "myeloid", "leukaemia", "." ]
[ "Protein" ]
LDL receptor is a Protein
650_task1
Sentence: Lymphocytes from CML patients lack a 47 kDa factor having affinity for a genomic sterol regulatory sequence. Deranged cellular cholesterol homeostasis has been widely recognized in the initiation as well as progression of various types of cancers including chronic myeloid leukaemia (CML). Since the human genomic sterol regulatory element (SRE) has been shown to regulate various key genes involved in this phenomenon, the present study revealed the existence of a unique 47 kDa protein factor having affinity for this SRE sequence in lymphocytes from normal subjects, as well as its absence in lymphocytes from untreated CML patients. However, this factor appeared when these CML patients achieved complete haematological remission (CHR) through alpha-interferon therapy. Furthermore, an inverse relationship was also observed between the LDL receptor gene expression at the transcriptional level and the binding affinity of this 47 kDa protein factor to the SRE sequence. Based upon these results we propose that this factor may have a role in pathophysiology of chronic myeloid leukaemia. Instructions: please typing these entity words according to sentence: LDL receptor Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Lymphocytes from CML patients lack a 47 kDa factor having affinity for a genomic sterol regulatory sequence. Deranged cellular cholesterol homeostasis has been widely recognized in the initiation as well as progression of various types of cancers including chronic myeloid leukaemia (CML). Since the human genomic sterol regulatory element (SRE) has been shown to regulate various key genes involved in this phenomenon, the present study revealed the existence of a unique 47 kDa protein factor having affinity for this SRE sequence in lymphocytes from normal subjects, as well as its absence in lymphocytes from untreated CML patients. However, this factor appeared when these CML patients achieved complete haematological remission (CHR) through alpha-interferon therapy. Furthermore, an inverse relationship was also observed between the LDL receptor gene expression at the transcriptional level and the binding affinity of this 47 kDa protein factor to the SRE sequence. Based upon these results we propose that this factor may have a role in pathophysiology of chronic myeloid leukaemia.
[ "Lymphocytes", "from", "CML", "patients", "lack", "a", "47", "kDa", "factor", "having", "affinity", "for", "a", "genomic", "sterol", "regulatory", "sequence", ".", "\n", "Deranged", "cellular", "cholesterol", "homeostasis", "has", "been", "widely", "recognized", "in", "the", "initiation", "as", "well", "as", "progression", "of", "various", "types", "of", "cancers", "including", "chronic", "myeloid", "leukaemia", "(", "CML", ")", ".", "Since", "the", "human", "genomic", "sterol", "regulatory", "element", "(", "SRE", ")", "has", "been", "shown", "to", "regulate", "various", "key", "genes", "involved", "in", "this", "phenomenon", ",", "the", "present", "study", "revealed", "the", "existence", "of", "a", "unique", "47", "kDa", "protein", "factor", "having", "affinity", "for", "this", "SRE", "sequence", "in", "lymphocytes", "from", "normal", "subjects", ",", "as", "well", "as", "its", "absence", "in", "lymphocytes", "from", "untreated", "CML", "patients", ".", "However", ",", "this", "factor", "appeared", "when", "these", "CML", "patients", "achieved", "complete", "haematological", "remission", "(", "CHR", ")", "through", "alpha", "-", "interferon", "therapy", ".", "Furthermore", ",", "an", "inverse", "relationship", "was", "also", "observed", "between", "the", "LDL", "receptor", "gene", "expression", "at", "the", "transcriptional", "level", "and", "the", "binding", "affinity", "of", "this", "47", "kDa", "protein", "factor", "to", "the", "SRE", "sequence", ".", "Based", "upon", "these", "results", "we", "propose", "that", "this", "factor", "may", "have", "a", "role", "in", "pathophysiology", "of", "chronic", "myeloid", "leukaemia", "." ]
[ "Protein" ]
LDL receptor
650_task2
Sentence: Lymphocytes from CML patients lack a 47 kDa factor having affinity for a genomic sterol regulatory sequence. Deranged cellular cholesterol homeostasis has been widely recognized in the initiation as well as progression of various types of cancers including chronic myeloid leukaemia (CML). Since the human genomic sterol regulatory element (SRE) has been shown to regulate various key genes involved in this phenomenon, the present study revealed the existence of a unique 47 kDa protein factor having affinity for this SRE sequence in lymphocytes from normal subjects, as well as its absence in lymphocytes from untreated CML patients. However, this factor appeared when these CML patients achieved complete haematological remission (CHR) through alpha-interferon therapy. Furthermore, an inverse relationship was also observed between the LDL receptor gene expression at the transcriptional level and the binding affinity of this 47 kDa protein factor to the SRE sequence. Based upon these results we propose that this factor may have a role in pathophysiology of chronic myeloid leukaemia. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Lymphocytes from CML patients lack a 47 kDa factor having affinity for a genomic sterol regulatory sequence. Deranged cellular cholesterol homeostasis has been widely recognized in the initiation as well as progression of various types of cancers including chronic myeloid leukaemia (CML). Since the human genomic sterol regulatory element (SRE) has been shown to regulate various key genes involved in this phenomenon, the present study revealed the existence of a unique 47 kDa protein factor having affinity for this SRE sequence in lymphocytes from normal subjects, as well as its absence in lymphocytes from untreated CML patients. However, this factor appeared when these CML patients achieved complete haematological remission (CHR) through alpha-interferon therapy. Furthermore, an inverse relationship was also observed between the LDL receptor gene expression at the transcriptional level and the binding affinity of this 47 kDa protein factor to the SRE sequence. Based upon these results we propose that this factor may have a role in pathophysiology of chronic myeloid leukaemia.
[ "Lymphocytes", "from", "CML", "patients", "lack", "a", "47", "kDa", "factor", "having", "affinity", "for", "a", "genomic", "sterol", "regulatory", "sequence", ".", "\n", "Deranged", "cellular", "cholesterol", "homeostasis", "has", "been", "widely", "recognized", "in", "the", "initiation", "as", "well", "as", "progression", "of", "various", "types", "of", "cancers", "including", "chronic", "myeloid", "leukaemia", "(", "CML", ")", ".", "Since", "the", "human", "genomic", "sterol", "regulatory", "element", "(", "SRE", ")", "has", "been", "shown", "to", "regulate", "various", "key", "genes", "involved", "in", "this", "phenomenon", ",", "the", "present", "study", "revealed", "the", "existence", "of", "a", "unique", "47", "kDa", "protein", "factor", "having", "affinity", "for", "this", "SRE", "sequence", "in", "lymphocytes", "from", "normal", "subjects", ",", "as", "well", "as", "its", "absence", "in", "lymphocytes", "from", "untreated", "CML", "patients", ".", "However", ",", "this", "factor", "appeared", "when", "these", "CML", "patients", "achieved", "complete", "haematological", "remission", "(", "CHR", ")", "through", "alpha", "-", "interferon", "therapy", ".", "Furthermore", ",", "an", "inverse", "relationship", "was", "also", "observed", "between", "the", "LDL", "receptor", "gene", "expression", "at", "the", "transcriptional", "level", "and", "the", "binding", "affinity", "of", "this", "47", "kDa", "protein", "factor", "to", "the", "SRE", "sequence", ".", "Based", "upon", "these", "results", "we", "propose", "that", "this", "factor", "may", "have", "a", "role", "in", "pathophysiology", "of", "chronic", "myeloid", "leukaemia", "." ]
[ "Protein" ]
thyroid is an umlsterm, carcinoma is an umlsterm, retrospective study is an umlsterm, patients is an umlsterm, surgery is an umlsterm, thyroid is an umlsterm, carcinoma is an umlsterm, tissue is an umlsterm, analysis is an umlsterm, patients is an umlsterm, postoperative is an umlsterm, tumours is an umlsterm, lymph node is an umlsterm, metastasis is an umlsterm, patients is an umlsterm, tumour is an umlsterm, recurrence is an umlsterm, survival is an umlsterm, patients is an umlsterm, tumours is an umlsterm, analysis is an umlsterm, metastasis is an umlsterm, risk factors is an umlsterm, survival is an umlsterm, findings is an umlsterm, thyroid is an umlsterm, carcinoma is an umlsterm
DerChirurg.80690186.eng.abstr_task0
Sentence: The prognostic significance of e-cadherin in papillary thyroid carcinoma was evaluated in a retrospective study . From September 1985 to December 1996 , 113 patients underwent surgery for papillary thyroid carcinoma . Seventy-eight formalin-fixed , paraffin-embedded tissue samples were available for immunohistochemical analysis of e-cadherin expression . In 74 of these 78 patients the postoperative course is known for 2 months to 35.2 years ( median 3.6 years , mean : 4.9 +/- 4.8 years ) . Reduced or negative e-cadherin expression ( = 20 % ) was associated with advanced T categories of the primary tumours and higher rates of synchronous lymph node involvement and distant metastasis . During follow-up in this group of patients locoregional tumour recurrence occurred more frequently and survival was shorter than in patients with tumours which exhibited e-cadherin expression of > 20 % . Statistical analysis revealed e-cadherin expression ( = 20 %/ > 20 % ) , synchronous distant metastasis ( M0/pM1, cM1) and radicality of resection ( R0/R1, 2 ) as significant risk factors for survival . Our findings provide evidence that e-cadherin is a prognostic factor in papillary thyroid carcinoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The prognostic significance of e-cadherin in papillary thyroid carcinoma was evaluated in a retrospective study . From September 1985 to December 1996 , 113 patients underwent surgery for papillary thyroid carcinoma . Seventy-eight formalin-fixed , paraffin-embedded tissue samples were available for immunohistochemical analysis of e-cadherin expression . In 74 of these 78 patients the postoperative course is known for 2 months to 35.2 years ( median 3.6 years , mean : 4.9 +/- 4.8 years ) . Reduced or negative e-cadherin expression ( = 20 % ) was associated with advanced T categories of the primary tumours and higher rates of synchronous lymph node involvement and distant metastasis . During follow-up in this group of patients locoregional tumour recurrence occurred more frequently and survival was shorter than in patients with tumours which exhibited e-cadherin expression of > 20 % . Statistical analysis revealed e-cadherin expression ( = 20 %/ > 20 % ) , synchronous distant metastasis ( M0/pM1, cM1) and radicality of resection ( R0/R1, 2 ) as significant risk factors for survival . Our findings provide evidence that e-cadherin is a prognostic factor in papillary thyroid carcinoma .
[ "The", "prognostic", "significance", "of", "e", "-", "cadherin", "in", "papillary", "thyroid", "carcinoma", "was", "evaluated", "in", "a", "retrospective", "study", ".", "From", "September", "1985", "to", "December", "1996", ",", "113", "patients", "underwent", "surgery", "for", "papillary", "thyroid", "carcinoma", ".", "Seventy", "-", "eight", "formalin", "-", "fixed", ",", "paraffin", "-", "embedded", "tissue", "samples", "were", "available", "for", "immunohistochemical", "analysis", "of", "e", "-", "cadherin", "expression", ".", "In", "74", "of", "these", "78", "patients", "the", "postoperative", "course", "is", "known", "for", "2", "months", "to", "35.2", "years", "(", "median", "3.6", "years", ",", "mean", ":", "4.9", "+", "/-", "4.8", "years", ")", ".", "Reduced", "or", "negative", "e", "-", "cadherin", "expression", "(", "=", "20", "%", ")", "was", "associated", "with", "advanced", "T", "categories", "of", "the", "primary", "tumours", "and", "higher", "rates", "of", "synchronous", "lymph", "node", "involvement", "and", "distant", "metastasis", ".", "During", "follow", "-", "up", "in", "this", "group", "of", "patients", "locoregional", "tumour", "recurrence", "occurred", "more", "frequently", "and", "survival", "was", "shorter", "than", "in", "patients", "with", "tumours", "which", "exhibited", "e", "-", "cadherin", "expression", "of", ">", "20", "%", ".", "Statistical", "analysis", "revealed", "e", "-", "cadherin", "expression", "(", "=", "20", "%", "/", ">", "20", "%", ")", ",", "synchronous", "distant", "metastasis", "(", "M0", "/", "pM1", ",", "cM1", ")", "and", "radicality", "of", "resection", "(", "R0", "/", "R1", ",", "2", ")", "as", "significant", "risk", "factors", "for", "survival", ".", "Our", "findings", "provide", "evidence", "that", "e", "-", "cadherin", "is", "a", "prognostic", "factor", "in", "papillary", "thyroid", "carcinoma", "." ]
[ "umlsterm" ]
thyroid is an umlsterm, carcinoma is an umlsterm, retrospective study is an umlsterm, patients is an umlsterm, surgery is an umlsterm, thyroid is an umlsterm, carcinoma is an umlsterm, tissue is an umlsterm, analysis is an umlsterm, patients is an umlsterm, postoperative is an umlsterm, tumours is an umlsterm, lymph node is an umlsterm, metastasis is an umlsterm, patients is an umlsterm, tumour is an umlsterm, recurrence is an umlsterm, survival is an umlsterm, patients is an umlsterm, tumours is an umlsterm, analysis is an umlsterm, metastasis is an umlsterm, risk factors is an umlsterm, survival is an umlsterm, findings is an umlsterm, thyroid is an umlsterm, carcinoma is an umlsterm
DerChirurg.80690186.eng.abstr_task1
Sentence: The prognostic significance of e-cadherin in papillary thyroid carcinoma was evaluated in a retrospective study . From September 1985 to December 1996 , 113 patients underwent surgery for papillary thyroid carcinoma . Seventy-eight formalin-fixed , paraffin-embedded tissue samples were available for immunohistochemical analysis of e-cadherin expression . In 74 of these 78 patients the postoperative course is known for 2 months to 35.2 years ( median 3.6 years , mean : 4.9 +/- 4.8 years ) . Reduced or negative e-cadherin expression ( = 20 % ) was associated with advanced T categories of the primary tumours and higher rates of synchronous lymph node involvement and distant metastasis . During follow-up in this group of patients locoregional tumour recurrence occurred more frequently and survival was shorter than in patients with tumours which exhibited e-cadherin expression of > 20 % . Statistical analysis revealed e-cadherin expression ( = 20 %/ > 20 % ) , synchronous distant metastasis ( M0/pM1, cM1) and radicality of resection ( R0/R1, 2 ) as significant risk factors for survival . Our findings provide evidence that e-cadherin is a prognostic factor in papillary thyroid carcinoma . Instructions: please typing these entity words according to sentence: thyroid, carcinoma, retrospective study, patients, surgery, thyroid, carcinoma, tissue, analysis, patients, postoperative, tumours, lymph node, metastasis, patients, tumour, recurrence, survival, patients, tumours, analysis, metastasis, risk factors, survival, findings, thyroid, carcinoma Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The prognostic significance of e-cadherin in papillary thyroid carcinoma was evaluated in a retrospective study . From September 1985 to December 1996 , 113 patients underwent surgery for papillary thyroid carcinoma . Seventy-eight formalin-fixed , paraffin-embedded tissue samples were available for immunohistochemical analysis of e-cadherin expression . In 74 of these 78 patients the postoperative course is known for 2 months to 35.2 years ( median 3.6 years , mean : 4.9 +/- 4.8 years ) . Reduced or negative e-cadherin expression ( = 20 % ) was associated with advanced T categories of the primary tumours and higher rates of synchronous lymph node involvement and distant metastasis . During follow-up in this group of patients locoregional tumour recurrence occurred more frequently and survival was shorter than in patients with tumours which exhibited e-cadherin expression of > 20 % . Statistical analysis revealed e-cadherin expression ( = 20 %/ > 20 % ) , synchronous distant metastasis ( M0/pM1, cM1) and radicality of resection ( R0/R1, 2 ) as significant risk factors for survival . Our findings provide evidence that e-cadherin is a prognostic factor in papillary thyroid carcinoma .
[ "The", "prognostic", "significance", "of", "e", "-", "cadherin", "in", "papillary", "thyroid", "carcinoma", "was", "evaluated", "in", "a", "retrospective", "study", ".", "From", "September", "1985", "to", "December", "1996", ",", "113", "patients", "underwent", "surgery", "for", "papillary", "thyroid", "carcinoma", ".", "Seventy", "-", "eight", "formalin", "-", "fixed", ",", "paraffin", "-", "embedded", "tissue", "samples", "were", "available", "for", "immunohistochemical", "analysis", "of", "e", "-", "cadherin", "expression", ".", "In", "74", "of", "these", "78", "patients", "the", "postoperative", "course", "is", "known", "for", "2", "months", "to", "35.2", "years", "(", "median", "3.6", "years", ",", "mean", ":", "4.9", "+", "/-", "4.8", "years", ")", ".", "Reduced", "or", "negative", "e", "-", "cadherin", "expression", "(", "=", "20", "%", ")", "was", "associated", "with", "advanced", "T", "categories", "of", "the", "primary", "tumours", "and", "higher", "rates", "of", "synchronous", "lymph", "node", "involvement", "and", "distant", "metastasis", ".", "During", "follow", "-", "up", "in", "this", "group", "of", "patients", "locoregional", "tumour", "recurrence", "occurred", "more", "frequently", "and", "survival", "was", "shorter", "than", "in", "patients", "with", "tumours", "which", "exhibited", "e", "-", "cadherin", "expression", "of", ">", "20", "%", ".", "Statistical", "analysis", "revealed", "e", "-", "cadherin", "expression", "(", "=", "20", "%", "/", ">", "20", "%", ")", ",", "synchronous", "distant", "metastasis", "(", "M0", "/", "pM1", ",", "cM1", ")", "and", "radicality", "of", "resection", "(", "R0", "/", "R1", ",", "2", ")", "as", "significant", "risk", "factors", "for", "survival", ".", "Our", "findings", "provide", "evidence", "that", "e", "-", "cadherin", "is", "a", "prognostic", "factor", "in", "papillary", "thyroid", "carcinoma", "." ]
[ "umlsterm" ]
thyroid, carcinoma, retrospective study, patients, surgery, thyroid, carcinoma, tissue, analysis, patients, postoperative, tumours, lymph node, metastasis, patients, tumour, recurrence, survival, patients, tumours, analysis, metastasis, risk factors, survival, findings, thyroid, carcinoma
DerChirurg.80690186.eng.abstr_task2
Sentence: The prognostic significance of e-cadherin in papillary thyroid carcinoma was evaluated in a retrospective study . From September 1985 to December 1996 , 113 patients underwent surgery for papillary thyroid carcinoma . Seventy-eight formalin-fixed , paraffin-embedded tissue samples were available for immunohistochemical analysis of e-cadherin expression . In 74 of these 78 patients the postoperative course is known for 2 months to 35.2 years ( median 3.6 years , mean : 4.9 +/- 4.8 years ) . Reduced or negative e-cadherin expression ( = 20 % ) was associated with advanced T categories of the primary tumours and higher rates of synchronous lymph node involvement and distant metastasis . During follow-up in this group of patients locoregional tumour recurrence occurred more frequently and survival was shorter than in patients with tumours which exhibited e-cadherin expression of > 20 % . Statistical analysis revealed e-cadherin expression ( = 20 %/ > 20 % ) , synchronous distant metastasis ( M0/pM1, cM1) and radicality of resection ( R0/R1, 2 ) as significant risk factors for survival . Our findings provide evidence that e-cadherin is a prognostic factor in papillary thyroid carcinoma . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The prognostic significance of e-cadherin in papillary thyroid carcinoma was evaluated in a retrospective study . From September 1985 to December 1996 , 113 patients underwent surgery for papillary thyroid carcinoma . Seventy-eight formalin-fixed , paraffin-embedded tissue samples were available for immunohistochemical analysis of e-cadherin expression . In 74 of these 78 patients the postoperative course is known for 2 months to 35.2 years ( median 3.6 years , mean : 4.9 +/- 4.8 years ) . Reduced or negative e-cadherin expression ( = 20 % ) was associated with advanced T categories of the primary tumours and higher rates of synchronous lymph node involvement and distant metastasis . During follow-up in this group of patients locoregional tumour recurrence occurred more frequently and survival was shorter than in patients with tumours which exhibited e-cadherin expression of > 20 % . Statistical analysis revealed e-cadherin expression ( = 20 %/ > 20 % ) , synchronous distant metastasis ( M0/pM1, cM1) and radicality of resection ( R0/R1, 2 ) as significant risk factors for survival . Our findings provide evidence that e-cadherin is a prognostic factor in papillary thyroid carcinoma .
[ "The", "prognostic", "significance", "of", "e", "-", "cadherin", "in", "papillary", "thyroid", "carcinoma", "was", "evaluated", "in", "a", "retrospective", "study", ".", "From", "September", "1985", "to", "December", "1996", ",", "113", "patients", "underwent", "surgery", "for", "papillary", "thyroid", "carcinoma", ".", "Seventy", "-", "eight", "formalin", "-", "fixed", ",", "paraffin", "-", "embedded", "tissue", "samples", "were", "available", "for", "immunohistochemical", "analysis", "of", "e", "-", "cadherin", "expression", ".", "In", "74", "of", "these", "78", "patients", "the", "postoperative", "course", "is", "known", "for", "2", "months", "to", "35.2", "years", "(", "median", "3.6", "years", ",", "mean", ":", "4.9", "+", "/-", "4.8", "years", ")", ".", "Reduced", "or", "negative", "e", "-", "cadherin", "expression", "(", "=", "20", "%", ")", "was", "associated", "with", "advanced", "T", "categories", "of", "the", "primary", "tumours", "and", "higher", "rates", "of", "synchronous", "lymph", "node", "involvement", "and", "distant", "metastasis", ".", "During", "follow", "-", "up", "in", "this", "group", "of", "patients", "locoregional", "tumour", "recurrence", "occurred", "more", "frequently", "and", "survival", "was", "shorter", "than", "in", "patients", "with", "tumours", "which", "exhibited", "e", "-", "cadherin", "expression", "of", ">", "20", "%", ".", "Statistical", "analysis", "revealed", "e", "-", "cadherin", "expression", "(", "=", "20", "%", "/", ">", "20", "%", ")", ",", "synchronous", "distant", "metastasis", "(", "M0", "/", "pM1", ",", "cM1", ")", "and", "radicality", "of", "resection", "(", "R0", "/", "R1", ",", "2", ")", "as", "significant", "risk", "factors", "for", "survival", ".", "Our", "findings", "provide", "evidence", "that", "e", "-", "cadherin", "is", "a", "prognostic", "factor", "in", "papillary", "thyroid", "carcinoma", "." ]
[ "umlsterm" ]
serum is a Organism_substance, plasma is a Organism_substance, plasma is a Organism_substance, bone is a Tissue, surface is a Tissue, bone is a Tissue, soft tissues is a Tissue, plasma is a Organism_substance, bone ash is a Organism_substance, intestinal is a Multi-tissue_structure, bone is a Tissue
PMID-3930969_task0
Sentence: The effect of aflatoxin B1 on the utilization of serum calcium. The mathematical analysis for plasma disappearance curve of aflatoxicosed animals, subsequently injected with 45Ca was determined. The analysis showed that the three main compartments of the calcium pool (plasma, bone and the labile calcium pool on the surface of bone and soft tissues) had been affected. Specifically, the fractional rate constant for migration of 45Ca from plasma pool to the labile pool had been diminished to its third value. This led to a corresponding reduction in the calcium content of the bone ash. The probable mechanism by which aflatoxin B1 affects calcium dynamics may be interpreted by the inhibitory effect of aflatoxin in the hydroxylation mechanism of vitamin D3 into an active intermediate. During aflatoxicosis (induction of 15 days) the animals entered a state of calcium deficiency, secondary to intestinal absorption inhibition. This was followed by bone resorption and disturbance of the fractional removal rate constant among different calcium compartments. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Multi-tissue_structure, Organism_substance
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The effect of aflatoxin B1 on the utilization of serum calcium. The mathematical analysis for plasma disappearance curve of aflatoxicosed animals, subsequently injected with 45Ca was determined. The analysis showed that the three main compartments of the calcium pool (plasma, bone and the labile calcium pool on the surface of bone and soft tissues) had been affected. Specifically, the fractional rate constant for migration of 45Ca from plasma pool to the labile pool had been diminished to its third value. This led to a corresponding reduction in the calcium content of the bone ash. The probable mechanism by which aflatoxin B1 affects calcium dynamics may be interpreted by the inhibitory effect of aflatoxin in the hydroxylation mechanism of vitamin D3 into an active intermediate. During aflatoxicosis (induction of 15 days) the animals entered a state of calcium deficiency, secondary to intestinal absorption inhibition. This was followed by bone resorption and disturbance of the fractional removal rate constant among different calcium compartments.
[ "The", "effect", "of", "aflatoxin", "B1", "on", "the", "utilization", "of", "serum", "calcium", ".", "\n", "The", "mathematical", "analysis", "for", "plasma", "disappearance", "curve", "of", "aflatoxicosed", "animals", ",", "subsequently", "injected", "with", "45Ca", "was", "determined", ".", "The", "analysis", "showed", "that", "the", "three", "main", "compartments", "of", "the", "calcium", "pool", "(", "plasma", ",", "bone", "and", "the", "labile", "calcium", "pool", "on", "the", "surface", "of", "bone", "and", "soft", "tissues", ")", "had", "been", "affected", ".", "Specifically", ",", "the", "fractional", "rate", "constant", "for", "migration", "of", "45Ca", "from", "plasma", "pool", "to", "the", "labile", "pool", "had", "been", "diminished", "to", "its", "third", "value", ".", "This", "led", "to", "a", "corresponding", "reduction", "in", "the", "calcium", "content", "of", "the", "bone", "ash", ".", "The", "probable", "mechanism", "by", "which", "aflatoxin", "B1", "affects", "calcium", "dynamics", "may", "be", "interpreted", "by", "the", "inhibitory", "effect", "of", "aflatoxin", "in", "the", "hydroxylation", "mechanism", "of", "vitamin", "D3", "into", "an", "active", "intermediate", ".", "During", "aflatoxicosis", "(", "induction", "of", "15", "days", ")", "the", "animals", "entered", "a", "state", "of", "calcium", "deficiency", ",", "secondary", "to", "intestinal", "absorption", "inhibition", ".", "This", "was", "followed", "by", "bone", "resorption", "and", "disturbance", "of", "the", "fractional", "removal", "rate", "constant", "among", "different", "calcium", "compartments", ".", "\n" ]
[ "Tissue", "Multi-tissue_structure", "Organism_substance" ]
serum is a Organism_substance, plasma is a Organism_substance, plasma is a Organism_substance, bone is a Tissue, surface is a Tissue, bone is a Tissue, soft tissues is a Tissue, plasma is a Organism_substance, bone ash is a Organism_substance, intestinal is a Multi-tissue_structure, bone is a Tissue
PMID-3930969_task1
Sentence: The effect of aflatoxin B1 on the utilization of serum calcium. The mathematical analysis for plasma disappearance curve of aflatoxicosed animals, subsequently injected with 45Ca was determined. The analysis showed that the three main compartments of the calcium pool (plasma, bone and the labile calcium pool on the surface of bone and soft tissues) had been affected. Specifically, the fractional rate constant for migration of 45Ca from plasma pool to the labile pool had been diminished to its third value. This led to a corresponding reduction in the calcium content of the bone ash. The probable mechanism by which aflatoxin B1 affects calcium dynamics may be interpreted by the inhibitory effect of aflatoxin in the hydroxylation mechanism of vitamin D3 into an active intermediate. During aflatoxicosis (induction of 15 days) the animals entered a state of calcium deficiency, secondary to intestinal absorption inhibition. This was followed by bone resorption and disturbance of the fractional removal rate constant among different calcium compartments. Instructions: please typing these entity words according to sentence: serum, plasma, plasma, bone, surface, bone, soft tissues, plasma, bone ash, intestinal, bone Options: Tissue, Multi-tissue_structure, Organism_substance
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The effect of aflatoxin B1 on the utilization of serum calcium. The mathematical analysis for plasma disappearance curve of aflatoxicosed animals, subsequently injected with 45Ca was determined. The analysis showed that the three main compartments of the calcium pool (plasma, bone and the labile calcium pool on the surface of bone and soft tissues) had been affected. Specifically, the fractional rate constant for migration of 45Ca from plasma pool to the labile pool had been diminished to its third value. This led to a corresponding reduction in the calcium content of the bone ash. The probable mechanism by which aflatoxin B1 affects calcium dynamics may be interpreted by the inhibitory effect of aflatoxin in the hydroxylation mechanism of vitamin D3 into an active intermediate. During aflatoxicosis (induction of 15 days) the animals entered a state of calcium deficiency, secondary to intestinal absorption inhibition. This was followed by bone resorption and disturbance of the fractional removal rate constant among different calcium compartments.
[ "The", "effect", "of", "aflatoxin", "B1", "on", "the", "utilization", "of", "serum", "calcium", ".", "\n", "The", "mathematical", "analysis", "for", "plasma", "disappearance", "curve", "of", "aflatoxicosed", "animals", ",", "subsequently", "injected", "with", "45Ca", "was", "determined", ".", "The", "analysis", "showed", "that", "the", "three", "main", "compartments", "of", "the", "calcium", "pool", "(", "plasma", ",", "bone", "and", "the", "labile", "calcium", "pool", "on", "the", "surface", "of", "bone", "and", "soft", "tissues", ")", "had", "been", "affected", ".", "Specifically", ",", "the", "fractional", "rate", "constant", "for", "migration", "of", "45Ca", "from", "plasma", "pool", "to", "the", "labile", "pool", "had", "been", "diminished", "to", "its", "third", "value", ".", "This", "led", "to", "a", "corresponding", "reduction", "in", "the", "calcium", "content", "of", "the", "bone", "ash", ".", "The", "probable", "mechanism", "by", "which", "aflatoxin", "B1", "affects", "calcium", "dynamics", "may", "be", "interpreted", "by", "the", "inhibitory", "effect", "of", "aflatoxin", "in", "the", "hydroxylation", "mechanism", "of", "vitamin", "D3", "into", "an", "active", "intermediate", ".", "During", "aflatoxicosis", "(", "induction", "of", "15", "days", ")", "the", "animals", "entered", "a", "state", "of", "calcium", "deficiency", ",", "secondary", "to", "intestinal", "absorption", "inhibition", ".", "This", "was", "followed", "by", "bone", "resorption", "and", "disturbance", "of", "the", "fractional", "removal", "rate", "constant", "among", "different", "calcium", "compartments", ".", "\n" ]
[ "Tissue", "Multi-tissue_structure", "Organism_substance" ]
serum, plasma, plasma, bone, surface, bone, soft tissues, plasma, bone ash, intestinal, bone
PMID-3930969_task2
Sentence: The effect of aflatoxin B1 on the utilization of serum calcium. The mathematical analysis for plasma disappearance curve of aflatoxicosed animals, subsequently injected with 45Ca was determined. The analysis showed that the three main compartments of the calcium pool (plasma, bone and the labile calcium pool on the surface of bone and soft tissues) had been affected. Specifically, the fractional rate constant for migration of 45Ca from plasma pool to the labile pool had been diminished to its third value. This led to a corresponding reduction in the calcium content of the bone ash. The probable mechanism by which aflatoxin B1 affects calcium dynamics may be interpreted by the inhibitory effect of aflatoxin in the hydroxylation mechanism of vitamin D3 into an active intermediate. During aflatoxicosis (induction of 15 days) the animals entered a state of calcium deficiency, secondary to intestinal absorption inhibition. This was followed by bone resorption and disturbance of the fractional removal rate constant among different calcium compartments. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The effect of aflatoxin B1 on the utilization of serum calcium. The mathematical analysis for plasma disappearance curve of aflatoxicosed animals, subsequently injected with 45Ca was determined. The analysis showed that the three main compartments of the calcium pool (plasma, bone and the labile calcium pool on the surface of bone and soft tissues) had been affected. Specifically, the fractional rate constant for migration of 45Ca from plasma pool to the labile pool had been diminished to its third value. This led to a corresponding reduction in the calcium content of the bone ash. The probable mechanism by which aflatoxin B1 affects calcium dynamics may be interpreted by the inhibitory effect of aflatoxin in the hydroxylation mechanism of vitamin D3 into an active intermediate. During aflatoxicosis (induction of 15 days) the animals entered a state of calcium deficiency, secondary to intestinal absorption inhibition. This was followed by bone resorption and disturbance of the fractional removal rate constant among different calcium compartments.
[ "The", "effect", "of", "aflatoxin", "B1", "on", "the", "utilization", "of", "serum", "calcium", ".", "\n", "The", "mathematical", "analysis", "for", "plasma", "disappearance", "curve", "of", "aflatoxicosed", "animals", ",", "subsequently", "injected", "with", "45Ca", "was", "determined", ".", "The", "analysis", "showed", "that", "the", "three", "main", "compartments", "of", "the", "calcium", "pool", "(", "plasma", ",", "bone", "and", "the", "labile", "calcium", "pool", "on", "the", "surface", "of", "bone", "and", "soft", "tissues", ")", "had", "been", "affected", ".", "Specifically", ",", "the", "fractional", "rate", "constant", "for", "migration", "of", "45Ca", "from", "plasma", "pool", "to", "the", "labile", "pool", "had", "been", "diminished", "to", "its", "third", "value", ".", "This", "led", "to", "a", "corresponding", "reduction", "in", "the", "calcium", "content", "of", "the", "bone", "ash", ".", "The", "probable", "mechanism", "by", "which", "aflatoxin", "B1", "affects", "calcium", "dynamics", "may", "be", "interpreted", "by", "the", "inhibitory", "effect", "of", "aflatoxin", "in", "the", "hydroxylation", "mechanism", "of", "vitamin", "D3", "into", "an", "active", "intermediate", ".", "During", "aflatoxicosis", "(", "induction", "of", "15", "days", ")", "the", "animals", "entered", "a", "state", "of", "calcium", "deficiency", ",", "secondary", "to", "intestinal", "absorption", "inhibition", ".", "This", "was", "followed", "by", "bone", "resorption", "and", "disturbance", "of", "the", "fractional", "removal", "rate", "constant", "among", "different", "calcium", "compartments", ".", "\n" ]
[ "Tissue", "Multi-tissue_structure", "Organism_substance" ]
PGNs is a protein, Ca(2 is a compound, annexin V is a protein, ATP is a compound
DS.d684_task0
Sentence: Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]
Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration.
[ "Exposure", "of", "erythrocytes", "to", "PGNs", "increased", "cytosolic", "Ca(2", "+", ")", "concentration", ",", "increased", "ceramide", "formation", ",", "enhanced", "the", "percentage", "of", "annexin", "V", "-", "binding", "erythrocytes", ",", "decreased", "erythrocyte", "forward", "scatter", ",", "and", "lowered", "the", "intracellular", "ATP", "concentration", "." ]
[ "protein", "compound" ]
PGNs is a protein, Ca(2 is a compound, annexin V is a protein, ATP is a compound
DS.d684_task1
Sentence: Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration. Instructions: please typing these entity words according to sentence: PGNs, Ca(2, annexin V, ATP Options: compound, protein
[ "O", "O", "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]
Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration.
[ "Exposure", "of", "erythrocytes", "to", "PGNs", "increased", "cytosolic", "Ca(2", "+", ")", "concentration", ",", "increased", "ceramide", "formation", ",", "enhanced", "the", "percentage", "of", "annexin", "V", "-", "binding", "erythrocytes", ",", "decreased", "erythrocyte", "forward", "scatter", ",", "and", "lowered", "the", "intracellular", "ATP", "concentration", "." ]
[ "protein", "compound" ]
PGNs, Ca(2, annexin V, ATP
DS.d684_task2
Sentence: Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O" ]
Exposure of erythrocytes to PGNs increased cytosolic Ca(2+) concentration, increased ceramide formation, enhanced the percentage of annexin V-binding erythrocytes, decreased erythrocyte forward scatter, and lowered the intracellular ATP concentration.
[ "Exposure", "of", "erythrocytes", "to", "PGNs", "increased", "cytosolic", "Ca(2", "+", ")", "concentration", ",", "increased", "ceramide", "formation", ",", "enhanced", "the", "percentage", "of", "annexin", "V", "-", "binding", "erythrocytes", ",", "decreased", "erythrocyte", "forward", "scatter", ",", "and", "lowered", "the", "intracellular", "ATP", "concentration", "." ]
[ "protein", "compound" ]
Uvea is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Therapieverfahren is an umlsterm, Patienten is an umlsterm, Melanomen is an umlsterm, Biologie is an umlsterm, Hautmelanoms is an umlsterm, Metastasen is an umlsterm, Metastasen is an umlsterm, Leber is an umlsterm, Metastasen is an umlsterm, Patienten is an umlsterm, Interleukin-2 is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Ueberleben is an umlsterm, Patienten is an umlsterm
DerHautarzt.80490770.ger.abstr_task0
Sentence: Trotz der primaeren Entwicklung in der Uvea werden Patienten mit metastasierendem Uveamelanom in der dermatologischen Onkologie vorgestellt . Diese Patienten werden haeufig mit Therapieverfahren behandelt , die fuer Patienten mit metastasierenden kutanen Melanomen etabliert wurden . Allerdings divergiert sowohl die Biologie als auch das Metastasierungsverhalten des Uveamelanoms von dem des Hautmelanoms . Lymphogene Metastasen treten nie , haematogene Metastasen treten oft spaet auf , wobei die Leber - oft solitaer - das am haeufigsten befallene Organ ist . Die Ueberlebensprognose nach Auftreten hepatischer Metastasen ist mit 2 bis 5 Monaten sehr schlecht . Wir berichten ueber 3 Patienten mit metastasierendem Uveamelanom , die eine Immunochemotherapie mit Interferon-2b, Interleukin-2 und Fotemustin erhalten haben . Mit dieser Therapie konnte bei einem der Patienten eine partielle Remission von mehr als 49 Monaten Dauer erzielt werden . Die beiden anderen Patienten erfuhren eine Stabilisierung der Erkrankung ueber 8 und 16 Monate . Dieser therapeutische Erfolg spiegelt sich in einem im Vergleich zu historischen Kontrollen deutlich verlaengerten Ueberleben der Patienten von 14 , 43+ und 59+ Monaten wider . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Trotz der primaeren Entwicklung in der Uvea werden Patienten mit metastasierendem Uveamelanom in der dermatologischen Onkologie vorgestellt . Diese Patienten werden haeufig mit Therapieverfahren behandelt , die fuer Patienten mit metastasierenden kutanen Melanomen etabliert wurden . Allerdings divergiert sowohl die Biologie als auch das Metastasierungsverhalten des Uveamelanoms von dem des Hautmelanoms . Lymphogene Metastasen treten nie , haematogene Metastasen treten oft spaet auf , wobei die Leber - oft solitaer - das am haeufigsten befallene Organ ist . Die Ueberlebensprognose nach Auftreten hepatischer Metastasen ist mit 2 bis 5 Monaten sehr schlecht . Wir berichten ueber 3 Patienten mit metastasierendem Uveamelanom , die eine Immunochemotherapie mit Interferon-2b, Interleukin-2 und Fotemustin erhalten haben . Mit dieser Therapie konnte bei einem der Patienten eine partielle Remission von mehr als 49 Monaten Dauer erzielt werden . Die beiden anderen Patienten erfuhren eine Stabilisierung der Erkrankung ueber 8 und 16 Monate . Dieser therapeutische Erfolg spiegelt sich in einem im Vergleich zu historischen Kontrollen deutlich verlaengerten Ueberleben der Patienten von 14 , 43+ und 59+ Monaten wider .
[ "Trotz", "der", "primaeren", "Entwicklung", "in", "der", "Uvea", "werden", "Patienten", "mit", "metastasierendem", "Uveamelanom", "in", "der", "dermatologischen", "Onkologie", "vorgestellt", ".", "Diese", "Patienten", "werden", "haeufig", "mit", "Therapieverfahren", "behandelt", ",", "die", "fuer", "Patienten", "mit", "metastasierenden", "kutanen", "Melanomen", "etabliert", "wurden", ".", "Allerdings", "divergiert", "sowohl", "die", "Biologie", "als", "auch", "das", "Metastasierungsverhalten", "des", "Uveamelanoms", "von", "dem", "des", "Hautmelanoms", ".", "Lymphogene", "Metastasen", "treten", "nie", ",", "haematogene", "Metastasen", "treten", "oft", "spaet", "auf", ",", "wobei", "die", "Leber", "-", "oft", "solitaer", "-", "das", "am", "haeufigsten", "befallene", "Organ", "ist", ".", "Die", "Ueberlebensprognose", "nach", "Auftreten", "hepatischer", "Metastasen", "ist", "mit", "2", "bis", "5", "Monaten", "sehr", "schlecht", ".", "Wir", "berichten", "ueber", "3", "Patienten", "mit", "metastasierendem", "Uveamelanom", ",", "die", "eine", "Immunochemotherapie", "mit", "Interferon-2b", ",", "Interleukin-2", "und", "Fotemustin", "erhalten", "haben", ".", "Mit", "dieser", "Therapie", "konnte", "bei", "einem", "der", "Patienten", "eine", "partielle", "Remission", "von", "mehr", "als", "49", "Monaten", "Dauer", "erzielt", "werden", ".", "Die", "beiden", "anderen", "Patienten", "erfuhren", "eine", "Stabilisierung", "der", "Erkrankung", "ueber", "8", "und", "16", "Monate", ".", "Dieser", "therapeutische", "Erfolg", "spiegelt", "sich", "in", "einem", "im", "Vergleich", "zu", "historischen", "Kontrollen", "deutlich", "verlaengerten", "Ueberleben", "der", "Patienten", "von", "14", ",", "43", "+", "und", "59", "+", "Monaten", "wider", "." ]
[ "umlsterm" ]
Uvea is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Therapieverfahren is an umlsterm, Patienten is an umlsterm, Melanomen is an umlsterm, Biologie is an umlsterm, Hautmelanoms is an umlsterm, Metastasen is an umlsterm, Metastasen is an umlsterm, Leber is an umlsterm, Metastasen is an umlsterm, Patienten is an umlsterm, Interleukin-2 is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Ueberleben is an umlsterm, Patienten is an umlsterm
DerHautarzt.80490770.ger.abstr_task1
Sentence: Trotz der primaeren Entwicklung in der Uvea werden Patienten mit metastasierendem Uveamelanom in der dermatologischen Onkologie vorgestellt . Diese Patienten werden haeufig mit Therapieverfahren behandelt , die fuer Patienten mit metastasierenden kutanen Melanomen etabliert wurden . Allerdings divergiert sowohl die Biologie als auch das Metastasierungsverhalten des Uveamelanoms von dem des Hautmelanoms . Lymphogene Metastasen treten nie , haematogene Metastasen treten oft spaet auf , wobei die Leber - oft solitaer - das am haeufigsten befallene Organ ist . Die Ueberlebensprognose nach Auftreten hepatischer Metastasen ist mit 2 bis 5 Monaten sehr schlecht . Wir berichten ueber 3 Patienten mit metastasierendem Uveamelanom , die eine Immunochemotherapie mit Interferon-2b, Interleukin-2 und Fotemustin erhalten haben . Mit dieser Therapie konnte bei einem der Patienten eine partielle Remission von mehr als 49 Monaten Dauer erzielt werden . Die beiden anderen Patienten erfuhren eine Stabilisierung der Erkrankung ueber 8 und 16 Monate . Dieser therapeutische Erfolg spiegelt sich in einem im Vergleich zu historischen Kontrollen deutlich verlaengerten Ueberleben der Patienten von 14 , 43+ und 59+ Monaten wider . Instructions: please typing these entity words according to sentence: Uvea, Patienten, Patienten, Therapieverfahren, Patienten, Melanomen, Biologie, Hautmelanoms, Metastasen, Metastasen, Leber, Metastasen, Patienten, Interleukin-2, Therapie, Patienten, Patienten, Ueberleben, Patienten Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Trotz der primaeren Entwicklung in der Uvea werden Patienten mit metastasierendem Uveamelanom in der dermatologischen Onkologie vorgestellt . Diese Patienten werden haeufig mit Therapieverfahren behandelt , die fuer Patienten mit metastasierenden kutanen Melanomen etabliert wurden . Allerdings divergiert sowohl die Biologie als auch das Metastasierungsverhalten des Uveamelanoms von dem des Hautmelanoms . Lymphogene Metastasen treten nie , haematogene Metastasen treten oft spaet auf , wobei die Leber - oft solitaer - das am haeufigsten befallene Organ ist . Die Ueberlebensprognose nach Auftreten hepatischer Metastasen ist mit 2 bis 5 Monaten sehr schlecht . Wir berichten ueber 3 Patienten mit metastasierendem Uveamelanom , die eine Immunochemotherapie mit Interferon-2b, Interleukin-2 und Fotemustin erhalten haben . Mit dieser Therapie konnte bei einem der Patienten eine partielle Remission von mehr als 49 Monaten Dauer erzielt werden . Die beiden anderen Patienten erfuhren eine Stabilisierung der Erkrankung ueber 8 und 16 Monate . Dieser therapeutische Erfolg spiegelt sich in einem im Vergleich zu historischen Kontrollen deutlich verlaengerten Ueberleben der Patienten von 14 , 43+ und 59+ Monaten wider .
[ "Trotz", "der", "primaeren", "Entwicklung", "in", "der", "Uvea", "werden", "Patienten", "mit", "metastasierendem", "Uveamelanom", "in", "der", "dermatologischen", "Onkologie", "vorgestellt", ".", "Diese", "Patienten", "werden", "haeufig", "mit", "Therapieverfahren", "behandelt", ",", "die", "fuer", "Patienten", "mit", "metastasierenden", "kutanen", "Melanomen", "etabliert", "wurden", ".", "Allerdings", "divergiert", "sowohl", "die", "Biologie", "als", "auch", "das", "Metastasierungsverhalten", "des", "Uveamelanoms", "von", "dem", "des", "Hautmelanoms", ".", "Lymphogene", "Metastasen", "treten", "nie", ",", "haematogene", "Metastasen", "treten", "oft", "spaet", "auf", ",", "wobei", "die", "Leber", "-", "oft", "solitaer", "-", "das", "am", "haeufigsten", "befallene", "Organ", "ist", ".", "Die", "Ueberlebensprognose", "nach", "Auftreten", "hepatischer", "Metastasen", "ist", "mit", "2", "bis", "5", "Monaten", "sehr", "schlecht", ".", "Wir", "berichten", "ueber", "3", "Patienten", "mit", "metastasierendem", "Uveamelanom", ",", "die", "eine", "Immunochemotherapie", "mit", "Interferon-2b", ",", "Interleukin-2", "und", "Fotemustin", "erhalten", "haben", ".", "Mit", "dieser", "Therapie", "konnte", "bei", "einem", "der", "Patienten", "eine", "partielle", "Remission", "von", "mehr", "als", "49", "Monaten", "Dauer", "erzielt", "werden", ".", "Die", "beiden", "anderen", "Patienten", "erfuhren", "eine", "Stabilisierung", "der", "Erkrankung", "ueber", "8", "und", "16", "Monate", ".", "Dieser", "therapeutische", "Erfolg", "spiegelt", "sich", "in", "einem", "im", "Vergleich", "zu", "historischen", "Kontrollen", "deutlich", "verlaengerten", "Ueberleben", "der", "Patienten", "von", "14", ",", "43", "+", "und", "59", "+", "Monaten", "wider", "." ]
[ "umlsterm" ]
Uvea, Patienten, Patienten, Therapieverfahren, Patienten, Melanomen, Biologie, Hautmelanoms, Metastasen, Metastasen, Leber, Metastasen, Patienten, Interleukin-2, Therapie, Patienten, Patienten, Ueberleben, Patienten
DerHautarzt.80490770.ger.abstr_task2
Sentence: Trotz der primaeren Entwicklung in der Uvea werden Patienten mit metastasierendem Uveamelanom in der dermatologischen Onkologie vorgestellt . Diese Patienten werden haeufig mit Therapieverfahren behandelt , die fuer Patienten mit metastasierenden kutanen Melanomen etabliert wurden . Allerdings divergiert sowohl die Biologie als auch das Metastasierungsverhalten des Uveamelanoms von dem des Hautmelanoms . Lymphogene Metastasen treten nie , haematogene Metastasen treten oft spaet auf , wobei die Leber - oft solitaer - das am haeufigsten befallene Organ ist . Die Ueberlebensprognose nach Auftreten hepatischer Metastasen ist mit 2 bis 5 Monaten sehr schlecht . Wir berichten ueber 3 Patienten mit metastasierendem Uveamelanom , die eine Immunochemotherapie mit Interferon-2b, Interleukin-2 und Fotemustin erhalten haben . Mit dieser Therapie konnte bei einem der Patienten eine partielle Remission von mehr als 49 Monaten Dauer erzielt werden . Die beiden anderen Patienten erfuhren eine Stabilisierung der Erkrankung ueber 8 und 16 Monate . Dieser therapeutische Erfolg spiegelt sich in einem im Vergleich zu historischen Kontrollen deutlich verlaengerten Ueberleben der Patienten von 14 , 43+ und 59+ Monaten wider . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Trotz der primaeren Entwicklung in der Uvea werden Patienten mit metastasierendem Uveamelanom in der dermatologischen Onkologie vorgestellt . Diese Patienten werden haeufig mit Therapieverfahren behandelt , die fuer Patienten mit metastasierenden kutanen Melanomen etabliert wurden . Allerdings divergiert sowohl die Biologie als auch das Metastasierungsverhalten des Uveamelanoms von dem des Hautmelanoms . Lymphogene Metastasen treten nie , haematogene Metastasen treten oft spaet auf , wobei die Leber - oft solitaer - das am haeufigsten befallene Organ ist . Die Ueberlebensprognose nach Auftreten hepatischer Metastasen ist mit 2 bis 5 Monaten sehr schlecht . Wir berichten ueber 3 Patienten mit metastasierendem Uveamelanom , die eine Immunochemotherapie mit Interferon-2b, Interleukin-2 und Fotemustin erhalten haben . Mit dieser Therapie konnte bei einem der Patienten eine partielle Remission von mehr als 49 Monaten Dauer erzielt werden . Die beiden anderen Patienten erfuhren eine Stabilisierung der Erkrankung ueber 8 und 16 Monate . Dieser therapeutische Erfolg spiegelt sich in einem im Vergleich zu historischen Kontrollen deutlich verlaengerten Ueberleben der Patienten von 14 , 43+ und 59+ Monaten wider .
[ "Trotz", "der", "primaeren", "Entwicklung", "in", "der", "Uvea", "werden", "Patienten", "mit", "metastasierendem", "Uveamelanom", "in", "der", "dermatologischen", "Onkologie", "vorgestellt", ".", "Diese", "Patienten", "werden", "haeufig", "mit", "Therapieverfahren", "behandelt", ",", "die", "fuer", "Patienten", "mit", "metastasierenden", "kutanen", "Melanomen", "etabliert", "wurden", ".", "Allerdings", "divergiert", "sowohl", "die", "Biologie", "als", "auch", "das", "Metastasierungsverhalten", "des", "Uveamelanoms", "von", "dem", "des", "Hautmelanoms", ".", "Lymphogene", "Metastasen", "treten", "nie", ",", "haematogene", "Metastasen", "treten", "oft", "spaet", "auf", ",", "wobei", "die", "Leber", "-", "oft", "solitaer", "-", "das", "am", "haeufigsten", "befallene", "Organ", "ist", ".", "Die", "Ueberlebensprognose", "nach", "Auftreten", "hepatischer", "Metastasen", "ist", "mit", "2", "bis", "5", "Monaten", "sehr", "schlecht", ".", "Wir", "berichten", "ueber", "3", "Patienten", "mit", "metastasierendem", "Uveamelanom", ",", "die", "eine", "Immunochemotherapie", "mit", "Interferon-2b", ",", "Interleukin-2", "und", "Fotemustin", "erhalten", "haben", ".", "Mit", "dieser", "Therapie", "konnte", "bei", "einem", "der", "Patienten", "eine", "partielle", "Remission", "von", "mehr", "als", "49", "Monaten", "Dauer", "erzielt", "werden", ".", "Die", "beiden", "anderen", "Patienten", "erfuhren", "eine", "Stabilisierung", "der", "Erkrankung", "ueber", "8", "und", "16", "Monate", ".", "Dieser", "therapeutische", "Erfolg", "spiegelt", "sich", "in", "einem", "im", "Vergleich", "zu", "historischen", "Kontrollen", "deutlich", "verlaengerten", "Ueberleben", "der", "Patienten", "von", "14", ",", "43", "+", "und", "59", "+", "Monaten", "wider", "." ]
[ "umlsterm" ]
actin is a Individual_protein, villin is a Individual_protein, fimbrin is a Individual_protein
727_task0
Sentence: The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]
The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.
[ "The", "isolated", "intestinal", "microvillus", "cytoskeleton", "(", "core", ")", "consists", "of", "four", "major", "proteins", ":", "actin", ",", "villin", ",", "fimbrin", "and", "brush", "border", "myosin", "-", "I." ]
[ "Individual_protein" ]
actin is a Individual_protein, villin is a Individual_protein, fimbrin is a Individual_protein
727_task1
Sentence: The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I. Instructions: please typing these entity words according to sentence: actin, villin, fimbrin Options: Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]
The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.
[ "The", "isolated", "intestinal", "microvillus", "cytoskeleton", "(", "core", ")", "consists", "of", "four", "major", "proteins", ":", "actin", ",", "villin", ",", "fimbrin", "and", "brush", "border", "myosin", "-", "I." ]
[ "Individual_protein" ]
actin, villin, fimbrin
727_task2
Sentence: The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]
The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.
[ "The", "isolated", "intestinal", "microvillus", "cytoskeleton", "(", "core", ")", "consists", "of", "four", "major", "proteins", ":", "actin", ",", "villin", ",", "fimbrin", "and", "brush", "border", "myosin", "-", "I." ]
[ "Individual_protein" ]
IL-6 is a protein, cortisol is a compound
DS.d1485_task0
Sentence: No main effect of group assignment on TSST responses was found for IL-6, cortisol or POMS scores. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O" ]
No main effect of group assignment on TSST responses was found for IL-6, cortisol or POMS scores.
[ "No", "main", "effect", "of", "group", "assignment", "on", "TSST", "responses", "was", "found", "for", "IL-6", ",", "cortisol", "or", "POMS", "scores", "." ]
[ "compound", "protein" ]
IL-6 is a protein, cortisol is a compound
DS.d1485_task1
Sentence: No main effect of group assignment on TSST responses was found for IL-6, cortisol or POMS scores. Instructions: please typing these entity words according to sentence: IL-6, cortisol Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O" ]
No main effect of group assignment on TSST responses was found for IL-6, cortisol or POMS scores.
[ "No", "main", "effect", "of", "group", "assignment", "on", "TSST", "responses", "was", "found", "for", "IL-6", ",", "cortisol", "or", "POMS", "scores", "." ]
[ "compound", "protein" ]
IL-6, cortisol
DS.d1485_task2
Sentence: No main effect of group assignment on TSST responses was found for IL-6, cortisol or POMS scores. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-compound", "O", "O", "O", "O" ]
No main effect of group assignment on TSST responses was found for IL-6, cortisol or POMS scores.
[ "No", "main", "effect", "of", "group", "assignment", "on", "TSST", "responses", "was", "found", "for", "IL-6", ",", "cortisol", "or", "POMS", "scores", "." ]
[ "compound", "protein" ]
interleukin-4 is a Protein, interleukin-5 is a Protein, interleukin ( IL)-2 is a Protein, IL-3 is a Protein, IL-4 is a Protein, IL-10 is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, promoter is a Entity, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-5 is a Protein, IL-2 is a Protein, IL-5 is a Protein, promoter is a Entity, P sequence is a Entity, IL-4 is a Protein, P65 is a Protein, P65 is a Protein, P50 is a Protein, P65 is a Protein, IL-4 is a Protein, IL-5 is a Protein
8083467_task0
Sentence: Signals and nuclear factors that regulate the expression of interleukin-4 and interleukin-5 genes in helper T cells. Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however, cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals, PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and nuclear factor for activated T cell (NF-AT). In electromobility shift assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the regulation of IL-4 and IL-5 genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O" ]
Signals and nuclear factors that regulate the expression of interleukin-4 and interleukin-5 genes in helper T cells. Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however, cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals, PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and nuclear factor for activated T cell (NF-AT). In electromobility shift assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the regulation of IL-4 and IL-5 genes.
[ "Signals", "and", "nuclear", "factors", "that", "regulate", "the", "expression", "of", "interleukin-4", "and", "interleukin-5", "genes", "in", "helper", "T", "cells", ".", "\n", "Mouse", "thymoma", "line", "EL-4", "cells", "produce", "cytokines", "such", "as", "interleukin", "(", "IL)-2", ",", "IL-3", ",", "IL-4", ",", "IL-10", ",", "and", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "in", "response", "to", "phorbol", "12-myristate", "13-acetate", "(", "PMA", ")", ".", "EL-4", "cells", "also", "produce", "low", "levels", "of", "IL-5", "when", "stimulated", "by", "PMA", "alone", ";", "however", ",", "cAMP", "greatly", "augments", "PMA", "-", "dependent", "IL-5", "production", ".", "A", "transient", "transfection", "assay", "revealed", "that", "two", "signals", ",", "PMA", "and", "cAMP", ",", "are", "required", "for", "optimal", "activation", "of", "the", "IL-5", "promoter", ".", "In", "contrast", ",", "cAMP", "almost", "completely", "inhibited", "the", "PMA", "-", "dependent", "activation", "of", "the", "endogenous", "IL-2", "gene", ",", "as", "well", "as", "the", "transfected", "IL-2", "promoter", ".", "These", "results", "indicate", "that", "the", "IL-5", "gene", "is", "positively", "regulated", "by", "cAMP", "in", "a", "manner", "opposite", "to", "that", "for", "the", "IL-2", "gene", ".", "One", "of", "the", "nuclear", "factors", "(", "NFs", ")", "that", "regulates", "the", "response", "of", "the", "IL-5", "promoter", "to", "cAMP", "and", "PMA", "has", "properties", "similar", "to", "NF", "for", "activated", "t", "cell", ".", "The", "P", "sequence", "of", "the", "IL-4", "gene", ",", "defined", "as", "a", "responsive", "element", "for", "PMA", "and", "calcium", "ionophore", "(", "A23187", ")", ",", "shares", "sequence", "similarity", "with", "the", "NF", "kappa", "B", "and", "the", "NF", "-", "activated", "T", "cell", "binding", "sites", ".", "We", "attempted", "to", "determine", "whether", "NF(P", ")", ",", "a", "nuclear", "factor", "specific", "for", "the", "P", "sequence", ",", "is", "related", "to", "NF", "-", "kappa", "B", "and", "nuclear", "factor", "for", "activated", "T", "cell", "(", "NF", "-", "AT", ")", ".", "In", "electromobility", "shift", "assays", "both", "NF", "-", "kappa", "B", "(", "P65", "or", "P65", "/", "P50", "heterodimer", ")", "and", "NF", "-", "AT", "bound", "to", "the", "P", "sequence", ".", "However", ",", "sequence", "specificity", "of", "NF", "-", "AT", "was", "more", "similar", "to", "that", "of", "NF(P", ")", ",", "and", "only", "a", "small", "amount", "of", "P65", "was", "detected", "in", "NF(P", ")", ".", "These", "results", "indicate", "that", "a", "component", "or", "components", "of", "NF", "-", "AT", "have", "the", "potential", "to", "reconstitute", "NF(P", ")", ",", "whereas", "NF", "-", "kappa", "B", "alone", "does", "not", "account", "for", "NF(P", ")", "in", "Jurkat", "crude", "extract", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "NF", "-", "AT", "-", "like", "factors", "are", "involved", "in", "the", "regulation", "of", "IL-4", "and", "IL-5", "genes", "." ]
[ "Protein", "Entity" ]
interleukin-4 is a Protein, interleukin-5 is a Protein, interleukin ( IL)-2 is a Protein, IL-3 is a Protein, IL-4 is a Protein, IL-10 is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, promoter is a Entity, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-5 is a Protein, IL-2 is a Protein, IL-5 is a Protein, promoter is a Entity, P sequence is a Entity, IL-4 is a Protein, P65 is a Protein, P65 is a Protein, P50 is a Protein, P65 is a Protein, IL-4 is a Protein, IL-5 is a Protein
8083467_task1
Sentence: Signals and nuclear factors that regulate the expression of interleukin-4 and interleukin-5 genes in helper T cells. Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however, cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals, PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and nuclear factor for activated T cell (NF-AT). In electromobility shift assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the regulation of IL-4 and IL-5 genes. Instructions: please typing these entity words according to sentence: interleukin-4, interleukin-5, interleukin ( IL)-2, IL-3, IL-4, IL-10, granulocyte - macrophage colony - stimulating factor, IL-5, IL-5, IL-5, promoter, IL-2, IL-2, promoter, IL-5, IL-2, IL-5, promoter, P sequence, IL-4, P65, P65, P50, P65, IL-4, IL-5 Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O" ]
Signals and nuclear factors that regulate the expression of interleukin-4 and interleukin-5 genes in helper T cells. Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however, cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals, PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and nuclear factor for activated T cell (NF-AT). In electromobility shift assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the regulation of IL-4 and IL-5 genes.
[ "Signals", "and", "nuclear", "factors", "that", "regulate", "the", "expression", "of", "interleukin-4", "and", "interleukin-5", "genes", "in", "helper", "T", "cells", ".", "\n", "Mouse", "thymoma", "line", "EL-4", "cells", "produce", "cytokines", "such", "as", "interleukin", "(", "IL)-2", ",", "IL-3", ",", "IL-4", ",", "IL-10", ",", "and", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "in", "response", "to", "phorbol", "12-myristate", "13-acetate", "(", "PMA", ")", ".", "EL-4", "cells", "also", "produce", "low", "levels", "of", "IL-5", "when", "stimulated", "by", "PMA", "alone", ";", "however", ",", "cAMP", "greatly", "augments", "PMA", "-", "dependent", "IL-5", "production", ".", "A", "transient", "transfection", "assay", "revealed", "that", "two", "signals", ",", "PMA", "and", "cAMP", ",", "are", "required", "for", "optimal", "activation", "of", "the", "IL-5", "promoter", ".", "In", "contrast", ",", "cAMP", "almost", "completely", "inhibited", "the", "PMA", "-", "dependent", "activation", "of", "the", "endogenous", "IL-2", "gene", ",", "as", "well", "as", "the", "transfected", "IL-2", "promoter", ".", "These", "results", "indicate", "that", "the", "IL-5", "gene", "is", "positively", "regulated", "by", "cAMP", "in", "a", "manner", "opposite", "to", "that", "for", "the", "IL-2", "gene", ".", "One", "of", "the", "nuclear", "factors", "(", "NFs", ")", "that", "regulates", "the", "response", "of", "the", "IL-5", "promoter", "to", "cAMP", "and", "PMA", "has", "properties", "similar", "to", "NF", "for", "activated", "t", "cell", ".", "The", "P", "sequence", "of", "the", "IL-4", "gene", ",", "defined", "as", "a", "responsive", "element", "for", "PMA", "and", "calcium", "ionophore", "(", "A23187", ")", ",", "shares", "sequence", "similarity", "with", "the", "NF", "kappa", "B", "and", "the", "NF", "-", "activated", "T", "cell", "binding", "sites", ".", "We", "attempted", "to", "determine", "whether", "NF(P", ")", ",", "a", "nuclear", "factor", "specific", "for", "the", "P", "sequence", ",", "is", "related", "to", "NF", "-", "kappa", "B", "and", "nuclear", "factor", "for", "activated", "T", "cell", "(", "NF", "-", "AT", ")", ".", "In", "electromobility", "shift", "assays", "both", "NF", "-", "kappa", "B", "(", "P65", "or", "P65", "/", "P50", "heterodimer", ")", "and", "NF", "-", "AT", "bound", "to", "the", "P", "sequence", ".", "However", ",", "sequence", "specificity", "of", "NF", "-", "AT", "was", "more", "similar", "to", "that", "of", "NF(P", ")", ",", "and", "only", "a", "small", "amount", "of", "P65", "was", "detected", "in", "NF(P", ")", ".", "These", "results", "indicate", "that", "a", "component", "or", "components", "of", "NF", "-", "AT", "have", "the", "potential", "to", "reconstitute", "NF(P", ")", ",", "whereas", "NF", "-", "kappa", "B", "alone", "does", "not", "account", "for", "NF(P", ")", "in", "Jurkat", "crude", "extract", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "NF", "-", "AT", "-", "like", "factors", "are", "involved", "in", "the", "regulation", "of", "IL-4", "and", "IL-5", "genes", "." ]
[ "Protein", "Entity" ]
interleukin-4, interleukin-5, interleukin ( IL)-2, IL-3, IL-4, IL-10, granulocyte - macrophage colony - stimulating factor, IL-5, IL-5, IL-5, promoter, IL-2, IL-2, promoter, IL-5, IL-2, IL-5, promoter, P sequence, IL-4, P65, P65, P50, P65, IL-4, IL-5
8083467_task2
Sentence: Signals and nuclear factors that regulate the expression of interleukin-4 and interleukin-5 genes in helper T cells. Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however, cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals, PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and nuclear factor for activated T cell (NF-AT). In electromobility shift assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the regulation of IL-4 and IL-5 genes. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O" ]
Signals and nuclear factors that regulate the expression of interleukin-4 and interleukin-5 genes in helper T cells. Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however, cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals, PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and nuclear factor for activated T cell (NF-AT). In electromobility shift assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the regulation of IL-4 and IL-5 genes.
[ "Signals", "and", "nuclear", "factors", "that", "regulate", "the", "expression", "of", "interleukin-4", "and", "interleukin-5", "genes", "in", "helper", "T", "cells", ".", "\n", "Mouse", "thymoma", "line", "EL-4", "cells", "produce", "cytokines", "such", "as", "interleukin", "(", "IL)-2", ",", "IL-3", ",", "IL-4", ",", "IL-10", ",", "and", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "in", "response", "to", "phorbol", "12-myristate", "13-acetate", "(", "PMA", ")", ".", "EL-4", "cells", "also", "produce", "low", "levels", "of", "IL-5", "when", "stimulated", "by", "PMA", "alone", ";", "however", ",", "cAMP", "greatly", "augments", "PMA", "-", "dependent", "IL-5", "production", ".", "A", "transient", "transfection", "assay", "revealed", "that", "two", "signals", ",", "PMA", "and", "cAMP", ",", "are", "required", "for", "optimal", "activation", "of", "the", "IL-5", "promoter", ".", "In", "contrast", ",", "cAMP", "almost", "completely", "inhibited", "the", "PMA", "-", "dependent", "activation", "of", "the", "endogenous", "IL-2", "gene", ",", "as", "well", "as", "the", "transfected", "IL-2", "promoter", ".", "These", "results", "indicate", "that", "the", "IL-5", "gene", "is", "positively", "regulated", "by", "cAMP", "in", "a", "manner", "opposite", "to", "that", "for", "the", "IL-2", "gene", ".", "One", "of", "the", "nuclear", "factors", "(", "NFs", ")", "that", "regulates", "the", "response", "of", "the", "IL-5", "promoter", "to", "cAMP", "and", "PMA", "has", "properties", "similar", "to", "NF", "for", "activated", "t", "cell", ".", "The", "P", "sequence", "of", "the", "IL-4", "gene", ",", "defined", "as", "a", "responsive", "element", "for", "PMA", "and", "calcium", "ionophore", "(", "A23187", ")", ",", "shares", "sequence", "similarity", "with", "the", "NF", "kappa", "B", "and", "the", "NF", "-", "activated", "T", "cell", "binding", "sites", ".", "We", "attempted", "to", "determine", "whether", "NF(P", ")", ",", "a", "nuclear", "factor", "specific", "for", "the", "P", "sequence", ",", "is", "related", "to", "NF", "-", "kappa", "B", "and", "nuclear", "factor", "for", "activated", "T", "cell", "(", "NF", "-", "AT", ")", ".", "In", "electromobility", "shift", "assays", "both", "NF", "-", "kappa", "B", "(", "P65", "or", "P65", "/", "P50", "heterodimer", ")", "and", "NF", "-", "AT", "bound", "to", "the", "P", "sequence", ".", "However", ",", "sequence", "specificity", "of", "NF", "-", "AT", "was", "more", "similar", "to", "that", "of", "NF(P", ")", ",", "and", "only", "a", "small", "amount", "of", "P65", "was", "detected", "in", "NF(P", ")", ".", "These", "results", "indicate", "that", "a", "component", "or", "components", "of", "NF", "-", "AT", "have", "the", "potential", "to", "reconstitute", "NF(P", ")", ",", "whereas", "NF", "-", "kappa", "B", "alone", "does", "not", "account", "for", "NF(P", ")", "in", "Jurkat", "crude", "extract", ".", "Taken", "together", ",", "these", "results", "suggest", "that", "NF", "-", "AT", "-", "like", "factors", "are", "involved", "in", "the", "regulation", "of", "IL-4", "and", "IL-5", "genes", "." ]
[ "Protein", "Entity" ]
probiotic intervention is a Intervention_Pharmacological, risk of is a Outcome_Adverse-effects, neuropsychiatric disorders is a Outcome_Physical, childhood is a Participant_Age, Seventy - five is a Participant_Sample-size, infants is a Participant_Age, randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 is a Participant_Condition, or placebo during the first is a Participant_Condition, Gut microbiota is a Outcome_Physical, the blood group secretor type is a Outcome_Physical, of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) is a Outcome_Physical, y , ADHD is a Outcome_Mental, The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life is a Outcome_Physical, the risk of neuropsychiatric disorder development is a Outcome_Adverse-effects
70448_task0
Sentence: A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood : a randomized trial . BACKGROUND Recent experimental evidence suggests that gut microbiota may alter function within the nervous system providing new insight on the mechanism of neuropsychiatric disorders . METHODS Seventy-five infants who were randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 ) or placebo during the first 6 mo of life were followed-up for 13 y . Gut microbiota was assessed at the age of 3 wk , 3 , 6 , 12 , 18 , 24 mo , and 13 y using fluorescein in situ hybridization ( FISH ) and qPCR , and indirectly by determining the blood group secretor type at the age of 13 y . The diagnoses of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria . RESULTS At the age of 13 y , ADHD or AS was diagnosed in 6/35 ( 17.1 % ) children in the placebo and none in the probiotic group ( P = 0.008 ) . The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life was lower in affected children 8.26 ( 1.24 ) log cells/g than in healthy children 9.12 ( 0.64 ) log cells/g ; P = 0.03 . CONCLUSION Probiotic supplementation early in life may reduce the risk of neuropsychiatric disorder development later in childhood possible by mechanisms not limited to gut microbiota composition . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood : a randomized trial . BACKGROUND Recent experimental evidence suggests that gut microbiota may alter function within the nervous system providing new insight on the mechanism of neuropsychiatric disorders . METHODS Seventy-five infants who were randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 ) or placebo during the first 6 mo of life were followed-up for 13 y . Gut microbiota was assessed at the age of 3 wk , 3 , 6 , 12 , 18 , 24 mo , and 13 y using fluorescein in situ hybridization ( FISH ) and qPCR , and indirectly by determining the blood group secretor type at the age of 13 y . The diagnoses of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria . RESULTS At the age of 13 y , ADHD or AS was diagnosed in 6/35 ( 17.1 % ) children in the placebo and none in the probiotic group ( P = 0.008 ) . The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life was lower in affected children 8.26 ( 1.24 ) log cells/g than in healthy children 9.12 ( 0.64 ) log cells/g ; P = 0.03 . CONCLUSION Probiotic supplementation early in life may reduce the risk of neuropsychiatric disorder development later in childhood possible by mechanisms not limited to gut microbiota composition .
[ "A", "possible", "link", "between", "early", "probiotic", "intervention", "and", "the", "risk", "of", "neuropsychiatric", "disorders", "later", "in", "childhood", ":", "a", "randomized", "trial", ".", "BACKGROUND", "Recent", "experimental", "evidence", "suggests", "that", "gut", "microbiota", "may", "alter", "function", "within", "the", "nervous", "system", "providing", "new", "insight", "on", "the", "mechanism", "of", "neuropsychiatric", "disorders", ".", "METHODS", "Seventy", "-", "five", "infants", "who", "were", "randomized", "to", "receive", "Lactobacillus", "rhamnosus", "GG", "(", "ATCC", "53103", ")", "or", "placebo", "during", "the", "first", "6", "mo", "of", "life", "were", "followed", "-", "up", "for", "13", "y", ".", "Gut", "microbiota", "was", "assessed", "at", "the", "age", "of", "3", "wk", ",", "3", ",", "6", ",", "12", ",", "18", ",", "24", "mo", ",", "and", "13", "y", "using", "fluorescein", "in", "situ", "hybridization", "(", "FISH", ")", "and", "qPCR", ",", "and", "indirectly", "by", "determining", "the", "blood", "group", "secretor", "type", "at", "the", "age", "of", "13", "y", ".", "The", "diagnoses", "of", "attention", "deficit", "hyperactivity", "disorder", "(", "ADHD", ")", "and", "Asperger", "syndrome", "(", "AS", ")", "by", "a", "child", "neurologist", "or", "psychiatrist", "were", "based", "on", "ICD-10", "diagnostic", "criteria", ".", "RESULTS", "At", "the", "age", "of", "13", "y", ",", "ADHD", "or", "AS", "was", "diagnosed", "in", "6/35", "(", "17.1", "%", ")", "children", "in", "the", "placebo", "and", "none", "in", "the", "probiotic", "group", "(", "P", "=", "0.008", ")", ".", "The", "mean", "(", "SD", ")", "numbers", "of", "Bifidobacterium", "species", "bacteria", "in", "feces", "during", "the", "first", "6", "mo", "of", "life", "was", "lower", "in", "affected", "children", "8.26", "(", "1.24", ")", "log", "cells", "/", "g", "than", "in", "healthy", "children", "9.12", "(", "0.64", ")", "log", "cells", "/", "g", ";", "P", "=", "0.03", ".", "CONCLUSION", "Probiotic", "supplementation", "early", "in", "life", "may", "reduce", "the", "risk", "of", "neuropsychiatric", "disorder", "development", "later", "in", "childhood", "possible", "by", "mechanisms", "not", "limited", "to", "gut", "microbiota", "composition", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Age", "Outcome_Mental", "Intervention_Control" ]
probiotic intervention is a Intervention_Pharmacological, risk of is a Outcome_Adverse-effects, neuropsychiatric disorders is a Outcome_Physical, childhood is a Participant_Age, Seventy - five is a Participant_Sample-size, infants is a Participant_Age, randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 is a Participant_Condition, or placebo during the first is a Participant_Condition, Gut microbiota is a Outcome_Physical, the blood group secretor type is a Outcome_Physical, of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) is a Outcome_Physical, y , ADHD is a Outcome_Mental, The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life is a Outcome_Physical, the risk of neuropsychiatric disorder development is a Outcome_Adverse-effects
70448_task1
Sentence: A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood : a randomized trial . BACKGROUND Recent experimental evidence suggests that gut microbiota may alter function within the nervous system providing new insight on the mechanism of neuropsychiatric disorders . METHODS Seventy-five infants who were randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 ) or placebo during the first 6 mo of life were followed-up for 13 y . Gut microbiota was assessed at the age of 3 wk , 3 , 6 , 12 , 18 , 24 mo , and 13 y using fluorescein in situ hybridization ( FISH ) and qPCR , and indirectly by determining the blood group secretor type at the age of 13 y . The diagnoses of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria . RESULTS At the age of 13 y , ADHD or AS was diagnosed in 6/35 ( 17.1 % ) children in the placebo and none in the probiotic group ( P = 0.008 ) . The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life was lower in affected children 8.26 ( 1.24 ) log cells/g than in healthy children 9.12 ( 0.64 ) log cells/g ; P = 0.03 . CONCLUSION Probiotic supplementation early in life may reduce the risk of neuropsychiatric disorder development later in childhood possible by mechanisms not limited to gut microbiota composition . Instructions: please typing these entity words according to sentence: probiotic intervention, risk of, neuropsychiatric disorders, childhood, Seventy - five, infants, randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103, or placebo during the first, Gut microbiota, the blood group secretor type, of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ), y , ADHD, The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life, the risk of neuropsychiatric disorder development Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood : a randomized trial . BACKGROUND Recent experimental evidence suggests that gut microbiota may alter function within the nervous system providing new insight on the mechanism of neuropsychiatric disorders . METHODS Seventy-five infants who were randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 ) or placebo during the first 6 mo of life were followed-up for 13 y . Gut microbiota was assessed at the age of 3 wk , 3 , 6 , 12 , 18 , 24 mo , and 13 y using fluorescein in situ hybridization ( FISH ) and qPCR , and indirectly by determining the blood group secretor type at the age of 13 y . The diagnoses of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria . RESULTS At the age of 13 y , ADHD or AS was diagnosed in 6/35 ( 17.1 % ) children in the placebo and none in the probiotic group ( P = 0.008 ) . The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life was lower in affected children 8.26 ( 1.24 ) log cells/g than in healthy children 9.12 ( 0.64 ) log cells/g ; P = 0.03 . CONCLUSION Probiotic supplementation early in life may reduce the risk of neuropsychiatric disorder development later in childhood possible by mechanisms not limited to gut microbiota composition .
[ "A", "possible", "link", "between", "early", "probiotic", "intervention", "and", "the", "risk", "of", "neuropsychiatric", "disorders", "later", "in", "childhood", ":", "a", "randomized", "trial", ".", "BACKGROUND", "Recent", "experimental", "evidence", "suggests", "that", "gut", "microbiota", "may", "alter", "function", "within", "the", "nervous", "system", "providing", "new", "insight", "on", "the", "mechanism", "of", "neuropsychiatric", "disorders", ".", "METHODS", "Seventy", "-", "five", "infants", "who", "were", "randomized", "to", "receive", "Lactobacillus", "rhamnosus", "GG", "(", "ATCC", "53103", ")", "or", "placebo", "during", "the", "first", "6", "mo", "of", "life", "were", "followed", "-", "up", "for", "13", "y", ".", "Gut", "microbiota", "was", "assessed", "at", "the", "age", "of", "3", "wk", ",", "3", ",", "6", ",", "12", ",", "18", ",", "24", "mo", ",", "and", "13", "y", "using", "fluorescein", "in", "situ", "hybridization", "(", "FISH", ")", "and", "qPCR", ",", "and", "indirectly", "by", "determining", "the", "blood", "group", "secretor", "type", "at", "the", "age", "of", "13", "y", ".", "The", "diagnoses", "of", "attention", "deficit", "hyperactivity", "disorder", "(", "ADHD", ")", "and", "Asperger", "syndrome", "(", "AS", ")", "by", "a", "child", "neurologist", "or", "psychiatrist", "were", "based", "on", "ICD-10", "diagnostic", "criteria", ".", "RESULTS", "At", "the", "age", "of", "13", "y", ",", "ADHD", "or", "AS", "was", "diagnosed", "in", "6/35", "(", "17.1", "%", ")", "children", "in", "the", "placebo", "and", "none", "in", "the", "probiotic", "group", "(", "P", "=", "0.008", ")", ".", "The", "mean", "(", "SD", ")", "numbers", "of", "Bifidobacterium", "species", "bacteria", "in", "feces", "during", "the", "first", "6", "mo", "of", "life", "was", "lower", "in", "affected", "children", "8.26", "(", "1.24", ")", "log", "cells", "/", "g", "than", "in", "healthy", "children", "9.12", "(", "0.64", ")", "log", "cells", "/", "g", ";", "P", "=", "0.03", ".", "CONCLUSION", "Probiotic", "supplementation", "early", "in", "life", "may", "reduce", "the", "risk", "of", "neuropsychiatric", "disorder", "development", "later", "in", "childhood", "possible", "by", "mechanisms", "not", "limited", "to", "gut", "microbiota", "composition", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Age", "Outcome_Mental", "Intervention_Control" ]
probiotic intervention, risk of, neuropsychiatric disorders, childhood, Seventy - five, infants, randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103, or placebo during the first, Gut microbiota, the blood group secretor type, of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ), y , ADHD, The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life, the risk of neuropsychiatric disorder development
70448_task2
Sentence: A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood : a randomized trial . BACKGROUND Recent experimental evidence suggests that gut microbiota may alter function within the nervous system providing new insight on the mechanism of neuropsychiatric disorders . METHODS Seventy-five infants who were randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 ) or placebo during the first 6 mo of life were followed-up for 13 y . Gut microbiota was assessed at the age of 3 wk , 3 , 6 , 12 , 18 , 24 mo , and 13 y using fluorescein in situ hybridization ( FISH ) and qPCR , and indirectly by determining the blood group secretor type at the age of 13 y . The diagnoses of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria . RESULTS At the age of 13 y , ADHD or AS was diagnosed in 6/35 ( 17.1 % ) children in the placebo and none in the probiotic group ( P = 0.008 ) . The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life was lower in affected children 8.26 ( 1.24 ) log cells/g than in healthy children 9.12 ( 0.64 ) log cells/g ; P = 0.03 . CONCLUSION Probiotic supplementation early in life may reduce the risk of neuropsychiatric disorder development later in childhood possible by mechanisms not limited to gut microbiota composition . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Age", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood : a randomized trial . BACKGROUND Recent experimental evidence suggests that gut microbiota may alter function within the nervous system providing new insight on the mechanism of neuropsychiatric disorders . METHODS Seventy-five infants who were randomized to receive Lactobacillus rhamnosus GG ( ATCC 53103 ) or placebo during the first 6 mo of life were followed-up for 13 y . Gut microbiota was assessed at the age of 3 wk , 3 , 6 , 12 , 18 , 24 mo , and 13 y using fluorescein in situ hybridization ( FISH ) and qPCR , and indirectly by determining the blood group secretor type at the age of 13 y . The diagnoses of attention deficit hyperactivity disorder ( ADHD ) and Asperger syndrome ( AS ) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria . RESULTS At the age of 13 y , ADHD or AS was diagnosed in 6/35 ( 17.1 % ) children in the placebo and none in the probiotic group ( P = 0.008 ) . The mean ( SD ) numbers of Bifidobacterium species bacteria in feces during the first 6 mo of life was lower in affected children 8.26 ( 1.24 ) log cells/g than in healthy children 9.12 ( 0.64 ) log cells/g ; P = 0.03 . CONCLUSION Probiotic supplementation early in life may reduce the risk of neuropsychiatric disorder development later in childhood possible by mechanisms not limited to gut microbiota composition .
[ "A", "possible", "link", "between", "early", "probiotic", "intervention", "and", "the", "risk", "of", "neuropsychiatric", "disorders", "later", "in", "childhood", ":", "a", "randomized", "trial", ".", "BACKGROUND", "Recent", "experimental", "evidence", "suggests", "that", "gut", "microbiota", "may", "alter", "function", "within", "the", "nervous", "system", "providing", "new", "insight", "on", "the", "mechanism", "of", "neuropsychiatric", "disorders", ".", "METHODS", "Seventy", "-", "five", "infants", "who", "were", "randomized", "to", "receive", "Lactobacillus", "rhamnosus", "GG", "(", "ATCC", "53103", ")", "or", "placebo", "during", "the", "first", "6", "mo", "of", "life", "were", "followed", "-", "up", "for", "13", "y", ".", "Gut", "microbiota", "was", "assessed", "at", "the", "age", "of", "3", "wk", ",", "3", ",", "6", ",", "12", ",", "18", ",", "24", "mo", ",", "and", "13", "y", "using", "fluorescein", "in", "situ", "hybridization", "(", "FISH", ")", "and", "qPCR", ",", "and", "indirectly", "by", "determining", "the", "blood", "group", "secretor", "type", "at", "the", "age", "of", "13", "y", ".", "The", "diagnoses", "of", "attention", "deficit", "hyperactivity", "disorder", "(", "ADHD", ")", "and", "Asperger", "syndrome", "(", "AS", ")", "by", "a", "child", "neurologist", "or", "psychiatrist", "were", "based", "on", "ICD-10", "diagnostic", "criteria", ".", "RESULTS", "At", "the", "age", "of", "13", "y", ",", "ADHD", "or", "AS", "was", "diagnosed", "in", "6/35", "(", "17.1", "%", ")", "children", "in", "the", "placebo", "and", "none", "in", "the", "probiotic", "group", "(", "P", "=", "0.008", ")", ".", "The", "mean", "(", "SD", ")", "numbers", "of", "Bifidobacterium", "species", "bacteria", "in", "feces", "during", "the", "first", "6", "mo", "of", "life", "was", "lower", "in", "affected", "children", "8.26", "(", "1.24", ")", "log", "cells", "/", "g", "than", "in", "healthy", "children", "9.12", "(", "0.64", ")", "log", "cells", "/", "g", ";", "P", "=", "0.03", ".", "CONCLUSION", "Probiotic", "supplementation", "early", "in", "life", "may", "reduce", "the", "risk", "of", "neuropsychiatric", "disorder", "development", "later", "in", "childhood", "possible", "by", "mechanisms", "not", "limited", "to", "gut", "microbiota", "composition", "." ]
[ "Outcome_Physical", "Participant_Condition", "Outcome_Adverse-effects", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Age", "Outcome_Mental", "Intervention_Control" ]
vitamin D is an umlsterm, regulation is an umlsterm, bone is an umlsterm, metabolism is an umlsterm, regulation is an umlsterm, treatment is an umlsterm, 1-hydroxycholecalciferol is an umlsterm, disease is an umlsterm, bone is an umlsterm, metabolism is an umlsterm, patients is an umlsterm, rheumatoid arthritis is an umlsterm
ZfuerRheumatologie.0059i028.eng.abstr_task0
Sentence: Active vitamin D metabolites are not only involved in the regulation of bone metabolism but exerts immunomodulatory effects important in the regulation of inflammatory processes . The purpose of the present study was to evaluate the effects of a short-time treatment with 1-hydroxycholecalciferol on both disease activity and bone metabolism in patients with rheumatoid arthritis ( RA ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]
Active vitamin D metabolites are not only involved in the regulation of bone metabolism but exerts immunomodulatory effects important in the regulation of inflammatory processes . The purpose of the present study was to evaluate the effects of a short-time treatment with 1-hydroxycholecalciferol on both disease activity and bone metabolism in patients with rheumatoid arthritis ( RA ) .
[ "Active", "vitamin", "D", "metabolites", "are", "not", "only", "involved", "in", "the", "regulation", "of", "bone", "metabolism", "but", "exerts", "immunomodulatory", "effects", "important", "in", "the", "regulation", "of", "inflammatory", "processes", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "evaluate", "the", "effects", "of", "a", "short", "-", "time", "treatment", "with", "1-hydroxycholecalciferol", "on", "both", "disease", "activity", "and", "bone", "metabolism", "in", "patients", "with", "rheumatoid", "arthritis", "(", "RA", ")", "." ]
[ "umlsterm" ]
vitamin D is an umlsterm, regulation is an umlsterm, bone is an umlsterm, metabolism is an umlsterm, regulation is an umlsterm, treatment is an umlsterm, 1-hydroxycholecalciferol is an umlsterm, disease is an umlsterm, bone is an umlsterm, metabolism is an umlsterm, patients is an umlsterm, rheumatoid arthritis is an umlsterm
ZfuerRheumatologie.0059i028.eng.abstr_task1
Sentence: Active vitamin D metabolites are not only involved in the regulation of bone metabolism but exerts immunomodulatory effects important in the regulation of inflammatory processes . The purpose of the present study was to evaluate the effects of a short-time treatment with 1-hydroxycholecalciferol on both disease activity and bone metabolism in patients with rheumatoid arthritis ( RA ) . Instructions: please typing these entity words according to sentence: vitamin D, regulation, bone, metabolism, regulation, treatment, 1-hydroxycholecalciferol, disease, bone, metabolism, patients, rheumatoid arthritis Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]
Active vitamin D metabolites are not only involved in the regulation of bone metabolism but exerts immunomodulatory effects important in the regulation of inflammatory processes . The purpose of the present study was to evaluate the effects of a short-time treatment with 1-hydroxycholecalciferol on both disease activity and bone metabolism in patients with rheumatoid arthritis ( RA ) .
[ "Active", "vitamin", "D", "metabolites", "are", "not", "only", "involved", "in", "the", "regulation", "of", "bone", "metabolism", "but", "exerts", "immunomodulatory", "effects", "important", "in", "the", "regulation", "of", "inflammatory", "processes", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "evaluate", "the", "effects", "of", "a", "short", "-", "time", "treatment", "with", "1-hydroxycholecalciferol", "on", "both", "disease", "activity", "and", "bone", "metabolism", "in", "patients", "with", "rheumatoid", "arthritis", "(", "RA", ")", "." ]
[ "umlsterm" ]
vitamin D, regulation, bone, metabolism, regulation, treatment, 1-hydroxycholecalciferol, disease, bone, metabolism, patients, rheumatoid arthritis
ZfuerRheumatologie.0059i028.eng.abstr_task2
Sentence: Active vitamin D metabolites are not only involved in the regulation of bone metabolism but exerts immunomodulatory effects important in the regulation of inflammatory processes . The purpose of the present study was to evaluate the effects of a short-time treatment with 1-hydroxycholecalciferol on both disease activity and bone metabolism in patients with rheumatoid arthritis ( RA ) . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]
Active vitamin D metabolites are not only involved in the regulation of bone metabolism but exerts immunomodulatory effects important in the regulation of inflammatory processes . The purpose of the present study was to evaluate the effects of a short-time treatment with 1-hydroxycholecalciferol on both disease activity and bone metabolism in patients with rheumatoid arthritis ( RA ) .
[ "Active", "vitamin", "D", "metabolites", "are", "not", "only", "involved", "in", "the", "regulation", "of", "bone", "metabolism", "but", "exerts", "immunomodulatory", "effects", "important", "in", "the", "regulation", "of", "inflammatory", "processes", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "evaluate", "the", "effects", "of", "a", "short", "-", "time", "treatment", "with", "1-hydroxycholecalciferol", "on", "both", "disease", "activity", "and", "bone", "metabolism", "in", "patients", "with", "rheumatoid", "arthritis", "(", "RA", ")", "." ]
[ "umlsterm" ]
warm saline mouth rinse is a Intervention_Physical, prevention of alveolar osteitis is a Outcome_Physical, warm saline rinse is a Intervention_Physical, patients aged 16 and above is a Participant_Age, Oral Surgery Clinic is a Participant_Condition, non - surgical extraction of pathologic teeth is a Participant_Condition, experimental group ( n = 80 ) is a Participant_Sample-size, gargle 6 times daily with warm saline is a Intervention_Physical, no such instructions is a Intervention_Other, second group ( n = 80 ) is a Participant_Sample-size, controls is a Intervention_Control, development of alveolar osteitis is a Outcome_Physical, overall prevalence of alveolar osteitis is a Outcome_Physical, risk of development of alveolar osteitis is a Outcome_Physical, Warm saline mouth rinse is a Intervention_Physical
70724_task0
Sentence: Role of warm saline mouth rinse in prevention of alveolar osteitis : a randomized controlled trial . BACKGROUND The present study was aimed at determining the role warm saline rinse in the prevention of alveolar osteitis following dental extractions . MATERIALS AND METHODS Apparently patients aged 16 and above who were referred to the Oral Surgery Clinic of our institution , with an indication for non-surgical extraction of pathologic teeth were prospectively and uniformly randomized into warm saline group and control . The experimental group ( n = 80 ) were instructed to gargle 6 times daily with warm saline and no such instructions were given to the second group ( n = 80 ) to serve as controls . Information on demographic , indications for extraction , and development of alveolar osteitis were obtained and analyzed . Comparative statistics were done using Pearson 's chi square or Fisher 's exact test as appropriate . A p value of less than 0.05 was considered significant . RESULTS The demographic and other baseline parameters such as indications for extractions were comparable among the study groups ( p > 0.05 ) . The overall prevalence of alveolar osteitis was 13.7 % . There was a statistical significant difference between the study groups with respect to development of alveolar osteitis ( X2 = 15.00 , df = 1 , p = 0.001 ) .The risk of development of alveolar osteitis was 4 times higher in the control group ( OR = 4.33 , P = 0.001 ) . CONCLUSION Warm saline mouth rinse instruction is beneficial in the prevention of development of alveolar osteitis after dental extractions . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size
[ "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Role of warm saline mouth rinse in prevention of alveolar osteitis : a randomized controlled trial . BACKGROUND The present study was aimed at determining the role warm saline rinse in the prevention of alveolar osteitis following dental extractions . MATERIALS AND METHODS Apparently patients aged 16 and above who were referred to the Oral Surgery Clinic of our institution , with an indication for non-surgical extraction of pathologic teeth were prospectively and uniformly randomized into warm saline group and control . The experimental group ( n = 80 ) were instructed to gargle 6 times daily with warm saline and no such instructions were given to the second group ( n = 80 ) to serve as controls . Information on demographic , indications for extraction , and development of alveolar osteitis were obtained and analyzed . Comparative statistics were done using Pearson 's chi square or Fisher 's exact test as appropriate . A p value of less than 0.05 was considered significant . RESULTS The demographic and other baseline parameters such as indications for extractions were comparable among the study groups ( p > 0.05 ) . The overall prevalence of alveolar osteitis was 13.7 % . There was a statistical significant difference between the study groups with respect to development of alveolar osteitis ( X2 = 15.00 , df = 1 , p = 0.001 ) .The risk of development of alveolar osteitis was 4 times higher in the control group ( OR = 4.33 , P = 0.001 ) . CONCLUSION Warm saline mouth rinse instruction is beneficial in the prevention of development of alveolar osteitis after dental extractions .
[ "Role", "of", "warm", "saline", "mouth", "rinse", "in", "prevention", "of", "alveolar", "osteitis", ":", "a", "randomized", "controlled", "trial", ".", "BACKGROUND", "The", "present", "study", "was", "aimed", "at", "determining", "the", "role", "warm", "saline", "rinse", "in", "the", "prevention", "of", "alveolar", "osteitis", "following", "dental", "extractions", ".", "MATERIALS", "AND", "METHODS", "Apparently", "patients", "aged", "16", "and", "above", "who", "were", "referred", "to", "the", "Oral", "Surgery", "Clinic", "of", "our", "institution", ",", "with", "an", "indication", "for", "non", "-", "surgical", "extraction", "of", "pathologic", "teeth", "were", "prospectively", "and", "uniformly", "randomized", "into", "warm", "saline", "group", "and", "control", ".", "The", "experimental", "group", "(", "n", "=", "80", ")", "were", "instructed", "to", "gargle", "6", "times", "daily", "with", "warm", "saline", "and", "no", "such", "instructions", "were", "given", "to", "the", "second", "group", "(", "n", "=", "80", ")", "to", "serve", "as", "controls", ".", "Information", "on", "demographic", ",", "indications", "for", "extraction", ",", "and", "development", "of", "alveolar", "osteitis", "were", "obtained", "and", "analyzed", ".", "Comparative", "statistics", "were", "done", "using", "Pearson", "'", "s", "chi", "square", "or", "Fisher", "'", "s", "exact", "test", "as", "appropriate", ".", "A", "p", "value", "of", "less", "than", "0.05", "was", "considered", "significant", ".", "RESULTS", "The", "demographic", "and", "other", "baseline", "parameters", "such", "as", "indications", "for", "extractions", "were", "comparable", "among", "the", "study", "groups", "(", "p", ">", "0.05", ")", ".", "The", "overall", "prevalence", "of", "alveolar", "osteitis", "was", "13.7", "%", ".", "There", "was", "a", "statistical", "significant", "difference", "between", "the", "study", "groups", "with", "respect", "to", "development", "of", "alveolar", "osteitis", "(", "X2", "=", "15.00", ",", "df", "=", "1", ",", "p", "=", "0.001", ")", ".The", "risk", "of", "development", "of", "alveolar", "osteitis", "was", "4", "times", "higher", "in", "the", "control", "group", "(", "OR", "=", "4.33", ",", "P", "=", "0.001", ")", ".", "CONCLUSION", "Warm", "saline", "mouth", "rinse", "instruction", "is", "beneficial", "in", "the", "prevention", "of", "development", "of", "alveolar", "osteitis", "after", "dental", "extractions", "." ]
[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Participant_Sample-size", "Participant_Age", "Intervention_Other", "Intervention_Control" ]
warm saline mouth rinse is a Intervention_Physical, prevention of alveolar osteitis is a Outcome_Physical, warm saline rinse is a Intervention_Physical, patients aged 16 and above is a Participant_Age, Oral Surgery Clinic is a Participant_Condition, non - surgical extraction of pathologic teeth is a Participant_Condition, experimental group ( n = 80 ) is a Participant_Sample-size, gargle 6 times daily with warm saline is a Intervention_Physical, no such instructions is a Intervention_Other, second group ( n = 80 ) is a Participant_Sample-size, controls is a Intervention_Control, development of alveolar osteitis is a Outcome_Physical, overall prevalence of alveolar osteitis is a Outcome_Physical, risk of development of alveolar osteitis is a Outcome_Physical, Warm saline mouth rinse is a Intervention_Physical
70724_task1
Sentence: Role of warm saline mouth rinse in prevention of alveolar osteitis : a randomized controlled trial . BACKGROUND The present study was aimed at determining the role warm saline rinse in the prevention of alveolar osteitis following dental extractions . MATERIALS AND METHODS Apparently patients aged 16 and above who were referred to the Oral Surgery Clinic of our institution , with an indication for non-surgical extraction of pathologic teeth were prospectively and uniformly randomized into warm saline group and control . The experimental group ( n = 80 ) were instructed to gargle 6 times daily with warm saline and no such instructions were given to the second group ( n = 80 ) to serve as controls . Information on demographic , indications for extraction , and development of alveolar osteitis were obtained and analyzed . Comparative statistics were done using Pearson 's chi square or Fisher 's exact test as appropriate . A p value of less than 0.05 was considered significant . RESULTS The demographic and other baseline parameters such as indications for extractions were comparable among the study groups ( p > 0.05 ) . The overall prevalence of alveolar osteitis was 13.7 % . There was a statistical significant difference between the study groups with respect to development of alveolar osteitis ( X2 = 15.00 , df = 1 , p = 0.001 ) .The risk of development of alveolar osteitis was 4 times higher in the control group ( OR = 4.33 , P = 0.001 ) . CONCLUSION Warm saline mouth rinse instruction is beneficial in the prevention of development of alveolar osteitis after dental extractions . Instructions: please typing these entity words according to sentence: warm saline mouth rinse, prevention of alveolar osteitis, warm saline rinse, patients aged 16 and above, Oral Surgery Clinic, non - surgical extraction of pathologic teeth, experimental group ( n = 80 ), gargle 6 times daily with warm saline, no such instructions, second group ( n = 80 ), controls, development of alveolar osteitis, overall prevalence of alveolar osteitis, risk of development of alveolar osteitis, Warm saline mouth rinse Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size
[ "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Role of warm saline mouth rinse in prevention of alveolar osteitis : a randomized controlled trial . BACKGROUND The present study was aimed at determining the role warm saline rinse in the prevention of alveolar osteitis following dental extractions . MATERIALS AND METHODS Apparently patients aged 16 and above who were referred to the Oral Surgery Clinic of our institution , with an indication for non-surgical extraction of pathologic teeth were prospectively and uniformly randomized into warm saline group and control . The experimental group ( n = 80 ) were instructed to gargle 6 times daily with warm saline and no such instructions were given to the second group ( n = 80 ) to serve as controls . Information on demographic , indications for extraction , and development of alveolar osteitis were obtained and analyzed . Comparative statistics were done using Pearson 's chi square or Fisher 's exact test as appropriate . A p value of less than 0.05 was considered significant . RESULTS The demographic and other baseline parameters such as indications for extractions were comparable among the study groups ( p > 0.05 ) . The overall prevalence of alveolar osteitis was 13.7 % . There was a statistical significant difference between the study groups with respect to development of alveolar osteitis ( X2 = 15.00 , df = 1 , p = 0.001 ) .The risk of development of alveolar osteitis was 4 times higher in the control group ( OR = 4.33 , P = 0.001 ) . CONCLUSION Warm saline mouth rinse instruction is beneficial in the prevention of development of alveolar osteitis after dental extractions .
[ "Role", "of", "warm", "saline", "mouth", "rinse", "in", "prevention", "of", "alveolar", "osteitis", ":", "a", "randomized", "controlled", "trial", ".", "BACKGROUND", "The", "present", "study", "was", "aimed", "at", "determining", "the", "role", "warm", "saline", "rinse", "in", "the", "prevention", "of", "alveolar", "osteitis", "following", "dental", "extractions", ".", "MATERIALS", "AND", "METHODS", "Apparently", "patients", "aged", "16", "and", "above", "who", "were", "referred", "to", "the", "Oral", "Surgery", "Clinic", "of", "our", "institution", ",", "with", "an", "indication", "for", "non", "-", "surgical", "extraction", "of", "pathologic", "teeth", "were", "prospectively", "and", "uniformly", "randomized", "into", "warm", "saline", "group", "and", "control", ".", "The", "experimental", "group", "(", "n", "=", "80", ")", "were", "instructed", "to", "gargle", "6", "times", "daily", "with", "warm", "saline", "and", "no", "such", "instructions", "were", "given", "to", "the", "second", "group", "(", "n", "=", "80", ")", "to", "serve", "as", "controls", ".", "Information", "on", "demographic", ",", "indications", "for", "extraction", ",", "and", "development", "of", "alveolar", "osteitis", "were", "obtained", "and", "analyzed", ".", "Comparative", "statistics", "were", "done", "using", "Pearson", "'", "s", "chi", "square", "or", "Fisher", "'", "s", "exact", "test", "as", "appropriate", ".", "A", "p", "value", "of", "less", "than", "0.05", "was", "considered", "significant", ".", "RESULTS", "The", "demographic", "and", "other", "baseline", "parameters", "such", "as", "indications", "for", "extractions", "were", "comparable", "among", "the", "study", "groups", "(", "p", ">", "0.05", ")", ".", "The", "overall", "prevalence", "of", "alveolar", "osteitis", "was", "13.7", "%", ".", "There", "was", "a", "statistical", "significant", "difference", "between", "the", "study", "groups", "with", "respect", "to", "development", "of", "alveolar", "osteitis", "(", "X2", "=", "15.00", ",", "df", "=", "1", ",", "p", "=", "0.001", ")", ".The", "risk", "of", "development", "of", "alveolar", "osteitis", "was", "4", "times", "higher", "in", "the", "control", "group", "(", "OR", "=", "4.33", ",", "P", "=", "0.001", ")", ".", "CONCLUSION", "Warm", "saline", "mouth", "rinse", "instruction", "is", "beneficial", "in", "the", "prevention", "of", "development", "of", "alveolar", "osteitis", "after", "dental", "extractions", "." ]
[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Participant_Sample-size", "Participant_Age", "Intervention_Other", "Intervention_Control" ]
warm saline mouth rinse, prevention of alveolar osteitis, warm saline rinse, patients aged 16 and above, Oral Surgery Clinic, non - surgical extraction of pathologic teeth, experimental group ( n = 80 ), gargle 6 times daily with warm saline, no such instructions, second group ( n = 80 ), controls, development of alveolar osteitis, overall prevalence of alveolar osteitis, risk of development of alveolar osteitis, Warm saline mouth rinse
70724_task2
Sentence: Role of warm saline mouth rinse in prevention of alveolar osteitis : a randomized controlled trial . BACKGROUND The present study was aimed at determining the role warm saline rinse in the prevention of alveolar osteitis following dental extractions . MATERIALS AND METHODS Apparently patients aged 16 and above who were referred to the Oral Surgery Clinic of our institution , with an indication for non-surgical extraction of pathologic teeth were prospectively and uniformly randomized into warm saline group and control . The experimental group ( n = 80 ) were instructed to gargle 6 times daily with warm saline and no such instructions were given to the second group ( n = 80 ) to serve as controls . Information on demographic , indications for extraction , and development of alveolar osteitis were obtained and analyzed . Comparative statistics were done using Pearson 's chi square or Fisher 's exact test as appropriate . A p value of less than 0.05 was considered significant . RESULTS The demographic and other baseline parameters such as indications for extractions were comparable among the study groups ( p > 0.05 ) . The overall prevalence of alveolar osteitis was 13.7 % . There was a statistical significant difference between the study groups with respect to development of alveolar osteitis ( X2 = 15.00 , df = 1 , p = 0.001 ) .The risk of development of alveolar osteitis was 4 times higher in the control group ( OR = 4.33 , P = 0.001 ) . CONCLUSION Warm saline mouth rinse instruction is beneficial in the prevention of development of alveolar osteitis after dental extractions . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Role of warm saline mouth rinse in prevention of alveolar osteitis : a randomized controlled trial . BACKGROUND The present study was aimed at determining the role warm saline rinse in the prevention of alveolar osteitis following dental extractions . MATERIALS AND METHODS Apparently patients aged 16 and above who were referred to the Oral Surgery Clinic of our institution , with an indication for non-surgical extraction of pathologic teeth were prospectively and uniformly randomized into warm saline group and control . The experimental group ( n = 80 ) were instructed to gargle 6 times daily with warm saline and no such instructions were given to the second group ( n = 80 ) to serve as controls . Information on demographic , indications for extraction , and development of alveolar osteitis were obtained and analyzed . Comparative statistics were done using Pearson 's chi square or Fisher 's exact test as appropriate . A p value of less than 0.05 was considered significant . RESULTS The demographic and other baseline parameters such as indications for extractions were comparable among the study groups ( p > 0.05 ) . The overall prevalence of alveolar osteitis was 13.7 % . There was a statistical significant difference between the study groups with respect to development of alveolar osteitis ( X2 = 15.00 , df = 1 , p = 0.001 ) .The risk of development of alveolar osteitis was 4 times higher in the control group ( OR = 4.33 , P = 0.001 ) . CONCLUSION Warm saline mouth rinse instruction is beneficial in the prevention of development of alveolar osteitis after dental extractions .
[ "Role", "of", "warm", "saline", "mouth", "rinse", "in", "prevention", "of", "alveolar", "osteitis", ":", "a", "randomized", "controlled", "trial", ".", "BACKGROUND", "The", "present", "study", "was", "aimed", "at", "determining", "the", "role", "warm", "saline", "rinse", "in", "the", "prevention", "of", "alveolar", "osteitis", "following", "dental", "extractions", ".", "MATERIALS", "AND", "METHODS", "Apparently", "patients", "aged", "16", "and", "above", "who", "were", "referred", "to", "the", "Oral", "Surgery", "Clinic", "of", "our", "institution", ",", "with", "an", "indication", "for", "non", "-", "surgical", "extraction", "of", "pathologic", "teeth", "were", "prospectively", "and", "uniformly", "randomized", "into", "warm", "saline", "group", "and", "control", ".", "The", "experimental", "group", "(", "n", "=", "80", ")", "were", "instructed", "to", "gargle", "6", "times", "daily", "with", "warm", "saline", "and", "no", "such", "instructions", "were", "given", "to", "the", "second", "group", "(", "n", "=", "80", ")", "to", "serve", "as", "controls", ".", "Information", "on", "demographic", ",", "indications", "for", "extraction", ",", "and", "development", "of", "alveolar", "osteitis", "were", "obtained", "and", "analyzed", ".", "Comparative", "statistics", "were", "done", "using", "Pearson", "'", "s", "chi", "square", "or", "Fisher", "'", "s", "exact", "test", "as", "appropriate", ".", "A", "p", "value", "of", "less", "than", "0.05", "was", "considered", "significant", ".", "RESULTS", "The", "demographic", "and", "other", "baseline", "parameters", "such", "as", "indications", "for", "extractions", "were", "comparable", "among", "the", "study", "groups", "(", "p", ">", "0.05", ")", ".", "The", "overall", "prevalence", "of", "alveolar", "osteitis", "was", "13.7", "%", ".", "There", "was", "a", "statistical", "significant", "difference", "between", "the", "study", "groups", "with", "respect", "to", "development", "of", "alveolar", "osteitis", "(", "X2", "=", "15.00", ",", "df", "=", "1", ",", "p", "=", "0.001", ")", ".The", "risk", "of", "development", "of", "alveolar", "osteitis", "was", "4", "times", "higher", "in", "the", "control", "group", "(", "OR", "=", "4.33", ",", "P", "=", "0.001", ")", ".", "CONCLUSION", "Warm", "saline", "mouth", "rinse", "instruction", "is", "beneficial", "in", "the", "prevention", "of", "development", "of", "alveolar", "osteitis", "after", "dental", "extractions", "." ]
[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Participant_Sample-size", "Participant_Age", "Intervention_Other", "Intervention_Control" ]
Cognitive behavioral therapy is a Intervention_Psychological, anxiety in children with autism spectrum disorders : is a Participant_Condition, Children with autism spectrum disorders is a Participant_Condition, functional impairment is a Outcome_Mental, cognitive behavioral therapy ( CBT ) is a Intervention_Psychological, children with ASD is a Participant_Condition, anxiety reduction is a Outcome_Mental, Forty children ( 7 - 11 years old ) were randomly assigned is a Participant_Age, 3-month waitlist is a Intervention_Educational, anxiety symptom checklists is a Outcome_Mental, Clinical Global Impressions - Improvement scale criteria is a Outcome_Mental, parent reports of child anxiety is a Outcome_Mental
39699_task0
Sentence: Cognitive behavioral therapy for anxiety in children with autism spectrum disorders : a randomized , controlled trial . BACKGROUND Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment . This study tested a modular cognitive behavioral therapy ( CBT ) program for children with this profile . A standard CBT program was augmented with multiple treatment components designed to accommodate or remediate the social and adaptive skill deficits of children with ASD that could pose barriers to anxiety reduction . METHOD Forty children ( 7-11 years old ) were randomly assigned to 16 sessions of CBT or a 3-month waitlist ( 36 completed treatment or waitlist ) . Therapists worked with individual families . The CBT model emphasized behavioral experimentation , parent-training , and school consultation . Independent evaluators blind to treatment condition conducted structured diagnostic interviews and parents and children completed anxiety symptom checklists at baseline and posttreatment/postwaitlist . RESULTS In intent-to-treat analyses , 78.5 % of the CBT group met Clinical Global Impressions-Improvement scale criteria for positive treatment response at posttreatment , as compared to only 8.7 % of the waitlist group . CBT also outperformed the waitlist on diagnostic outcomes and parent reports of child anxiety , but not children 's self-reports . Treatment gains were maintained at 3-month follow-up . CONCLUSIONS The CBT manual employed in this study is one of the first adaptations of an evidence-based treatment for children with autism spectrum disorders . Remission of anxiety disorders appears to be an achievable goal among high-functioning children with autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Mental
[ "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cognitive behavioral therapy for anxiety in children with autism spectrum disorders : a randomized , controlled trial . BACKGROUND Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment . This study tested a modular cognitive behavioral therapy ( CBT ) program for children with this profile . A standard CBT program was augmented with multiple treatment components designed to accommodate or remediate the social and adaptive skill deficits of children with ASD that could pose barriers to anxiety reduction . METHOD Forty children ( 7-11 years old ) were randomly assigned to 16 sessions of CBT or a 3-month waitlist ( 36 completed treatment or waitlist ) . Therapists worked with individual families . The CBT model emphasized behavioral experimentation , parent-training , and school consultation . Independent evaluators blind to treatment condition conducted structured diagnostic interviews and parents and children completed anxiety symptom checklists at baseline and posttreatment/postwaitlist . RESULTS In intent-to-treat analyses , 78.5 % of the CBT group met Clinical Global Impressions-Improvement scale criteria for positive treatment response at posttreatment , as compared to only 8.7 % of the waitlist group . CBT also outperformed the waitlist on diagnostic outcomes and parent reports of child anxiety , but not children 's self-reports . Treatment gains were maintained at 3-month follow-up . CONCLUSIONS The CBT manual employed in this study is one of the first adaptations of an evidence-based treatment for children with autism spectrum disorders . Remission of anxiety disorders appears to be an achievable goal among high-functioning children with autism .
[ "Cognitive", "behavioral", "therapy", "for", "anxiety", "in", "children", "with", "autism", "spectrum", "disorders", ":", "a", "randomized", ",", "controlled", "trial", ".", "BACKGROUND", "Children", "with", "autism", "spectrum", "disorders", "often", "present", "with", "comorbid", "anxiety", "disorders", "that", "cause", "significant", "functional", "impairment", ".", "This", "study", "tested", "a", "modular", "cognitive", "behavioral", "therapy", "(", "CBT", ")", "program", "for", "children", "with", "this", "profile", ".", "A", "standard", "CBT", "program", "was", "augmented", "with", "multiple", "treatment", "components", "designed", "to", "accommodate", "or", "remediate", "the", "social", "and", "adaptive", "skill", "deficits", "of", "children", "with", "ASD", "that", "could", "pose", "barriers", "to", "anxiety", "reduction", ".", "METHOD", "Forty", "children", "(", "7", "-", "11", "years", "old", ")", "were", "randomly", "assigned", "to", "16", "sessions", "of", "CBT", "or", "a", "3-month", "waitlist", "(", "36", "completed", "treatment", "or", "waitlist", ")", ".", "Therapists", "worked", "with", "individual", "families", ".", "The", "CBT", "model", "emphasized", "behavioral", "experimentation", ",", "parent", "-", "training", ",", "and", "school", "consultation", ".", "Independent", "evaluators", "blind", "to", "treatment", "condition", "conducted", "structured", "diagnostic", "interviews", "and", "parents", "and", "children", "completed", "anxiety", "symptom", "checklists", "at", "baseline", "and", "posttreatment", "/", "postwaitlist", ".", "RESULTS", "In", "intent", "-", "to", "-", "treat", "analyses", ",", "78.5", "%", "of", "the", "CBT", "group", "met", "Clinical", "Global", "Impressions", "-", "Improvement", "scale", "criteria", "for", "positive", "treatment", "response", "at", "posttreatment", ",", "as", "compared", "to", "only", "8.7", "%", "of", "the", "waitlist", "group", ".", "CBT", "also", "outperformed", "the", "waitlist", "on", "diagnostic", "outcomes", "and", "parent", "reports", "of", "child", "anxiety", ",", "but", "not", "children", "'", "s", "self", "-", "reports", ".", "Treatment", "gains", "were", "maintained", "at", "3-month", "follow", "-", "up", ".", "CONCLUSIONS", "The", "CBT", "manual", "employed", "in", "this", "study", "is", "one", "of", "the", "first", "adaptations", "of", "an", "evidence", "-", "based", "treatment", "for", "children", "with", "autism", "spectrum", "disorders", ".", "Remission", "of", "anxiety", "disorders", "appears", "to", "be", "an", "achievable", "goal", "among", "high", "-", "functioning", "children", "with", "autism", "." ]
[ "Participant_Age", "Outcome_Mental", "Participant_Condition", "Intervention_Psychological", "Intervention_Educational" ]
Cognitive behavioral therapy is a Intervention_Psychological, anxiety in children with autism spectrum disorders : is a Participant_Condition, Children with autism spectrum disorders is a Participant_Condition, functional impairment is a Outcome_Mental, cognitive behavioral therapy ( CBT ) is a Intervention_Psychological, children with ASD is a Participant_Condition, anxiety reduction is a Outcome_Mental, Forty children ( 7 - 11 years old ) were randomly assigned is a Participant_Age, 3-month waitlist is a Intervention_Educational, anxiety symptom checklists is a Outcome_Mental, Clinical Global Impressions - Improvement scale criteria is a Outcome_Mental, parent reports of child anxiety is a Outcome_Mental
39699_task1
Sentence: Cognitive behavioral therapy for anxiety in children with autism spectrum disorders : a randomized , controlled trial . BACKGROUND Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment . This study tested a modular cognitive behavioral therapy ( CBT ) program for children with this profile . A standard CBT program was augmented with multiple treatment components designed to accommodate or remediate the social and adaptive skill deficits of children with ASD that could pose barriers to anxiety reduction . METHOD Forty children ( 7-11 years old ) were randomly assigned to 16 sessions of CBT or a 3-month waitlist ( 36 completed treatment or waitlist ) . Therapists worked with individual families . The CBT model emphasized behavioral experimentation , parent-training , and school consultation . Independent evaluators blind to treatment condition conducted structured diagnostic interviews and parents and children completed anxiety symptom checklists at baseline and posttreatment/postwaitlist . RESULTS In intent-to-treat analyses , 78.5 % of the CBT group met Clinical Global Impressions-Improvement scale criteria for positive treatment response at posttreatment , as compared to only 8.7 % of the waitlist group . CBT also outperformed the waitlist on diagnostic outcomes and parent reports of child anxiety , but not children 's self-reports . Treatment gains were maintained at 3-month follow-up . CONCLUSIONS The CBT manual employed in this study is one of the first adaptations of an evidence-based treatment for children with autism spectrum disorders . Remission of anxiety disorders appears to be an achievable goal among high-functioning children with autism . Instructions: please typing these entity words according to sentence: Cognitive behavioral therapy, anxiety in children with autism spectrum disorders :, Children with autism spectrum disorders, functional impairment, cognitive behavioral therapy ( CBT ), children with ASD, anxiety reduction, Forty children ( 7 - 11 years old ) were randomly assigned, 3-month waitlist, anxiety symptom checklists, Clinical Global Impressions - Improvement scale criteria, parent reports of child anxiety Options: Intervention_Psychological, Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Mental
[ "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cognitive behavioral therapy for anxiety in children with autism spectrum disorders : a randomized , controlled trial . BACKGROUND Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment . This study tested a modular cognitive behavioral therapy ( CBT ) program for children with this profile . A standard CBT program was augmented with multiple treatment components designed to accommodate or remediate the social and adaptive skill deficits of children with ASD that could pose barriers to anxiety reduction . METHOD Forty children ( 7-11 years old ) were randomly assigned to 16 sessions of CBT or a 3-month waitlist ( 36 completed treatment or waitlist ) . Therapists worked with individual families . The CBT model emphasized behavioral experimentation , parent-training , and school consultation . Independent evaluators blind to treatment condition conducted structured diagnostic interviews and parents and children completed anxiety symptom checklists at baseline and posttreatment/postwaitlist . RESULTS In intent-to-treat analyses , 78.5 % of the CBT group met Clinical Global Impressions-Improvement scale criteria for positive treatment response at posttreatment , as compared to only 8.7 % of the waitlist group . CBT also outperformed the waitlist on diagnostic outcomes and parent reports of child anxiety , but not children 's self-reports . Treatment gains were maintained at 3-month follow-up . CONCLUSIONS The CBT manual employed in this study is one of the first adaptations of an evidence-based treatment for children with autism spectrum disorders . Remission of anxiety disorders appears to be an achievable goal among high-functioning children with autism .
[ "Cognitive", "behavioral", "therapy", "for", "anxiety", "in", "children", "with", "autism", "spectrum", "disorders", ":", "a", "randomized", ",", "controlled", "trial", ".", "BACKGROUND", "Children", "with", "autism", "spectrum", "disorders", "often", "present", "with", "comorbid", "anxiety", "disorders", "that", "cause", "significant", "functional", "impairment", ".", "This", "study", "tested", "a", "modular", "cognitive", "behavioral", "therapy", "(", "CBT", ")", "program", "for", "children", "with", "this", "profile", ".", "A", "standard", "CBT", "program", "was", "augmented", "with", "multiple", "treatment", "components", "designed", "to", "accommodate", "or", "remediate", "the", "social", "and", "adaptive", "skill", "deficits", "of", "children", "with", "ASD", "that", "could", "pose", "barriers", "to", "anxiety", "reduction", ".", "METHOD", "Forty", "children", "(", "7", "-", "11", "years", "old", ")", "were", "randomly", "assigned", "to", "16", "sessions", "of", "CBT", "or", "a", "3-month", "waitlist", "(", "36", "completed", "treatment", "or", "waitlist", ")", ".", "Therapists", "worked", "with", "individual", "families", ".", "The", "CBT", "model", "emphasized", "behavioral", "experimentation", ",", "parent", "-", "training", ",", "and", "school", "consultation", ".", "Independent", "evaluators", "blind", "to", "treatment", "condition", "conducted", "structured", "diagnostic", "interviews", "and", "parents", "and", "children", "completed", "anxiety", "symptom", "checklists", "at", "baseline", "and", "posttreatment", "/", "postwaitlist", ".", "RESULTS", "In", "intent", "-", "to", "-", "treat", "analyses", ",", "78.5", "%", "of", "the", "CBT", "group", "met", "Clinical", "Global", "Impressions", "-", "Improvement", "scale", "criteria", "for", "positive", "treatment", "response", "at", "posttreatment", ",", "as", "compared", "to", "only", "8.7", "%", "of", "the", "waitlist", "group", ".", "CBT", "also", "outperformed", "the", "waitlist", "on", "diagnostic", "outcomes", "and", "parent", "reports", "of", "child", "anxiety", ",", "but", "not", "children", "'", "s", "self", "-", "reports", ".", "Treatment", "gains", "were", "maintained", "at", "3-month", "follow", "-", "up", ".", "CONCLUSIONS", "The", "CBT", "manual", "employed", "in", "this", "study", "is", "one", "of", "the", "first", "adaptations", "of", "an", "evidence", "-", "based", "treatment", "for", "children", "with", "autism", "spectrum", "disorders", ".", "Remission", "of", "anxiety", "disorders", "appears", "to", "be", "an", "achievable", "goal", "among", "high", "-", "functioning", "children", "with", "autism", "." ]
[ "Participant_Age", "Outcome_Mental", "Participant_Condition", "Intervention_Psychological", "Intervention_Educational" ]
Cognitive behavioral therapy, anxiety in children with autism spectrum disorders :, Children with autism spectrum disorders, functional impairment, cognitive behavioral therapy ( CBT ), children with ASD, anxiety reduction, Forty children ( 7 - 11 years old ) were randomly assigned, 3-month waitlist, anxiety symptom checklists, Clinical Global Impressions - Improvement scale criteria, parent reports of child anxiety
39699_task2
Sentence: Cognitive behavioral therapy for anxiety in children with autism spectrum disorders : a randomized , controlled trial . BACKGROUND Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment . This study tested a modular cognitive behavioral therapy ( CBT ) program for children with this profile . A standard CBT program was augmented with multiple treatment components designed to accommodate or remediate the social and adaptive skill deficits of children with ASD that could pose barriers to anxiety reduction . METHOD Forty children ( 7-11 years old ) were randomly assigned to 16 sessions of CBT or a 3-month waitlist ( 36 completed treatment or waitlist ) . Therapists worked with individual families . The CBT model emphasized behavioral experimentation , parent-training , and school consultation . Independent evaluators blind to treatment condition conducted structured diagnostic interviews and parents and children completed anxiety symptom checklists at baseline and posttreatment/postwaitlist . RESULTS In intent-to-treat analyses , 78.5 % of the CBT group met Clinical Global Impressions-Improvement scale criteria for positive treatment response at posttreatment , as compared to only 8.7 % of the waitlist group . CBT also outperformed the waitlist on diagnostic outcomes and parent reports of child anxiety , but not children 's self-reports . Treatment gains were maintained at 3-month follow-up . CONCLUSIONS The CBT manual employed in this study is one of the first adaptations of an evidence-based treatment for children with autism spectrum disorders . Remission of anxiety disorders appears to be an achievable goal among high-functioning children with autism . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cognitive behavioral therapy for anxiety in children with autism spectrum disorders : a randomized , controlled trial . BACKGROUND Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment . This study tested a modular cognitive behavioral therapy ( CBT ) program for children with this profile . A standard CBT program was augmented with multiple treatment components designed to accommodate or remediate the social and adaptive skill deficits of children with ASD that could pose barriers to anxiety reduction . METHOD Forty children ( 7-11 years old ) were randomly assigned to 16 sessions of CBT or a 3-month waitlist ( 36 completed treatment or waitlist ) . Therapists worked with individual families . The CBT model emphasized behavioral experimentation , parent-training , and school consultation . Independent evaluators blind to treatment condition conducted structured diagnostic interviews and parents and children completed anxiety symptom checklists at baseline and posttreatment/postwaitlist . RESULTS In intent-to-treat analyses , 78.5 % of the CBT group met Clinical Global Impressions-Improvement scale criteria for positive treatment response at posttreatment , as compared to only 8.7 % of the waitlist group . CBT also outperformed the waitlist on diagnostic outcomes and parent reports of child anxiety , but not children 's self-reports . Treatment gains were maintained at 3-month follow-up . CONCLUSIONS The CBT manual employed in this study is one of the first adaptations of an evidence-based treatment for children with autism spectrum disorders . Remission of anxiety disorders appears to be an achievable goal among high-functioning children with autism .
[ "Cognitive", "behavioral", "therapy", "for", "anxiety", "in", "children", "with", "autism", "spectrum", "disorders", ":", "a", "randomized", ",", "controlled", "trial", ".", "BACKGROUND", "Children", "with", "autism", "spectrum", "disorders", "often", "present", "with", "comorbid", "anxiety", "disorders", "that", "cause", "significant", "functional", "impairment", ".", "This", "study", "tested", "a", "modular", "cognitive", "behavioral", "therapy", "(", "CBT", ")", "program", "for", "children", "with", "this", "profile", ".", "A", "standard", "CBT", "program", "was", "augmented", "with", "multiple", "treatment", "components", "designed", "to", "accommodate", "or", "remediate", "the", "social", "and", "adaptive", "skill", "deficits", "of", "children", "with", "ASD", "that", "could", "pose", "barriers", "to", "anxiety", "reduction", ".", "METHOD", "Forty", "children", "(", "7", "-", "11", "years", "old", ")", "were", "randomly", "assigned", "to", "16", "sessions", "of", "CBT", "or", "a", "3-month", "waitlist", "(", "36", "completed", "treatment", "or", "waitlist", ")", ".", "Therapists", "worked", "with", "individual", "families", ".", "The", "CBT", "model", "emphasized", "behavioral", "experimentation", ",", "parent", "-", "training", ",", "and", "school", "consultation", ".", "Independent", "evaluators", "blind", "to", "treatment", "condition", "conducted", "structured", "diagnostic", "interviews", "and", "parents", "and", "children", "completed", "anxiety", "symptom", "checklists", "at", "baseline", "and", "posttreatment", "/", "postwaitlist", ".", "RESULTS", "In", "intent", "-", "to", "-", "treat", "analyses", ",", "78.5", "%", "of", "the", "CBT", "group", "met", "Clinical", "Global", "Impressions", "-", "Improvement", "scale", "criteria", "for", "positive", "treatment", "response", "at", "posttreatment", ",", "as", "compared", "to", "only", "8.7", "%", "of", "the", "waitlist", "group", ".", "CBT", "also", "outperformed", "the", "waitlist", "on", "diagnostic", "outcomes", "and", "parent", "reports", "of", "child", "anxiety", ",", "but", "not", "children", "'", "s", "self", "-", "reports", ".", "Treatment", "gains", "were", "maintained", "at", "3-month", "follow", "-", "up", ".", "CONCLUSIONS", "The", "CBT", "manual", "employed", "in", "this", "study", "is", "one", "of", "the", "first", "adaptations", "of", "an", "evidence", "-", "based", "treatment", "for", "children", "with", "autism", "spectrum", "disorders", ".", "Remission", "of", "anxiety", "disorders", "appears", "to", "be", "an", "achievable", "goal", "among", "high", "-", "functioning", "children", "with", "autism", "." ]
[ "Participant_Age", "Outcome_Mental", "Participant_Condition", "Intervention_Psychological", "Intervention_Educational" ]
oral is a Organism_subdivision, atrial is a Immaterial_anatomical_entity, atrial is a Immaterial_anatomical_entity
PMC-2793023-sec-09_task0
Sentence: Follow-up Patients were followed up at the outpatient clinic at 1, 4, and 7 months after the ablation procedure and every 6 months thereafter. Routine 24 or 48 h Holter monitoring was performed before each appointment, and a 12-lead electrocardiogram was obtained at each visit. Patients were asked to report to the emergency room or our arrhythmia unit for an ECG if any symptom suggestive of recurrence occurred between scheduled visits. After the ablation procedure, all patients received anti-arrhythmic treatment for at least 1 month to protect against early recurrences and continued oral anticoagulation for a minimum of 2 months to maintain an international normalized ratio between 2.0 and 3.0. Additionally, magnetic resonance angiography was repeated at 3-6 months after the procedure to evaluate the presence of PV stenosis. Arrhythmia recurrence was defined as a documented AF or atrial flutter episode of >30 s. Arrhythmic episodes within the first 3 months after the CPVA (healing period) were not considered in the evaluation of final success rates because they are often described as transient recurrences related to atrial inflammatory processes following RF lesions.26 The endpoint of the study was freedom from arrhythmia recurrence after a single CPVA procedure, without anti-arrhythmic medication. A minimum follow-up of 3 months was required. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Immaterial_anatomical_entity, Organism_subdivision
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Follow-up Patients were followed up at the outpatient clinic at 1, 4, and 7 months after the ablation procedure and every 6 months thereafter. Routine 24 or 48 h Holter monitoring was performed before each appointment, and a 12-lead electrocardiogram was obtained at each visit. Patients were asked to report to the emergency room or our arrhythmia unit for an ECG if any symptom suggestive of recurrence occurred between scheduled visits. After the ablation procedure, all patients received anti-arrhythmic treatment for at least 1 month to protect against early recurrences and continued oral anticoagulation for a minimum of 2 months to maintain an international normalized ratio between 2.0 and 3.0. Additionally, magnetic resonance angiography was repeated at 3-6 months after the procedure to evaluate the presence of PV stenosis. Arrhythmia recurrence was defined as a documented AF or atrial flutter episode of >30 s. Arrhythmic episodes within the first 3 months after the CPVA (healing period) were not considered in the evaluation of final success rates because they are often described as transient recurrences related to atrial inflammatory processes following RF lesions.26 The endpoint of the study was freedom from arrhythmia recurrence after a single CPVA procedure, without anti-arrhythmic medication. A minimum follow-up of 3 months was required.
[ "Follow", "-", "up", "\n", "Patients", "were", "followed", "up", "at", "the", "outpatient", "clinic", "at", "1", ",", "4", ",", "and", "7", "months", "after", "the", "ablation", "procedure", "and", "every", "6", "months", "thereafter", ".", "Routine", "24", "or", "48", "h", "Holter", "monitoring", "was", "performed", "before", "each", "appointment", ",", "and", "a", "12-lead", "electrocardiogram", "was", "obtained", "at", "each", "visit", ".", "Patients", "were", "asked", "to", "report", "to", "the", "emergency", "room", "or", "our", "arrhythmia", "unit", "for", "an", "ECG", "if", "any", "symptom", "suggestive", "of", "recurrence", "occurred", "between", "scheduled", "visits", ".", "\n", "After", "the", "ablation", "procedure", ",", "all", "patients", "received", "anti", "-", "arrhythmic", "treatment", "for", "at", "least", "1", "month", "to", "protect", "against", "early", "recurrences", "and", "continued", "oral", "anticoagulation", "for", "a", "minimum", "of", "2", "months", "to", "maintain", "an", "international", "normalized", "ratio", "between", "2.0", "and", "3.0", ".", "Additionally", ",", "magnetic", "resonance", "angiography", "was", "repeated", "at", "3", "-", "6", "months", "after", "the", "procedure", "to", "evaluate", "the", "presence", "of", "PV", "stenosis", ".", "\n", "Arrhythmia", "recurrence", "was", "defined", "as", "a", "documented", "AF", "or", "atrial", "flutter", "episode", "of", ">", "30", "s.", "Arrhythmic", "episodes", "within", "the", "first", "3", "months", "after", "the", "CPVA", "(", "healing", "period", ")", "were", "not", "considered", "in", "the", "evaluation", "of", "final", "success", "rates", "because", "they", "are", "often", "described", "as", "transient", "recurrences", "related", "to", "atrial", "inflammatory", "processes", "following", "RF", "lesions.26", "\n", "The", "endpoint", "of", "the", "study", "was", "freedom", "from", "arrhythmia", "recurrence", "after", "a", "single", "CPVA", "procedure", ",", "without", "anti", "-", "arrhythmic", "medication", ".", "\n", "A", "minimum", "follow", "-", "up", "of", "3", "months", "was", "required", ".", "\n" ]
[ "Immaterial_anatomical_entity", "Organism_subdivision" ]
oral is a Organism_subdivision, atrial is a Immaterial_anatomical_entity, atrial is a Immaterial_anatomical_entity
PMC-2793023-sec-09_task1
Sentence: Follow-up Patients were followed up at the outpatient clinic at 1, 4, and 7 months after the ablation procedure and every 6 months thereafter. Routine 24 or 48 h Holter monitoring was performed before each appointment, and a 12-lead electrocardiogram was obtained at each visit. Patients were asked to report to the emergency room or our arrhythmia unit for an ECG if any symptom suggestive of recurrence occurred between scheduled visits. After the ablation procedure, all patients received anti-arrhythmic treatment for at least 1 month to protect against early recurrences and continued oral anticoagulation for a minimum of 2 months to maintain an international normalized ratio between 2.0 and 3.0. Additionally, magnetic resonance angiography was repeated at 3-6 months after the procedure to evaluate the presence of PV stenosis. Arrhythmia recurrence was defined as a documented AF or atrial flutter episode of >30 s. Arrhythmic episodes within the first 3 months after the CPVA (healing period) were not considered in the evaluation of final success rates because they are often described as transient recurrences related to atrial inflammatory processes following RF lesions.26 The endpoint of the study was freedom from arrhythmia recurrence after a single CPVA procedure, without anti-arrhythmic medication. A minimum follow-up of 3 months was required. Instructions: please typing these entity words according to sentence: oral, atrial, atrial Options: Immaterial_anatomical_entity, Organism_subdivision
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Follow-up Patients were followed up at the outpatient clinic at 1, 4, and 7 months after the ablation procedure and every 6 months thereafter. Routine 24 or 48 h Holter monitoring was performed before each appointment, and a 12-lead electrocardiogram was obtained at each visit. Patients were asked to report to the emergency room or our arrhythmia unit for an ECG if any symptom suggestive of recurrence occurred between scheduled visits. After the ablation procedure, all patients received anti-arrhythmic treatment for at least 1 month to protect against early recurrences and continued oral anticoagulation for a minimum of 2 months to maintain an international normalized ratio between 2.0 and 3.0. Additionally, magnetic resonance angiography was repeated at 3-6 months after the procedure to evaluate the presence of PV stenosis. Arrhythmia recurrence was defined as a documented AF or atrial flutter episode of >30 s. Arrhythmic episodes within the first 3 months after the CPVA (healing period) were not considered in the evaluation of final success rates because they are often described as transient recurrences related to atrial inflammatory processes following RF lesions.26 The endpoint of the study was freedom from arrhythmia recurrence after a single CPVA procedure, without anti-arrhythmic medication. A minimum follow-up of 3 months was required.
[ "Follow", "-", "up", "\n", "Patients", "were", "followed", "up", "at", "the", "outpatient", "clinic", "at", "1", ",", "4", ",", "and", "7", "months", "after", "the", "ablation", "procedure", "and", "every", "6", "months", "thereafter", ".", "Routine", "24", "or", "48", "h", "Holter", "monitoring", "was", "performed", "before", "each", "appointment", ",", "and", "a", "12-lead", "electrocardiogram", "was", "obtained", "at", "each", "visit", ".", "Patients", "were", "asked", "to", "report", "to", "the", "emergency", "room", "or", "our", "arrhythmia", "unit", "for", "an", "ECG", "if", "any", "symptom", "suggestive", "of", "recurrence", "occurred", "between", "scheduled", "visits", ".", "\n", "After", "the", "ablation", "procedure", ",", "all", "patients", "received", "anti", "-", "arrhythmic", "treatment", "for", "at", "least", "1", "month", "to", "protect", "against", "early", "recurrences", "and", "continued", "oral", "anticoagulation", "for", "a", "minimum", "of", "2", "months", "to", "maintain", "an", "international", "normalized", "ratio", "between", "2.0", "and", "3.0", ".", "Additionally", ",", "magnetic", "resonance", "angiography", "was", "repeated", "at", "3", "-", "6", "months", "after", "the", "procedure", "to", "evaluate", "the", "presence", "of", "PV", "stenosis", ".", "\n", "Arrhythmia", "recurrence", "was", "defined", "as", "a", "documented", "AF", "or", "atrial", "flutter", "episode", "of", ">", "30", "s.", "Arrhythmic", "episodes", "within", "the", "first", "3", "months", "after", "the", "CPVA", "(", "healing", "period", ")", "were", "not", "considered", "in", "the", "evaluation", "of", "final", "success", "rates", "because", "they", "are", "often", "described", "as", "transient", "recurrences", "related", "to", "atrial", "inflammatory", "processes", "following", "RF", "lesions.26", "\n", "The", "endpoint", "of", "the", "study", "was", "freedom", "from", "arrhythmia", "recurrence", "after", "a", "single", "CPVA", "procedure", ",", "without", "anti", "-", "arrhythmic", "medication", ".", "\n", "A", "minimum", "follow", "-", "up", "of", "3", "months", "was", "required", ".", "\n" ]
[ "Immaterial_anatomical_entity", "Organism_subdivision" ]
oral, atrial, atrial
PMC-2793023-sec-09_task2
Sentence: Follow-up Patients were followed up at the outpatient clinic at 1, 4, and 7 months after the ablation procedure and every 6 months thereafter. Routine 24 or 48 h Holter monitoring was performed before each appointment, and a 12-lead electrocardiogram was obtained at each visit. Patients were asked to report to the emergency room or our arrhythmia unit for an ECG if any symptom suggestive of recurrence occurred between scheduled visits. After the ablation procedure, all patients received anti-arrhythmic treatment for at least 1 month to protect against early recurrences and continued oral anticoagulation for a minimum of 2 months to maintain an international normalized ratio between 2.0 and 3.0. Additionally, magnetic resonance angiography was repeated at 3-6 months after the procedure to evaluate the presence of PV stenosis. Arrhythmia recurrence was defined as a documented AF or atrial flutter episode of >30 s. Arrhythmic episodes within the first 3 months after the CPVA (healing period) were not considered in the evaluation of final success rates because they are often described as transient recurrences related to atrial inflammatory processes following RF lesions.26 The endpoint of the study was freedom from arrhythmia recurrence after a single CPVA procedure, without anti-arrhythmic medication. A minimum follow-up of 3 months was required. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_subdivision", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Follow-up Patients were followed up at the outpatient clinic at 1, 4, and 7 months after the ablation procedure and every 6 months thereafter. Routine 24 or 48 h Holter monitoring was performed before each appointment, and a 12-lead electrocardiogram was obtained at each visit. Patients were asked to report to the emergency room or our arrhythmia unit for an ECG if any symptom suggestive of recurrence occurred between scheduled visits. After the ablation procedure, all patients received anti-arrhythmic treatment for at least 1 month to protect against early recurrences and continued oral anticoagulation for a minimum of 2 months to maintain an international normalized ratio between 2.0 and 3.0. Additionally, magnetic resonance angiography was repeated at 3-6 months after the procedure to evaluate the presence of PV stenosis. Arrhythmia recurrence was defined as a documented AF or atrial flutter episode of >30 s. Arrhythmic episodes within the first 3 months after the CPVA (healing period) were not considered in the evaluation of final success rates because they are often described as transient recurrences related to atrial inflammatory processes following RF lesions.26 The endpoint of the study was freedom from arrhythmia recurrence after a single CPVA procedure, without anti-arrhythmic medication. A minimum follow-up of 3 months was required.
[ "Follow", "-", "up", "\n", "Patients", "were", "followed", "up", "at", "the", "outpatient", "clinic", "at", "1", ",", "4", ",", "and", "7", "months", "after", "the", "ablation", "procedure", "and", "every", "6", "months", "thereafter", ".", "Routine", "24", "or", "48", "h", "Holter", "monitoring", "was", "performed", "before", "each", "appointment", ",", "and", "a", "12-lead", "electrocardiogram", "was", "obtained", "at", "each", "visit", ".", "Patients", "were", "asked", "to", "report", "to", "the", "emergency", "room", "or", "our", "arrhythmia", "unit", "for", "an", "ECG", "if", "any", "symptom", "suggestive", "of", "recurrence", "occurred", "between", "scheduled", "visits", ".", "\n", "After", "the", "ablation", "procedure", ",", "all", "patients", "received", "anti", "-", "arrhythmic", "treatment", "for", "at", "least", "1", "month", "to", "protect", "against", "early", "recurrences", "and", "continued", "oral", "anticoagulation", "for", "a", "minimum", "of", "2", "months", "to", "maintain", "an", "international", "normalized", "ratio", "between", "2.0", "and", "3.0", ".", "Additionally", ",", "magnetic", "resonance", "angiography", "was", "repeated", "at", "3", "-", "6", "months", "after", "the", "procedure", "to", "evaluate", "the", "presence", "of", "PV", "stenosis", ".", "\n", "Arrhythmia", "recurrence", "was", "defined", "as", "a", "documented", "AF", "or", "atrial", "flutter", "episode", "of", ">", "30", "s.", "Arrhythmic", "episodes", "within", "the", "first", "3", "months", "after", "the", "CPVA", "(", "healing", "period", ")", "were", "not", "considered", "in", "the", "evaluation", "of", "final", "success", "rates", "because", "they", "are", "often", "described", "as", "transient", "recurrences", "related", "to", "atrial", "inflammatory", "processes", "following", "RF", "lesions.26", "\n", "The", "endpoint", "of", "the", "study", "was", "freedom", "from", "arrhythmia", "recurrence", "after", "a", "single", "CPVA", "procedure", ",", "without", "anti", "-", "arrhythmic", "medication", ".", "\n", "A", "minimum", "follow", "-", "up", "of", "3", "months", "was", "required", ".", "\n" ]
[ "Immaterial_anatomical_entity", "Organism_subdivision" ]
Phospholipase A2 is a GENE-Y, p - bromophenacyl bromide is a CHEMICAL, arachidonyl trifluoromethyl ketone is a CHEMICAL, interleukin-2 is a GENE-Y, IL-2 is a GENE-Y
10207608_task0
Sentence: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]
Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.
[ "Phospholipase", "A2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "and", "arachidonyl", "trifluoromethyl", "ketone", "suppressed", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Phospholipase A2 is a GENE-Y, p - bromophenacyl bromide is a CHEMICAL, arachidonyl trifluoromethyl ketone is a CHEMICAL, interleukin-2 is a GENE-Y, IL-2 is a GENE-Y
10207608_task1
Sentence: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Instructions: please typing these entity words according to sentence: Phospholipase A2, p - bromophenacyl bromide, arachidonyl trifluoromethyl ketone, interleukin-2, IL-2 Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]
Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.
[ "Phospholipase", "A2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "and", "arachidonyl", "trifluoromethyl", "ketone", "suppressed", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Phospholipase A2, p - bromophenacyl bromide, arachidonyl trifluoromethyl ketone, interleukin-2, IL-2
10207608_task2
Sentence: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]
Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.
[ "Phospholipase", "A2", "inhibitors", "p", "-", "bromophenacyl", "bromide", "and", "arachidonyl", "trifluoromethyl", "ketone", "suppressed", "interleukin-2", "(", "IL-2", ")", "expression", "in", "murine", "primary", "splenocytes", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
neuroendocrine organ tumors is a Cancer, tumor is a Cancer, multiple endocrine neoplasia is a Cancer, MEN is a Cancer, tumor is a Cancer, MEN1 is a Cancer, tumors is a Cancer, pituitary is a Organ, thyroid is a Organ, parathyroid is a Organ, pancreas is a Organ, pituitary is a Organ, pancreatic islets is a Multi-tissue_structure, p18(-/- ) and Men1(+/- ) cells is a Cell, p18(-/- ) ; Men1(+/- ) cells is a Cell, tumors is a Cancer, tumors is a Cancer, cell is a Cell, tumor is a Cancer
PMID-17145768_task0
Sentence: p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18(Ink4c) and p27(Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates, the p18(-/-); Men1(+/-) mice develop tumors at an accelerated rate and with an increased incidence in the pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18(-/-) and Men1(+/-) cells and was further increased in p18(-/-); Men1(+/-) cells. The remaining wild-type Men1 allele was lost in most tumors from Men1(+/-) mice but was retained in most tumors from p18(-/-); Men1(+/-) mice. Combined mutations of p27(-/-) and Men1(+/-), in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18 and Men1 and suggest that Men1 may regulate additional factor(s) that interact with p18 and p27 differently. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Cancer, Organ, Cell
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "B-Organ", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "B-Organ", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18(Ink4c) and p27(Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates, the p18(-/-); Men1(+/-) mice develop tumors at an accelerated rate and with an increased incidence in the pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18(-/-) and Men1(+/-) cells and was further increased in p18(-/-); Men1(+/-) cells. The remaining wild-type Men1 allele was lost in most tumors from Men1(+/-) mice but was retained in most tumors from p18(-/-); Men1(+/-) mice. Combined mutations of p27(-/-) and Men1(+/-), in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18 and Men1 and suggest that Men1 may regulate additional factor(s) that interact with p18 and p27 differently.
[ "p18Ink4c", ",", "but", "not", "p27Kip1", ",", "collaborates", "with", "Men1", "to", "suppress", "neuroendocrine", "organ", "tumors", ".", "\n", "Mutant", "mice", "lacking", "both", "cyclin", "-", "dependent", "kinase", "(", "CDK", ")", "inhibitors", "p18(Ink4c", ")", "and", "p27(Kip1", ")", "develop", "a", "tumor", "spectrum", "reminiscent", "of", "human", "multiple", "endocrine", "neoplasia", "(", "MEN", ")", "syndromes", ".", "To", "determine", "how", "p18", "and", "p27", "genetically", "interact", "with", "Men1", ",", "the", "tumor", "suppressor", "gene", "mutated", "in", "familial", "MEN1", ",", "we", "characterized", "p18-Men1", "and", "p27-Men1", "double", "mutant", "mice", ".", "Compared", "with", "their", "corresponding", "single", "mutant", "littermates", ",", "the", "p18(-/-", ")", ";", "Men1(+/-", ")", "mice", "develop", "tumors", "at", "an", "accelerated", "rate", "and", "with", "an", "increased", "incidence", "in", "the", "pituitary", ",", "thyroid", ",", "parathyroid", ",", "and", "pancreas", ".", "In", "the", "pituitary", "and", "pancreatic", "islets", ",", "phosphorylation", "of", "the", "retinoblastoma", "(", "Rb", ")", "protein", "at", "both", "CDK2", "and", "CDK4/6", "sites", "was", "increased", "in", "p18(-/-", ")", "and", "Men1(+/-", ")", "cells", "and", "was", "further", "increased", "in", "p18(-/-", ")", ";", "Men1(+/-", ")", "cells", ".", "The", "remaining", "wild", "-", "type", "Men1", "allele", "was", "lost", "in", "most", "tumors", "from", "Men1(+/-", ")", "mice", "but", "was", "retained", "in", "most", "tumors", "from", "p18(-/-", ")", ";", "Men1(+/-", ")", "mice", ".", "Combined", "mutations", "of", "p27(-/-", ")", "and", "Men1(+/-", ")", ",", "in", "contrast", ",", "did", "not", "exhibit", "noticeable", "synergistic", "stimulation", "of", "Rb", "kinase", "activity", ",", "cell", "proliferation", ",", "and", "tumor", "growth", ".", "These", "results", "demonstrate", "that", "functional", "collaboration", "exists", "between", "p18", "and", "Men1", "and", "suggest", "that", "Men1", "may", "regulate", "additional", "factor(s", ")", "that", "interact", "with", "p18", "and", "p27", "differently", ".", "\n" ]
[ "Cancer", "Cell", "Multi-tissue_structure", "Organ" ]
neuroendocrine organ tumors is a Cancer, tumor is a Cancer, multiple endocrine neoplasia is a Cancer, MEN is a Cancer, tumor is a Cancer, MEN1 is a Cancer, tumors is a Cancer, pituitary is a Organ, thyroid is a Organ, parathyroid is a Organ, pancreas is a Organ, pituitary is a Organ, pancreatic islets is a Multi-tissue_structure, p18(-/- ) and Men1(+/- ) cells is a Cell, p18(-/- ) ; Men1(+/- ) cells is a Cell, tumors is a Cancer, tumors is a Cancer, cell is a Cell, tumor is a Cancer
PMID-17145768_task1
Sentence: p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18(Ink4c) and p27(Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates, the p18(-/-); Men1(+/-) mice develop tumors at an accelerated rate and with an increased incidence in the pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18(-/-) and Men1(+/-) cells and was further increased in p18(-/-); Men1(+/-) cells. The remaining wild-type Men1 allele was lost in most tumors from Men1(+/-) mice but was retained in most tumors from p18(-/-); Men1(+/-) mice. Combined mutations of p27(-/-) and Men1(+/-), in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18 and Men1 and suggest that Men1 may regulate additional factor(s) that interact with p18 and p27 differently. Instructions: please typing these entity words according to sentence: neuroendocrine organ tumors, tumor, multiple endocrine neoplasia, MEN, tumor, MEN1, tumors, pituitary, thyroid, parathyroid, pancreas, pituitary, pancreatic islets, p18(-/- ) and Men1(+/- ) cells, p18(-/- ) ; Men1(+/- ) cells, tumors, tumors, cell, tumor Options: Multi-tissue_structure, Cancer, Organ, Cell
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "B-Organ", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "B-Organ", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18(Ink4c) and p27(Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates, the p18(-/-); Men1(+/-) mice develop tumors at an accelerated rate and with an increased incidence in the pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18(-/-) and Men1(+/-) cells and was further increased in p18(-/-); Men1(+/-) cells. The remaining wild-type Men1 allele was lost in most tumors from Men1(+/-) mice but was retained in most tumors from p18(-/-); Men1(+/-) mice. Combined mutations of p27(-/-) and Men1(+/-), in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18 and Men1 and suggest that Men1 may regulate additional factor(s) that interact with p18 and p27 differently.
[ "p18Ink4c", ",", "but", "not", "p27Kip1", ",", "collaborates", "with", "Men1", "to", "suppress", "neuroendocrine", "organ", "tumors", ".", "\n", "Mutant", "mice", "lacking", "both", "cyclin", "-", "dependent", "kinase", "(", "CDK", ")", "inhibitors", "p18(Ink4c", ")", "and", "p27(Kip1", ")", "develop", "a", "tumor", "spectrum", "reminiscent", "of", "human", "multiple", "endocrine", "neoplasia", "(", "MEN", ")", "syndromes", ".", "To", "determine", "how", "p18", "and", "p27", "genetically", "interact", "with", "Men1", ",", "the", "tumor", "suppressor", "gene", "mutated", "in", "familial", "MEN1", ",", "we", "characterized", "p18-Men1", "and", "p27-Men1", "double", "mutant", "mice", ".", "Compared", "with", "their", "corresponding", "single", "mutant", "littermates", ",", "the", "p18(-/-", ")", ";", "Men1(+/-", ")", "mice", "develop", "tumors", "at", "an", "accelerated", "rate", "and", "with", "an", "increased", "incidence", "in", "the", "pituitary", ",", "thyroid", ",", "parathyroid", ",", "and", "pancreas", ".", "In", "the", "pituitary", "and", "pancreatic", "islets", ",", "phosphorylation", "of", "the", "retinoblastoma", "(", "Rb", ")", "protein", "at", "both", "CDK2", "and", "CDK4/6", "sites", "was", "increased", "in", "p18(-/-", ")", "and", "Men1(+/-", ")", "cells", "and", "was", "further", "increased", "in", "p18(-/-", ")", ";", "Men1(+/-", ")", "cells", ".", "The", "remaining", "wild", "-", "type", "Men1", "allele", "was", "lost", "in", "most", "tumors", "from", "Men1(+/-", ")", "mice", "but", "was", "retained", "in", "most", "tumors", "from", "p18(-/-", ")", ";", "Men1(+/-", ")", "mice", ".", "Combined", "mutations", "of", "p27(-/-", ")", "and", "Men1(+/-", ")", ",", "in", "contrast", ",", "did", "not", "exhibit", "noticeable", "synergistic", "stimulation", "of", "Rb", "kinase", "activity", ",", "cell", "proliferation", ",", "and", "tumor", "growth", ".", "These", "results", "demonstrate", "that", "functional", "collaboration", "exists", "between", "p18", "and", "Men1", "and", "suggest", "that", "Men1", "may", "regulate", "additional", "factor(s", ")", "that", "interact", "with", "p18", "and", "p27", "differently", ".", "\n" ]
[ "Cancer", "Cell", "Multi-tissue_structure", "Organ" ]
neuroendocrine organ tumors, tumor, multiple endocrine neoplasia, MEN, tumor, MEN1, tumors, pituitary, thyroid, parathyroid, pancreas, pituitary, pancreatic islets, p18(-/- ) and Men1(+/- ) cells, p18(-/- ) ; Men1(+/- ) cells, tumors, tumors, cell, tumor
PMID-17145768_task2
Sentence: p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18(Ink4c) and p27(Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates, the p18(-/-); Men1(+/-) mice develop tumors at an accelerated rate and with an increased incidence in the pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18(-/-) and Men1(+/-) cells and was further increased in p18(-/-); Men1(+/-) cells. The remaining wild-type Men1 allele was lost in most tumors from Men1(+/-) mice but was retained in most tumors from p18(-/-); Men1(+/-) mice. Combined mutations of p27(-/-) and Men1(+/-), in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18 and Men1 and suggest that Men1 may regulate additional factor(s) that interact with p18 and p27 differently. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "B-Organ", "O", "B-Organ", "O", "O", "B-Organ", "O", "O", "O", "B-Organ", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18(Ink4c) and p27(Kip1) develop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates, the p18(-/-); Men1(+/-) mice develop tumors at an accelerated rate and with an increased incidence in the pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18(-/-) and Men1(+/-) cells and was further increased in p18(-/-); Men1(+/-) cells. The remaining wild-type Men1 allele was lost in most tumors from Men1(+/-) mice but was retained in most tumors from p18(-/-); Men1(+/-) mice. Combined mutations of p27(-/-) and Men1(+/-), in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18 and Men1 and suggest that Men1 may regulate additional factor(s) that interact with p18 and p27 differently.
[ "p18Ink4c", ",", "but", "not", "p27Kip1", ",", "collaborates", "with", "Men1", "to", "suppress", "neuroendocrine", "organ", "tumors", ".", "\n", "Mutant", "mice", "lacking", "both", "cyclin", "-", "dependent", "kinase", "(", "CDK", ")", "inhibitors", "p18(Ink4c", ")", "and", "p27(Kip1", ")", "develop", "a", "tumor", "spectrum", "reminiscent", "of", "human", "multiple", "endocrine", "neoplasia", "(", "MEN", ")", "syndromes", ".", "To", "determine", "how", "p18", "and", "p27", "genetically", "interact", "with", "Men1", ",", "the", "tumor", "suppressor", "gene", "mutated", "in", "familial", "MEN1", ",", "we", "characterized", "p18-Men1", "and", "p27-Men1", "double", "mutant", "mice", ".", "Compared", "with", "their", "corresponding", "single", "mutant", "littermates", ",", "the", "p18(-/-", ")", ";", "Men1(+/-", ")", "mice", "develop", "tumors", "at", "an", "accelerated", "rate", "and", "with", "an", "increased", "incidence", "in", "the", "pituitary", ",", "thyroid", ",", "parathyroid", ",", "and", "pancreas", ".", "In", "the", "pituitary", "and", "pancreatic", "islets", ",", "phosphorylation", "of", "the", "retinoblastoma", "(", "Rb", ")", "protein", "at", "both", "CDK2", "and", "CDK4/6", "sites", "was", "increased", "in", "p18(-/-", ")", "and", "Men1(+/-", ")", "cells", "and", "was", "further", "increased", "in", "p18(-/-", ")", ";", "Men1(+/-", ")", "cells", ".", "The", "remaining", "wild", "-", "type", "Men1", "allele", "was", "lost", "in", "most", "tumors", "from", "Men1(+/-", ")", "mice", "but", "was", "retained", "in", "most", "tumors", "from", "p18(-/-", ")", ";", "Men1(+/-", ")", "mice", ".", "Combined", "mutations", "of", "p27(-/-", ")", "and", "Men1(+/-", ")", ",", "in", "contrast", ",", "did", "not", "exhibit", "noticeable", "synergistic", "stimulation", "of", "Rb", "kinase", "activity", ",", "cell", "proliferation", ",", "and", "tumor", "growth", ".", "These", "results", "demonstrate", "that", "functional", "collaboration", "exists", "between", "p18", "and", "Men1", "and", "suggest", "that", "Men1", "may", "regulate", "additional", "factor(s", ")", "that", "interact", "with", "p18", "and", "p27", "differently", ".", "\n" ]
[ "Cancer", "Cell", "Multi-tissue_structure", "Organ" ]
stem cell is an umlsterm, future is an umlsterm, stem cell transplantation is an umlsterm, therapy is an umlsterm, treatment is an umlsterm, immunologic is an umlsterm, deficiencies is an umlsterm, congenital is an umlsterm, metabolic disorders is an umlsterm, future is an umlsterm, vehicle is an umlsterm, gene therapy is an umlsterm, Stem cells is an umlsterm, bone marrow is an umlsterm, blood is an umlsterm, umbilical cord blood is an umlsterm, biology is an umlsterm, stem cells is an umlsterm, procedures is an umlsterm, stem cell is an umlsterm, marketing is an umlsterm, legislation is an umlsterm, stem cell is an umlsterm, marketing is an umlsterm, person is an umlsterm
Bundesgesundheitsblatt.90420105.eng.abstr_task0
Sentence: In principle , haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives . They are the basis for stem cell transplantation , e.g. for rescue of haematopoiesis after high dose cytotoxic therapy , for treatment of immunologic deficiencies and congenital metabolic disorders , and , in the future , a vehicle for gene therapy . Stem cells may be obtained from bone marrow , peripheral blood , or umbilical cord blood . This article provides an overview of the biology of stem cells , procedures for their collection , the legal basis for the manufacture of stem cell preparations , and essential requirements for their marketing authorisation . According to German legislation , stem cell preparations are medicinal products necessitating a marketing authorisation , if they are not produced for a certain ill person , but manufactured beforehand and banked until needed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In principle , haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives . They are the basis for stem cell transplantation , e.g. for rescue of haematopoiesis after high dose cytotoxic therapy , for treatment of immunologic deficiencies and congenital metabolic disorders , and , in the future , a vehicle for gene therapy . Stem cells may be obtained from bone marrow , peripheral blood , or umbilical cord blood . This article provides an overview of the biology of stem cells , procedures for their collection , the legal basis for the manufacture of stem cell preparations , and essential requirements for their marketing authorisation . According to German legislation , stem cell preparations are medicinal products necessitating a marketing authorisation , if they are not produced for a certain ill person , but manufactured beforehand and banked until needed .
[ "In", "principle", ",", "haematopoietic", "stem", "cell", "preparations", "offer", "a", "paramount", "array", "of", "clinical", "opportunities", "and", "future", "perspectives", ".", "They", "are", "the", "basis", "for", "stem", "cell", "transplantation", ",", "e.g", ".", "for", "rescue", "of", "haematopoiesis", "after", "high", "dose", "cytotoxic", "therapy", ",", "for", "treatment", "of", "immunologic", "deficiencies", "and", "congenital", "metabolic", "disorders", ",", "and", ",", "in", "the", "future", ",", "a", "vehicle", "for", "gene", "therapy", ".", "Stem", "cells", "may", "be", "obtained", "from", "bone", "marrow", ",", "peripheral", "blood", ",", "or", "umbilical", "cord", "blood", ".", "This", "article", "provides", "an", "overview", "of", "the", "biology", "of", "stem", "cells", ",", "procedures", "for", "their", "collection", ",", "the", "legal", "basis", "for", "the", "manufacture", "of", "stem", "cell", "preparations", ",", "and", "essential", "requirements", "for", "their", "marketing", "authorisation", ".", "According", "to", "German", "legislation", ",", "stem", "cell", "preparations", "are", "medicinal", "products", "necessitating", "a", "marketing", "authorisation", ",", "if", "they", "are", "not", "produced", "for", "a", "certain", "ill", "person", ",", "but", "manufactured", "beforehand", "and", "banked", "until", "needed", "." ]
[ "umlsterm" ]
stem cell is an umlsterm, future is an umlsterm, stem cell transplantation is an umlsterm, therapy is an umlsterm, treatment is an umlsterm, immunologic is an umlsterm, deficiencies is an umlsterm, congenital is an umlsterm, metabolic disorders is an umlsterm, future is an umlsterm, vehicle is an umlsterm, gene therapy is an umlsterm, Stem cells is an umlsterm, bone marrow is an umlsterm, blood is an umlsterm, umbilical cord blood is an umlsterm, biology is an umlsterm, stem cells is an umlsterm, procedures is an umlsterm, stem cell is an umlsterm, marketing is an umlsterm, legislation is an umlsterm, stem cell is an umlsterm, marketing is an umlsterm, person is an umlsterm
Bundesgesundheitsblatt.90420105.eng.abstr_task1
Sentence: In principle , haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives . They are the basis for stem cell transplantation , e.g. for rescue of haematopoiesis after high dose cytotoxic therapy , for treatment of immunologic deficiencies and congenital metabolic disorders , and , in the future , a vehicle for gene therapy . Stem cells may be obtained from bone marrow , peripheral blood , or umbilical cord blood . This article provides an overview of the biology of stem cells , procedures for their collection , the legal basis for the manufacture of stem cell preparations , and essential requirements for their marketing authorisation . According to German legislation , stem cell preparations are medicinal products necessitating a marketing authorisation , if they are not produced for a certain ill person , but manufactured beforehand and banked until needed . Instructions: please typing these entity words according to sentence: stem cell, future, stem cell transplantation, therapy, treatment, immunologic, deficiencies, congenital, metabolic disorders, future, vehicle, gene therapy, Stem cells, bone marrow, blood, umbilical cord blood, biology, stem cells, procedures, stem cell, marketing, legislation, stem cell, marketing, person Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In principle , haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives . They are the basis for stem cell transplantation , e.g. for rescue of haematopoiesis after high dose cytotoxic therapy , for treatment of immunologic deficiencies and congenital metabolic disorders , and , in the future , a vehicle for gene therapy . Stem cells may be obtained from bone marrow , peripheral blood , or umbilical cord blood . This article provides an overview of the biology of stem cells , procedures for their collection , the legal basis for the manufacture of stem cell preparations , and essential requirements for their marketing authorisation . According to German legislation , stem cell preparations are medicinal products necessitating a marketing authorisation , if they are not produced for a certain ill person , but manufactured beforehand and banked until needed .
[ "In", "principle", ",", "haematopoietic", "stem", "cell", "preparations", "offer", "a", "paramount", "array", "of", "clinical", "opportunities", "and", "future", "perspectives", ".", "They", "are", "the", "basis", "for", "stem", "cell", "transplantation", ",", "e.g", ".", "for", "rescue", "of", "haematopoiesis", "after", "high", "dose", "cytotoxic", "therapy", ",", "for", "treatment", "of", "immunologic", "deficiencies", "and", "congenital", "metabolic", "disorders", ",", "and", ",", "in", "the", "future", ",", "a", "vehicle", "for", "gene", "therapy", ".", "Stem", "cells", "may", "be", "obtained", "from", "bone", "marrow", ",", "peripheral", "blood", ",", "or", "umbilical", "cord", "blood", ".", "This", "article", "provides", "an", "overview", "of", "the", "biology", "of", "stem", "cells", ",", "procedures", "for", "their", "collection", ",", "the", "legal", "basis", "for", "the", "manufacture", "of", "stem", "cell", "preparations", ",", "and", "essential", "requirements", "for", "their", "marketing", "authorisation", ".", "According", "to", "German", "legislation", ",", "stem", "cell", "preparations", "are", "medicinal", "products", "necessitating", "a", "marketing", "authorisation", ",", "if", "they", "are", "not", "produced", "for", "a", "certain", "ill", "person", ",", "but", "manufactured", "beforehand", "and", "banked", "until", "needed", "." ]
[ "umlsterm" ]
stem cell, future, stem cell transplantation, therapy, treatment, immunologic, deficiencies, congenital, metabolic disorders, future, vehicle, gene therapy, Stem cells, bone marrow, blood, umbilical cord blood, biology, stem cells, procedures, stem cell, marketing, legislation, stem cell, marketing, person
Bundesgesundheitsblatt.90420105.eng.abstr_task2
Sentence: In principle , haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives . They are the basis for stem cell transplantation , e.g. for rescue of haematopoiesis after high dose cytotoxic therapy , for treatment of immunologic deficiencies and congenital metabolic disorders , and , in the future , a vehicle for gene therapy . Stem cells may be obtained from bone marrow , peripheral blood , or umbilical cord blood . This article provides an overview of the biology of stem cells , procedures for their collection , the legal basis for the manufacture of stem cell preparations , and essential requirements for their marketing authorisation . According to German legislation , stem cell preparations are medicinal products necessitating a marketing authorisation , if they are not produced for a certain ill person , but manufactured beforehand and banked until needed . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In principle , haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives . They are the basis for stem cell transplantation , e.g. for rescue of haematopoiesis after high dose cytotoxic therapy , for treatment of immunologic deficiencies and congenital metabolic disorders , and , in the future , a vehicle for gene therapy . Stem cells may be obtained from bone marrow , peripheral blood , or umbilical cord blood . This article provides an overview of the biology of stem cells , procedures for their collection , the legal basis for the manufacture of stem cell preparations , and essential requirements for their marketing authorisation . According to German legislation , stem cell preparations are medicinal products necessitating a marketing authorisation , if they are not produced for a certain ill person , but manufactured beforehand and banked until needed .
[ "In", "principle", ",", "haematopoietic", "stem", "cell", "preparations", "offer", "a", "paramount", "array", "of", "clinical", "opportunities", "and", "future", "perspectives", ".", "They", "are", "the", "basis", "for", "stem", "cell", "transplantation", ",", "e.g", ".", "for", "rescue", "of", "haematopoiesis", "after", "high", "dose", "cytotoxic", "therapy", ",", "for", "treatment", "of", "immunologic", "deficiencies", "and", "congenital", "metabolic", "disorders", ",", "and", ",", "in", "the", "future", ",", "a", "vehicle", "for", "gene", "therapy", ".", "Stem", "cells", "may", "be", "obtained", "from", "bone", "marrow", ",", "peripheral", "blood", ",", "or", "umbilical", "cord", "blood", ".", "This", "article", "provides", "an", "overview", "of", "the", "biology", "of", "stem", "cells", ",", "procedures", "for", "their", "collection", ",", "the", "legal", "basis", "for", "the", "manufacture", "of", "stem", "cell", "preparations", ",", "and", "essential", "requirements", "for", "their", "marketing", "authorisation", ".", "According", "to", "German", "legislation", ",", "stem", "cell", "preparations", "are", "medicinal", "products", "necessitating", "a", "marketing", "authorisation", ",", "if", "they", "are", "not", "produced", "for", "a", "certain", "ill", "person", ",", "but", "manufactured", "beforehand", "and", "banked", "until", "needed", "." ]
[ "umlsterm" ]
clenbuterol is an umlsterm, time is an umlsterm, Clenbuterol is an umlsterm, muscle proteins is an umlsterm, clenbuterol is an umlsterm, nerve growth factor is an umlsterm, NGF is an umlsterm, neuron is an umlsterm, Side effects is an umlsterm, tremor is an umlsterm, headache is an umlsterm, abnormalities is an umlsterm, values is an umlsterm, hypokalemia is an umlsterm, hypoglycemia is an umlsterm, medication is an umlsterm, fatigue is an umlsterm, muscles is an umlsterm, clenbuterol is an umlsterm, treatment is an umlsterm, amyotrophic lateral sclerosis is an umlsterm, treatment is an umlsterm
DerNervenarzt.90701112.eng.abstr_task0
Sentence: The anabolic effects of clenbuterol have been recognized for a long time . Clenbuterol augments the expression of specific muscle proteins with a differential effect on type I and type II fibres . Furthermore , clenbuterol induces the synthesis of endogenous nerve growth factor ( NGF ) and may itself be a myotrophic factor released by neuron endings . Side effects inclde tremor and headache and dose dependent abnormalities of labaratory values ( hypokalemia , hypoglycemia ) . After long-term medication increasing fatigue of muscles has been observed . Decreased expression of b2-adrenergic receptors may limit the expected functional improvement . The efficacy of clenbuterol as symptomatic treatment of amyotrophic lateral sclerosis has not been proved . Controlled treatment trials are warranted to assess this question . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
The anabolic effects of clenbuterol have been recognized for a long time . Clenbuterol augments the expression of specific muscle proteins with a differential effect on type I and type II fibres . Furthermore , clenbuterol induces the synthesis of endogenous nerve growth factor ( NGF ) and may itself be a myotrophic factor released by neuron endings . Side effects inclde tremor and headache and dose dependent abnormalities of labaratory values ( hypokalemia , hypoglycemia ) . After long-term medication increasing fatigue of muscles has been observed . Decreased expression of b2-adrenergic receptors may limit the expected functional improvement . The efficacy of clenbuterol as symptomatic treatment of amyotrophic lateral sclerosis has not been proved . Controlled treatment trials are warranted to assess this question .
[ "The", "anabolic", "effects", "of", "clenbuterol", "have", "been", "recognized", "for", "a", "long", "time", ".", "Clenbuterol", "augments", "the", "expression", "of", "specific", "muscle", "proteins", "with", "a", "differential", "effect", "on", "type", "I", "and", "type", "II", "fibres", ".", "Furthermore", ",", "clenbuterol", "induces", "the", "synthesis", "of", "endogenous", "nerve", "growth", "factor", "(", "NGF", ")", "and", "may", "itself", "be", "a", "myotrophic", "factor", "released", "by", "neuron", "endings", ".", "Side", "effects", "inclde", "tremor", "and", "headache", "and", "dose", "dependent", "abnormalities", "of", "labaratory", "values", "(", "hypokalemia", ",", "hypoglycemia", ")", ".", "After", "long", "-", "term", "medication", "increasing", "fatigue", "of", "muscles", "has", "been", "observed", ".", "Decreased", "expression", "of", "b2-adrenergic", "receptors", "may", "limit", "the", "expected", "functional", "improvement", ".", "The", "efficacy", "of", "clenbuterol", "as", "symptomatic", "treatment", "of", "amyotrophic", "lateral", "sclerosis", "has", "not", "been", "proved", ".", "Controlled", "treatment", "trials", "are", "warranted", "to", "assess", "this", "question", "." ]
[ "umlsterm" ]
clenbuterol is an umlsterm, time is an umlsterm, Clenbuterol is an umlsterm, muscle proteins is an umlsterm, clenbuterol is an umlsterm, nerve growth factor is an umlsterm, NGF is an umlsterm, neuron is an umlsterm, Side effects is an umlsterm, tremor is an umlsterm, headache is an umlsterm, abnormalities is an umlsterm, values is an umlsterm, hypokalemia is an umlsterm, hypoglycemia is an umlsterm, medication is an umlsterm, fatigue is an umlsterm, muscles is an umlsterm, clenbuterol is an umlsterm, treatment is an umlsterm, amyotrophic lateral sclerosis is an umlsterm, treatment is an umlsterm
DerNervenarzt.90701112.eng.abstr_task1
Sentence: The anabolic effects of clenbuterol have been recognized for a long time . Clenbuterol augments the expression of specific muscle proteins with a differential effect on type I and type II fibres . Furthermore , clenbuterol induces the synthesis of endogenous nerve growth factor ( NGF ) and may itself be a myotrophic factor released by neuron endings . Side effects inclde tremor and headache and dose dependent abnormalities of labaratory values ( hypokalemia , hypoglycemia ) . After long-term medication increasing fatigue of muscles has been observed . Decreased expression of b2-adrenergic receptors may limit the expected functional improvement . The efficacy of clenbuterol as symptomatic treatment of amyotrophic lateral sclerosis has not been proved . Controlled treatment trials are warranted to assess this question . Instructions: please typing these entity words according to sentence: clenbuterol, time, Clenbuterol, muscle proteins, clenbuterol, nerve growth factor, NGF, neuron, Side effects, tremor, headache, abnormalities, values, hypokalemia, hypoglycemia, medication, fatigue, muscles, clenbuterol, treatment, amyotrophic lateral sclerosis, treatment Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
The anabolic effects of clenbuterol have been recognized for a long time . Clenbuterol augments the expression of specific muscle proteins with a differential effect on type I and type II fibres . Furthermore , clenbuterol induces the synthesis of endogenous nerve growth factor ( NGF ) and may itself be a myotrophic factor released by neuron endings . Side effects inclde tremor and headache and dose dependent abnormalities of labaratory values ( hypokalemia , hypoglycemia ) . After long-term medication increasing fatigue of muscles has been observed . Decreased expression of b2-adrenergic receptors may limit the expected functional improvement . The efficacy of clenbuterol as symptomatic treatment of amyotrophic lateral sclerosis has not been proved . Controlled treatment trials are warranted to assess this question .
[ "The", "anabolic", "effects", "of", "clenbuterol", "have", "been", "recognized", "for", "a", "long", "time", ".", "Clenbuterol", "augments", "the", "expression", "of", "specific", "muscle", "proteins", "with", "a", "differential", "effect", "on", "type", "I", "and", "type", "II", "fibres", ".", "Furthermore", ",", "clenbuterol", "induces", "the", "synthesis", "of", "endogenous", "nerve", "growth", "factor", "(", "NGF", ")", "and", "may", "itself", "be", "a", "myotrophic", "factor", "released", "by", "neuron", "endings", ".", "Side", "effects", "inclde", "tremor", "and", "headache", "and", "dose", "dependent", "abnormalities", "of", "labaratory", "values", "(", "hypokalemia", ",", "hypoglycemia", ")", ".", "After", "long", "-", "term", "medication", "increasing", "fatigue", "of", "muscles", "has", "been", "observed", ".", "Decreased", "expression", "of", "b2-adrenergic", "receptors", "may", "limit", "the", "expected", "functional", "improvement", ".", "The", "efficacy", "of", "clenbuterol", "as", "symptomatic", "treatment", "of", "amyotrophic", "lateral", "sclerosis", "has", "not", "been", "proved", ".", "Controlled", "treatment", "trials", "are", "warranted", "to", "assess", "this", "question", "." ]
[ "umlsterm" ]
clenbuterol, time, Clenbuterol, muscle proteins, clenbuterol, nerve growth factor, NGF, neuron, Side effects, tremor, headache, abnormalities, values, hypokalemia, hypoglycemia, medication, fatigue, muscles, clenbuterol, treatment, amyotrophic lateral sclerosis, treatment
DerNervenarzt.90701112.eng.abstr_task2
Sentence: The anabolic effects of clenbuterol have been recognized for a long time . Clenbuterol augments the expression of specific muscle proteins with a differential effect on type I and type II fibres . Furthermore , clenbuterol induces the synthesis of endogenous nerve growth factor ( NGF ) and may itself be a myotrophic factor released by neuron endings . Side effects inclde tremor and headache and dose dependent abnormalities of labaratory values ( hypokalemia , hypoglycemia ) . After long-term medication increasing fatigue of muscles has been observed . Decreased expression of b2-adrenergic receptors may limit the expected functional improvement . The efficacy of clenbuterol as symptomatic treatment of amyotrophic lateral sclerosis has not been proved . Controlled treatment trials are warranted to assess this question . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
The anabolic effects of clenbuterol have been recognized for a long time . Clenbuterol augments the expression of specific muscle proteins with a differential effect on type I and type II fibres . Furthermore , clenbuterol induces the synthesis of endogenous nerve growth factor ( NGF ) and may itself be a myotrophic factor released by neuron endings . Side effects inclde tremor and headache and dose dependent abnormalities of labaratory values ( hypokalemia , hypoglycemia ) . After long-term medication increasing fatigue of muscles has been observed . Decreased expression of b2-adrenergic receptors may limit the expected functional improvement . The efficacy of clenbuterol as symptomatic treatment of amyotrophic lateral sclerosis has not been proved . Controlled treatment trials are warranted to assess this question .
[ "The", "anabolic", "effects", "of", "clenbuterol", "have", "been", "recognized", "for", "a", "long", "time", ".", "Clenbuterol", "augments", "the", "expression", "of", "specific", "muscle", "proteins", "with", "a", "differential", "effect", "on", "type", "I", "and", "type", "II", "fibres", ".", "Furthermore", ",", "clenbuterol", "induces", "the", "synthesis", "of", "endogenous", "nerve", "growth", "factor", "(", "NGF", ")", "and", "may", "itself", "be", "a", "myotrophic", "factor", "released", "by", "neuron", "endings", ".", "Side", "effects", "inclde", "tremor", "and", "headache", "and", "dose", "dependent", "abnormalities", "of", "labaratory", "values", "(", "hypokalemia", ",", "hypoglycemia", ")", ".", "After", "long", "-", "term", "medication", "increasing", "fatigue", "of", "muscles", "has", "been", "observed", ".", "Decreased", "expression", "of", "b2-adrenergic", "receptors", "may", "limit", "the", "expected", "functional", "improvement", ".", "The", "efficacy", "of", "clenbuterol", "as", "symptomatic", "treatment", "of", "amyotrophic", "lateral", "sclerosis", "has", "not", "been", "proved", ".", "Controlled", "treatment", "trials", "are", "warranted", "to", "assess", "this", "question", "." ]
[ "umlsterm" ]
L is a Protein, R - PK is a Protein, L - PK is a Protein, L is a Protein, erythroid promoter is a Entity, R - PK is a Protein, GATA-1 is a Protein, R - PK is a Protein, hGATA-1 is a Protein, R - PK is a Protein, promoter is a Entity
536_task0
Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O" ]
Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.
[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", "." ]
[ "Entity", "Protein" ]
L is a Protein, R - PK is a Protein, L - PK is a Protein, L is a Protein, erythroid promoter is a Entity, R - PK is a Protein, GATA-1 is a Protein, R - PK is a Protein, hGATA-1 is a Protein, R - PK is a Protein, promoter is a Entity
536_task1
Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please typing these entity words according to sentence: L, R - PK, L - PK, L, erythroid promoter, R - PK, GATA-1, R - PK, hGATA-1, R - PK, promoter Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O" ]
Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.
[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", "." ]
[ "Entity", "Protein" ]
L, R - PK, L - PK, L, erythroid promoter, R - PK, GATA-1, R - PK, hGATA-1, R - PK, promoter
536_task2
Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O" ]
Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.
[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", "." ]
[ "Entity", "Protein" ]
p65 is a Protein, p50 is a Protein, p65 is a Protein, p65 is a Protein, p65 is a Protein, cathepsin G is a Protein, proteinase 3 is a Protein, p65 is a Protein, p65 is a Protein
7931077_task0
Sentence: A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells.
[ "A", "family", "of", "serine", "proteases", "expressed", "exclusively", "in", "myelo", "-", "monocytic", "cells", "specifically", "processes", "the", "nuclear", "factor", "-", "kappa", "B", "subunit", "p65", "in", "vitro", "and", "may", "impair", "human", "immunodeficiency", "virus", "replication", "in", "these", "cells", ".", "\n", "Two", "groups", "of", "U937", "promonocytic", "cells", "were", "obtained", "by", "limiting", "dilution", "cloning", "which", "differed", "strikingly", "in", "their", "ability", "to", "support", "human", "immunodeficiency", "virus", "1", "(", "HIV-1", ")", "replication", ".", "\"", "Plus", "\"", "clones", "replicated", "the", "virus", "efficiently", ",", "whereas", "\"", "minus", "\"", "clones", "did", "not", ".", "We", "examined", "these", "clones", "for", "differences", "in", "nuclear", "factor", "(", "NF)-kappa", "B", "activity", "which", "might", "account", "for", "the", "observed", "phenomenon", ".", "Stimulation", "of", "plus", "clones", "liberated", "the", "classical", "p50-p65", "complex", "from", "cytoplasmic", "pools", ",", "whereas", "minus", "clones", "produced", "an", "apparently", "novel", ",", "faster", "-", "migrating", "complex", ",", "as", "judged", "by", "electrophoretic", "mobility", "shift", "assays", ".", "It", "is", "surprising", "that", "the", "faster", "-", "migrating", "complex", "was", "composed", "also", "of", "p50", "and", "p65", ".", "However", ",", "the", "p65", "subunit", "was", "COOH", "-", "terminally", "truncated", ",", "as", "shown", "by", "immunoprecipitation", ".", "The", "truncation", "resulted", "from", "limited", "proteolysis", "of", "p65", "during", "cellular", "extraction", "which", "released", "particular", "lysosomal", "serine", "proteases", ",", "such", "as", "elastase", ",", "cathepsin", "G", ",", "and", "proteinase", "3", ".", "These", "specific", "proteases", "are", "coordinately", "expressed", "and", "were", "present", "exclusively", "in", "the", "minus", "U937", "clones", ",", "but", "not", "in", "the", "plus", "clones", ",", "as", "demonstrated", "in", "the", "case", "of", "cathepsin", "G.", "In", "addition", ",", "these", "proteases", "were", "detected", "in", "certain", "subclones", "of", "THP-1", "and", "HL-60", "cells", "and", "in", "primary", "monocytes", ",", "in", "each", "case", "correlating", "with", "the", "truncated", "from", "of", "p65", ".", "We", "demonstrate", "in", "vitro", "cleavage", "of", "p65", "by", "purified", "elastase", "and", "cathepsin", "G.", "It", "is", "possible", "that", "particular", "serine", "proteases", "may", "have", "inhibiting", "effects", "on", "the", "replication", "of", "HIV-1", "in", "myelo", "-", "monocytic", "cells", ".", "The", "data", "also", "demonstrate", "that", "special", "precautions", "must", "be", "taken", "when", "making", "extracts", "from", "myelo", "-", "monocytic", "cells", "." ]
[ "Protein" ]
p65 is a Protein, p50 is a Protein, p65 is a Protein, p65 is a Protein, p65 is a Protein, cathepsin G is a Protein, proteinase 3 is a Protein, p65 is a Protein, p65 is a Protein
7931077_task1
Sentence: A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells. Instructions: please typing these entity words according to sentence: p65, p50, p65, p65, p65, cathepsin G, proteinase 3, p65, p65 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells.
[ "A", "family", "of", "serine", "proteases", "expressed", "exclusively", "in", "myelo", "-", "monocytic", "cells", "specifically", "processes", "the", "nuclear", "factor", "-", "kappa", "B", "subunit", "p65", "in", "vitro", "and", "may", "impair", "human", "immunodeficiency", "virus", "replication", "in", "these", "cells", ".", "\n", "Two", "groups", "of", "U937", "promonocytic", "cells", "were", "obtained", "by", "limiting", "dilution", "cloning", "which", "differed", "strikingly", "in", "their", "ability", "to", "support", "human", "immunodeficiency", "virus", "1", "(", "HIV-1", ")", "replication", ".", "\"", "Plus", "\"", "clones", "replicated", "the", "virus", "efficiently", ",", "whereas", "\"", "minus", "\"", "clones", "did", "not", ".", "We", "examined", "these", "clones", "for", "differences", "in", "nuclear", "factor", "(", "NF)-kappa", "B", "activity", "which", "might", "account", "for", "the", "observed", "phenomenon", ".", "Stimulation", "of", "plus", "clones", "liberated", "the", "classical", "p50-p65", "complex", "from", "cytoplasmic", "pools", ",", "whereas", "minus", "clones", "produced", "an", "apparently", "novel", ",", "faster", "-", "migrating", "complex", ",", "as", "judged", "by", "electrophoretic", "mobility", "shift", "assays", ".", "It", "is", "surprising", "that", "the", "faster", "-", "migrating", "complex", "was", "composed", "also", "of", "p50", "and", "p65", ".", "However", ",", "the", "p65", "subunit", "was", "COOH", "-", "terminally", "truncated", ",", "as", "shown", "by", "immunoprecipitation", ".", "The", "truncation", "resulted", "from", "limited", "proteolysis", "of", "p65", "during", "cellular", "extraction", "which", "released", "particular", "lysosomal", "serine", "proteases", ",", "such", "as", "elastase", ",", "cathepsin", "G", ",", "and", "proteinase", "3", ".", "These", "specific", "proteases", "are", "coordinately", "expressed", "and", "were", "present", "exclusively", "in", "the", "minus", "U937", "clones", ",", "but", "not", "in", "the", "plus", "clones", ",", "as", "demonstrated", "in", "the", "case", "of", "cathepsin", "G.", "In", "addition", ",", "these", "proteases", "were", "detected", "in", "certain", "subclones", "of", "THP-1", "and", "HL-60", "cells", "and", "in", "primary", "monocytes", ",", "in", "each", "case", "correlating", "with", "the", "truncated", "from", "of", "p65", ".", "We", "demonstrate", "in", "vitro", "cleavage", "of", "p65", "by", "purified", "elastase", "and", "cathepsin", "G.", "It", "is", "possible", "that", "particular", "serine", "proteases", "may", "have", "inhibiting", "effects", "on", "the", "replication", "of", "HIV-1", "in", "myelo", "-", "monocytic", "cells", ".", "The", "data", "also", "demonstrate", "that", "special", "precautions", "must", "be", "taken", "when", "making", "extracts", "from", "myelo", "-", "monocytic", "cells", "." ]
[ "Protein" ]
p65, p50, p65, p65, p65, cathepsin G, proteinase 3, p65, p65
7931077_task2
Sentence: A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. Two groups of U937 promonocytic cells were obtained by limiting dilution cloning which differed strikingly in their ability to support human immunodeficiency virus 1 (HIV-1) replication. "Plus" clones replicated the virus efficiently, whereas "minus" clones did not. We examined these clones for differences in nuclear factor (NF)-kappa B activity which might account for the observed phenomenon. Stimulation of plus clones liberated the classical p50-p65 complex from cytoplasmic pools, whereas minus clones produced an apparently novel, faster-migrating complex, as judged by electrophoretic mobility shift assays. It is surprising that the faster-migrating complex was composed also of p50 and p65. However, the p65 subunit was COOH-terminally truncated, as shown by immunoprecipitation. The truncation resulted from limited proteolysis of p65 during cellular extraction which released particular lysosomal serine proteases, such as elastase, cathepsin G, and proteinase 3. These specific proteases are coordinately expressed and were present exclusively in the minus U937 clones, but not in the plus clones, as demonstrated in the case of cathepsin G. In addition, these proteases were detected in certain subclones of THP-1 and HL-60 cells and in primary monocytes, in each case correlating with the truncated from of p65. We demonstrate in vitro cleavage of p65 by purified elastase and cathepsin G. It is possible that particular serine proteases may have inhibiting effects on the replication of HIV-1 in myelo-monocytic cells. The data also demonstrate that special precautions must be taken when making extracts from myelo-monocytic cells.
[ "A", "family", "of", "serine", "proteases", "expressed", "exclusively", "in", "myelo", "-", "monocytic", "cells", "specifically", "processes", "the", "nuclear", "factor", "-", "kappa", "B", "subunit", "p65", "in", "vitro", "and", "may", "impair", "human", "immunodeficiency", "virus", "replication", "in", "these", "cells", ".", "\n", "Two", "groups", "of", "U937", "promonocytic", "cells", "were", "obtained", "by", "limiting", "dilution", "cloning", "which", "differed", "strikingly", "in", "their", "ability", "to", "support", "human", "immunodeficiency", "virus", "1", "(", "HIV-1", ")", "replication", ".", "\"", "Plus", "\"", "clones", "replicated", "the", "virus", "efficiently", ",", "whereas", "\"", "minus", "\"", "clones", "did", "not", ".", "We", "examined", "these", "clones", "for", "differences", "in", "nuclear", "factor", "(", "NF)-kappa", "B", "activity", "which", "might", "account", "for", "the", "observed", "phenomenon", ".", "Stimulation", "of", "plus", "clones", "liberated", "the", "classical", "p50-p65", "complex", "from", "cytoplasmic", "pools", ",", "whereas", "minus", "clones", "produced", "an", "apparently", "novel", ",", "faster", "-", "migrating", "complex", ",", "as", "judged", "by", "electrophoretic", "mobility", "shift", "assays", ".", "It", "is", "surprising", "that", "the", "faster", "-", "migrating", "complex", "was", "composed", "also", "of", "p50", "and", "p65", ".", "However", ",", "the", "p65", "subunit", "was", "COOH", "-", "terminally", "truncated", ",", "as", "shown", "by", "immunoprecipitation", ".", "The", "truncation", "resulted", "from", "limited", "proteolysis", "of", "p65", "during", "cellular", "extraction", "which", "released", "particular", "lysosomal", "serine", "proteases", ",", "such", "as", "elastase", ",", "cathepsin", "G", ",", "and", "proteinase", "3", ".", "These", "specific", "proteases", "are", "coordinately", "expressed", "and", "were", "present", "exclusively", "in", "the", "minus", "U937", "clones", ",", "but", "not", "in", "the", "plus", "clones", ",", "as", "demonstrated", "in", "the", "case", "of", "cathepsin", "G.", "In", "addition", ",", "these", "proteases", "were", "detected", "in", "certain", "subclones", "of", "THP-1", "and", "HL-60", "cells", "and", "in", "primary", "monocytes", ",", "in", "each", "case", "correlating", "with", "the", "truncated", "from", "of", "p65", ".", "We", "demonstrate", "in", "vitro", "cleavage", "of", "p65", "by", "purified", "elastase", "and", "cathepsin", "G.", "It", "is", "possible", "that", "particular", "serine", "proteases", "may", "have", "inhibiting", "effects", "on", "the", "replication", "of", "HIV-1", "in", "myelo", "-", "monocytic", "cells", ".", "The", "data", "also", "demonstrate", "that", "special", "precautions", "must", "be", "taken", "when", "making", "extracts", "from", "myelo", "-", "monocytic", "cells", "." ]
[ "Protein" ]
combined organ transplantation is a Procedure, extra - renal organ and / or islet cell transplant is a Scope, previous is a Temporal, non - renal solid organ and / or islet cell transplantation is a Scope, Infection with HIV is a Condition
NCT01531257_exc_task0
Sentence: 1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Temporal, Condition, Procedure
[ "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent
[ "1", ".", "Need", "for", "combined", "organ", "transplantation", "with", "an", "extra", "-", "renal", "organ", "and", "/", "or", "islet", "cell", "transplant", ".", "\n", "2", ".", "Recipients", "of", "previous", "non", "-", "renal", "solid", "organ", "and", "/", "or", "islet", "cell", "transplantation", ".", "\n", "3", ".", "Infection", "with", "HIV", ".", "\n", "4", ".", "Inability", "or", "unwillingness", "of", "a", "participant", "and", "/", "or", "guardian", "to", "provide", "informed", "consent", " \n \n" ]
[ "Scope", "Procedure", "Condition", "Qualifier", "Temporal" ]
combined organ transplantation is a Procedure, extra - renal organ and / or islet cell transplant is a Scope, previous is a Temporal, non - renal solid organ and / or islet cell transplantation is a Scope, Infection with HIV is a Condition
NCT01531257_exc_task1
Sentence: 1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent Instructions: please typing these entity words according to sentence: combined organ transplantation, extra - renal organ and / or islet cell transplant, previous, non - renal solid organ and / or islet cell transplantation, Infection with HIV Options: Scope, Temporal, Condition, Procedure
[ "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent
[ "1", ".", "Need", "for", "combined", "organ", "transplantation", "with", "an", "extra", "-", "renal", "organ", "and", "/", "or", "islet", "cell", "transplant", ".", "\n", "2", ".", "Recipients", "of", "previous", "non", "-", "renal", "solid", "organ", "and", "/", "or", "islet", "cell", "transplantation", ".", "\n", "3", ".", "Infection", "with", "HIV", ".", "\n", "4", ".", "Inability", "or", "unwillingness", "of", "a", "participant", "and", "/", "or", "guardian", "to", "provide", "informed", "consent", " \n \n" ]
[ "Scope", "Procedure", "Condition", "Qualifier", "Temporal" ]
combined organ transplantation, extra - renal organ and / or islet cell transplant, previous, non - renal solid organ and / or islet cell transplantation, Infection with HIV
NCT01531257_exc_task2
Sentence: 1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
1. Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant. 2. Recipients of previous non-renal solid organ and/or islet cell transplantation. 3. Infection with HIV. 4. Inability or unwillingness of a participant and/or guardian to provide informed consent
[ "1", ".", "Need", "for", "combined", "organ", "transplantation", "with", "an", "extra", "-", "renal", "organ", "and", "/", "or", "islet", "cell", "transplant", ".", "\n", "2", ".", "Recipients", "of", "previous", "non", "-", "renal", "solid", "organ", "and", "/", "or", "islet", "cell", "transplantation", ".", "\n", "3", ".", "Infection", "with", "HIV", ".", "\n", "4", ".", "Inability", "or", "unwillingness", "of", "a", "participant", "and", "/", "or", "guardian", "to", "provide", "informed", "consent", " \n \n" ]
[ "Scope", "Procedure", "Condition", "Qualifier", "Temporal" ]
Therapieoptimierung is an umlsterm, Lungenkarzinome is an umlsterm, Patienten is an umlsterm, Radiotherapie is an umlsterm, Tumorregression is an umlsterm, Tumorregression is an umlsterm, Tumorgewebe is an umlsterm, Tumorregression is an umlsterm, Patienten is an umlsterm, Regressionsgrade is an umlsterm, Therapie is an umlsterm, Tumornekrose is an umlsterm, Granulationsgewebe is an umlsterm, Patienten is an umlsterm, Regressionsgrade is an umlsterm, Patienten is an umlsterm, Regressionsgrade is an umlsterm
DerPathologe.70180131.ger.abstr_task0
Sentence: Im Rahmen einer Multicenterstudie zur Therapieoptimierung lokal fortgeschrittener nichtkleinzelliger Lungenkarzinome wurden Resektionspraeparate von 35 Patienten nach neoadjuvanter Chemo- und Radiotherapie histologisch aufgearbeitet und dem folgenden Regressionsgrading zugeordnet : Grad I : keine oder nur geringe , i . allg. spontane Tumorregression , Grad II a : unvollstaendige Tumorregression mit mehr als 10 % und Grad II b : weniger als 10 % vitalem Tumorgewebe sowie Grad III : komplette Tumorregression . Bei 15 Patienten der Regressionsgrade II a bis III konnten als charakteristischer Ausdruck eines Ansprechens auf die neoadjuvante Therapie verschieden grosse angedeutet kokardenfoermige Herde mit zentraler Tumornekrose , meist schmalem Schaumzellsaum , gefaessreichem Granulationsgewebe und peripherer Vernarbung nachgewiesen werden . Bei den als " Responder " zusammengefassten Patienten der Regressionsgrade II b und III lag mit 27,9 Monaten eine signifikant laengere mediane Ueberlebenszeit vor als bei den als " Nonresponder " zusammengefassten Patienten der Regressionsgrade I und II a mit 12,7 Monaten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Im Rahmen einer Multicenterstudie zur Therapieoptimierung lokal fortgeschrittener nichtkleinzelliger Lungenkarzinome wurden Resektionspraeparate von 35 Patienten nach neoadjuvanter Chemo- und Radiotherapie histologisch aufgearbeitet und dem folgenden Regressionsgrading zugeordnet : Grad I : keine oder nur geringe , i . allg. spontane Tumorregression , Grad II a : unvollstaendige Tumorregression mit mehr als 10 % und Grad II b : weniger als 10 % vitalem Tumorgewebe sowie Grad III : komplette Tumorregression . Bei 15 Patienten der Regressionsgrade II a bis III konnten als charakteristischer Ausdruck eines Ansprechens auf die neoadjuvante Therapie verschieden grosse angedeutet kokardenfoermige Herde mit zentraler Tumornekrose , meist schmalem Schaumzellsaum , gefaessreichem Granulationsgewebe und peripherer Vernarbung nachgewiesen werden . Bei den als " Responder " zusammengefassten Patienten der Regressionsgrade II b und III lag mit 27,9 Monaten eine signifikant laengere mediane Ueberlebenszeit vor als bei den als " Nonresponder " zusammengefassten Patienten der Regressionsgrade I und II a mit 12,7 Monaten .
[ "Im", "Rahmen", "einer", "Multicenterstudie", "zur", "Therapieoptimierung", "lokal", "fortgeschrittener", "nichtkleinzelliger", "Lungenkarzinome", "wurden", "Resektionspraeparate", "von", "35", "Patienten", "nach", "neoadjuvanter", "Chemo-", "und", "Radiotherapie", "histologisch", "aufgearbeitet", "und", "dem", "folgenden", "Regressionsgrading", "zugeordnet", ":", "Grad", "I", ":", "keine", "oder", "nur", "geringe", ",", "i", ".", "allg", ".", "spontane", "Tumorregression", ",", "Grad", "II", "a", ":", "unvollstaendige", "Tumorregression", "mit", "mehr", "als", "10", "%", "und", "Grad", "II", "b", ":", "weniger", "als", "10", "%", "vitalem", "Tumorgewebe", "sowie", "Grad", "III", ":", "komplette", "Tumorregression", ".", "Bei", "15", "Patienten", "der", "Regressionsgrade", "II", "a", "bis", "III", "konnten", "als", "charakteristischer", "Ausdruck", "eines", "Ansprechens", "auf", "die", "neoadjuvante", "Therapie", "verschieden", "grosse", "angedeutet", "kokardenfoermige", "Herde", "mit", "zentraler", "Tumornekrose", ",", "meist", "schmalem", "Schaumzellsaum", ",", "gefaessreichem", "Granulationsgewebe", "und", "peripherer", "Vernarbung", "nachgewiesen", "werden", ".", "Bei", "den", "als", "\"", "Responder", "\"", "zusammengefassten", "Patienten", "der", "Regressionsgrade", "II", "b", "und", "III", "lag", "mit", "27,9", "Monaten", "eine", "signifikant", "laengere", "mediane", "Ueberlebenszeit", "vor", "als", "bei", "den", "als", "\"", "Nonresponder", "\"", "zusammengefassten", "Patienten", "der", "Regressionsgrade", "I", "und", "II", "a", "mit", "12,7", "Monaten", "." ]
[ "umlsterm" ]
Therapieoptimierung is an umlsterm, Lungenkarzinome is an umlsterm, Patienten is an umlsterm, Radiotherapie is an umlsterm, Tumorregression is an umlsterm, Tumorregression is an umlsterm, Tumorgewebe is an umlsterm, Tumorregression is an umlsterm, Patienten is an umlsterm, Regressionsgrade is an umlsterm, Therapie is an umlsterm, Tumornekrose is an umlsterm, Granulationsgewebe is an umlsterm, Patienten is an umlsterm, Regressionsgrade is an umlsterm, Patienten is an umlsterm, Regressionsgrade is an umlsterm
DerPathologe.70180131.ger.abstr_task1
Sentence: Im Rahmen einer Multicenterstudie zur Therapieoptimierung lokal fortgeschrittener nichtkleinzelliger Lungenkarzinome wurden Resektionspraeparate von 35 Patienten nach neoadjuvanter Chemo- und Radiotherapie histologisch aufgearbeitet und dem folgenden Regressionsgrading zugeordnet : Grad I : keine oder nur geringe , i . allg. spontane Tumorregression , Grad II a : unvollstaendige Tumorregression mit mehr als 10 % und Grad II b : weniger als 10 % vitalem Tumorgewebe sowie Grad III : komplette Tumorregression . Bei 15 Patienten der Regressionsgrade II a bis III konnten als charakteristischer Ausdruck eines Ansprechens auf die neoadjuvante Therapie verschieden grosse angedeutet kokardenfoermige Herde mit zentraler Tumornekrose , meist schmalem Schaumzellsaum , gefaessreichem Granulationsgewebe und peripherer Vernarbung nachgewiesen werden . Bei den als " Responder " zusammengefassten Patienten der Regressionsgrade II b und III lag mit 27,9 Monaten eine signifikant laengere mediane Ueberlebenszeit vor als bei den als " Nonresponder " zusammengefassten Patienten der Regressionsgrade I und II a mit 12,7 Monaten . Instructions: please typing these entity words according to sentence: Therapieoptimierung, Lungenkarzinome, Patienten, Radiotherapie, Tumorregression, Tumorregression, Tumorgewebe, Tumorregression, Patienten, Regressionsgrade, Therapie, Tumornekrose, Granulationsgewebe, Patienten, Regressionsgrade, Patienten, Regressionsgrade Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Im Rahmen einer Multicenterstudie zur Therapieoptimierung lokal fortgeschrittener nichtkleinzelliger Lungenkarzinome wurden Resektionspraeparate von 35 Patienten nach neoadjuvanter Chemo- und Radiotherapie histologisch aufgearbeitet und dem folgenden Regressionsgrading zugeordnet : Grad I : keine oder nur geringe , i . allg. spontane Tumorregression , Grad II a : unvollstaendige Tumorregression mit mehr als 10 % und Grad II b : weniger als 10 % vitalem Tumorgewebe sowie Grad III : komplette Tumorregression . Bei 15 Patienten der Regressionsgrade II a bis III konnten als charakteristischer Ausdruck eines Ansprechens auf die neoadjuvante Therapie verschieden grosse angedeutet kokardenfoermige Herde mit zentraler Tumornekrose , meist schmalem Schaumzellsaum , gefaessreichem Granulationsgewebe und peripherer Vernarbung nachgewiesen werden . Bei den als " Responder " zusammengefassten Patienten der Regressionsgrade II b und III lag mit 27,9 Monaten eine signifikant laengere mediane Ueberlebenszeit vor als bei den als " Nonresponder " zusammengefassten Patienten der Regressionsgrade I und II a mit 12,7 Monaten .
[ "Im", "Rahmen", "einer", "Multicenterstudie", "zur", "Therapieoptimierung", "lokal", "fortgeschrittener", "nichtkleinzelliger", "Lungenkarzinome", "wurden", "Resektionspraeparate", "von", "35", "Patienten", "nach", "neoadjuvanter", "Chemo-", "und", "Radiotherapie", "histologisch", "aufgearbeitet", "und", "dem", "folgenden", "Regressionsgrading", "zugeordnet", ":", "Grad", "I", ":", "keine", "oder", "nur", "geringe", ",", "i", ".", "allg", ".", "spontane", "Tumorregression", ",", "Grad", "II", "a", ":", "unvollstaendige", "Tumorregression", "mit", "mehr", "als", "10", "%", "und", "Grad", "II", "b", ":", "weniger", "als", "10", "%", "vitalem", "Tumorgewebe", "sowie", "Grad", "III", ":", "komplette", "Tumorregression", ".", "Bei", "15", "Patienten", "der", "Regressionsgrade", "II", "a", "bis", "III", "konnten", "als", "charakteristischer", "Ausdruck", "eines", "Ansprechens", "auf", "die", "neoadjuvante", "Therapie", "verschieden", "grosse", "angedeutet", "kokardenfoermige", "Herde", "mit", "zentraler", "Tumornekrose", ",", "meist", "schmalem", "Schaumzellsaum", ",", "gefaessreichem", "Granulationsgewebe", "und", "peripherer", "Vernarbung", "nachgewiesen", "werden", ".", "Bei", "den", "als", "\"", "Responder", "\"", "zusammengefassten", "Patienten", "der", "Regressionsgrade", "II", "b", "und", "III", "lag", "mit", "27,9", "Monaten", "eine", "signifikant", "laengere", "mediane", "Ueberlebenszeit", "vor", "als", "bei", "den", "als", "\"", "Nonresponder", "\"", "zusammengefassten", "Patienten", "der", "Regressionsgrade", "I", "und", "II", "a", "mit", "12,7", "Monaten", "." ]
[ "umlsterm" ]
Therapieoptimierung, Lungenkarzinome, Patienten, Radiotherapie, Tumorregression, Tumorregression, Tumorgewebe, Tumorregression, Patienten, Regressionsgrade, Therapie, Tumornekrose, Granulationsgewebe, Patienten, Regressionsgrade, Patienten, Regressionsgrade
DerPathologe.70180131.ger.abstr_task2
Sentence: Im Rahmen einer Multicenterstudie zur Therapieoptimierung lokal fortgeschrittener nichtkleinzelliger Lungenkarzinome wurden Resektionspraeparate von 35 Patienten nach neoadjuvanter Chemo- und Radiotherapie histologisch aufgearbeitet und dem folgenden Regressionsgrading zugeordnet : Grad I : keine oder nur geringe , i . allg. spontane Tumorregression , Grad II a : unvollstaendige Tumorregression mit mehr als 10 % und Grad II b : weniger als 10 % vitalem Tumorgewebe sowie Grad III : komplette Tumorregression . Bei 15 Patienten der Regressionsgrade II a bis III konnten als charakteristischer Ausdruck eines Ansprechens auf die neoadjuvante Therapie verschieden grosse angedeutet kokardenfoermige Herde mit zentraler Tumornekrose , meist schmalem Schaumzellsaum , gefaessreichem Granulationsgewebe und peripherer Vernarbung nachgewiesen werden . Bei den als " Responder " zusammengefassten Patienten der Regressionsgrade II b und III lag mit 27,9 Monaten eine signifikant laengere mediane Ueberlebenszeit vor als bei den als " Nonresponder " zusammengefassten Patienten der Regressionsgrade I und II a mit 12,7 Monaten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Im Rahmen einer Multicenterstudie zur Therapieoptimierung lokal fortgeschrittener nichtkleinzelliger Lungenkarzinome wurden Resektionspraeparate von 35 Patienten nach neoadjuvanter Chemo- und Radiotherapie histologisch aufgearbeitet und dem folgenden Regressionsgrading zugeordnet : Grad I : keine oder nur geringe , i . allg. spontane Tumorregression , Grad II a : unvollstaendige Tumorregression mit mehr als 10 % und Grad II b : weniger als 10 % vitalem Tumorgewebe sowie Grad III : komplette Tumorregression . Bei 15 Patienten der Regressionsgrade II a bis III konnten als charakteristischer Ausdruck eines Ansprechens auf die neoadjuvante Therapie verschieden grosse angedeutet kokardenfoermige Herde mit zentraler Tumornekrose , meist schmalem Schaumzellsaum , gefaessreichem Granulationsgewebe und peripherer Vernarbung nachgewiesen werden . Bei den als " Responder " zusammengefassten Patienten der Regressionsgrade II b und III lag mit 27,9 Monaten eine signifikant laengere mediane Ueberlebenszeit vor als bei den als " Nonresponder " zusammengefassten Patienten der Regressionsgrade I und II a mit 12,7 Monaten .
[ "Im", "Rahmen", "einer", "Multicenterstudie", "zur", "Therapieoptimierung", "lokal", "fortgeschrittener", "nichtkleinzelliger", "Lungenkarzinome", "wurden", "Resektionspraeparate", "von", "35", "Patienten", "nach", "neoadjuvanter", "Chemo-", "und", "Radiotherapie", "histologisch", "aufgearbeitet", "und", "dem", "folgenden", "Regressionsgrading", "zugeordnet", ":", "Grad", "I", ":", "keine", "oder", "nur", "geringe", ",", "i", ".", "allg", ".", "spontane", "Tumorregression", ",", "Grad", "II", "a", ":", "unvollstaendige", "Tumorregression", "mit", "mehr", "als", "10", "%", "und", "Grad", "II", "b", ":", "weniger", "als", "10", "%", "vitalem", "Tumorgewebe", "sowie", "Grad", "III", ":", "komplette", "Tumorregression", ".", "Bei", "15", "Patienten", "der", "Regressionsgrade", "II", "a", "bis", "III", "konnten", "als", "charakteristischer", "Ausdruck", "eines", "Ansprechens", "auf", "die", "neoadjuvante", "Therapie", "verschieden", "grosse", "angedeutet", "kokardenfoermige", "Herde", "mit", "zentraler", "Tumornekrose", ",", "meist", "schmalem", "Schaumzellsaum", ",", "gefaessreichem", "Granulationsgewebe", "und", "peripherer", "Vernarbung", "nachgewiesen", "werden", ".", "Bei", "den", "als", "\"", "Responder", "\"", "zusammengefassten", "Patienten", "der", "Regressionsgrade", "II", "b", "und", "III", "lag", "mit", "27,9", "Monaten", "eine", "signifikant", "laengere", "mediane", "Ueberlebenszeit", "vor", "als", "bei", "den", "als", "\"", "Nonresponder", "\"", "zusammengefassten", "Patienten", "der", "Regressionsgrade", "I", "und", "II", "a", "mit", "12,7", "Monaten", "." ]
[ "umlsterm" ]
other is a Qualifier, neoplasia is a Condition, Man is a Person
NCT02393287_exc_task0
Sentence: 1. Presence of other neoplasia 2. Man Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Person, Condition, Qualifier
[ "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "O", "O", "B-Person", "O" ]
1. Presence of other neoplasia 2. Man
[ "1", ".", "Presence", "of", "other", "neoplasia", "\n", "2", ".", "Man", " \n \n" ]
[ "Condition", "Qualifier", "Person" ]
other is a Qualifier, neoplasia is a Condition, Man is a Person
NCT02393287_exc_task1
Sentence: 1. Presence of other neoplasia 2. Man Instructions: please typing these entity words according to sentence: other, neoplasia, Man Options: Person, Condition, Qualifier
[ "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "O", "O", "B-Person", "O" ]
1. Presence of other neoplasia 2. Man
[ "1", ".", "Presence", "of", "other", "neoplasia", "\n", "2", ".", "Man", " \n \n" ]
[ "Condition", "Qualifier", "Person" ]
other, neoplasia, Man
NCT02393287_exc_task2
Sentence: 1. Presence of other neoplasia 2. Man Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "O", "O", "B-Person", "O" ]
1. Presence of other neoplasia 2. Man
[ "1", ".", "Presence", "of", "other", "neoplasia", "\n", "2", ".", "Man", " \n \n" ]
[ "Condition", "Qualifier", "Person" ]
ankyrin binding domain is a protein-domain, Tiam1 is a protein, CD44 is a protein
1.0alpha7.train.1281_task0
Sentence: The structural homology between the ankyrin binding domain of Tiam1 (the sequence between amino acids 717 and 727) and CD44 is quite striking ( Lokeshwar et al. 1994 ). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-domain, protein
[ "O", "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The structural homology between the ankyrin binding domain of Tiam1 (the sequence between amino acids 717 and 727) and CD44 is quite striking ( Lokeshwar et al. 1994 ).
[ "The", "structural", "homology", "between", "the", " ", "ankyrin", "binding", "domain", "of", " ", "Tiam1", "(", "the", "sequence", "between", "amino", "acids", "717", "and", "727", ")", "and", " ", "CD44", "is", "quite", "striking", "(", "Lokeshwar", "et", "al", ".", "1994", " ", ")", "." ]
[ "protein-domain", "protein-family", "protein" ]
ankyrin binding domain is a protein-domain, Tiam1 is a protein, CD44 is a protein
1.0alpha7.train.1281_task1
Sentence: The structural homology between the ankyrin binding domain of Tiam1 (the sequence between amino acids 717 and 727) and CD44 is quite striking ( Lokeshwar et al. 1994 ). Instructions: please typing these entity words according to sentence: ankyrin binding domain, Tiam1, CD44 Options: protein-domain, protein
[ "O", "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The structural homology between the ankyrin binding domain of Tiam1 (the sequence between amino acids 717 and 727) and CD44 is quite striking ( Lokeshwar et al. 1994 ).
[ "The", "structural", "homology", "between", "the", " ", "ankyrin", "binding", "domain", "of", " ", "Tiam1", "(", "the", "sequence", "between", "amino", "acids", "717", "and", "727", ")", "and", " ", "CD44", "is", "quite", "striking", "(", "Lokeshwar", "et", "al", ".", "1994", " ", ")", "." ]
[ "protein-domain", "protein-family", "protein" ]
ankyrin binding domain, Tiam1, CD44
1.0alpha7.train.1281_task2
Sentence: The structural homology between the ankyrin binding domain of Tiam1 (the sequence between amino acids 717 and 727) and CD44 is quite striking ( Lokeshwar et al. 1994 ). Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The structural homology between the ankyrin binding domain of Tiam1 (the sequence between amino acids 717 and 727) and CD44 is quite striking ( Lokeshwar et al. 1994 ).
[ "The", "structural", "homology", "between", "the", " ", "ankyrin", "binding", "domain", "of", " ", "Tiam1", "(", "the", "sequence", "between", "amino", "acids", "717", "and", "727", ")", "and", " ", "CD44", "is", "quite", "striking", "(", "Lokeshwar", "et", "al", ".", "1994", " ", ")", "." ]
[ "protein-domain", "protein-family", "protein" ]
Inborn is a Condition, preterm is a Condition, infants is a Person, between 28 0/7 and 34 0/7 weeks is a Value, gestation is a Measurement, fed is a Observation, donor human milk is a Observation
NCT02632266_inc_task0
Sentence: Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Observation, Measurement
[ "B-Condition", "B-Condition", "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Measurement", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O" ]
Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk
[ "Inborn", "preterm", "infants", "born", "between", "28", "0/7", "and", "34", "0/7", "weeks", "gestation", "and", "fed", "either", "mother", "'s", "own", "milk", "or", "donor", "human", "milk", "\n" ]
[ "Value", "Observation", "Measurement", "Person", "Condition" ]
Inborn is a Condition, preterm is a Condition, infants is a Person, between 28 0/7 and 34 0/7 weeks is a Value, gestation is a Measurement, fed is a Observation, donor human milk is a Observation
NCT02632266_inc_task1
Sentence: Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk Instructions: please typing these entity words according to sentence: Inborn, preterm, infants, between 28 0/7 and 34 0/7 weeks, gestation, fed, donor human milk Options: Condition, Value, Person, Observation, Measurement
[ "B-Condition", "B-Condition", "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Measurement", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O" ]
Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk
[ "Inborn", "preterm", "infants", "born", "between", "28", "0/7", "and", "34", "0/7", "weeks", "gestation", "and", "fed", "either", "mother", "'s", "own", "milk", "or", "donor", "human", "milk", "\n" ]
[ "Value", "Observation", "Measurement", "Person", "Condition" ]
Inborn, preterm, infants, between 28 0/7 and 34 0/7 weeks, gestation, fed, donor human milk
NCT02632266_inc_task2
Sentence: Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk Instructions: please extract entity words from the input sentence
[ "B-Condition", "B-Condition", "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Measurement", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O" ]
Inborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milk
[ "Inborn", "preterm", "infants", "born", "between", "28", "0/7", "and", "34", "0/7", "weeks", "gestation", "and", "fed", "either", "mother", "'s", "own", "milk", "or", "donor", "human", "milk", "\n" ]
[ "Value", "Observation", "Measurement", "Person", "Condition" ]
human histidine decarboxylase is a GENE-N
23411280_task0
Sentence: Inhibitory activity of Filipendula ulmaria constituents on recombinant human histidine decarboxylase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O" ]
Inhibitory activity of Filipendula ulmaria constituents on recombinant human histidine decarboxylase.
[ "Inhibitory", "activity", "of", "Filipendula", "ulmaria", "constituents", "on", "recombinant", "human", "histidine", "decarboxylase", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
human histidine decarboxylase is a GENE-N
23411280_task1
Sentence: Inhibitory activity of Filipendula ulmaria constituents on recombinant human histidine decarboxylase. Instructions: please typing these entity words according to sentence: human histidine decarboxylase Options: GENE-N
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O" ]
Inhibitory activity of Filipendula ulmaria constituents on recombinant human histidine decarboxylase.
[ "Inhibitory", "activity", "of", "Filipendula", "ulmaria", "constituents", "on", "recombinant", "human", "histidine", "decarboxylase", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]